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Abstract:
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder 
associated with arrhythmias and sudden death. Mutations in the desmosomal genes 
plakoglobin and desmoplakin have been associated with the disease, founding the 
hypothesis that ARVC is a disease of cell adhesion. The aim of this study was to 
identify novel ARVC-causing genes and mutations and elucidate the molecular 
pathogenetic pathways of selected mutations.
As part of this study, mutation analysis of the recognized ARVC genes and of further 
candidate genes was performed on a large cohort of ARVC patients. Several novel 
mutations were identified and three further desmosomal genes were linked to the 
disease: plakophilin2, desmocollin2 and desmoglein2. Heart and skin samples from 
ARVC patients were subjected to microscopic examination and immunohistochemistry 
to study the effect of the newly-identified mutations on the structure of cell adhesion 
complexes.
The functional effects of a particular novel mutation were thoroughly examined in vitro. 
S39_K40insS is the first dominant ARVC-causing plakoglobin mutation to be reported. 
Yeast-two-hybrid analysis was used to investigate the effect of S39_K40insS on the 
protein interactions established by plakoglobin. A HEK293 cell line stably expressing 
the mutant protein was generated and used to study the effects of S39_K40insS on 
desmosomal structure, cell proliferation, cell death, subcellular localization and 
expression levels of proteins involved in adhesion and signaling and cellular responses 
to defined mechanical load. A recombinant adenovirus expressing the mutant protein 
was generated and used to transfect neonatal rat ventricular cardiomyocytes, whose 
behavior and responses were subsequently analysed. The functional consequences of 
S39_K40insS were compared with those of PK2157del2, a previously reported 
recessive plakoglobin mutation known to underlie Naxos disease, a syndromic form of 
ARVC.
These results point towards novel mechanisms of disease pathogenesis, that apart 
from weakened cell-cell adhesion involve altered protein turnover kinetics and defects 
in signaling pathways. Similar studies should improve our understanding of ARVC and 
provide a more accurate diagnostic algorithm.
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INTRODUCTION:
1) Cardiomyopathies: definition and classification:
As John Goodwin has emphasized; classification serves to bridge the gap between 
ignorance and knowledge. Previously cardiomyopathies were defined as diseases of 
the heart muscle of unknown cause.1 The recent revision by the World Health 
Organisation defined specific cardiomyopathies as ventricular dysfunction resulting 
from the inability of the myocardium to deal with volume or pressure overload related to 
valve disease, hypertension, ischemia or inflammation or secondary to systemic 
disease. Intrinsic cardiomyopathies on the other hand, are disorders of the myocardium 
associated with cardiac dysfunction that are subdivided based mainly on their 
pathophysiology as dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 
(HCM), restrictive cardiomyopathy (RCM) and arrhythmogenic right ventricular 
cardiomyopathy (ARVC). Such a functional rather than etiological classification has 
drawbacks but reflects our current level of knowledge.2
a) Dilated cardiomyopathy:
DCM is a myocardial disorder with an estimated incidence of 1 per 2000, characterized 
by dilatation and contractile dysfunction of the left and/or the right ventricle (Figure 1). 
Histological changes include increase in myocyte length, loss of intracellular contractile 
myofibrils, increase in nuclear size, polyploidy, myocyte death by apoptosis and/or 
necrosis, interstitial fibrosis and increased numbers of interstitial macrophages and T 
lymphocytes.2 Many cases show increased expression of class II antigens in the 
myocardium while circulating auto-antibodies to a wide range of components of the 
myocyte are present. Whether these antibodies are the cause of myocyte injury or a 
secondary phenomenon constitutes a yet un-answered question.2 Although DCM has 
traditionally been regarded as a sporadic non-genetic disorder (“ idiopathic DCM” ), 
more recent studies suggest inherited gene defects as an important cause (“ familial 
DCM” ). The natural history of the disease is variable both between and within families. 
Affected individuals may have a relatively benign course, develop progressive heart 
failure or experience sudden death.3 The reported prevalence of familial DCM has 
varied between 10 and 35% according to the methods of detection and diagnostic 
criteria employed. De novo mutations, incomplete penetrance, small family size and the 
concurrent presence of conditions known to promote DCM, such as viral infection, 
alcohol excess and ischemia, may limit the recognition of the contribution that heritable 
gene mutations have in the overall incidence of DCM.4
Studies of families with DCM have revealed autosomal dominant, autosomal recessive, 
X-linked and maternal modes of inheritance.3 Some cases of familial DCM are caused
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by mutations in genes coding for cytoskeletal proteins such as dystrophin, desmin, 
metavinculin, |3- and 5-sarcoglycan, implicating defects in contractile-force transmission 
as one mechanism underlying this disorder.5 Sarcomere protein genes, previously 
associated with HCM, were shown to also underlie certain forms of DCM. These 
include the genes that code for p-myosin heavy chain (P-MHC), cardiac myosin binding 
protein C (cMyBP-C), cardiac troponin T and a-tropomyosin, suggesting that defects in 
force generation are also involved in the pathogenesis of the disorder.6 The discovery 
that mutations in the genes coding for lamin A, lamin C and emerin caused DCM raised 
intriguing questions about the role of the nuclear lamina proteins in heart physiology 
and pathology. Currently, no data exist to suggest that nuclear envelope proteins 
participate directly in either force transmission or force generation in cardiac myocytes. 
One possibility though is that such mutations might promote DCM by disruption of 
nuclear function possibly through altered transcription regulation (Figure 2).3 Point 
mutations in mitochondrial DNA have been found in a number of multi-system disorders 
that may have associated cardiac abnormalities, such as childhood-onset DCM.3 
Furthermore, mutations in G4.5, the gene encoding tafazzin, have been implicated in 
childhood-onset X-linked DCM.3 In a recent study, mutations in the genes coding for 
presenilin-1 and presenilin-2, proteins previously associated with Alzheimer disease, 
were found to underlie DCM with poor or favorable prognosis respectively. Calcium 
signaling was altered in presenilin mutation carriers implicating novel mechanisms of 
myocardial disease. 7 Although multiple clinical parameters have been proposed as 
predictors of mortality in DCM, it appears that family genotype may be the strongest 
determinant of outcome.3
Figure 1: A heart in dilated cardiomyopathy compared with a normal heart at end- 
systole.8
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Figure 2: Identified genes that result in dilated cardiomyopathy include cytoskeletal 
protein-encoding genes, sarcomeric protein-encoding genes and intermediate filament 
protein-encoding genes.9
b) H ypertrophic cardiom yopathy:
HCM is characterized by left ventricular hypertrophy that is usually asymmetric and can 
affect various regions of the ventricle (Figure 3). Typical histo-morphological changes 
include myocyte hypertrophy and myofibrillary disarray (Figure 4). The prevalence of 
HCM is as high as 1 in 500 young adults. Clinical presentation of the disease ranges 
from lifelong symptom-less forms to sudden cardiac death (SCD).10 Estimates for the 
prevalence of SCD vary according to the population studied, ranging from <1% to 3- 
6%.3 Diagnosis of HCM generally requires exclusion of secondary causes of 
hypertrophy such as hypertension or aortic stenosis.3
HCM is an autosomal dominant familial disease in about 50% of patients. Genetic 
analysis has causally linked several genes to HCM. The majority of these genes 
encode cardiac sarcomeric proteins that include a-MHC, (3-MHC, troponin T, troponin I,
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a-tropomyosin, myosin light chain-1, myosin light chain-2, cMyBP-C and titin while the 
more recently discovered PRKAG2 encodes the y2 subunit of AMP-activated protein 
kinase. All these proteins have different roles within the contraction-relaxation cycle and 
contribute to energy homeostasis in the heart.10 The defective protein may be 
integrated into the sarcomere and act in a dominant negative way resulting in 
diminished force production. Therefore, hypertrophy could possibly be a means of 
compensation for low force generation. Another potential mechanism for hypertrophy 
might be increased cardiac contractility. This mechanism occurs rarely with specific 
defects in myosin light chains 1 and 2 and a-tropomyosin genes that cause increased 
Ca+2 sensitivity and thus increased force production. By contrast with other HCM- 
causing defects, cMyBP-C mutants lacking the myosin-binding and titin-binding 
domains seemingly do not integrate into the sarcomere, causing HCM due to lack of 
functional protein (haploinsufficiency).10 Calcium appears to be a critical link between 
mechanical dysfunction of the sarcomere and induction of the hypertrophic gene 
program.3
It is now recognized that cases exist in which there is an increase in LV mass, with 
striking asymmetric or symmetric LV wall thickening, yet disarray is absent and 
mutations in the myofibrillary genes are not found. These cases indicate that other 
genes outside the sarcomeric complex can produce thick-walled LV. Mitochondrial 
gene disorders, glycogen-storage disease and Fabry’s disease are among the known 
causes of this phenomenon.2 Recently, mutations in the gene encoding the cytoskeletal 
muscle LIM protein have also been implicated in the HCM pathogenesis.3 
The extent of LV hypertrophy varies between different genes and even between 
members of a single family with the same gene mutation. These observations may be 
explained by a modifying role of additional genetic and/or environmental factors.3 The 
genes that cause HCM can be associated with dysplastic changes in the small 
intramural arteries, leading to a decrease in the lumen size. Such changes are 
associated with fibrosis such that HCM may progress to a more DCM-like phenotype.2 
Various risk algorithms based on clinical parameters have been proposed to identify 
individuals with an increased propensity for SCD. Given the complexity of the 
mechanisms that may precipitate SCD, it is not surprising that no single risk factor has 
been identified. In genotyped individuals though, prognosis varies considerably 
between different genes and between different mutations in the same gene. For 
example the Arg403Gln and Arg453Cys (3-MHC mutations, cardiac troponin T 
mutations and some a-tropomyosin mutations are “ high risk” mutations with reduced 
life expectancy and high rates of SCD, whereas the Val606Met (3-MHC mutation and 
cMyBP-C mutations are associated with a relatively benign course.3
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Figure 3: Illustrations of a normal heart (left) and a heart with hypertrophic 
cardiomyopathy. 11
Figure 4: Photomicrograph of myocardium from a patient with familial hypertrophic 
cardiomyopathy. The normal parallel arrangement of myocytes has been replaced with 
myocyte disarray and increased connective tissue.12
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c) Restrictive cardiomyopathy:
RCM is the least common of the four categories of cardiomyopathies and is 
characterized by restrictive filling and reduced diastolic volume of either or both 
ventricles with normal or near-normal systolic function and wall thickness.13 It is most 
frequently caused by pathological conditions that stiffen the myocardium such as 
endomyocardial disease, hemochromatosis, amyloidosis, sarcoidosis, Gaucher’s 
disease, Fabry’s disease, glycogen storage disease or radiation damage, the most 
common form being myocardial amyloid (Figure 5).3 It is usually easy to recognize 
amyloid on histology by its characteristic green color under polarized light after staining 
with Congo red dye. Other causes of restriction include diffuse perimyocyte fibrosis. 
This pattern of fibrosis is seen to a degree in many cases of DCM, but when it occurs in 
a uniform distribution it causes predominantly restriction. Another form of RCM is 
associated with myocyte disarray on biopsy, but without other clinical or morphological 
features of HCM .2
In some individuals RCM may occur in the absence of a precipitating condition. 
Idiopathic RCM is not generally recognized to have a familial predisposition; however 
several small families have been reported showing autosomal dominant or recessive 
patterns of inheritance. The prognosis in RCM varies according to the underlying 
cause, but the majority of individuals experience progressive deterioration due to 
congestive heart failure with a high incidence of premature mortality. The small size of 
the families reported precluded genetic linkage analysis and only one disease-causing 
gene, desmin, has been identified to date.3
Figure 5: Illustration of a heart with restrictive cardiomyopathy. Ventricles stiffen and 
lose their flexibility.14
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2) Arrhythmogenic right ventricular cardiomyopathy:
a) A 45-plus year iournev:
The very first cases of ARVC were supposed to have been published in 1961 under the 
term: “ auricularisation of right ventricular pressure curve” .15 The first typical cases 
though, of adults with monomorphic ventricular tachycardia (VT) of left bundle branch 
block (LBBB) morphology, indicating its right ventricular (RV) origin, and an enlarged 
RV in the presence of normal pulmonary vasculature were reported in 1977 by Guy 
Fontaine.16 Since the first description of 24 cases, the term dysplasia was applied to the 
condition, which was thought to arise from “an abnormality in the development of the 
RV musculature” .17 It was thus considered to be a malformation similar to that seen in 
Uhl’s anomaly, a congenital condition characterized by “an almost total absence of the 
RV myocardium” . Arrhythmogenic right ventricular dysplasia (ARVD) was at the time 
thought to be infrequent with an exceedingly low risk of sudden death (SD). 17 
In 1988, Thiene et al. conducted a postmortem series of individuals who had died 
suddenly in the Veneto region of North-eastern Italy. This study indicated that the 
incidence of the disease may be much higher than originally thought, while 
simultaneously drawing attention to the association with SD especially in young people 
engaged in strenuous activity. In fact in a large number of subjects, SD was the first 
manifestation of the disease. Two main histological patterns were identified; a 
lipomatous pattern characterized by partial or total replacement of myocytes primarily of 
the RV free wall with adipose tissue, mainly at the apex and infundibulum and a fibro­
lipomatous pattern which featured large areas of fibrosis with or without fat infiltration. 
Signs of progressive myocardial degeneration and apoptosis with or without 
inflammatory infiltrates were also observed.18 The strong familial preponderance of the 
disease became apparent in an extensive epidemiological study of ARVC in the same 
area.19 These observations managed to shake the belief that the disease was caused 
by abnormal embryogenesis.18 ARVC is now known to be a primary myocardial 
disease, as opposed to a developmental anomaly, and was included in the World 
Health Organization classification of cardiomyopathies in 1995.1
b) Natural history:
Early reports focused mainly on the peculiar RV involvement and the electrical 
instability precipitating VT and SD. Long-term follow-up data from clinical studies 
though, indicated that ARVC is a progressive heart muscle disease that with time may
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lead to more diffuse RV involvement and LV changes and may culminate in heart 
failure (HF).20 In fact, a study conducted by six collaborative medical centres showed 
macroscopic and/or histological LV involvement in 76% of the hearts analysed.21 Four 
distinct phases have been documented in the natural history of the disease. In the 
concealed phase, patients are often asymptomatic, but may nonetheless be at risk of 
SD, notably during extreme exertion. Structural changes, when present, are subtle and 
may be confined to one region; the so-called “ triangle of dysplasia” : the inflow, outflow 
and apical portions of the RV. Symptomatic ventricular arrhythmia is seen in the overt 
phase, accompanied by more obvious morphological and functional abnormalities of 
the RV. The third phase is characterised by diffuse RV disease, which results in right 
HF with relatively preserved LV function.22 Significant LV involvement with biventricular 
HF occurs in the advanced stage leading to a phenotype that may be difficult to 
distinguish clinically from DCM.20
c) Task Force diagnostic criteria:
Clinical diagnosis of ARVC is challenging owing to the non-specific nature of 
associated findings. Recognition of this difficulty led an international task force to 
propose standardised criteria for ARVC in 1994.23 Structural, histological, 
electrocardiographic, arrhythmic and genetic features of the disease are incorporated 
into the criteria, which are sub-divided into major and minor according to the specificity 
of their association with ARVC (Table 1). The presence of two major, one major and 
two minor or four minor criteria from different categories is considered diagnostic.22
Electrocardiographic findings:
ECG findings associated with ARVC are subdivided into depolarization/conduction and 
repolarisation abnormalities. In a cohort of 265 patients who fulfilled Task Force criteria 
for ARVC, RBBB was observed in 6%, while a further 14% showed incomplete RBBB. 
However, the relatively common occurrence of these findings among normal subjects 
precludes their inclusion in the diagnostic criteria. 24 Delayed depolarization confined to 
the right precordial leads (RPL) is considered more specific for ARVC. Prolongation of 
the QRS complex to >110ms in leads V1 to V3 in the absence of RBBB, reflecting slow 
conduction in the RV free wall, is a major criterion for ARVC and was identified in 98% 
of the patients in the above study (Figure 6).22,24 Epsilon waves are small amplitude 
deflections occurring between the end of the QRS complex and the beginning of the T 
wave and correspond to delayed electric potentials that originate in areas of healthy 
tissue surrounded by fibrofatty infiltrate (Figure 7).25 Highly suggestive of ARVC when 
localized to the RPL, they were found in 23% of patients in the above series.24 Epsilon
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waves may go unnoticed, though the sensitivity for their detection can be increased by 
suitably preparing the skin and recording the ECG at double speed and double 
amplitude.26 Also, a signal-averaged ECG (SAECG) facilitates detection of the 
equivalent sign of late potentials in 50-80% of established cases.22 
Repolarization abnormalities are common in ARVC. The characteristic pattern of T- 
wave inversion beyond V1 was present in 54% of confirmed cases and represents a 
minor criterion for ARVC in probands (Figure 7).24 The Task Force guidelines exclude 
T-wave changes secondary to RBBB, and stipulate age over 12 years, as altered 
repolarization may be a normal variant in children. Significantly higher prevalence of T- 
wave abnormalities has also been observed in apparently healthy Afro-Caribbean 
subjects and highly trained athletes. In the absence of a conspicuous family history and 
characteristic imaging abnormalities, these alterations should be considered most likely 
benign.22
Figure 6: Localised right precordial QRS prolongation with QRS duration > 110ms.24
P
Figure 7: Electrocardiogram of a patient with ascertained ARVD showing T-wave 
inversions and epsilon waves (indicated by the arrow).27
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Table 1: Diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy.22
Arrhythmic findings:
Ventricular arrhythmia of LBBB morphology is a minor criterion in probands. Sustained 
monomorphic VT, defined as a consecutive run of beats lasting at least 30 sec, was 
present in up to 65% of live index cases, while a further 29% showed non-sustained 
VT. Frequent premature ventricular contractions in excess of 1000 over a 24-hour 
period, were documented in 42% (Figure 8 ) .28
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Figure 8: VT with LBBB morphology induced during exercise test.26 
Histological findings:
The routine use of endomyocardial biopsy in the diagnosis of ARVC is not 
recommended for a number of reasons. The risks of perforation and tamponade 
preclude sampling from the thinned free wall of the diseased RV, the region prevalently 
affected by fibrofatty replacement. Instead, biopsies are taken from the RV portion of 
the inter-ventricular septum, which is relatively spared by ARVC. The presence of 
myocytes in various stages of cell death with evidence of fibrofatty replacement is one 
of the major criteria for ARVC. A negative biopsy is of no value excluding ARVC owing 
to the segmental nature of the disease, particularly in its early stages. Unequivocal 
positive findings may however confirm the diagnosis.22
Figure 9: Histological sample: fibrofatty infiltration of the right ventricle (H&E).
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Imaging findings:
Structural abnormalities in ARVC may be localized, in the form of patchy wall thinning 
and segmental dilatation, or diffuse with global dilatation of the RV. Functional 
impairment ranges from mild regional wall motion abnormalities to generalized 
hypokinesia.22
Right ventriculography offers clear views and was traditionally used as a diagnostic tool 
for ARVC as it can localize aneurysms and areas of dyskinesis particularly in the 
triangle of dysplasia.29 Drawbacks though include the lack of information about LV 
involvement and the unsuitability of an invasive technique for serial follow-up 
studies.22,27 Visualization of the right ventricle by echocardiography is not always 
satisfactory, particularly in the presence of thoracic deformities or obesity, but may be 
enhanced by the use of intravenous contrast.22 However, it has the advantage of being 
non-invasive, readily available and inexpensive. Furthermore, echocardiography allows 
the study of family members, while differential diagnosis is possible with respect to 
other entities associated with arrhythmias and RV dilatation.26 With the advance of 
imaging techniques and the development of software for objective analysis of the 
images obtained, echocardiography can help detect early abnormalities as well as 
progression of the disease.26 M mode and pulse tissue Doppler techniques are also 
considered useful for detection of abnormalities in diastolic tricuspid annular motion.30 
The non-invasive nature of cardiac magnetic resonance (CMR) and its unique ability to 
detect fatty tissue infiltration, while assessing volumes, function and regional wall 
motion has increased its popularity as a diagnostic tool but not without controversy.29 
High resolution CMR sequences are currently dependant on ECG gating. Multiple 
premature ventricular contractions or a highly variable heart rate result in poor image 
quality. The fast spin-echo sequences used to detect fatty replacement are also 
especially sensitive to respiratory and motion artefacts.22 Since the RV free wall can be 
studied by CMR in several planes, greater detail is provided compared to 
echocardiography and right ventriculography, which may lead to false positive 
interpretation. The normally thin wall of the RV may also appear to have focal wall 
motion abnormalities, without any structural abnormalities actually being present.29 
Despite its excellence in detecting fat, CMR has difficulties differentiating between 
intramural and epicardial fat.31 The hearts of most adults in the western countries 
contain varying physiological amounts of fat, found mainly in the sub-epicardial region 
(adipositas cordis).32 This epicardial fatty tissue is more abundant on the RV surface, is 
thicker in women and increases with increasing body weight. Furthermore, in a normal 
heart, a certain amount of fatty tissue is always present within the myocardium of the 
RV free wall, particularly at the level of the antero-lateral and apical regions. Differing 
from adipositas cordis, this fatty RV infiltration seems independent of gender and body
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weight while myocytes seem to be just pushed apart by the fat rather than 
degenerating.32 Finally, the subjectivity related to reading and interpreting the images 
and the lack of a standard protocol for ARVC diagnosis have reduced the faith in the 
value of CMR even further. 31A recent study has shown that the use of fat-suppressed 
in addition to non-fat-suppressed conventional T1-weighed spin-echo imaging 
increased inter-observer agreement and confidence in diagnosis and evaluation of 
intra-myocardial fatty infiltration in patients suspected for ARVC.33 With newer imaging 
systems, better quality images and more comprehensive protocols, the accuracy of
29CMR is likely to improve.
Further imaging techniques including nuclear ventriculo-scintigraphy, LV angiography, 
single photon emission and multi-detector row computer tomography have been used 
but were not sensitive or specific enough to become established as the gold standard 
for ARVC diagnosis.27'34 35
Electrophysiological testing (EP):
The invasive EP study, while not a routine component of the diagnostic work-up for 
ARVC may have a role in differentiating idiopathic right ventricular arrhythmias (IRVA) 
from ARVC. VT in ARVC is often inducible by programmed electrical stimulation, 
exhibits entrainment and is associated with fragmented diastolic potentials. In contrast, 
VT in IRVA frequently requires an isoprenaline infusion and/or burst pacing for 
provocation.22 An EP-associated risk however is the possible induction of ventricular 
fibrillation (VF).27 Ajmaline challenge during an EP study can also be used to 
differentiate ARVC from Brugada syndrome, since it can induce RPL QRS prolongation 
only in typical Brugada while it can unmask epsilon waves and induce RBBB with QRS 
prolongation in the left precordial leads only in ARVC. Still, the question remains 
whether systematic ajmaline challenge to exclude Brugada syndrome is of any value, 
especially since provocable ST-segment elevation in ARVC represents a risk factor of 
additional progressive conduction disease.36
d) Vast variation in ARVC:
The disease is thought to affect 1 in 5000 individuals in the general population; 
however this figure varies among different ethnic groups.37 In the Veneto region of Italy, 
the incidence of ARVC is as high as 6 in 10000 inhabitants.38 The true prevalence of 
the disease is not easy to estimate, as many cases undoubtedly remain undiagnosed, 
and the full spectrum of disease expression is only now being elucidated.22 Two recent 
studies conducted in a non-referral centre in Germany and in South-East Korea
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estimate that ARVC affects 1 in 1000 individuals.39,38 ARVC shows male predominance 
and is usually manifested in adolescence or early adulthood. Typical symptoms include 
dizziness, palpitations and syncope episodes which first appear at 33 ± 14 years of 
age, ranging from 13 to 73 years. Paediatric cases have been reported, while a foetus 
with arrhythmia in utero exhibited the very early stages of the condition.27 
The disease exhibits phenotypic variation both in its presentation and clinical course 
even amongst affected members of the same family. Some individuals may remain 
asymptomatic throughout life or experience minor symptoms, others may develop 
biventricular HF prompting heart transplantation, while in some cases SCD is the first 
manifestation of the disease.40 In the United States, ARVC accounts for approximately 
5% of SCDs in individuals under the age of 65 and is responsible for at least 3 to 4 % of 
deaths associated with physical activity in young athletes.37 In the Veneto region of Italy 
though, ARVC is the most common cause of sudden arrhythmic deaths in individuals 
under the age of 35, and the overwhelming cause of SD associated with exertion in 
young athletes.37 Still, because necropsy is not frequently performed in cases of SD in 
those aged 35 or older, the true incidence of the disease among cases of SD is 
probably under-estimated.41 Moreover, given the progressive nature of the disease, 
diagnosis may be missed at autopsy if structural abnormalities have not yet developed 
(concealed phase).22
The annual mortality rate of ARVC has been estimated at 3% without treatment and at 
1% with treatment.37 In contrast with the recognition of strenuous exercise as a trigger 
of SD in patients with ARVC, in the study performed in South-East Korea, most of the 
cases were found dead in bed or died suddenly during ordinary daily activity.39 A 
difference in the incidence of fatal ARVC may exist because of regional or genetic 
factors. Alternatively, it may be that autopsies are not always requested in Korea in 
cases of SCD during strenuous activity.39 Furthermore these observations do not 
exclude the possibility of sudden unexplained nocturnal death syndrome or Brugada 
syndrome being mis-diagnosed as ARVC.39 Interestingly, in the study conducted in 
Germany, patients experienced chest pain and tiredness, symptoms not commonly 
associated with ARVC, while the disease was shown to have a good prognosis with 
only 0.3% of annual SCD.38 Finally, the average age of onset of the disease amongst 
Chinese patients was significantly higher than in other groups studied, though this 
could be due to late diagnosis or late clinical presentation.42 Also, none of the patients 
in this study showed LV involvement, while 36.4% of the patients did not show any 
echocardiographic abnormalities.42
The spectrum of ARVC presentation and clinical course becomes even broader when 
familial cases are considered. In a study conducted in England, relatives of 67 ARVC
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index patients underwent cardiac evaluation.28 Of 298 relatives, 10% had ARVC based 
on the Task Force criteria, while a further 11% exhibited ECG, echocardiographic or 
Holter monitoring abnormalities without fulfilling the criteria for diagnosis. In the context 
of a familial disease, such subtle abnormalities may in fact represent early or mild
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disease expression.
Unusual presentations:
Although typical ARVC first manifests with palpitations, syncope or sudden cardiac 
death in adolescence or early adulthood and is characterized by arrhythmias originating 
primarily from dilated, hypo-kinetic right ventricles, over the past few years, a number of 
cases of unusual disease presentation have been published.
In 1999, the case of two siblings with ARVC was reported.43 The older sibling, 
previously considered healthy, died suddenly at age 17. The younger sibling developed 
congestive HF prompting cardiac transplantation at age 14. Macroscopic examination 
of the two hearts showed a thick cap of fibro-adipose tissue covering all of each RV. 
Microscopically, both left ventricles contained excessive myocyte disarray and multi­
focal fibrosis. The coronary arteries displayed intimal hyperplasia with disruption of the 
internal elastic lamina, similar to fibro-muscular dysplasia. Typically, ARVC does not 
affect the coronary arteries, is not characterized by disarray and does not progress to 
such advanced stages at such a young age. 43 Nemec et al. described the case of two 
patients who underwent heart transplantation with a clinical diagnosis of idiopathic 
DCM, while pathology demonstrated the end stage of ARVC with major LV 
involvement.44
In 2000, Suzuki et al. presented the case of a 43-year old man admitted to hospital 
because of congestive HF following a common cold.45 The RV function was preserved, 
but the LV function was severely and diffusely hypo-kinetic. An endomyocardial biopsy 
revealed mild infiltration of lymphocytes with focal myocyte necrosis. The observations 
were consistent with DCM and healing myocarditis. Progressive impairment, dilatation 
and thinning of both ventricles were observed on serial echocardiographic 
examinations; however the LV impairment had always been predominant in the 
patient’s clinical course. He died suddenly of VF and pump failure. The autopsy 
revealed evidence of apoptosis and extensive fibrofatty replacement of myocytes in 
both ventricles extending from the outer layer to the inner layer of the myocardium in 
the RV and to the middle layer of the LV, observations compatible with ARVC.45 
In 2001, the case of a 19-year old man, evaluated because of his sister’s SD, was 
published.46 He was given the diagnosis of ARVC based on electrocardiographic and 
echocardiographic abnormalities. The patient died at 33 years of age, while waiting for 
a heart transplant. At gross examination, huge cardiomegaly and paper-thin RV walls
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with transmural myocardial loss were evident. A large calcified plaque, 7 x 9 cm in size, 
was found at the level of the RV outflow tract. Calcification has not previously been 
implicated in ARVC, while it is commonly associated with RCM.46 
In 2002, the case of a 30-year old Caucasian woman presented with fatigue and 
dyspnoea on exertion was reported.47 Twelve-lead ECG was remarkable for ST- 
segment elevation in V1-V2, negative T-waves in V1-V6 and fractionated low-amplitude 
spiking electrical activity extending 300ms beyond the QRS complex in all leads. 
Angiography revealed RV global dilatation and hypo-kinesis with multiple aneurysms 
and mild LV involvement. The histological picture was compatible with ARVC. The 
finding of multiple delayed after-potentials extending into the T-wave is a very unusual 
finding in ARVC, while the down-slopping ST elevation in V1 and V2 is often seen in 
Brugada syndrome.47
In 2004, a 49-year old man was admitted to hospital after experiencing chest pain, 
palpitations and dizziness.48 On admission, ECG showed VT of LBBB morphology, 
which suddenly became unstable and prompted cardioversion. His post-conversion 
ECG showed inverted T-waves and Q-waves and he showed elevated cardiac markers 
indicative of myocardial infarction. Echocardiography showed a dilated RV. However 
based on chest pain of ischemic character, the finding of Q-waves with T-wave 
inversions at inferior leads and positive cardiac markers, the patient was treated as a 
case of acute coronary syndrome. An angiogram performed during follow-up showed 
normal coronary arteries but a dilated RV with dysplastic changes indicative of ARVC.48 
Around the same time another unusual case of ARVC was reported.49 A 76-year old 
woman with no previous history of disease, developed recurrent VT and VF, termed 
electrical storm as the first manifestation of ARVC. The diagnosis was confirmed post­
mortem, suggesting a tremendous variation regarding the age of onset of symptoms in 
ARVC.49
Collectively, these observations suggest that ARVC is a disease characterized by vast 
phenotypic variation, age-related progression and incomplete penetrance. A quarter of 
a century has passed since ARVC was first recognized as an individual clinical entity, 
and yet, this vast variation combined with the lack of a single diagnostic test capable of 
differentiating ARVC from different, yet overlapping clinical entities, still make diagnosis 
problematic. In fact, in a large study conducted at the John Hopkins medical centre, out 
of 89 patients who were referred for a re-evaluation for diagnosis of ARVC, only 27% 
actually met the Task Force criteria.50 This study demonstrated the high frequency of 
misdiagnosis of ARVC mainly due to over-reliance on the presence of intra-myocardial 
fat on MRI, incomplete diagnostic testing, lack of awareness of the Task Force criteria 
and a not yet clearly defined disease spectrum.50
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e) Etiology
In addition to a genetic cause of ARVC, dysontogenic, degenerative, infectious or 
inflammatory, apoptotic and myocyte trans-differentiation theories have been proposed 
either as a cause of or as environmental factors facilitating disease expression.37 
The dysontogenic theory is largely historical, but suggests that ARVC is a milder form 
of Uhl’s anomaly. The degenerative theory suggests that ARVC is a consequence of 
myocyte death due to inherited metabolic or ultra-structural defects. The infectious or 
inflammatory theory maintains that the disease results from previous myocarditis. 
Inflammatory infiltrates are common in histological specimens from patients with 
ARVC.37 Fontaine et al. found inflammatory infiltrates in 8 of 27 patients with ARVC51 
while Calabrese et al found foci of inflammatory infiltrates in 4 of 20 patients though all 
specimens were negative for enteroviral genomes indicating that enteroviruses may not 
be involved in the etiopathogenesis of the disease.52 In agreement with this finding, 
BALB/c mice inoculated with Coxsackie virus B3 showed evidence of increased 
myocardial degeneration and necrosis, extensive inflammation, large numbers of 
inflammatory infiltrates and extensive fibrosis primarily in the pericardial side of the RV 
myocardium.53 More recent studies though showed that myocarditis can mimic ARVC 
and that it may be super-imposed on an already affected heart accelerating disease 
progression, rather than being involved in the actual etiology of the disease.54 The 
apoptotic theory is supported by the finding of apoptosis and a high level of CPP-32, a 
cysteine protease required for apoptosis, which were detected in the RV myocardium of 
6 of 8 ARVC patients examined but not in 4 normal subjects.55 Finally, the trans­
differentiation theory is based on the hypothesis that myocardial cells can change from 
muscle to adipose tissue and the observation in one patient of “ transitional cells” at the 
interface between cardiac muscle and adipose tissue.37
f) Syndromic ARVC:
Naxos disease:
Palmoplantar keratosis (PPK) is a familial ectodermal defect characterised by 
hyperkeratosis of the palms and soles. After recurrent VT developed in two young 
patients with non-epidermolytic PPK and peculiar woolly hair (Figure 10) from the 
Greek island of Naxos, Protonotarios et al. sought evidence of cardiac abnormalities in 
families on this island that included members with these cutaneous abnormalities.56 A 
total of 9 individuals from 4 families were examined. The majority of the patients 
demonstrated ECG disorders including intra-ventricular conduction delays, T-wave 
inversions, abnormal Q waves, low voltage and arrhythmias of ventricular origin, mainly
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frequent ventricular extra-systoles and VT of LBBB morphology. Echocardiographic 
abnormalities consisted of cardiac enlargement mainly of the RV, wall motion 
abnormalities, and an echodense muscular type band originating from the right apex. 
The occurrence of strikingly similar cardiac anomalies in most of the patients with PPK 
and woolly hair could not be regarded as a coincidence. Thus a new familial, possibly 
autosomal recessive, disease entity was recognised in 1986 involving hair and skin 
abnormalities as well as a form of cardiomyopathy, which at the time was thought to 
exhibit characteristics of either DCM or ARVC.56 After the description of the first cases, 
further cases were identified in other Greek islands, Turkey57 and Saudi Arabia.58 The 
entity though was named Naxos disease due to the clustering of events in the island of 
Naxos.59 Indeed, the prevalence of the syndromic disease in the Greek islands is as 
high as 1 in 1000 individuals.60
The peculiar woolly hair phenotype appears at birth, the dermatosis appears in the first 
year of life, interestingly at skin regions exposed to increased mechanical stress, such 
as the palms and the soles, while the cardiac phenotype does not appear until 
puberty.59 Clinical and histological studies conducted over the past 20 years, comparing 
Naxos disease with ARVC showed that the heart disorder is identical in both cases 
(Figure 11).60 Therefore, after 1995, according to the Classification of World Health 
Organisation, Naxos disease is considered to be a recessive form of ARVC. Naxos 
disease is a rather progressive disease with adverse outcome especially in the young. 
The annual disease-related and SD-related mortality rate is 3% and 2.3% respectively. 
Risk factors for SD include history of syncope, appearance of symptoms and severely 
progressed disease in the RV before the age of 35 and LV involvement. The 
prevalence of heterozygotes in the island of Naxos is as high as 5% of the population. 
Apart from a small fraction of heterozygous individuals who show woolly hair and some 
minor electrocardiographic and echocardiographic abnormalities, not diagnostic of 
ARVC, heterozygotes show a normal clinical phenotype.60
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Figure 10: Cutaneous features of Naxos disease: Woolly hair (A), palmal (B) and 
plantar (C) keratoses.60
Figure 11: Two-dimensional echocardiogram of heart showing typical features of 
ARVC: right ventricular (RV) dilatation and multiple saccular aneurysmal segments 
(arrows). There is also right atrial (RA) dilatation. In contrast, left ventricle (LV) and left 
atrium (LA) are normal. Accompanying ECG shows abnormal T-wave inversion in leads 
V1 through V4| consistent with abnormal repolarization affecting RV.61
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Carvajal syndrome:
In 1998, the case of three families from Ecuador showing evidence of autosomal 
recessive inheritance of a syndromic disease affecting the hair, skin and heart was 
reported.62 The skin disease presented as a PPK with some non-volar involvement 
particularly at sites of pressure or abrasion. All epidermal lesions had the characteristic 
longitudinal hyperkeratosis of striated PPK. The hair was curly and woolly in texture 
(Figure 12). Cardiological investigation including ECG and echocardiographic 
examinations of a number of the affected family members reported the diagnosis of an 
LV-DCM often resulting in HF during adolescence. The newly-described entity was 
named Carvajal syndrome after the dermatologist who first described it.62
Figure 12: PPK and woolly hair in two affected family members.63
The heart of a child affected by Carvajal syndrome, who died of progressive HF at age 
11 years, was examined macroscopically and microscopically.64 The RV was only 
moderately dilated but it contained discrete inferior, apical and infundibular aneurysms 
with thin translucent walls. In contrast, the LV was widely dilated and contained shallow 
posterior and antero-septal aneurysms (Figure 13). Microscopic examination disclosed 
diffuse scarring of the free walls of both ventricles with extensive areas of myocardial 
loss and replacement fibrosis while there was no evidence of fatty infiltration in either 
ventricle. Myocyte hypertrophy and attenuation with bizarre nuclei and non-specific 
myocytolytic changes were prominent. Patchy foci of inflammatory cells were visible
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adjacent to degenerating myocytes and TUNEL staining revealed increased apoptotic 
rates (Figure 14).64
Figure 13: Gross photographs of the right (A, B) and left (C-E) sides of the heart. Both 
ventricles contained discrete regions of aneurysmal wall thinning. Affected areas 
included the subtricuspid posterior right ventricle (B), the posterior basal portion of the 
left ventricle (marked by an asterisk in D), and the anteroseptal portion of the left 
ventricle (E).64
Figure 14: Panoramic views of the right (A) and left (B) ventricular free walls showing 
extensive myocardial loss and replacement fibrosis. Higher magnification views of left 
ventricular myocardium showing myocyte hypertrophy and myocytolysis with bizarre 
nuclei (C); focal inflammatory infiltrates surrounding dying myocytes (D); replacement 
fibrosis (E); and myocyte apoptosis (F).64
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Overlapping syndromes:
Recently the case of a 17-year-old boy of Turkish origin was published.65 The boy was 
referred to the coronary care unit of the local hospital after complaining for dyspnea and 
palpitations. He had curly hair and PPK, also confirmed by skin biopsy. An ECG 
showed right axis deviation, low voltage, T-wave inversions and epsilon waves in V1- 
V3. On echocardiographic examination both ventricles were dilated and showed global 
hypokinesia. On Holter monitoring there were frequent supra-ventricular tachycardia 
attacks, but no complex arrhythmias were recorded. His younger brother, who did not 
show any cutaneous abnormalities, was diagnosed with ARVC without LV involvement 
based on ECG, echo and CMR findings. The grandfather of the patient had PPK, curly 
hair and a mild enlargement and systolic dysfunction of the RV. A clear differential 
diagnosis between Naxos disease and Carvajal syndrome could not be established 
indicating that the two entities may indeed represent different existences of the same 
pathogenetic pathway.65
A unique form of syndromic ARVC in Israel:
In 2003, Alcalai et al. reported a clinical syndrome consisting of SD with hair and skin 
abnormalities in a family from Israel.66 Family history was significant for 8 members 
who died suddenly during young adulthood. All of them had woolly hair and 
exceptionally dry skin in all parts of the body beginning at birth. During childhood, they 
presented with vesicular lesions on the extremities, particularly on the knees, palms 
and soles. Histological examination of a biopsy sample demonstrated features similar 
to pemphigus foliaceous. One living affected female, with similar cutaneous 
abnormalities presented with recurrent syncope at the age of 16. VT of RV origin was 
documented. 12-lead ECG demonstrated T-wave inversion with localized prolongation 
of the QRS complex. Echo revealed a mildly dilated RV without regional wall motion 
abnormalities or aneurysms and a normal LV. A diagnosis of ARVC was made based 
on ECG and echo abnormalities and a family history of SD. The constructed pedigree 
was suggestive of an autosomal-recessive inheritance pattern.66
The entities described above indicate that ARVC can be found in syndromic disease 
that involves a range of hair and skin abnormalities. They also highlight the broad 
spectrum of the disease, which despite being named arrhythmogenic right ventricular 
cardiomyopathy can in fact predominantly affect the LV resembling DCM.
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g) Naturally-occurring myocardial disease in animals:
Cardiomyopathy/woolly hair syndrome (CWH) of Poll Hereford calves:
A lethal autosomal recessive cardiocutaneous syndrome of Poll Hereford calves has 
been reported in Australia.46 Affected animals can be identified at birth by their 
distinctive woolly haircoat and ventricular arrhythmias. Electrocardiography has 
recorded low voltage, flat T-waves, complex ventricular extra-systoles and episodes of 
non-sustained VT. Death usually occurs within 12 weeks of birth and may be sudden 
(from VF often after physical exertion) or follow a period of congestive HF. In CWH, 
lesions can occur in both ventricles and include multi-focal to locally extensive 
myocardial loss with replacement fibrosis and occasionally areas of calcification (Figure 
15).67 The ventricular calcification is comparable to a phenomenon described also in a 
human patient, with calcification of the RV free wall. 46
Figure 15: (A) Distinctive woolly haircoat. (B, upper) Cross section of the heart reveals 
sub-epicardial myocardial loss with fibrous replacement of the right ventricular free wall. 
(B, lower) Cross section of the heart reveals the same pathologic process in both 
ventricles associated with calcification. (C) Right ventricular free wall with extensive 
sub-epicardial myocyte loss and replacement fibrosis embedding surviving myocytes.68
Spontaneously-occurring ARVC in the domestic cat:
Between 1995 and 1998, pathology archives of the animal medical centre in New York 
were reviewed for cases in which death appeared to be due to congestive HF.69 Of 26 
cases, 12 were suspected of ARVC on the basis of marked RV and atrial enlargements 
with grossly identifiable wall thinning. Clinical features included right-sided congenital 
HF, supra-ventricular tachy-arrhythmias, VT, polymorphic ventricular arrhythmias and
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RBBB. Out of the 12 cats, 8 died of cardiovascular disease. At autopsy, hearts of 
ARVC cats were characterised grossly by moderate to severe RV-cavity enlargement 
and wall thinning and apical aneurysm formation. Histology demonstrated pronounced 
RV lesions in all 12 cats, including marked myocardial injury (myocyte necrosis and 
atrophy) and repair (fibrous and/or fatty replacement). Injury and repair were also 
evident in the LV in 10 cats while 2 showed involvement of both atria. Evidence of 
increased apoptosis was detected in 9 animals.69
ARVC causing SD in Boxer dogs:
In a study performed at the Ohio State University College of Veterinary Medicine, 
ARVC was diagnosed in 23 Boxer dogs.70 Clinical events included SD, ventricular 
arrhythmias of suspected RV origin, syncope and HF. RV enlargement and aneurysms 
were a common finding. Striking histo-pathological abnormalities were present in each 
dog including severe RV myocyte loss with replacement by fatty or fibrofatty tissue. 
MRI demonstrated bright antero-lateral and/or infundibular RV myocardial signal, 
confirmed as fat by histopathology. Evidence of myocarditis was present in 14 and 
familial transmission was evident in 10 dogs.70
Collectively, the forms of cardiomyopathy described in all calves, felines and Boxer 
dogs are remarkably similar to ARVC in human patients with respect to both clinical 
and pathological features. These naturally occurring disease models may be a 
potentially important investigative tool that could enhance our understanding of the 
complex clinical and patho-physiological mechanisms operating in ARVC, as well as 
the molecular mechanisms responsible for its genesis.69
h) Management of ARVC:
Pharmacological therapy:
No evidence currently exists for the efficacy of any anti-arrhythmic agent in preventing 
SD. Drug treatment may however alleviate symptoms such as palpitations and dizzy 
spells secondary to multiple PVCs or runs of VT.22 The association of SD with 
strenuous activity, together with the observation that VT in ARVC is often preceded by 
an increased heart rate, suggests that sympathetic stimulation may be a precipitant. 
First-line use of beta-adrenergic receptor antagonists, where no contra-indications 
exist, is therefore reasonable. Amiodarone is recommended as add-on therapy if beta- 
blockers alone prove ineffective in suppressing VT.22 Greater caution is justified before 
commencing amiodarone in patients with frequent PVCs as the risk of side effects may 
outweigh the potential benefits of symptom control.22 After a clinical study conducted in
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Japan, Hiroi et al. suggested carvedilol as a first-line drug for some patients with ARVC 
demonstrating sympathetic over-activity, drawing attention to the drug’s ability to control 
arrhythmias while improving LV function.71 Standard HF therapy is indicated in later 
stages of the disease for patients with impaired ventricular function. Anticoagulation 
should be considered in patients with atrial fibrillation, marked ventricular dilatation or 
ventricular aneurysms.22
Invasive treatment strategies:
The implantable cardioverter defibrillator (ICD) confers the optimal protection against 
SD.22 Appropriate interventions occur frequently in ARVC patients, highlighting the 
likely survival benefit in this population. In current practice, an ICD is first-line therapy 
for all survivors of VF arrest, and is also offered to patients with VT that recurs or 
remains inducible in spite of drug therapy. Constraints to more widespread use include 
the potential complications of lead insertion into the diseased RV, infection, the 
requirement of multiple generator replacements, the risks of in-appropriate intervention 
and psychological repercussions associated with the device.22 Sustained monomorphic 
VT may also be susceptible to radiofrequency ablation.22 Owing to the progressive 
nature of the disease though, recurrence of VT is relatively common, and myocardial 
injury precludes repeated intervention.22
Disarticulation of the RV is used to completely isolate the RV free wall.27 This operation 
is based on the principle that the RV makes only a small contribution to cardiac 
hemodynamics and that the isolation of its free wall will prevent the transmission of 
abnormal rhythms to the LV. The efficacy of this operation in the prevention of VT is un­
questioned. Nevertheless, because of hemodynamic alterations, this extensive surgical 
approach should be used with caution. 27 Right ventricular cardiomyoplasty consists of 
wrapping the RV free walls with the left latissimus dorsi muscle flap.72 The distal part of 
the latissimus dorsi muscle is fixed to the diaphragm and then electro-stimulated. The 
results of a long-term clinical study conducted in France demonstrated hemodynamic 
and functional improvements following this operation without peri-operative mortality, 
long-term malignant arrhythmias or RV dysfunction-related deaths indicating that RV 
cardiomyoplasty may in fact be an effective treatment for ARVC patients with severe 
RV failure.72 Finally, heart transplantation is the ultimate form of therapy indicated in 
cases of extreme RV dilatation or severe LV involvement.27
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3) Work leading to the current hypothesis:
The beginning:
The identification of the genetic determinants underlying ARVC has been slow due to 
the difficulties in diagnosis and the vast variation characterizing the disease. However 
Naxos families, where co-segregation of the hair and skin features with cardiomyopathy 
allow diagnostic status to be more confidently assigned, presented a powerful model for 
gene identification in ARVC.73 Linkage analysis of 9 families mapped the disease locus 
to 17q21. A homozygously inherited disease haplotype was common to all the affected 
individuals supporting an autosomal recessive mode of inheritance as well as a founder 
effect.61 Coonar et al. hypothesized that a common ancestor had introduced a single 
copy of the disease gene to the genetically isolated population of Naxos, and then as a 
result of inbreeding, homozygous individuals arose bearing the phenotype of Naxos 
disease.61 The region of homozygosity was refined and found to contain the candidate 
gene plakoglobin, a member of the armadillo protein family and a constituent protein in 
adherens and desmosomal junctions, with adhesive and signalling properties.73 Mice 
with null mutations in plakoglobin, exhibit heart and skin abnormalities analogous to 
Naxos disease.74 A patient’s cDNA was thus screened for mutations in plakoglobin. A 2 
base pair deletion was identified at the 3’ end of the gene (2057del2), predicted to 
cause a frameshift and premature termination of translation truncating the C-terminal 
domain of the putative protein by 56 residues. Western blot analysis with an anti- 
plakoglobin antibody confirmed the presence of the mutant protein in a cardiac biopsy 
sample from a patient. Mutant plakoglobin migrated with a molecular weight of 75kDa, 
whereas plakoglobin expressed in a normal heart migrated with a molecular weight of 
82kDa. The plakoglobin deletion identified destroyed the Bst01 recognition site, 
allowing rapid screening in Naxos disease families through restriction digestion.73
Desmoplakin mutations underlying ARVC:
In 2000, a genome scan was performed on the three families from Ecuador, where 
Carvajal syndrome was first recognized.63 All affected members showed homozygosity 
at 6p23-p24, where the gene coding for desmoplakin lies. Histology of affected patient 
skin revealed large inter-cellular spaces between supra-basal keratinocytes indicating a 
cell adhesion defect underlying the disease. Desmoplakin is the most abundant protein 
of desmosomes and is important in the attachment of the intermediate filament (IF) 
network to the plasma membrane and in inter-cellular adhesion. Functionally therefore, 
desmoplakin was a good candidate for the disease gene. Sequence analysis revealed 
a deletion of a G nucleotide at position 7901 (7901 deIG), which segregated with the
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disease phenotype in all three families with all affected members homozygous for this 
variant.63
Following the recognition of 7901 deIG as the genetic determinant underlying Carvajal 
syndrome, a point mutation in desmoplakin was identified in the family from Israel 
presented with a similar cardiocutaneous phenotype, leading to a Gly2375Arg 
substitution in the protein.66 Only the one living affected individual was homozygous for 
the substitution suggesting an autosomal recessive manner of inheritance.66 In 2002, a 
genome scan in one Italian family affected by ARVC without associated cutaneous 
abnormalities was reported. An autosomal dominantly inherited mutation (S299R) was 
identified in exon 7 of desmoplakin, highlighting how different desmoplakin mutations 
may produce different clinical phenotypes with different modes of inheritance.75
Plakophilin2; another ARVC-causing desmosomal gene:
Plakophilins are proteins of the armadillo family that function in embryonic development 
and assembly of cell-cell junctions. Grossmann et al. ablated the plakophilin2 (PKP2) 
gene in mice. The resulting mutant mice exhibited lethal alterations in heart 
morphogenesis and stability at mid-gestation (E10.5-11), characterized by reduced 
trabeculation, disarrayed cytoskeleton, ruptures of cardiac walls and blood leakage into 
the pericardial cavity. In the absence of PKP2, desmoplakin dissociated from the 
plaques of adhering junctions that connect cardiomyocytes and formed granular 
aggregates in the cytoplasm.76 Based on these findings and on the implication of two 
further junctional proteins in ARVC pathogenesis, Gerull et al. hypothesized that 
mutations in human PKP2 may account for ARVC.77 Sequence analysis of 120 
Caucasians, diagnosed with ARVC according to the Task Force Criteria, revealed 25 
different heterozygous mutations in 32 probands. Of the 25 mutations, 12 were 
insertion/deletion mutations, 6 nonsense mutations, 4 missense mutations and 3 splice 
site mutations. Although the majority of mutations were detected in the carboxy- 
terminal half of the molecule, ARVC-causing PKP2 mutations were spread over the 
entire gene. Three mutations were observed in several unrelated patients suggesting 
an ancient founder effect or the presence of mutational hot spots throughout the 
gene.77
The implication of three junctional proteins in ARVC pathogenesis constituted the 
foundation for the hypothesis that ARVC may in fact be a disease of defected cell-cell 
adhesion, or more specifically a disease of the desmosome.
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4) Further genetic background:
Apart from the three genes presented above, seven further chromosomal loci have 
been associated with autosomal dominant or autosomal recessive forms of ARVC 
through chromosomal mapping (Table 2).
Type Chromosomal position
ARVC1 14q23-q24'8
ARVC2 1 q42-q43's
ARVC3 14q12-q2280
ARVC4 2q32.1-q32.381
ARVC5 3p238<!
ARVC6 10p12-p14“
ARVC7 10q2284
Table 2: ARVC-associated chromosomal loci
Out of these seven ARVC forms, ARVC2 was different in that it showed high 
penetrance, a 1:1 male to female ratio in affected individuals and was characterized by 
a particular form of effort-induced ventricular arrhythmias. Three candidate genes were 
mapped on the chromosomal region previously identified by linkage analysis (1q42- 
q43), one of which was RyR2, the gene coding for the cardiac ryanodine receptor.85 
When a number of families diagnosed with ARVC2 were screened for mutations in 
RyR2, six missense mutations were identified at highly conserved positions of the 
gene.86
RyR2 is the only ryanodine receptor isoform expressed in the heart. It is a homo- 
tetramer with a molecular weight of 565kDa, which transverses the membrane of the 
sarcoplasmic reticulum (SR) and is involved in the excitation-contraction coupling of the 
cardiomyocytes.87 Ca+2 that enters the cell during the plateau phase of the action 
potential through the L-type voltage-gated channels, activates the ryanodine receptors, 
which in turn release further calcium from the SR. The influx of Ca+2, together with the 
release of Ca+2 from the intracellular stores, greatly increases the levels of Ca+2 within 
the cell, which in turn binds troponin C thus switching on the contractile machinery. 
Following contraction of the cardiomyocytes, the ryanodine receptor closes, Na/Ca 
exchangers pump Ca+2 out of the cell and Ca+2 ATPase pumps transfer Ca+2 back to 
the SR so that the intracellular Ca+2 levels can drop and the cell can relax.88 The 
mutations identified in RyR2 were thought to increase the phosphorylation of the
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protein, thus not allowing it to close properly.89 This would result in Ca+2 leaking in to 
the cytoplasm. A prolonged increase in the intracellular level of Ca+2 could potentially 
provoke ventricular arrhythmias.89 However, although this hypothesis can explain the 
exercise-related arrhythmias, it does not explain the structural abnormalities 
characterizing the disease. More recent reports suggest that mutations in RyR2 are 
more likely to be causing catecholamine-induced VT rather than ARVC.
ARVC1 was mapped to chromosomal region 14q23-q24. Amongst that critical region, 
five genes are expressed in the heart, one of which is TGF(33. TGFP3 was considered 
to be a plausible candidate gene as it is known to induce fibrosis in vivo in a number of 
tissues. When screening of a number of patients diagnosed with ARVC1 did not reveal 
any mutations in the coding region of TGFp3, screening was extended to the regulatory 
regions of the gene.90 As a result two point mutations were identified, a transition at the 
promoter region and another transition at the 3’ un-translated region of the gene. In 
vitro studies using a luciferase reporter gene showed that both mutations increase the 
levels of expression of the gene two-fold compared to wild-type. The hypothesis was 
that if TGFP3 is over-expressed, it could induce fibrosis in the myocardium, which is 
one of the morphological features of ARVC.90 This finding, though interesting, raised a 
number of issues; no evidence was given that TGFP3 was up-regulated in vivo as well 
as in vitro and despite the fact that TGFp3 is known to induce fibrosis, there was no 
clear biological link between the mutations identified and ARVC.91 
In 2003, a mouse model of ARVC was identified by chance, during the testing of anti­
diabetic compounds on obese mice that were originally isolated on the basis of 
hyperglycemia. Examination of the heart of these mice showed massive fibrosis of the 
RV wall, degradation of cardiomyocytes, and macrophage infiltration. A retroposon 
insertion encoding a mutant form of the nuclear protein laminin receptor 1 (LAMR1) 
was identified by positional cloning, and was considered to be responsible for the 
cardiac phenotype observed. LAMR1 is one of the ribosomal proteins localized in the 
nucleus and is involved in apoptosis.92 To date though, there has been no report of 
LAMR1 contributing to the etiology of human ARVC.
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5) Cell-cell junctions:
When cells bear the stress...
Cells organized in tissues are in contact with secreted extracellular macro-molecules 
referred to as the extracellular matrix whose function is to hold the cells together and 
provide a means in which cells can migrate and interact. In addition, cells are held 
together by cell-cell junctions. Connective tissues and epithelial tissues represent the 
two extremes in which the structural roles played by the cell-matrix and cell-cell 
adhesion are radically different. In connective tissues, the extracellular matrix is 
plentiful and the cells within it sparsely distributed. The matrix is rich in fibrous 
polymers, especially collagen, and bears most of the mechanical stress to which the 
tissue is subjected, therefore constituting direct cell-cell attachment relatively 
unimportant. On the contrary in epithelial tissues the extracellular matrix is scanty, 
consisting mainly of a thin layer referred to as the basal lamina, which underlies cells 
bound together into sheets. Within epithelial tissues, it is the cells that bear most of the 
mechanical stress. Strong intracellular protein filaments cross the cytoplasm of each 
cell transmitting mechanical forces to neighboring cells. To achieve this, the filaments 
are directly or indirectly attached to transmembrane proteins on the plasma membrane, 
where specialized junctions are formed between adjacent cells or between cells and 
the underlying basal lamina.
Anchoring junctions:
Anchoring junctions are widely abundant in animals, but are not found in plants. They 
allow groups of cells to act as robust structural units by connecting the cytoskeletal 
elements of one cell to the cytoskeletal elements of adjacent cells or to the extracellular 
matrix. They are mostly abundant in tissues subjected to increased mechanical stress, 
such as the heart and the epidermis.93 Three types of anchoring junctions are 
recognized to date: the adherens junctions, which connect the actin microfilaments of 
one cell to the actin microfilaments of adjacent cells; the hemi-desmosomes, which 
connect the intermediate filaments of one cell to the matrix; and the desmosomes, 
which connect the intermediate filaments of one cell to the intermediate filaments of 
neighboring cells (Figure 16). All three types of anchoring junctions consist of two main 
groups of proteins: the intracellular attachment proteins, which connect the junction 
complex to the cytoskeletal elements of the cell, and the transmembrane linker 
proteins, which on the one end interact with the intracellular attachment proteins and on 
the other end associate with the matrix or with transmembrane linker proteins of a 
neighboring cell.94
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Figure 16: Anchoring junctions connecting adjacent cells to each other and to the basal 
lamina.
Desmosomes:
Of all the vertebrate intercellular junctions, desmosomes are perhaps the most 
specialized, arising later in metazoan evolution than their relatives, the adherens 
junctions. 93 Historically, desmosomes isolated from cow nose epidermis were 
separated to reveal a large number of bands by SDS-polyacrylamide gel 
electrophoresis, which indicated a level of complexity comparable to that shown for 
plasma membranes.95 Although the analogy with the plasma membrane was short­
lived, desmosomes do in fact bring together members of at least three protein families: 
the armadillo, the plakin and the cadherin protein families.96
Desmosomes are readily identified in transmission electron micrographs of 
conventional thin sections by their characteristic ultrastructural appearance. They 
consist of two principal domains: the extracellular core domain (ECD), or desmoglea, 
and the intracellular plaque. The intracellular plaque is commonly described as 
consisting of two regions: the outer dense plaque (ODP), 15-20nm wide and separated 
by an electron-lucent zone from a slightly less dense inner plaque (IDP), into which the 
intermediate filaments are seen to insert. The region between the inner phase of the 
ODP and the IF domain has also been referred to as the satellite region. Differing 
values have been reported regarding the width of these domains. The orientation of IFs 
at desmosomes is also unclear, although in classical thin sections, IFs are reported to 
converge towards the plaque and then loop away from it (Figure 17).97
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Figure 17: Desmosome ultrastructure and molecular model. An electron micrograph 
(right) and a molecular model (left) showing the various regions of the junction including 
the inner dense plaque (IDP), the outer dense plaque (ODP), the plasma membrane 
(P) and the dense midline (DM).98
Our current understanding of desmosomal structure comes from in vitro cell-culture 
domain mapping and reconstitution studies. The model driving these studies was based 
on adherens junctions, where microfilaments are tethered to the plasma membrane 
through a tripartite complex: a classic cadherin, such as E-cadherin, N-cadherin and P- 
cadherin, is coupled directly through its cytoplasmic tail to armadillo proteins, namely 
plakoglobin and beta-catenin, which in turn are linked to a-catenin, which binds to actin. 
Consequently it was predicted that IFs are also tethered to the plasma membrane by a 
linear complex. Desmosomal cadherins, mainly desmocollins and desmogleins, 
associate with armadillo proteins, mainly plakoglobin and plakophilins, which in turn 
bind members of the plakin family, primarily desmoplakin that links the cytoskeletal 
elements to the junction complex (Figure 18). 93 In agreement with this linear model, it 
was suggested that the N-terminal halves of desmocollins and desmogleins constitute 
the desmoglea; their C-terminal halves are embedded in the ODP along with 
plakoglobin, plakophilins and the N-terminal domain of desmoplakin, while the C- 
terminal domain of desmoplakin extends within the IDP.99 Several studies have indeed 
provided data consistent with this model. However, more recent studies suggest a more 
complex molecular map than the linear chain originally predicted, where each protein 
has several points of contact for more binding partners than initially thought.93 
Moreover, apart from the major desmosomal protein components presented,
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additionalminor components such as IFAP 300, pinin, desmocalmin, plectin, envoplakin 
and periplakin may also contribute to the plaque structure.97
Figure 18: Molecular model of the desmosome. This simplified model shows 
representative protein-protein interactions in which principal desmosomal components 
participate.93
Despite their critical role in maintaining adhesion and integrity, desmosomes are not 
static units. Instead, they are dynamic units that allow for cell motility and membrane 
elasticity, by assembling and disassembling in response to outside-in signalling from 
the micro-environment.99 This intrinsic elasticity may explain the way in which 
desmosomal adhesion is maintained throughout the entire cell cycle and even during 
mitosis when complete restructuring of the cells is taking place.100 The desmosomal 
canvas becomes even more colourful as different types of IFs bind desmosomal 
plaques in different tissue types. In epithelial tissues, desmosomes anchor keratin 
filaments to the membrane. In the myocardial and Purkinje fibre cells of the heart, they 
anchor desmin filaments to the membrane, while in the meningeal cells and the 
follicular dendritic cells of the lymph nodes, they associate with vimentin IFs.93 In fact, 
the first experiments showing an interaction between desmoplakin and desmin in the 
heart were performed in 1983.101 Desmin filaments not only attach to the membrane 
plaques, but remain attached to desmoplakin even after endocytotic internalisation of 
desmosomal domains by treatment of the cells with ethylene glycol tetra-acetic acid 
(EGTA).101 Furthermore, different desmosomal plaque components are found in 
different tissues.102 For instance, intestinal epithelial cells contain both plakophilin2 and
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plakophilin-3, whereas hepatocytes express only plakophilin2, indicating that there 
probably are functional differences between desmosomes in different cell types. 
Desmosome composition and structure not only varies from cell type to cell type but 
also during the process of differentiation and stratification in complex epithelia. In the 
epidermis, desmogleinl and desmocollinl are concentrated in the highly differentiated 
upper layer of the skin, while desmoglein3 and desmocollin3 are prominent in the basal 
and suprabasal layers (Figure 19). The specific distribution pattern of desmosomal 
components is not merely a result of differentiation but may in fact drive tissue 
morphogenesis. Alternating the ratio of desmoglein3 to desmogleinl in the mouse 
suprabasal epidermis by forced expression of desmoglein3, resulted in the acquisition 
of mucous epithelial traits and led to peri-natal lethality due to severe trans-epidermal 
water loss.98 Similar studies suggest that desmosomes are much more than tethers for 
intermediate filaments and that they have a role in tissue morphogenesis, organization
98and homeostasis and intracellular signalling.
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Figure 19: This schematic of the epidermis shows that proteins are expressed in a 
differentiation-dependent manner. For example, in the case of desmosomal cadherins, 
desmogleinl and desmocollinl are patterned in a gradient, with the highest level in the 
superficial layers and tapering off in the basal layers. Desmoglein3 and desmocollin3 
show an opposite pattern. Likewise, the armadillo family member plakophilinl is 
concentrated in junctions of the superficial layers, whereas plakophilin2 is found in 
desmosomes deeper in the epidermis.
Desmosomes in cultured cells assemble in response to cell-cell contact and increased 
levels of intracellular calcium. Perturbing intracellular Ca+2 stores with the Ca+2-ATPase 
inhibitor thapsigargin interferes with intercellular junction assembly even when the cells 
are in contact.93 Recently, Darier’s and Hailey-Hailey disease have been shown to arise
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101from mutations in the calcium ATPases ATP2A2 and ATP2C1, respectively. These 
disorders were long hypothesized to arise from defects in desmosomes, based on the 
loss of desmosomal structures and adhesion observed in patients. The finding that 
mutations in these molecular pumps cause these diseases supports the importance of 
intracellular Ca+2 homeostasis for desmosomal adhesion.103 104 Desmosome assembly 
in response to Ca+2 is reversible during the early stages, but ultimately desmosomes 
mature and can no longer be dissociated and endocytosed due to Ca+2 depletion. They 
do however re-acquire their Ca+2 dependency at the free edge of wounded epithelial 
sheets, and this process has been shown to depend on activation of protein kinase C 
(PKC).93 Indeed, treatment with 12-O-tetradecanoy 1-13-acetate, which activates PKC, 
induces desmosomal formation even in cells grown in low Ca+2- containing medium." 
Interestingly, restoration of Ca+2 levels in Ca+2-starved cultures does not lead to re­
translocation of endocytosed assembled structures to the cell surface, supporting that 
desmosomes are assembled at the plasma membrane and not in the cytoplasm.100 This 
observation however does not exclude the possibility that assembly may rely on 
cytoplasmic pools of plaque components.100
More junction types:
Hemi-desmosomes contribute to tissue integrity by attaching cells to the basal lamina. 
Transmembrane glycoproteins, known as integrins, link extracellular matrix proteins 
such as collagen, laminins and fibronectin, to the cytoskeletal network through adaptor 
molecules such as plectin and BP230.105
Apart from the anchoring junctions, the other major intercellular junctions recognized in 
vertebrates are the tight and the gap junctions. Tight junctions are occluding junctions 
that play a critical role in maintaining the concentration differences of small molecules 
across epithelial cell sheets.106 In 1958, Sjostrand et al described an area of 
specialization of the cardiomyocyte adhering surface composed of "three dark lines 
with two intervening less dense lines” , which he referred to as the "longitudinal 
connexion” .107 Years later, Jean Paul Revel coined the term "gap junctions” thus 
emphasizing the two key features: a gap between the cells and yet a junction between 
them. Of the various ways that cells "talk" to one another, communications via gap 
junctions is certainly the most direct. Composed of arrays of densely packed channels 
that link the cytoplasmic compartments of neighbouring cells, gap junctions provide a 
direct route by which cells can exchange ions and small molecules. In the heart, gap 
junctions are responsible for inter-cellular transfer of current and thus control the 
precise spatio-temporal pattern of electrical activation to coordinate the contractile 
activities of individual cells and ensure effective pump function.108
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A gap junction is formed by multiple intercellular channels, each of them formed by two 
hemi-channels referred to as connexons, oligomeric transmembrane proteins built by 6 
subunits that belong to the connexin family (Figure 20). Permeability and electric 
conductivity of gap junction channels is determined by molecular peculiarities of 
connexins, their capacity for phosphorylation and by extra- and intracellular factors.109 
The modern era of cardiac connexin biology began in 1987 with the cloning of 
connexin43 (Cx43), the major cardiac gap junction protein. With the advent of genomic 
sequencing, we now know that the human genome contains 21 different connexin 
genes. It has also become clear that with few exceptions, individual cells express 
multiple connexins. At least five connexins (Cx43, Cx40, Cx45, Cx31.9 and Cx37) are 
expressed in the heart. Four of these connexins are expressed by cardiac myocytes, 
but different regions of the heart express different amounts and combinations of the 
cardiac connexins. For example, atrial myocytes express abundant amounts of Cx43 
and Cx40, but only a very limited amount of Cx45. In contrast, ventricular myocytes 
express large amounts of Cx43 but only trace levels of Cx45 and no Cx40.110
Cell-cell junction dependency and the concept of the intercalated disc:
The cardiac plasma membrane incorporates a specialized region termed the 
intercalated disc which coordinates and facilitates intercellular adhesion and 
communication by bringing together adherens, desmosomal and gap junctions.111 
Adherens junctions arose first in evolution and also assemble first both during 
development and in individual cells that are stimulated to make junctions. When 
adherens junction formation is blocked through inhibitory antibodies, dominant-negative 
constructs or as a result of naturally-occurring mutations, desmosome assembly is 
inhibited or delayed. Adherens junction assembly is an active process that requires the 
engagement of N-cadherin and the active participation of the actin cytoskeleton. It has 
been proposed that desmosomes form passively, assembling in the gaps between 
adherens junctions.93 The purpose of adherens junctions then could be to bring the 
membranes into close proximity, thereby allowing desmosomal molecules to engage 
and cluster. 93 In agreement with this hypothesis, cells that express desmosomal 
protein components but lack a classic cadherin or a-catenin are unable to assemble
go
desmosomes. However, activation of PKC appears to by-pass the requirement for 
adherens junction components in certain cell lines, resulting in the induction of 
desmosome formation, indicating that adherens junctions may also provide important 
chemical signals for the assembly of desmosomes.98
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Figure 20: Gap junctions viewed by transmission electron microscopy: (A) by freeze- 
fracture to split membranes and (B) in ultra-thin sections. (C) A model of gap junction 
communication. 112
Additionally, experiments on adult rat cardiomyocytes have shown that the formation of 
adhering junctions is a pre-requisite for the assembly of gap junctions in the cardiac 
intercalated disc.113 This implies that during the establishment of cell-cell contacts, 
transmembrane cadherins form a zipper-like structure, coupled to a cytoplasmic protein 
plaque, thus strengthening the cell-cell contact and providing enough close membrane 
apposition to allow the assembly of connexins into gap junctions. This hypothesis is in 
good agreement with the observations that antibodies against classical cadherins, 
transfection of cells with cDNA encoding cell adhesion molecules and calcium 
depletion, which collectively inhibit cell-cell contact, significantly perturb the formation of 
communicating junctions.113,114 In contrast, loss of electrical junctions has no effect on 
the establishment of mechanical junctions between cardiac myocytes.115
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6) Major desmosomal components:
a) Desmosomal cadherins:
The family of the transmembrane desmosomal cadherins includes the desmocollins 
(Dscs) and the desmogleins (Dsgs). The genes coding for the members of this cadherin 
sub-family are clustered in chromosomal region 18q12.1 with the three desmocollin 
genes arranged in a head-to-tail orientation in opposite direction to the four head-to-tail 
oriented desmoglein genes. The order in which the genes are found in the cluster 
mirrors the spatial order in which the equivalent genes are expressed in the developing 
mouse embryo.116 The close proximity of these genes in both the human and mouse 
genome may be indicative of the presence of a shared regulatory region, perhaps in the 
form of a locus control region (LCR).117 Also, the fact that desmocollins show a higher 
sequence similarity to classical cadherins than to desmogleins may be mirroring the 
series of evolutionary events leading to the different cadherin sub-classes through gene 
duplication and mutation events.118 Each isoform has characteristic expression patterns 
with the type 2 isoforms showing the widest tissue distribution in epithelia and also in 
desmosome-bearing non-epithelial tissues, being for example the only isoforms 
expressed in the heart. In contrast, type 1 and 3 isoforms are detected only in certain 
stratified epithelia, with desmocollin 1 being especially restricted to the epidermis116 and 
desmoglein 4 being mostly abundant in the testes, the prostate gland and the salivary 
gland.119
At the amino acid level, the Dsc and Dsg isoforms within a single species exhibit 51-
55% sequence identity and the specific isoforms between mammalian species are
120identical in the range of 73-83%. The desmosomal cadherin extracellular domains 
are composed of four extracellular cadherin repeats (ECR) of about 110 amino acids in 
length and a membrane proximal extracellular domain, often named the extracellular 
anchor domain (EA). A major difference between Dscs and Dsgs resides in their 
cytoplasmic domains. Both reveal a membrane proximal intracellular anchor domain 
(IA) and an intracellular cadherin segment (ICS), which provides the binding site for 
plakoglobin. Specific for Dsgs is an extended intracellular domain containing a proline- 
rich region (IPL) followed by a repeated unit domain of 29 amino acid repeats (RUD) 
and a glycine-rich C-terminal desmoglein terminal domain (DTD).120 Desmocollin 
isoforms differ additionally from desmoglein isoforms in that they can be alternatively 
spliced. When exon 16 is incorporated in the transcript, it contains a stop codon, which 
signals termination of translation, giving rise to isoforms “ b” . When exon 16 is excluded 
from the transcript though, termination of translation occurs within exon 17, giving rise 
to the longer isoforms "a” . The C-terminus of the "b” splice variants lacks the ICS
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domain and thus is unable to bind plakoglobin and assemble into desmosomal 
complexes (Figure 21).121
Figure 21: Schematic representation of desmosomal cadherin structure.93
Like classical cadherins, desmosomal cadherin interactions are calcium-dependent. 
However, unlike classical cadherins, in order for desmocollins and desmogleins from 
opposing cells to confer strong adhesion, they must form heterodimers,122 with the first 
two ECRs of desmocollin isoforms and the first three ECRs of desmoglein isoforms 
being crucial for this interaction.123 Surface force measurements and bead aggregation 
assays though have suggested that extensive inter-digitation of cadherin molecules, 
rather than interactions at their tips, may be required for strong adhesion.124 X-ray 
structures of cadherin molecules have shown that all ECR domains adopt a 0-sandwich 
form with calcium ions bound to the loops joining individual domains.124 Furthermore, 
electron tomography examination of individual desmosomes has drawn attention to the 
importance of a Trp residue at the N-terminal domain of cadherins, which upon 
insertion into a pocket formed by 3 hydrophobic residues, highly conserved amongst all 
family members, confers both cis-adhesive and trans-intercellular bonding.124 
Numerous cis-interacting molecules propagating along the length of a junction indicate 
that full adhesion may in fact result from the sum of a large number of diverse, weaker 
interactions, and that even intracellular domains may be responsible for holding the 
groups together laterally (Figure 22).124 The calcium-dependency of these interactions 
has been shown by experiments where increasing concentrations of EGTA significantly 
reduce the number of desmocollin-desmoglein complexes.123 In 2001, Ishii et al 
provided evidence that desmosome assembly can tolerate large shifts in cadherin
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stoichiometry but is very sensitive to isoform-specific differences exhibited by 
desmocollins and desmogleins. 125
Figure 22: Schematic representations of cis- and trans-interactions between 
desmosomal cadherins conferring cell-cell adhesion.124
Certain members of the desmosomal cadherin family have been implicated in a number 
of acquired and inherited skin diseases.126 Pemphigus foliaceous, fogo selvagem and 
pemphigus vulgaris are autoimmune diseases characterized by blisters and erosions of 
the skin with additional mucose membranes in pemphigus vulgaris. The auto-antigens 
recognized by the antibodies are specific to Dsg1 in pemphigus foliaceous and fogo 
selvagem and to Dsg3 in pemphigus vulgaris. The antibodies target the ECRs of 
desmogleins, especially ECR3, disrupting their association with desmosomal cadherins 
in adjacent keratinocytes.127,128,129 Staphylococcal scalded skin syndrome affects 
primarily infants and young children and is characterized by fever, skin tenderness and 
erythrema leading to loss of large skin areas due to epidermal separation days or even 
hours after the onset of the disease. This reaction is induced by three exfoliative toxins,
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1 2 7secreted by Staphylococcus aureus: ETA, ETB and ETS. The toxins target and 
cleave the glutamic acid residue at position 381 of Dsg1, causing disruption of 
adhesion between adjacent keratinocytes and thus allowing bacteria to enter and
127flourish within the skin. Dominant mutations in the Dsg1 gene result in a completely 
different phenotype; striate palmoplantar keratoderma.130 Mutations in the mouse Dsg3 
gene lead to the so-called "balding phenotype” characterized by hair-loss, skin fragility 
and oral lesions.131 Histological and ultra-structural examination of skin samples has 
shown widening of intercellular spaces, dramatic reduction in desmosomal number as 
well as changes in desmosomal size and structure.131 Furthermore, desmosomal 
cadherins have been implicated in tumorigenesis, since loss of heterozygosity in the 
18q12 locus has been observed in cases of human squamous cell carcinomas.126 
Finally, localized autosomal recessive hypotrichosis is a disorder characterized by 
hypotrichosis of the scalp, chest, arms and legs, less dense facial hair and the 
presence of ingrown hair in patches of the scalp. Deletions in the Dsg4 gene were 
found in two families presented with this disorder.132
When keratinocytes are exposed to pemphigus vulgaris serum, there is a transient and
rapid increase of intracellular Ca+2 concentration and inositol triphosphate and a
1 ^consequent activation of protein kinase C, which subsequently activates p38MAPK. 
Interestingly, inhibition of phosphorylation of p38MAPK inhibits the cytoskeletal re­
organization that takes place in the frame of pemphigus and also inhibits blister 
formation in animal models.133 Furthermore, the balding mouse shows alterations in 
integrin expression, keratinocyte proliferation rates as well as inflammatory 
responses.131 Finally, when Dsc3 is mis-expressed in spinous keratinocytes, there are 
defects in differentiation including hyper-proliferation, abnormal keratinization as well as 
increased beta-catenin stability and enhanced signaling.133 Collectively, these 
observations suggest that the phenotypes described are not merely a result of defects 
in cell-cell adhesion, indicating a role of desmosomal cadherins in signaling cascades. 
Indeed, apart from their role as biological glues, desmosomal cadherins are now 
recognized to have a role in apoptosis, metastasis, cell-sorting, cell-positioning, 
morphogenesis and maintenance of ordered structures. 134135
b) The armadillo family of proteins: plakoqlobin
Plakoglobin (PG), also known as y-catenin is a major cytoplasmic protein that occurs 
both in a soluble and a membrane-associated form and is the only known constituent 
common to the sub-membranous plaques of both kinds of adhering junctions: the 
desmosomes and the adherens junctions.136 PG is a representative of a large multi­
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gene family of proteins defined by the occurrence of a variable number of “arm- 
repeats” , so-called after the protein encoded by the armadillo segment polarity gene of 
Drosophila melanogaster. 137 Like its homologs, p-catenin and armadillo, plakoglobin 
has a tri-partite structure composed of an N-terminal, a central and a C-terminal 
domain. In their mostly highly conserved central region, all three proteins are composed 
of a series of 13 imperfect 42-amino acid arm-repeats (Figure 23). X-ray 
crystallography of the p-catenin central region gave important insights into the structural 
features of this domain.120 A typical arm repeat consists of three a-helices which form a 
right-handed super-helix. The super-helical structure of the complete arm repeat region 
forms a long positively charged groove, representing the binding site for multiple 
ligands, including cadherins. Although the structure of the PG central domain has not 
yet been resolved, the high homology to p-catenin suggests that it forms a similar 
shallow basic groove. 120
Mapped to the chromosomal region 17q12-q22, the plakoglobin gene consists of 15 
exons, only 14 of which are translated and code for a 744 amino-acid protein. The 5’ 
portion of the gene is rich in GC- dinucleotides and PG expression is decreased upon 
hyper-methylation of this region suggesting that expression of the gene varies 
depending on post-translational modifications.138
Figure 23: Schematic representation of the plakoglobin protein structure.93
When the plakoglobin gene is ablated in mice, animals die between days 12 and 16 of 
embryogenesis owing to defects in heart function.139 Often, their ventricles burst, and 
pericardial tamponade appears to be the immediate cause of death. This tissue 
instability correlates with the absence of desmosomes and a redistribution of 
desmosomal proteins in the heart. In particular, typical desmosomes cannot be 
detected, and instead long mixed-types of junctions are observed, indicating that PG 
plays a crucial role in the architecture and stabilization of heart tissue as well as in the 
sorting of anchoring junction types. 139 Work performed on heart fibers obtained from 
PG-deficient embryonic mice suggests that PG is important for cardiac compliance but 
not necessary for the attachment of the myofibrillar apparatus to membrane 
junctions.140 Apart from its association with Naxos disease, PG has also been 
implicated in the autoimmune disease pemphigus vulgaris. Binding of pemphigus auto­
antibodies to Dsg3 causes phosphorylation of a serine residue on the cadherin
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molecule resulting in the dissociation of PG from the junctional complexes.141 Absence 
of PG from desmosomes leads to rapid depletion of Dsg3 from the membrane and 
hence the disease phenotype.141 In PG-null cell lines, incubation with pemphigus 
antibodies does not lead to depletion of cadherin molecules thus sparing the major 
cytoskeletal re-organization characterizing the disease.141
In Xenopus, plakoglobin is shown to play a critical role in the assembly, organization 
and maintenance of the cortical actin cytoskeleton,142 while over-expression of PG in 
embryos leads to neural axis duplication,143,144 indicating the currently widely 
recognized role of the armadillo protein in signaling pathways. In agreement with this 
belief, PG is recognized to have a role in cancer. Loss of heterozygosity in the PG gene 
has been observed in breast and ovarian tumors,145,146 a missense mutation leading to 
a substitution of a serine by a leucine residue at the N-terminal part of the protein has 
been found to underlie cases of gastric and pancreatic cancers,147 while PG expression 
is reduced or absent in a subset of human non-small cell lung carcinomas, indicating 
the putative tumor-suppressive role of the armadillo protein.148 Further reports indicate 
that proteolysis and altered localization of y-catenin are early markers for the response 
of cells to cisplatin, one of the most widely used anti-cancer chemo-therapeutic agents, 
and that reduced levels of y-catenin in resistant cells may indicate an important role of 
Y-catenin in mediating or modulating the toxicity of cisplatin in cancer cells.149,150 In 
contrast with these lines of evidence, histone deacetylase suppresses the expression of 
PG in human fibrosarcoma HT1080 cells, indicating a role of PG as an oncogene.151 
Collectively, these observations suggest that PG may have either a tumorigenic or a 
tumor-suppressing activity depending on the cell type and on its ability to activate 
downstream signaling pathways.
Plakophilins:
P ^O 01" is the prototypic member of the p120ctn subfamily of armadillo-related 
proteins.152 Members of the p ^O 01" family share a characteristic organization of their 
arm repeat domain, which suggests an ancient evolutionary relationship. There are two 
groups that differ in the degree of sequence similarity and intracellular localization. The 
first group includes the prototype WO** itself, ARVCF, 5-catenin/NPRAP and 
p0071/plakophilin4. These proteins share between 65 and 81.5% sequence similarity 
with each other in their arm domains and co-localize with classical cadherins at 
adherens junctions.152 The second group includes plakophilins 1, 2 and 3 (PKPs). 
These proteins share between 51 and 60.9% sequence similarity with each other in 
their arm domains and around 50% sequence similarity with the p120ctn arm domain.152 
So far, no binding partner has been identified that interacts with members of both 
groups supporting the view of distinct molecular functions. Although the sequences of
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all p^O^-related proteins are highly related, the corresponding genes are dispersed 
throughout the human genome, excluding the possibility of coordinated expression 
regulation as suggested for Dscs and Dsgs.152 The PKP1 gene is located at 1q32, the 
PKP2 gene at 12p13, the PKP3 gene at 11 p15 and the PKP4 gene at 2q24.152
Plakophilins are composed of an N-terminal head domain and a C-terminal domain
120containing 10 arm repeats separated by 3 conserved short insertions (Figure 24). 
PKP1 localizes at the desmosomes of stratified epithelia, simple epithelia, urothelium 
and certain complex epithelia.137 It is transcribed into two different mRNAs, one of 2.6kb 
and one of 5.3kb, the difference arising from alternative poly-adenylation of the 3’ end 
of the mRNA transcript. PKP1 has two splice variants; the most common short variant, 
PKP1a, and the rarer longer PKP1b variant, which has a 21-amino acid insert at exon 
7. The shorter isoform is found in all tissue types that form desmosomes, where it 
localizes both at the cell membrane and at the nucleus, while the longer isoform is 
confined to the nucleus.137 Similarly to PKP1, PKP2 has two splice variants, the shorter 
one lacking a 44-amino acid motif between the second and third armadillo repeat. 
PKP2 is found in the desmosomes of most tissues, including simple one-layered 
epithelia and non-epithelial tissues such as the myocardium, the Purkinje fibers of the 
heart and the dendritic cells of the lymphatic nodes. 153 As is the case in PKP1, the 
shorter PKP2 isoform is found both at the membrane and in the nucleus, while the 
longer isoform shows a strict nuclear localization. PKP1 and PKP2 have been shown to 
have overlapping but distinct properties, indicating that they may be involved in the 
formation of functionally different desmosomes, tailored for the needs of different 
tissues or of different developmental stages.154 PKP3 is found in all layers of stratified 
epithelia, in almost all simple epithelia apart from hepatocytes and in some non- 
epithelial tissues such as the dendritic cells of the lymph nodes. Finally, in mouse 
tissues, PKP4 is found in various epithelia, including the skin, the intestine and the liver 
and in non-epithelial tissues such as the heart and the brain.155
93Figure 24: Schematic representation of the plakophilin protein structure.
In 1997, McGrath et al first described the complete ablation of PKP1 in patients with a 
novel, autosomal recessive disorder that was termed skin-fragility ectodermal-dysplasia 
syndrome.156 In early life, affected individuals exhibit skin fragility with trauma-induced
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erosions and blistering, especially around the mouth and on the palms and soles. 
During childhood, hyperkeratosis of palmoplantar skin develops and there are plaques 
of crust-scale on the limbs and trunk. Scalp hair fails to develop normally and most 
patients show total or near-total alopecia. Histologically, there seems to be a "pinching 
o ff ’ of desmosomes with the plane of cleavage occurring immediately on the 
cytoplasmic side of the desmosomes. However, the presence of mostly intact, if
somewhat fragile, epidermis indicates that PKP1 is only an accessory desmosomal
1 ^ 2component.
It was recently shown that PKP2 is able to associate with p-catenin, and that over­
expression of PKP2 up-regulates the activity of the endogenous T cell factor (TCF)/p- 
catenin transcription complex, indicating that PKP2 may in fact act as a transducer of 
signals between the cell surface and the nucleus. 154 Additionally, Mertens et al first 
showed that nuclear PKP2 associates with components of the RNA polymerase III 
holo-enzyme. 157 So far, the functional role of PKP2 in this complex remains elusive, 
although it is tempting to speculate that PKP2 might coordinate intercellular adhesion 
and growth control.152 Recently, several RNA-binding proteins including poly A binding 
protein, fragile-X related protein and ras-GAP-SH3-binding protein were shown to 
partially co-distribute with PKP3 after sucrose gradient centrifugation. When cells are 
exposed to environmental stress, these proteins are found together with PKP3 in stress 
granules, cytoplasmic aggregates in which mRNAs accumulate in a stable, but 
translationally silenced state. Thus, PKP3 might have a function in post-transcriptional 
gene regulation through an interaction with RNA-binding proteins rather than a direct 
role in regulating gene transcription.152 Hatzfeld et al had previously reported that 
although the head domain of PKP1 could play a role in organizing the desmosomal 
plaque, the armadillo repeat domain might be involved in regulating the dynamics of 
actin cytoskeleton.158 Finally, like the other major desmosomal components described 
above, plakophilins seem to have a role in cancer. PKP1 mRNA expression was 
significantly elevated in head and neck squamous cell carcinoma, while PKP3 can 
function as an oncogene and may serve as a prognostic marker and therapeutic target 
for lung cancer.152 Regulatory mechanisms that shift the balance between cell contact
association and nuclear or cytoplasmic functions might contribute to a role in
1 ^ 2tumorigenesis.
c) The plakin protein family
The plakin proteins represent a family of very large cytolinker proteins that have 
multiple functions in the cross-talk of cytoskeletal networks by cross-linking actin
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microfilaments, microtubules and intermediate filaments to each other. They are also 
central components participating in the connection of different anchoring junctions with 
the cytoskeleton. Currently, seven plakin family members have been recognized: 
desmoplakin, plectin, envoplakin, periplakin, epiplakin, bullous pemphigoid antigen I 
and MACF1.120 Ancestral members of this gene family are similar to the Drosophila 
melanogaster protein shot, which contains both actin and microtubule-binding domains 
and has an essential role in a variety of morphogenetic processes. 159 Although several 
plakin family members bind IFs and localize to desmosomes, genetic studies indicate 
that only desmoplakin is indispensable for these intercellular junctions.159
Desmoplakin:
Desmoplakin (DP) consists of an N-terminal domain essential for targeting the molecule 
to the membrane, a central coiled-coil rod domain involved in dimerization and a 
globular C-terminal domain, which anchors the intermediate filaments to the junctional 
plaque. Within the N-terminal domain, two major heptad-containing regions, predicted 
to be largely a-helical have been designated as V and Y while three minor regions have 
been designated as W, X and Z. The N-terminal heptad set is interrupted by short non- 
heptad sequences, which allow folding of the a-helical stretches onto each other. 160 
The carboxy-terminal domain is composed of three plakin repeat domains (PRDs) 
named A, B and C, separated by a linker domain between repeat B and C. (Figure 25). 
Each repeat is composed of 4.5 copies of a 38-amino acid motif and forms a globular 
structure with a unique fold containing a conserved basic groove that may represent an 
IF binding site. Each PRD alone is able to bind vimentin filaments with relatively low 
affinity, while all three PRDs bind more strongly, consistent with the view that a 
sufficient number of weak but simultaneous interactions are required to confer stable 
adhesion. 120 Alternative splicing of the DP precursor mRNA generates two isoforms 
that differ in size (2871 residues in DPI versus 2232 residues in DPI I) and cell type 
distribution. DPI and DPII have identical N- and C- termini but their central a-helical 
domains are of different lengths. DP binds all desmin, vimentin and keratin IFs; 
however these interactions involve distinct regions within each protein partner. 
Moreover, electrostatic interactions and post-translational modifications seem to 
influence IF binding. For instance, phosphorylation of a specific serine residue within 
the C-terminal DP domain has been shown to modulate binding to IFs. 161
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Figure 25: Schematic representation of the desmoplakin molecule structure.93
The first mutations to be described in DP were an heterozygous nonsense mutation 
(Q331X) and a donor splice site mutation (939+1G -> A), in families with autosomal 
dominant striate PPK.162,163 Following the description of the Carvajal syndrome, another 
recessive DP genodermatosis was reported.164 The phenotype consisted of wooly hair, 
dystrophic nails and keratoderma without an associated cardiomyopathy and was thus 
termed skin fragility/wooly hair syndrome. Two unrelated cases were found to be 
compound heterozygotes for different combinations of nonsense/missense mutations 
(C809X/N287K and Q664X/R2366C).164 Interestingly, individuals who were 
heterozygous carriers of the respective nonsense mutations were phenotypically 
normal. 164 Apart from inherited abnormalities in the DP gene, the DP protein may also 
be targeted in a number of autoimmune diseases.165 Notably, antibodies to DP have 
been found in paraneoplastic pemphigus. There are also reports demonstrating the 
presence of anti-DP antibodies in pemphigus foliaceous, erythrema multiforme, bullous 
pemphigoid and mucosal dominant pemphigus vulgaris, although the significance of 
these auto-antibodies in the development of blisters remains unclear.165 
DP-null mouse embryos proceed through implantation but do not survive beyond E6.5 
owing to a loss or instability of desmosomes and tissue integrity.166 When the DP 
function in the extra-embryonic ectoderm is rescued, these animals survive several 
days longer but die shortly after gastrulation with major defects in the heart muscle, 
neuroepithelium, skin epithelium and microvasculature.167 Interestingly, endothelial cells 
of capillaries do not form desmosomes; however they possess unusual intercellular 
junctions composed of DP, PG and VE-cadherin.167 DP-null keratinocytes isolated from 
an epidermis-specific DP mouse knockout, have few desmosomes and are unable to 
undergo actin re-organization and membrane sealing during epithelial sheet formation. 
168 Moreover, knockdown of DP by siRNA in cultured endothelial cells prevents the 
formation of microvascular tubes.169 Finally, loss of DP may be of potential importance 
in the progression of breast cancer and metastasis.170 Collectively, these observations 
suggest that DP is much more than a molecular bridge that links the cell membrane to 
the cytoskeleton.171
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There is more to plakins than desmoplakin:
Plectin is a high-molecular mass protein of approximately 500kDa that is associated 
with filamentous actin, microtubules and IFs.172 Its structure resembles that of DP 
except that its plakin domain is preceded by an N-terminal actin-binding domain. 
Furthermore, plectin harbors 6 PRDs, denoted B1-5 and C. It is expressed in a variety 
of tissues, including the skin and striated muscle, where apart from its role as a 
cytolinker, it regulates actin and IF dynamics.172 A role of plectin in controlling important 
signaling pathways is now beginning to be explored. For instance, it has been shown 
that the kinase activity of Erk1/2, c-Src, and PKC6 is up-regulated in plectin-deficient 
keratinocytes. Furthermore, plectin interacts with the non-receptor tyrosine kinase Fer 
and the regulatory y1 subunit of AMP-activated protein kinase. 172 Mutations in the 
plectin gene have been implicated in epidermolysis bullosa, a heterogeneous group of 
genodermatoses characterized by fragility and blistering of the skin which is often 
associated with extra-cutaneous manifestations, such as muscular dystrophy and 
pyloric atresia. 173 ,174 Periplakin (190kDa) and envoplakin (210kDa) are closely related 
plakins that act as scaffolds for the formation of the cornified envelope and are also 
localized to desmosomes in differentiated keratinocytes. Since envoplakin does not 
contain a PRD, its association with IFs is likely to be indirect, possibly through the 
protein kazrin (Figure 26).172 Envoplakin and periplakin are believed to be involved in 
desmosomal formation; however their role must be dispensable, since deletion of these 
genes has only minor effects on intercellular adhesion.159
Figure 26: Schematic representation of the plectin, envoplakin and periplakin protein
0* 1
structure.
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d) Intermediate filaments; the largest family in the cvtoskeleton:
Intermediate filaments (IFs) are named such because their 7-1 Onm diameter is 
intermediate between that of actin (6nm) and tubulin (23nm).175 More than 50 IFs are 
recognized to date and based on their gene structure, sequence homology, and 
immunological and/or assembly properties can be divided into six categories. With the 
clear exception of type V, the lamins, all form IF arrays. Types I and II include the 
epithelial IF proteins called keratins. Type III includes vimentin, expressed in cells of 
mesenchymal origin, desmin which is characteristic of muscle cells, GFAP, found in 
glial cells, and peripherin, which localizes at the peripheral nervous system. Type IV IF 
proteins are found in neurons and include the neurofilament proteins NF-L, NF-M and 
NF-H and a-internexin. The VI class may include depending on different group criteria, 
nestin, synemin, paranemin and tanabin.176
A basic molecular structure is common to all intermediate filaments.177 A central a- 
helical rod domain is responsible for dimerization and higher order polymerization. This 
domain exists in four segments (1A, 1A, 2A and 2B) interrupted by three non-helical
linkers (L1, L12 and L2) and a helix polarity reversal known as the stutter sequence,
usually indicated as S. The rod domain is flanked by the more variable globular head 
and tail domains (V1, V2). The sequence prior to 1A, denoted helix initiation peptide 
(HIP/H1), and immediately after 2B, denoted helix termination peptide (HTP/H2), show 
a remarkable degree of evolutionary conservation (Figure 27).177 All IF proteins share 
common structural features enabling them to self-assemble into 10nm filaments in vitro 
in the absence of auxiliary proteins or factors.177 IFs are made of ~4.5nm protofibrils, 
which in turn are made of smaller protofilaments. Protofilaments contain linear arrays of 
IF dimers arranged in head-to-tail fashion. Most IF types are able to form homodimers. 
Keratins are unusual in that they form obligatory heterodimers of a type I and a type II 
subunit.177 These keratin pairs show great tissue specificity. For instance the type I K14 
and the type II K5 are the primary keratins of basal cells in stratifying squamous
epithelia, while in more suprabasal layers they are gradually replaced by K1/K10
heterodimers.175
Figure 27: Schematic diagram of basic intermediate filament structure.
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1 7 9Keratins have been implicated in a number of human diseases. Point mutations in 
the K14 and K5 genes were found to underlie epidermolysis bullosa simplex, while 
mutations in K1 and K10 have been associated with epidermolytic hyperkeratosis. 
Moreover, mutations in the K9 gene form the basis for many epidermolytic PPK 
cases.179 It is interesting how some of these human skin disorders are also caused by 
mutations in major desmosomal genes, indicating disorder genetic heterogeneity and 
highlighting the pivotal role of IF proteins in maintaining tissue integrity. Mutations in 
type IV IF proteins underlie a collection of motor neuron diseases, including familial and 
sporadic amyotrophic lateral sclerosis, infantile spinal muscular atrophy and hereditary
179sensory motor neuropathy.
Desmin-related myopathy was originally described as skeletal and cardiac myopathy, 
morphologically characterized by abnormal accumulation of desmin within muscle 
fibers. This definition focused attention on desmin as a key molecule associated with a 
diverse group of clinically and pathologically related entities.180 Molecular studies of 
these disorders demonstrated that some are truly caused by mutations in desmin, while 
another form is associated with mutations in aB-crystallin, a chaperone that stabilizes 
desmin molecules by preventing their aggregation.181 Desminopathy may manifest as a 
relentlessly progressive skeletal myopathy with no signs of cardiac involvement. In
other cases cardiomyopathy is the leading or even the exclusive feature, while
180respiratory insufficiency may also be a major manifestation and the cause of death. 
Desmin-null mice develop and reproduce, indicating that desmin is not essential for 
myogenic commitment or for myoblast fusion and differentiation, but they show a 
number of abnormalities including heart fibrosis, ischemia and disorganized, distended 
and non-aligned skeletal and smooth muscle fibers.182 As with all adhesion molecules, 
the function of IF proteins has long been thought to be merely structural. However, this 
single function does not explain their diverse tissue and differentiation-specific 
expression patterns and cannot explain all phenotypic abnormalities in IF-related 
human disease. Evidence is now emerging that IFs also act as an important framework 
for the modulation and control of essential cell processes, in particular signal 
transduction events.176 Upon extracellular stimuli, signaling intermediates, in particular 
protein kinases and phosphatases are activated. These active molecules may interact 
with the IF cytoskeleton leading to different architectural alterations such as collapse, 
re-organization or altered solubilization of IF sub-units.176 Alternatively, in some cases, 
the presence of specific subunits in the IF cytoskeleton may serve as an anchoring site 
for these signaling intermediates, precluding their transduction to other cellular 
compartments. 176
59
HYPOTHESIS:
We propose that ARVC is a highly clinically and genetically heterogeneous disease 
caused by defects in cell-cell adhesion and disruption of signaling pathway cascades. 
Three lines of evidence indicate that ARVC is a disease of the desmosome: the 
identification of ARVC-related mutations in junctional components, the involvement of 
desmosomes in other forms of human disease and the phenotypic and histological 
abnormalities exhibited by knockout mice. Weakened cell-cell adhesion reduces the 
ability of cells to withstand physical stress, and as a result they dissociate from the 
beating myocardium and undergo programmed cell death. As the regenerative 
properties of the adult heart are limited, dying cells are replaced by fat and fibrous 
tissue, thus providing the substrate for the generation of fatal arrhythmias and the 
development of heart failure characterizing the disease. This hypothesis provides a 
potential explanation for the high prevalence of the disorder in athletes, the frequent 
occurrence of ventricular tachyarrhythmias and sudden cardiac death during exercise 
and the rare manifestation of the disease in infancy, as at this stage of development the 
heart is still capable of regeneration.
However, the involvement of all proteins implicated in ARVC pathogenesis in signaling 
processes and the spectrum of abnormalities exhibited both by humans and mouse 
models, cannot merely be explained by mechanical defects. Disruption of signaling 
pathways could provide a potential explanation for the predominant involvement of the 
right ventricle, the strikingly different phenotypes that may arise from similar genetic 
alterations, and the risk of fatal arrhythmias in the early stages of the disease when no 
structural or microscopic abnormalities are yet manifested. In conclusion we suggest 
that there is more to ARVC than adhesion. Defects in structural bonds are only part of 
the story, the rest of which includes multiple pathways and molecules, which have only 
recently started to be explored.
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CHAPTER 1:
“Genetic studies of familial ARVC: 
identification of novel causative mutations
and genes”
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CLINICAL EVALUATION AND GENETIC SCREENING:
A weekly ARVC clinic, headed by W. J. McKenna, is currently operating at the Heart 
Hospital. All probands that fulfill ARVC diagnostic criteria undergo assessment at the 
time of diagnosis, and relatives are invited for clinical evaluation. The clinical 
assessment includes:
• RV and LV morphology and systolic function: 2D echo Doppler/tissue Doppler
• Diastolic function: Doppler tissue imaging, mitral & pulmonary venous flow
• Exercise capacity: symptom limited bicycle exercise with metabolic gas 
exchange measurements
• Electrocardiography: 12 lead, signal-averaged, exercise and 24h Holter
• CMR of selected patients
Thus far, approximately 220 probands and >600 relatives have been evaluated 
clinically. Following clinical evaluation, blood was obtained from each proband or family 
member, so that DNA could be used for mutation analysis. Following the same 
procedure, 70 probands were evaluated in Muenster, Germany and another 30 
probands were evaluated in Greece and Cyprus, and DNA samples sent to our 
laboratory for genetic screening.
All probands were screened for mutations in the known ARVC-causing genes: 
desmoplakin I, plakophilin2a and plakoglobin and in the additional candidate genes: 
desmocollin2a, desmoglein2 and desmin. These specific isoforms were selected for 
screening as they constitute the major cardiac desmosomal components. Sequencing 
primers were designed and conditions were optimized for the amplification of each 
exon (Appendix: 1). Two hundred ethnically-matched non-ARVC control individuals 
were screened using the same methods to ensure that the newly identified mutations 
were indeed pathogenic. Whenever possible, relatives were screened and pedigrees 
were constructed.
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METHODS:
1) DNA extraction from blood/body fluid and paraffin-embedded tissue blocks:
DNA extraction was performed using a QIAampmini Kit (QIAGEN) according to the 
instructions of the handbook. Briefly:
Blood/plasma:
Samples were equilibrated to room temperature. QIAGEN protease was added to 1.5ml 
micro-centrifuge tubes. Sample (200pl) followed by AL lysis buffer was added to each 
micro-centrifuge tube and mixed by pulse vortexing. Samples were then incubated at 
56°C for 10min. Following incubation, the micro-centrifuge tubes were briefly 
centrifuged; ethanol was added and mixed by pulse vortexing.
Paraffin-embedded tissue:
Tissue (25 mg) was cut in small pieces and placed in 1.5ml micro-centrifuge tubes. ATL 
tissue lysis buffer was added to each tube followed by proteinase K and mixed by pulse 
vortexing. The samples were then incubated at 56°C for 1-4 hrs and occasionally mixed 
by vortexing until lysis was complete. Following incubation the samples were briefly 
centrifuged, AL lysis buffer was added and mixed by pulse vortexing. The samples 
were then incubated at 70°C for 10min. Following incubation the samples were briefly 
centrifuged, ethanol was added and mixed by pulse vortexing.
Blood, plasma and tissue:
The mixture was applied on Spin columns assembled to 2ml collection tubes and the 
tubes were centrifuged at 8000rpm for 1min. The filtrate was discarded, the Spin 
column was assembled to a new collection tube and AW1 wash buffer was added 
followed by centrifugation at 8000rpm for 1min. The filtrate was discarded, the Spin 
column was assembled to a new collection tube and AW2 wash buffer was added 
followed by centrifugation at 13200rpm for 3min. The collection tube was discarded, the 
Spin column was placed in a 1.5 ml micro-centrifuge tube and distilled water was 
added. The samples were equilibrated to room temperature for 1min and then were 
centrifuged at 8000rpm for 1min. This technique is predicted to yield 6pg of DNA in 
200|il of distilled water (30ng/pl).
2) Polymerase chain reaction (PCR):
AmpliTaq Gold polymerase was used for fragments shorter than 400 base pairs. For 
each PCR reaction the following were added:
2.5|il of 10xPCR buffer containing 1.5mM MgCI2 (Applied Biosystems)
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1 pi of dNTP mix, 2.5mM each of dATP, dGTP, dCTP and dTTP (Invitrogen)
1 (j.l of 25mM MgCI2 (Roche)
10 pmoles of forward primer (Invitrogen)
10 pmoles of reverse primer (Invitrogen)
0.1 pi of Ampli Taq Gold polymerase enzyme,5 units/pl (Applied Biosystems) 
75 ng of DNA template. Distilled water was added to a total volume of 26.5 pi 
PCR reactions were performed under the following program:
96°C for 10min
96°C for 30 sec
45 - 68°C for 30 sec 35-40 cycles 
72°C for 1min
72°C for 7min
4°C oo
GC-rich PCR system was used for fragments with a high content in G and C bases. 
For each PCR reaction the following were added:
5pl of GC-rich 10x PCR reaction buffer with dimethyl sulfoxide (DMSO, Roche)
1 pi of dNTP mix, 2.5mM each of dATP, dGTP, dCTP and dTTP (Invitrogen)
10 pmoles of forward primer (Invitrogen)
10 pmoles of reverse primer (Invitrogen)
2.5 pi of GC-rich resolution solution (Roche)
0.5 pi of GC-rich system enzyme mix,2 units/pl (Roche)
75 ng of DNA template. Distilled water was added to a total volume of 25 pi 
PCR reactions were performed under the following program:
95°C for 3min
95°C for 30 sec 
60 - 68°C for 30 sec 
72°C for 45 sec
35 cycles
72°C for 7min
4°C oo
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The annealing temperature and the number of cycles varied according to the fragment 
amplified. All PCR reactions were performed on a Gene Amp PCR System 9700 
(Applied Biosystems) using Thermo-Fast 96-well plates (ABgene).
3) PCR product purification:
PCR products were purified using a GFX-96 PCR Purification Kit (Amersham 
Biosciences) or a QIAquick PCR purification Kit (QIAGEN) according to the handbook. 
Briefly:
A GFX-96 plate was assembled on a wash plate and binding buffer was added to each 
well. The PCR products were transferred to the wells and mixed with the binding buffer. 
The plate was then centrifuged at 1800rpm for 2min. Following centrifugation, the flow­
through was discarded, the wash plate was re-assembled to the GFX-96 plate and 
wash buffer was added to each well. The plate was then centrifuged at 1800rpm for 
5min, the flow-through discarded and the plate centrifuged again at 1800rpm for 1min 
to remove residual ethanol. The GFX-96 plate was assembled on a collection plate, 20 
pi of distilled water was added to each well, the plate was left to equilibrate to room 
temperature for 1min and then centrifuged at 1800rpm for 2min. Alternatively:
Five volumes of PB binding buffer were added to one volume of PCR sample and 
mixed. A QIAquick spin column was assembled to a 2ml collection tube; the sample 
was transferred in the column and centrifuged at 13200rpm for 1min. Following 
centrifugation the flow-through was discarded and the spin column was re-assembled 
on the collection tube. PE wash buffer was added and the columns were centrifuged at 
13200rpm for 1min. The flow-through was discarded; the column was assembled again 
on the collection tube and centrifuged for an additional 1min at 13200rpm. Following 
that, the column was placed on a 1.5 ml micro-centrifuge tube, 20 pi of EB elution 
buffer was added, the tubes were allowed to equilibrate to room temperature for 1min 
and then centrifuged at 13200rpm for 1min.
4) Agarose gel electrophoresis:
For small DNA fragments, 2% agarose gels were prepared from agarose powder 
(SIGMA) and 1x Tris borate EDTA (TBE, SIGMA) buffer. For larger DNA fragments, 1% 
agarose gels were prepared. PCR product (5-10 pi) was loaded on the gel along with 
1KB Ladder Mix (Fermentas) for reference purposes. The voltage for electrophoresis 
was set at 100-150 Volts, while the duration varied according to the size of the DNA 
fragments.
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5) Amplification reaction for direct sequencing:
For sequencing purposes, samples were amplified using a BigDye Terminator v3.1 
cycle sequencing Kit (Applied Biosystems) according to the protocol. Briefly:
For each sample the following were added:
3-10 ng of forward or reverse primer.
1 fil of BigDye Terminator cycle sequencing mix (Applied Biosystems)
150-600 ng of DNA template. Distilled water was added to a total volume of 10 pil 
Sequencing reactions were performed under the following program:
96°C for 2min
96°C for 
50°C for 
60°C for
4°C
10 sec 
5 sec 
4min
00
25 cycles
6) Purification of sequencing reaction products:
Purification of sequencing reaction products was performed using a DyeEx 96 Kit 
(QIAGEN) according to the protocol. Briefly:
The DyeEx 96 plate was assembled on top of the collection plate and centrifuged at 
2660rpm for 3min. The flow-through was discarded and the DyeEx 96 plate was placed 
on top of a Thermo-Fast 96-well plate (ABgene). The sequencing reaction products 
were transferred to the plate and the plate centrifuged at 2660rpm for 3min. The 
samples were then dried down at 70°C for 40min on a thermal cycler, formamide 
(Applied Biosystems) was added to each well and the samples were sequenced on an 
ABI3100 sequencer. DT3100POP6{BDv3}v1.mob was used as a mobility file, 
RapidSeq36_POP6DefaultModule was used as a run module and BC- 
3100POP6RR_SeqOffFtOff.saz was used as an analysis module. The data were 
analyzed by Sequencing analysis program v3.7 and viewed on SeqScape v1.1.
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RESULTS AND DISCUSSION:
1) Desmoplakin I:
Family A1:
The proband (A1.4), a young woman, seeked cardiac evaluation following the SCD of 
her sister (A1.1). Histological examination of a heart autopsy sample obtained from 
A1.1 showed massive fibrofatty infiltration, with degenerating residual myocytes 
embedded within fat and scar tissue, consistent with a diagnosis of ARVC. A1.4 
presented with palpitations and pre-syncope episodes. Her resting 12-lead ECG 
showed inverted T-waves in precordial leads V1 and V3, and flat T-waves in V2. She 
showed PVCs on Holter monitoring, which however did not exceed 1000 over a 24- 
hour period. On echo, her LV was normal and her RV showed slightly reduced tissue 
Doppler velocities. On MRI her RV was mildly dilated but with preserved function. An 
ICD, implanted in 2004, has since discharged appropriately.
A1.5 also presented with palpitations and pre-syncope. Her resting 12-lead ECG 
showed no abnormalities. However, she had >1000 PVCs/24 hr on Holter monitoring. 
Echocardiography showed RV wall motion abnormalities, which were subsequently 
confirmed by contrast echo and MRI. An ICD, implanted in 2005, has since discharged 
appropriately. Their mother (A1.2) was normal on ECG and echo. An MRI was not 
performed. Their father (A1.3) reported no symptoms but he showed increased QRS 
duration in right precordial leads on ECG and 1356 PVCs/24 hr on Holter monitoring. 
Echo and MRI showed a mildly dilated LV, a normal-sized RV but with one area of 
hypokinesia at the RV apex. Based on the modified diagnostic criteria, applied to 
relatives of an individual with documented ARVC at postmortem, the findings for A1.4, 
A1.5 and A1.3 were considered diagnostic. A1.17 (aged 14 upon examination) reported 
occasional “dizzy spells” . His ECG was normal, but on echo he showed a mildly dilated 
LV. All other family members were normal as shown by ECG and echo studies.
A C to T transition leading to a substitution of an arginine codon by a stop codon in the 
desmoplakin gene was identified in the family (R1113X, Figure 1). The mutation is 
predicted to lead to premature termination of translation and subsequent truncation of 
the C-terminus and part of the central domain of the molecule. All affected individuals 
were heterozygous carriers for the mutation. A1.17 (aged 14), A1.18 (aged 12), A1.13 
(aged 8) and A1.14 (aged 4) were also found to be carriers, however due to their young 
age do not show any phenotypic abnormalities (Figure 2). It was suggested that they 
undergo cardiac evaluation on a yearly basis. DNA was extracted from a heart sample 
of A1.1 preserved in paraffin and tested for the presence of R1113X. A1.1 was also 
found to be a carrier of the mutation.
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Figure 1: Electropherograms of the sense strand showing the wildtype (A) and mutant 
(B) sequences. C3337T is indicated by the arrow.
A1.11 A1.3 A1.2
Proband
SCD, 35 ys
A1.5 A1.4
A1.1
A1.15 A1.16 A1.17 A1.18 A1.19 A1.13 A1.14
Figure 2: Pedigree of family A1 shows autosomal dominant mode of inheritance.
Family A157:
The proband (A157.1) was evaluated at the clinic following a longstanding history of 
palpitations and pre-syncope. Her sister died suddenly at age 26 and postmortem 
examination demonstrated features of acute cardiac failure. In 2003, A157.1 showed a 
dilated LV with impaired systolic function on echo, which was considered consistent 
with familial DCM. She was thus commenced on standard HF therapy with an ACE 
inhibitor and a beta-blocker. However, her arrhythmic symptoms persisted and 
ambulatory ECG monitoring documented in excess of 15,000 PVCs in a 24-hour period 
with occasional triplets and runs of non-sustained VT. Non-sustained VT of RV origin
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was also observed during exercise testing. Amiodarone was thus commenced to 
improve arrhythmic control. An MRI study performed in 2004 demonstrated a dilated 
RV, with mildly impaired systolic function, prominent regional wall motion abnormalities 
and fatty replacement of the myocardium. The LV was also mildly dilated with slight 
impairment of systolic function. The appearances were considered strongly suggestive 
of ARVC, which as mentioned in the introduction, can mimic DCM in later stages. She 
was last seen in clinic in 2006. A 12-lead ECG demonstrated sinus rhythm with a rate 
of 53, left axis deviation and early transition. T-waves were attenuated in V1-V3 and 
inverted in V4-V6 and the inferior leads. There were signs of an intra-ventricular 
conduction delay in the inferior leads with an RSR complex in III and AVF. A SA-ECG 
using a 40Hz filter was positive for late potentials in all 3 parameters assessed (QRSD 
of 117, RMS 40 of 18.5, LAS of 37). 2D echocardiography showed a mildly dilated LV 
with slight impairment of global contractility (LV ejection fraction 45-50% compared to 
30-40% on previous echo). Diastolic function was slightly impaired with a delayed 
relaxation filling pattern and elevated filling pressures. The RV was also mildly dilated 
with slight diffuse impairment of systolic function. The mid-lateral free wall was 
associated with marked sub-endocardial trabeculation and reversed TDI diastolic 
velocities. As seen previously, a PFO was observed with a mild left-to-right shunt, 
although this did not appear to have any hemodynamic influence. A157.1 underwent 
metabolic exercise testing, during which she achieved a peak heart rate of 120 
(predicted 177) and her respiratory exchange ratio was 1.0, indicating sufficient 
workload. Of note, her peak rate on exercise was unchanged from previous occasion, 
and is likely to be limited by beta blockade. No ventricular arrhythmia was noted during 
the test. She was discouraged from participating in any kind of competitive sport and 
endurance training and was discharged on carvedilol, ramipril and amiodarone while 
the possibility of ICD implantation is currently under discussion. Her son (A157.3) and 
two daughters (A157.5 and A157.6) are completely asymptomatic and all their 
investigations were within normal limits.
The proband’s sister (A157.2) has a longstanding history of intermittent sustained 
palpitation. The episodes are of variable duration and frequency with no identified 
specific triggers and are often associated with pre-syncopal symptoms. She is 
experiencing 3-4 episodes of light headedness and near-syncope per week and she 
also experienced one syncopal episode in 2001. There is no history of exertional 
dyspnea. A recent 12-lead ECG demonstrated sinus rhythm with a rate of 85, normal 
QRS axis, and preserved R wave progression. There were signs of an intra-ventricular 
conduction delay in the inferior leads and V3. T-waves were attenuated in V3-V6, in a 
pattern resembling that on A157.1’s ECG. A SA-ECG fulfilled numerical criteria for late 
potentials in the Z lead. 2D echocardiography showed a slightly dilated LV with normal
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wall thickness. However, the septum and distal apex appeared hypo-kinetic and global 
contractility was at the lower limit of normal (ejection fraction 50-55%). Of note, the mid 
posterior, mid lateral and posterior apical walls appeared heavily trabeculated with 
deep intra-myocardial recesses. The appearances were considered strongly suggestive 
of non-compaction cardiomyopathy. The RV appeared normal in both size and function. 
A157.2 additionally underwent metabolic exercise testing, during which she achieved a 
peak heart rate of 159 (predicted: 180) and her respiratory exchange ratio was 1.07. 
Frequent isolated ventricular extra-systoles of both RV and LV origin were observed 
during the test. An endo-myocardial biopsy consisting of 3 fragments was obtained in 
2005. There was fibro-adipose infiltration in two of the fragments with increased fibrous 
tissue, consistent with ARVC. A skin biopsy showed no significant pathological 
abnormality. The specimen was bisected and a sample submitted for electron 
microscopy. Overall the architecture of the desmosomes appeared to be preserved, 
although there was focal loss of cohesion between some of the keratinocytes affecting 
maturation. The significance of this finding is uncertain but may be related to ARVC 
pathogenesis.
One of the proband’s cousins (A157.11) was also diagnosed with ARVC in Belgium. 
His father had died of congestive heart failure, aged 56. Two more of the proband’s 
cousins (A157.15 and A157.16) were also diagnosed with the disease after cardiac 
evaluation performed at their local medical facilities in Belgium. A157.17, A157.8, 
A157.9 and A157.10 were all seen in the clinic and found normal.
A deletion of a G nucleotide was found in the proband at exon 22 of desmoplakin 
(3045delG). The mutation changes the frame of translation, inserts eight novel amino 
acids downstream, followed by a stop codon, which is predicted to terminate translation 
within the central domain of the molecule (S1015fsX1023, Figure 3). A157.1, A157.2, 
A157.11, A157.15 and A157.16 were carriers of the novel mutation. A157.3 was also 
found to be a carrier. Given his young age and his positive genotype, his negative 
phenotype does not exclude the concealed phase of the disease (Figure 4).
A
Figure 3: Electropherograms of the sense strands showing the wildtype (A) and mutant 
(B) desmoplakin sequences. 3045delG is indicated by the arrow.
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Figure 4: The pedigree of family A157 shows autosomal dominant manner of 
inheritance. The proband is indicated by the arrow. Obligatory carriers of 3045delG 
based on the constructed pedigree are indicated by the “ * ” sign.
Family A12:
The proband, a woman aged 19 upon examination, (A12.1) was referred to a hospital in 
Greece for cardiac evaluation following multiple episodes of pre-syncope. Her resting 
12-lead ECG showed inverted T-waves and 24-hour Holter monitoring demonstrated 
frequent ventricular extra-systoles (>1000). Echocardiography showed a globally 
dilated RV with regional wall motion abnormalities and preserved LV function. She 
matched 1 major and 3minor Task Force criteria and was thus given the diagnosis of 
ARVC. An ICD was implanted, which has since discharged appropriately. Her mother 
(A12.2) demonstrated frequent ventricular extra-systoles and runs of non-sustained VT 
on 24-hour Holter monitoring and echocardiography revealed a mildly dilated LV with 
preserved RV function. She matched the modified diagnostic criteria for ARVC with
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predominant LV involvement. The proband’s grandfather died suddenly aged 29, 
however no postmortem data is available. The proband’s brother (A12.3), aunt (A12.4) 
and grandmother (A12.5) were examined and found normal.
A T->A transition was identified in the family at exon 23 of desmoplakin (T4736A). The 
mutation alters a leucine residue for a stop codon and is predicted to terminate 
translation within the central domain of the molecule (L1486X, Figure 5). Both A12.1 
and A12.2 were found to be carriers of the mutation. A12.3, A12.4 and A12.5 were 
homozygous for the wildtype allele. Since A12.5 was not a carrier of L1486X, the 
grandfather was considered an obligatory carrier of the mutation (Figure 6).
A
Figure 5: Electropherograms of the sense strands showing the wildtype (A) and mutant 
(B) desmoplakin sequences. T4736A is indicated by the arrow.
A 1 2 .5
A 1 2 .2 A 1 2 .4
A 1 2 .3 A 12.1
Figure 6: The pedigree of family A12 shows autosomal dominant manner of 
inheritance. The proband is indicated by the arrow.
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Family A208:
The proband, a 48-year-old woman upon examination, (A208.2) has had ectopic beats 
for many years and had undergone cardiac evaluation including 12-lead ECG and 2D 
echocardiography on numerous occasions but no abnormalities other than isolated 
ectopics had been identified. The proband’s daughter (A208.1) died suddenly while 
doing aerobics at home in 2003. She had a history of palpitation and exertional pre­
syncope but had never fainted. She had not undergone medical evaluation for these 
symptoms. She was extremely fit and active and very health conscious. She was 
known to have a low blood pressure (90/50). The proband has re-married and has a 
12-year son (A208.3). She also has a sister (A208.4) and a brother (A208.5), who are 
in their mid-sixties. A208.3, A208.4 and A208.5 appeared normal upon cardiac 
evaluation. The proband’s father died aged 68 from cancer and her mother died in her 
mid-80s. No unexplained early deaths in the family were reported. The proband’s ex- 
husband (A208.6) is now aged 53. He has had tachycardias for many years but has not 
undergone evaluation. He is one of 4 brothers. His siblings (A208.8, A208.9 and 
A208.10) have not undergone cardiac evaluation either but have not complained of any 
disease-related symptoms. A208.6’s parents lived into their mid-70’s to die from 
coronary artery disease and cancer. A208.6’s mother though had had a brother, who 
apparently had died suddenly at a young age, although the details are sketchy 
(indicated with a grey symbol on the family pedigree). A208.6 has also re-married and 
has a 13-year old son (A208.7), who is well. The autopsy report of A208.1 reported 
striking circumferential fibro-adipose replacement of the LV myocardium advancing 
from the epicardium to the endocardium. The changes were present at all levels of 
sampling of the LV including the septum. The fibro-adipose replacement was more 
striking at the posterior wall of the LV. No RV abnormalities were detected. She was 
given the diagnosis of left-sided ARVC based on postmortem findings. Her two children 
(A208.11 and A208.12) are currently 8 and 5 years old, respectively, and they are both 
well. ECG and echo studies performed recently revealed no abnormalities (Figure 7). 
DNA was extracted from a heart sample of A208.1 preserved in paraffin and screened 
for mutations in ARVC-implicated genes. A G->A transition was identified at the splice 
site following exon 7 of the desmoplakin gene (1218+1 G -> A, Figure 8). The mutation 
is thought to insert 24 novel amino acids following the predicted end of exon 7 followed 
by a premature stop codon. All family members declined genetic screening and 
therefore the pattern of inheritance of 1218+1 G-> A could not be established and the 
individuals at potential risk of developing the disease could not be identified.
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Figure 7: The pedigree of family A208. The proband is indicated by the arrow.
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Figure 8: Electropherograms of the sense strands showing the wildtype (A) and mutant 
(B) desmoplakin sequences. 1218+1 G-> A is indicated by the arrow.
Family A131:
The index case (A131.1) was a girl who presented at birth with bullous dermatitis, 
pressure-related skin fragility and sparse, woolly scalp hair. By her first birthday, she 
had developed total alopecia (Figure 9) and PPK, which was more prominent over
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pressure points on the soles (Figure 10). There was no evidence of nail dystrophy or 
teeth abnormalities. At age 27 months, she developed right-sided hemiparesis due to 
a cerebral infarct which prompted cardiac evaluation. An ECG at that time showed left 
axis deviation with non-specific repolarization changes (Figure 11) while X-ray and 
echocardiography revealed massive LV enlargement (LV end-diastolic diameter, 
48mm, Figure 12) with severe impairment of systolic function (LV end-systolic diameter, 
42mm ejection fraction, 28%; LV fractional shortening, 13%). No arrhythmias were 
noted during 24-hour ambulatory ECG monitoring. Cardiac catheterization revealed a 
mean pulmonary artery pressure of 20 mmHg and mean aortic pressure of 48 mmHg. 
Follow-up ECG studies showed isolated ventricular ectopy and repolarization 
abnormalities but no overall disease progression as seen by echocardiography. She 
suffered SCD death at age 9 years. Postmortem examination was declined by her 
parents.
There were no manifestations of clinical features of this cardiocutaneous syndrome in 
other family members. The proband’s mother (A131.3) reported a spontaneous 
abortion during her first pregnancy. She was diagnosed with hyperthyroidism but was 
otherwise healthy. Her ECG and echocardiogram were normal. There were two 
deaths amongst her siblings, one due to cyanotic congenital heart disease (A131.9, 
indicated by a grey symbol on the family pedigree) and the other related to acute 
lymphoblastic leukemia at age 6 years (A137.10). One living sibling had ulcerative 
colitis (A131.7) and another was healthy (A131.8). The maternal grandmother 
(A131.11) had been diagnosed with idiopathic DCM but lived until age 74 years 
(indicated by a grey symbol on the family pedigree). She showed no evidence of hair 
or skin abnormalities. Echocardiography performed shortly prior to her death showed 
an LV end-diastolic diameter of 64mm and an estimated ejection fraction of 30%. The 
proband’s father (A131.4) was healthy; ECG and 2D echocardiography studies showed 
no abnormalities. The paternal grandmother (A131.6) had had a breast neoplasm 
removed and had also reported a spontaneous abortion. ECG and echocardiography 
studies of the maternal siblings, the paternal parents (A131.6 and A131.5) and the 
proband’s brother (A131.2) showed no cardiac anomalies.
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Figure 9: The picture shows the proband’s scalp. A131.1 had lost virtually all her hair 
by her first birthday.
Figure 10: A131.1 had developed profound PPK, more prominent at pressure points on 
the soles.
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Figure 11: ECG of A131.1 obtained at age 27 months. Findings include left axis 
deviation and non-specific repolarization abnormalities indicative of ischemic heart 
disease.
Figure 12: The proband’s X-ray revealed massive cardiomegaly.
A131.1 was initially screened for mutations in plakoglobin, the gene known to underlie 
Naxos disease. Sequence analysis indicated the absence of the 2157del2 mutation or 
any other mutation in the plakoglobin gene. Thus, the proband was screened for 
mutations in other genes implicated in ARVC. We identified a C->T transition in 
desmoplakin, which is predicted to lead to a substitution of a glutamine codon with a 
stop codon within the central domain of the molecule (Q1446X) (Figure 13). This 
mutation is predicted to lead to premature termination of translation and truncation of
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the entire C-terminus of the protein. Further screening of the proband revealed a 
second mutation in desmoplakin, which is predicted to cause premature termination of 
translation within the N-terminal domain (Q673X) (Figure 14). Sequence analysis of 
the patient’s family showed maternal inheritance (A131.3) of Q1446X and paternal 
inheritance (A131.4) of Q673X. A131.2 and A131.6 were carriers of the Q673X
mutation, while both A131.7 and A131.8 were homozygous for the wildtype 
desmoplakin allele (Figure 15). The clinical characteristics and genotype of this family 
are included in: Ward et at. “Multiple desmosomal gene mutations in familial ARVC 
result in a more severe phenotype” ; manuscript submitted to Circulation and Asimaki et 
al. “Compound heterozygosity for two novel mutations in desmoplakin underlies a 
unique cardiocutaneous syndrome” ; manuscript submitted to Journal of the American 
Academy of Dermatology.
A. B
Figure 13: Electropherograms of the sense strands showing the wildtype (A) and (B) 
mutant desmoplakin sequences. Q1446X is indicated by the arrow.
A B
Figure 14: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmoplakin sequences. Q673X is indicated by the arrow.
78
A131.11
A131.6A131.5
A131.3 A131.9 A131.10 A131.7 A131.8A131.4
A131.2 A131.1
Figure 15: The pedigree of family A131.1. “ +” indicates the carriers of Q1446X. “ * " 
indicates the carriers of Q673X. The proband, indicated by the arrow, is a compound 
heterozygote for both novel nonsense desmoplakin mutations.
Discussion:
Collectively, 6 novel desmoplakin mutations were identified in 5 probands and their 
family members, wherever genetic screening was permitted. All mutations are predicted 
to cause premature termination of translation and sub-sequent truncation of variable 
lengths of the desmoplakin molecule (summarized in Table 1). The mutations were not 
found in 400 ethnically-matched control chromosomes, which eliminates the possibility 
of their being uncommon polymorphisms. All probands were screened for mutations in 
plakoglobin, plakophilin2, desmoglein2 and desmocollin2 and found to be negative. It is 
likely therefore that the mutations identified are indeed pathogenic. None of the 6 
sequence changes disrupts any of the known restriction enzyme sites, and therefore, 
could not be confirmed by restriction digest.
With the exception of family A208, where lack of genetic data prevented establishing 
the mode of inheritance, desmoplakin mutations in families A1, A157 and A12 seem to 
be inherited in an autosomal dominant manner. R1113X, S1015fsX1023 and L1486X 
show high penetrance, with all carriers being affected by the disease apart from young 
individuals, who are though at risk of developing the disease later in life. Desmosomal 
mutations can exert pathogenic effects at three levels: the desmosome composition 
and function level, the intercalated disc level (given the interdependency between 
different junction types on these specialized heart regions) and by disrupting signaling 
pathways. At the desmosome level, mutations can have pathogenic effects due to
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haploinsufficiency, and thus insufficient incorporation of the protein at the junctions, due 
to absence of formation of essential protein-protein interactions or due to mutated 
molecules getting incorporated in the junction thus leading to disrupted desmosome 
structure and reduction in the number of functional desmosomes.183
Family Mutation Predicted outcome
A1 R1113X
z Y X w V Rod segment ___  A
A157 S1015fs
X1023
Z Y X  W  V Rod segment ___  A
A12 L1486X
Z Y X  W  V Rod A B C
A208 1218+1
G->A
Z Y X w V
A131 Q1446X
Z Y X  W  V Rod A B C
A131 Q673X
Z Y W V I   Rod segment ___  A
Table 1: All novel desmoplakin mutations identified signal premature termination of 
translation and are predicted to truncate the molecule at varying points (indicated by 
the arrows).
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Bornslaeger et al. generated A431 cell lines stably expressing desmoplakin N-terminal 
only polypeptides. In these cells, the truncated molecule co-localized at cell-cell 
interfaces with desmosomal proteins, markedly disrupting the distribution of 
endogenous DP and leading to a total breakdown of the IF network.184 Furthermore, in 
these cells, adherens junction components were found to co-localize with desmosomal 
components in mixed-type junctions.184
Carriers of R1113X, S1015fsX1023 or L1486X, show some form of cardiomyopathy but 
no further phenotypic abnormalities and can lead a relatively normal life. Furthermore, 
electron microscopy of a skin sample from A157.2 showed normal numbers of 
presumably functional desmosomes (data not shown). Were the mutations to be acting 
in a dominant negative manner, as described by Bornslaeger et al, a worse phenotype 
would have been expected. It is therefore suggested that these mutations act through 
haploinsufficiency. Whether the truncated molecules are not translated at all, because 
of mRNA nonsense mediated decay, or whether they are expressed but do not get 
incorporated in the junctions is not known. Western blotting analysis from patient 
samples would demonstrate the presence of the mutated proteins, while 
immunofluorescence studies using antibodies that recognize different desmoplakin 
domains, would indicate their sub-cellular distribution.
Lapouge et al recently reported that DP constructs encompassing the B-subdomain 
and the linker region, the linker region only, or constructs lacking the 51 C-terminal 
amino acid extremity, can bind to desmin though weakly.185 On the other hand, 
constructs encompassing the C subdomain only, the C subdomain with the C-terminal 
extremity or the C-terminal extremity only cannot bind to desmin filaments.185 
Desmoplakin molecules bearing either of the R1113X, S1015fsX1023 or L1486X 
mutations lack all A, B and C subdomains as well as the linker and the C-terminal 
extremity region. Therefore, even if these molecules were indeed expressed and 
managed to localize to cardiac desmosomes, they would not have been able to anchor 
the intermediate filaments. It is possible that in tissues not subjected to increased 
mechanical stress, such as most epithelia, a single functional desmoplakin copy is 
sufficient to confer adhesion, but in the heart, in the absence of one functional copy, a 
cardiomyopathy phenotype emerges.
Early genotype-phenotype correlations suggest that when the C-terminal part of 
desmoplakin is missing, it is the LV that gets primarily affected, while missense 
mutations that disrupt desmosomal protein interactions sparing the cytoskeleton tend to 
cause a predominant RV phenotype.186 In the cases presented herein, members of the 
same family, carrying the same mutation, may show either typical ARVC or left-sided 
ARVC mimicking DCM. Modifier genes or environmental factors are likely to affect the 
ultimate phenotype.
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Fontao et al reported that the linker region between the B and C subdomain is 
important for the binding of DP to K8/K18 keratin heterodimers, while the C subdomain
187alone is crucial but not sufficient for the interaction of DP with K5/K14 pairs. 
Collectively, it was shown that only residues amongst the C-terminal domain of 
desmoplakin are responsible for binding to all keratins.187 Given the fact that the skin is 
also subjected to increased mechanical stress, it is curious that carriers of R1113X, 
S1015fsX1023 or L1486X do not show any gross cutaneous abnormalities. It may be 
that other plakins, such as plectin, envoplakin or periplakin, can compensate for the 
loss of DP in the skin only. It is also possible that one functional allele, although unable 
to confer strong adhesion in the heart, is able to do so at the skin. It may also be that 
the same mutation has different tissue-specific effects on downstream signaling 
pathways. Still, autosomal dominant desmoplakin mutations acting through 
haploinsufficiency have previously been shown to cause striated palmoplantar 
keratoderma without associated cardiomyopathy.188 In these cases, Western 
immunoblotting failed to demonstrate the presence of the mutant protein. It may 
therefore be that the presence of both desmoplakin copies, even if one is truncated, 
protects from PPK and helps maintain the epidermal integrity. If this assumption is 
indeed true, then R1113X, S1015fsX1023 and L1486X should not activate nonsense 
mRNA decay, and the truncated proteins should therefore be present whether they 
manage to localize at the cell junctions or not. At this point though, these conclusions 
are merely speculations.
Of all cases presented above, family A131 is perhaps the most interesting. It is the first 
report of compound heterozygosity for two novel nonsense desmoplakin mutations 
identified in a child of Spanish origin who presented with palmoplantar hyperkeratosis, 
complete alopecia and early-onset cardiomyopathy leading to hemiparesis and SCD in 
childhood. The absence of cardiocutaneous abnormalities in carrier family members 
suggests that the mode of inheritance for Q1446X and Q673X is autosomal recessive 
or autosomal dominant with low penetrance. Genetic studies in mice indicate that 
desmoplakin is an indispensable protein. Desmoplakin-null embryos do not survive 
beyond E6.5 owing to a loss or instability of desmosomes. When provided with 
wildtype extra-embryonic tissue, these embryos die shortly after gastrulation due to 
major defects in heart muscle, neuroepithelium, skin epithelium and microvasculature. 
Despite the numerous phenotypic abnormalities, the compound heterozygosity 
presented herein did not lead to embryonic lethality. Instead, the proband managed to 
survive until 9 years of age, suggesting that at least one of the two truncated proteins is 
expressed and does make it to the desmosomes. Western blotting would be required 
though to confirm this hypothesis.
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When keratinocytes come into initial contact during development and wound healing, 
filopodia extend into neighboring cells to form an adhesion zipper on which adherens 
junctions are formed to seal the sheet of epithelial cells. Desmosomes are formed 
passively along the long axis of filopodial associations. In the absence of desmoplakin, 
the cohesion cascade stops at the adhesion zipper stage. 189 However, this blockage in 
adhesion can be rescued by the lone expression of the N-terminal domain of 
desmoplakin. Indeed, the head of the plakin protein not only gets incorporated into 
desmosomal plaques and restores adhesion, but it also promotes the association of 
intermediate filaments with the plasma membrane in a parallel fashion.190 Isolated N- 
terminal domains of desmoplakin can orient plakophilins such that intermediate 
filaments can associate with the cell junctions in a parallel orientation, whereas the full- 
length desmoplakin containing its C-terminal domain anchors the filaments in a vertical 
fashion.191 It can therefore be suggested that tissue organization is disrupted only when 
cells bearing the truncated protein are subjected to stress. The N-terminal domain of 
desmoplakin is known to bind plakoglobin.192 Q673X, apart from disrupting the 
interaction of DP to IFs, could also disrupt the interaction of DP with plakoglobin. 
Plakoglobin is shown to reduce proliferation in hair follicles by premature termination of 
the growth phase of the hair cycle.192 If Q673X does indeed interfere with the normal 
interaction between DP and PG, it could have an effect on the hair phenotype as well, 
thus explaining the hair abnormalities exhibited by A131.1.
Recently Jonkman et al described a patient who died in the neonatal period due to 
transcutaneous fluid loss through erosions of large skin areas.193 The child also 
presented with alopecia, nail loss and neonatal teeth but showed no cardiac or other 
internal organ abnormalities. This novel phenotype, named lethal acantholytic 
epidermolysis bullosa, was linked to compound heterozygosity for a 
nonsense/frameshift combination of desmoplakin mutations, both predicted to cause 
premature termination of translation. Although the molecular pathology of desmoplakin 
in Jonkman’s report is comparable to that of the case presented here, the phenotype is 
strikingly different.193 How similar changes at the genetic level can have such different 
effects at the phenotypic level is still not understood.
Since the identification of the mutations presented herein, additional ARVC-associated 
mutations were reported in the literature. In 2004, a novel dominant mutation in 
desmoplakin (2034insA) causing left-sided ARVC with arrhythmias of LV origin, lateral 
T-wave inversion and late gadolinium enhancement in the LV on MRI was presented.194 
In 2006, the case of a patient with a recessively inherited ARVC with left and right 
ventricular involvement, epidermolytic PPK and wooly hair was presented.195 The 
patient showed a severe heart phenotype with an early onset and rapid progression to 
HF at 4 years of age. A homozygous nonsense mutation (R1267X) was found in exon
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23 of the DP gene, which resulted in an isoform specific truncation, and subsequent 
instability and loss of only the longer DP isoform.195 Finally, Yang et al reported 4 novel 
DP variants in ARVC patients: V30M, Q90R, W223X and R2834H.196 In vitro analysis 
demonstrated that the N-terminal mutants (V30M and Q90R) failed to localize to the 
cell membrane and also failed to immunoprecipitate plakoglobin. Analysis of mouse 
embryos expressing cardiac-specific trans-genes, bearing either the V30M or the Q90R 
mutation, revealed evidence of profound ventricular dilatation resulting in early 
embryonic lethality. On the contrary, mice expressing the R2834H mutation, under a 
cardiac-specific promoter, did survive but showed increased cardiomyocyte apoptosis, 
cardiac fibrosis and lipid accumulation along with ventricular enlargement and cardiac 
dysfunction in both ventricles. These mice also displayed interruption of the DP-desmin 
interaction at intercalated discs (IDs) and marked ultra-structural changes of the IDs.196 
Collectively, these results identify desmoplakin as an important genetic determinant in 
ARVC pathogenesis, though many questions still remain unanswered.
2) Plakoglobin:
Family D0074:
The proband (11:1), a 48-year-old man of German origin upon examination, had first 
experienced syncope at the age of 39 years. After a documented episode of sustained 
VT, he was admitted to the University Hospital of Muenster, Germany for further 
diagnostic evaluation and management. ECG demonstrated QRS prolongation and T- 
wave inversion in right precordial leads and late potentials. Angiography showed 
moderate, global RV dilatation and regional wall motion abnormalities without LV 
involvement. Sustained monomorphic VT of LBBB morphology was induced at 
electrophysiological study. Endomyocardial biopsy showed extensive fibrofatty 
replacement of RV muscle with patchy mononuclear inflammatory infiltrate. He fulfilled 
the Task Force criteria for the diagnosis of ARVC. An ICD implanted in 1997 has since 
discharged appropriately. The proband’s skin and hair appeared grossly normal upon 
physical examination. Individuals ll:2 and ll:3 were diagnosed with ARVC after cardiac 
evaluation at their local medical facilities based on 12-lead and 24-hour ECG and echo 
abnormalities. Both ll:2 and ll:3 have offspring who refused clinical and genetic 
screening and who were not included in the family pedigree. Individual 1:1 died aged 
70 of HF (indicated by a grey symbol on the family pedigree). Individual ll:4 underwent 
cardiac evaluation and was found to be normal. We identified an insertion of 3 bases in 
the gene coding for plakoglobin (118_119insGCA). This mutation has not been 
previously reported. It does not disrupt the frame of translation but is predicted to result 
in the insertion of an additional serine residue at amino acid position 39 within the N-
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terminal domain of plakoglobin (S39_K40insS, Figure 16). Individuals expressing the 
S39_K40insS mutation showed an autosomal dominant mode of inheritance of ARVC 
and the mutation co-segregated with the disease phenotype in the family (Figure 17). 
The clinical characteristics and genotype of this family are included in: Asimaki et al. “A 
novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular 
cardiomyopathy” ; manuscript in press, The American Journal of Human Genetics.
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Figure 16: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) plakoglobin sequences. S39_K40insS is indicated by the arrow.
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Figure 17: The pedigree of family D0074. The proband is indicated by the arrow. 
Discussion:
A novel autosomal dominant plakoglobin mutation (S39_K40insS) was identified in a 
German family affected by ARVC. Recently, an uncommon polymorphism in 
plakoglobin (L697M) was shown to co-segregate with a nonsense mutation in 
desmoplakin (R1267X) in a family with early-onset ARVC.195 It has been suggested 
that L697M could have a negative modifier effect on the cardiac phenotype in the 
presence of R1267X.195 In the family presented herein the L697M polymorphism was
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not present and genotyping of other desmosomal candidate genes including 
desmoplakin and plakophilin2 did not reveal additional mutations. S39_K40insS co­
segregated with the disease phenotype and was not found in 400 ethnically-matched 
control chromosomes. It is likely, therefore, that this mutation is in fact pathogenic 
rather than a modifying polymorphism.
The index case was part of a larger cohort of ARVC patients who were screened for 
mutations in candidate desmosomal genes. The cohort included >200 individuals of 
English origin, 70 individuals of German origin and 30 individuals of Greek/Cypriot 
origin. The mutation presented herein was the only plakoglobin mutation identified in 
the cohort, suggesting that plakoglobin mutations are uncommon in an unselected 
population of ARVC patients. None of the individuals affected by the S39_K40insS 
mutation showed apparent cutaneous abnormalities, in contrast to those seen in 
patients with Naxos disease. This might be explained by the dominant mode of 
inheritance of S39_K40insS. It is likely that the different clinical phenotypes produced 
by S39_K40insS and 2057del2, the mutation known to cause Naxos disease, may 
result from differential effects of the mutations on the various plakoglobin binding 
partners and the downstream effects on signalling, but this must be analyzed in detail in 
future studies. In vitro investigations pointing towards the mechanisms of pathogenesis 
of this novel mutation are presented in detail in chapters 3 and 4.
3) Plakophilin2a:
Family A170:
The proband (A170.1) was first seen by a pediatrician at age 10 weeks due to 
shortness of breath and sweating with exertion since birth. Investigations demonstrated 
coarctation of the aorta with patent ductus arteriosus, severe LV hypertrophy and non­
obstructive bicuspid aortic valve. Surgery to repair the coarctation was performed when 
A170.1 was 3 months old. He was discharged on furosemide and spironolactone but 
was readmitted at the hospital 1 week later due to persistent hypertension and treated 
with propanolol. Following the operation, he was followed regularly until the death of his 
father (A170.2), at 37 years of age. The postmortem examination at the time cited 
“ floppy mitral valve” as the cause of death, although the RV was mildly enlarged. 
Subsequent review of histology revealed areas of fibrosis in both ventricles. ARVC was 
suspected as the cause of death of another relative (A170.10), who died suddenly 
during physical exercise at 22 years of age. His father (A170.9) refused clinical 
evaluation. Cardiac evaluation of other immediate family members (A170.4, A170.4, 
A170.6, A170.7 and A170.8) was unremarkable. The 89-year old paternal grandmother 
(A170.3) though was found to have an abnormal ECG of RBBB morphology, but it
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could have been due to age-related conduction disease. Echocardiography showed no 
abnormalities and she refused further clinical evaluation. She did not fulfill the Task 
Force criteria but in the context of familial ARVC, these mild abnormalities may 
represent a mild form of the disease (indicated by a grey symbol on the family 
pedigree). In 2004, the proband died suddenly while playing rugby at 15 years of age. 
He was last seen in clinic 2 years prior to his death. His ECG was normal and his echo 
showed normal LV and RV size and systolic function. The postmortem examination 
showed cardiac enlargement with concentric LV hypertrophy. There were areas of 
fibrosis and thinning in the RV anterior wall extending to the inter-ventricular septum. 
The rest of the RV appeared normal apart from a mild dilatation. Histological 
examination showed extensive replacement of myocardial tissue by fibrosis in the 
macroscopically scarred area of the RV as well as in other random RV samples. There 
was also focal but histologically similar fibrosis in several samples from the LV.
A deletion of a C nucleotide was found in the family in the gene coding for plakophilin2 
(1709delC). The mutation alters the frame of translation, inserts 6 novel amino acids 
downstream followed by a stop codon, which signals premature termination of 
translation within the fifth armadillo repeat domain of the protein (V570fs576X, 
Figure: 18). The paternal grandmother (A170.3) and her brother (A170.9) were also 
carriers of the mutation. All other clinically normal family members were gene negative 
(Figure: 19).197
BA
Figure 18: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. 1709delG is indicated by the arrow.
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Figure 19: The pedigree of family A170 shows autosomal dominant manner of 
inheritance of V570fs576X with low penetrance. The proband is indicated by the arrow.
Family A198:
In this family, a C->T transition was identified in exon 5 of the plakophilin2 gene 
(1237C>T). The mutation is predicted to substitute an arginine residue with a stop 
codon, and therefore signal premature termination of translation within the armadillo 
repeat domain of the protein (R413X). Further clinical and genetic data on this family 
are presented in a later section of this chapter.
Family CYP1:
The proband (111:1) presented for the first time with syncope aged 16 years. His ECG 
was abnormal and on 24-hr Holter monitoring he showed episodes of non-sustained 
VT. Imaging studies showed evidence of typical ARVC with LV involvement. He fulfilled 
2 major and 2 minor Task Force criteria. He died suddenly, aged 20 years. Post­
mortem examination showed extensive fibrofatty replacement of both ventricles, 
confirming the original diagnosis. The proband’s father (ll:5) is affected by typical 
ARVC. His ECG shows prolongation of QRS duration and inverted T-waves in 
precordial leads V1-V3, he shows multiple ventricular extrasystoles and an 
electrophysiological study induced sustained VT. On echo, he shows global dilatation 
and hypokinesia of the RV without LV involvement. He is currently being treated with 
sotalol. The proband’s brother (lll:3) fulfils 2 major and 2 minor Task Force criteria. His 
ECG is abnormal with T-wave inversions and prolongation of the QRS duration, he has
documented frequent extra-systoles and episodes of non-sustained VT, and on echo 
he shows global RV involvement and hypokinesia of the LV antero-lateral wall. 
Recently, he had an ICD implanted. The proband’s aunt (11:4) fulfils 2 major and 2 minor 
criteria for typical ARVC as well. Her ECG shows T-wave inversions in the right 
precordial leads, while on echo her RV is globally affected with preserved LV function. 
She also has frequent extra-systoles and a biopsy sample obtained from the inter­
ventricular septum showed extensive fibrofatty replacement. All other family members 
examined were clinically normal.
A novel deletion of 10 bases was found in the family in exon 3 of the plakophilin2 gene 
(971_980del10). This mutation is predicted to cause a frameshift and introduce a 
premature stop codon in the N-terminal domain of the plakophilin2 molecule 
(G324fsX348, Figure:20). All affected members in the family (111:3, 11:4 and 11:5) are 
carriers of the novel mutation, while one family member (11:3) is genotype-positive but 
phenotype negative at 61 years of age (Figure:21).198
Figure 20: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. 971_980del10 is indicated by the arrow.
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Figure 21: The pedigree of family CYP1 shows autosomal dominant manner of 
inheritance of G324fsX348 with low penetrance. The proband is indicated by the arrow.
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Family CYP10:
The proband (111:12), a man of Cypriot origin, died aged 61 of non-cardiac etiology. 
Prior to his death, he showed T-wave inversions and prolongation of QRS duration on 
ECG and global dilatation and hypokinesia of the RV with preserved LV function on 
echo. A biopsy sample obtained showed fibrofatty replacement of the RV, consistent 
with an ARVC diagnosis. Ablation was performed successfully at the time to treat 
frequent episodes of sustained VT. The proband’s daughter (IV: 12), 29 years of age 
upon examination, showed T-wave inversions on ECG, segmental hypokinesia of the 
RV and frequent extrasystoles. Together with the family history of ARVC, she fulfilled 1 
major and 3 minor Task Force criteria, and was therefore considered affected. The 
proband’s nephew (IV: 10) died aged 18. Post-mortem examination concluded sudden 
cardiac death, but further details are sketchy. Given the family history though, the 
possibility that he was also affected by ARVC is high (indicated by a grey symbol on the 
pedigree). Two of his siblings are also affected. IV:8 showed T-wave inversions in the 
right precordial leads, frequent extra-systoles and regional hypokinesia of the RV. IV:9 
showed no typical ECG abnormalities, except for a pathological S-wave upstroke. His 
RV though was globally dilated and an apical aneurysm was identified on echo. He also 
had frequent extra-systoles. Surprisingly their mother (111:10) is clinically normal. The 
proband has 4 other siblings (lll:5, lll:7, lll:8 and lll:9) who are clinically normal. Ill:5 
has three children (IV:4, IV:5 and IV:6) and two grand-children (V:1 and V:2) who are 
also clinically normal. The proband also has 7 first cousins (111:1, lll:2, lll:3, 111:14, 111:15, 
111:16 and 111:17), all of whom are clinically normal apart from IIl:3. Ill:3 showed T-wave 
inversions in V1-V4 and segmental RV hypokinesia. No arrhythmic episodes have been 
documented though. Together with the family history, lll:3 fulfilled 1 major and 2 minor 
criteria and was therefore considered affected. Ill: 3 has three children: IV: 1, IV:2 and 
IV:3. IV:3 showed multiple ECG abnormalities including T-wave inversions in V1-V3, 
prolongation of QRS duration and epsilon waves. IV:3 also showed diffuse RV 
involvement with preserved LV function and has had a defibrillator implanted after a 
documented episode of sustained VT. IV:3’s brother (IV:2), 39 years of age upon 
examination, had a normal ECG and only mild hypokinesia at the RV apex. By itself, 
this finding does not constitute a specific criterion and the individual did not fulfill the 
Task Force criteria. However, in the context of a familial disease, even this minor 
abnormality may represent a mild form of ARVC. He was therefore indicated by a grey 
symbol at the family pedigree. To summarize, 6 family members are affected by ARVC, 
one member shows only minor abnormalities, which may or may not represent a mild 
form of the disease, and one family member is suspected to have died of ARVC, aged 
18, although clear post-mortem details are not available.
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A novel deletion of 50 bases was identified in the family at exon 13 of the plakophilin2 
gene (2569del50). This mutation is predicted to result in a frameshift and premature 
termination of translation within the C-terminal part of the protein (R857fsX858, 
Figure:22). 25 family members were genotyped, 10 of whom were carriers of the novel 
mutation. All living clearly affected individuals (lll:3, IV:3, IV:8, IV:9 and IV: 12) were 
carriers of R857fsX858. IV:2 was also a carrier. The remaining 4 carriers (111:10, 111:14, 
IV:6 and V:2) were clinically normal. 111:10, 111:14 are in their late sixties, IV:6 is 39 years 
old, however V:2 is only 12 and may therefore be at risk of developing the disease later 
on in life. Interestingly, although IV:6 is a carrier, her mother (lll:5), who is a sister of the 
proband, is not. IV:6’s father (III: 6) had died of non-cardiac reasons and was 
unavailable for genotyping. He was thus considered an obligate carrier. Based on the 
constructed pedigree (Figure:23), three more deceased individuals (11:1, ll:3 and ll:6) 
were considered obliterate carriers. All 4 obliterate carriers were indicated with a 
diagonal-line pattern on the family pedigree. The fact that lll:6 was considered an 
obliterate carrier of R857fsX858 though not directly related to the proband, may 
suggest a founder effect in the small, inbred society of Cyprus, or alternatively, a 
mutational hotspot in the plakophilin2 gene, indicating that ARVC-causing mutations 
may in fact be much more common that originally thought.198
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Figure 22: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. 2569del50 is indicated by the arrow.
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Figure 23: The pedigree of family CYP10 shows autosomal dominant manner of 
inheritance for R857fsX858 with incomplete penetrance. The proband is indicated by 
the arrow.
Family GR1:
The proband (lll:2) died suddenly aged 23 years. Post-mortem examination showed 
typical features of ARVC. In particular, there was extensive fibrofatty replacement of the 
RV with degenerating myocytes embedded within areas of fat and fibrous tissue. An 
ECG performed a few months prior to the proband’s death was pathological, showing 
inverted T-waves in V1-V4 precordial leads and low voltage. The proband’s father (ll:2) 
showed T-wave inversions in V1-V3 on ECG, minor hypokinesia of the RV on echo, 
late potentials on SA-ECG, and frequent extra-systoles on 24-hour Holter monitoring. 
He is currently being treated with sotalol. The proband’s sister (111:1) is clinically normal. 
The proband’s uncle (ll:3) is also affected by typical ARVC. In particular he showed T- 
wave inversions on ECG, late potentials on SA-ECG, diffuse RV involvement on echo, 
a normal LV, documented episodes of non-sustained VT, and an electrophysiological 
study induced an episode of sustained VT. A proband’s aunt (ll:5) is clinically normal.
A deletion was identified in the family in exon 13 of the plakophilin2 gene (2509delA). 
The deletion, has been previously seen in ARVC patients, and is predicted to lead to
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the introduction of a number of additional amino acid residues at the C-terminal domain 
of the protein (V837fsX930, Figure:24).77 Both 11:2 and 11:3 are carriers of the mutation, 
while 11:5 is homozygote for the wildtype allele. 11:3 and 11:4 have declined clinical 
examination and genotyping of their daughter (111:3), because of her young age
(Figure:25). 198
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Figure 24: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. 2509delA is indicated by the arrow.
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Figure 25: The pedigree of family GR1 shows autosomal dominant manner of 
inheritance for V837fsX930 with high penetrance. The proband is indicated by the 
arrow.
Family GR2:
The proband (III: 1), currently a young man, is affected by a severe form of ARVC. 
Specifically, he showed ECG abnormalities, which include T-wave inversions, 
prolongation of QRS duration and epsilon waves and imaging abnormalities, which 
include global dilatation and hypokinesia of the RV. The LV function though was
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preserved. He also has had episodes of sustained and non-sustained VT and had a 
defibrillator implanted recently. His mother (11:1) is also affected by the disease. In 
particular, she had a pathological ECG, similar to that of the proband, ventricular 
arrhythmias, and diffuse RV involvement on echo and MRI. The proband’s brother 
(lll:2) is clinically normal.
The same mutation identified in family GR1 was also identified in family GR2 
(V837fsX930). Both 111:1 and 11:1 were carriers of the mutation, while lll:2 was gene 
negative (Figure:26).198
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Figure 26: The constructed pedigree of family GR2. Although both affected members 
of the family are carriers of the mutation, and one non-affected individual is gene- 
negative, which could imply a mutation with high penetrance, the small size of the 
pedigree does not allow us to draw definite conclusions as to the manner of inheritance 
of V837fsX930 in this family. The proband is indicated by the arrow.
Family GR3:
The proband (II: 1), currently a young man, shows features of biventricular ARVC. In 
particular, he showed inverted T-waves and prolongation of QRS duration in both right 
and left precordial leads, global RV and segmental LV involvement on echo, and 
documented episodes of sustained VT, which prompted the implantation of a 
defibrillator. The proband’s mother (1:1) is clinically normal. His father though (l:2) 
showed late potentials on SA-ECG and segmental RV hypokinesia on echo. He only 
matches two minor Task Force criteria and was thus indicated by a grey symbol on the 
family pedigree (Figure:27).
The proband is a carrier of the same mutation identified in families GR1 and GR2 
(V837fsX930). Surprisingly, neither his father nor his mother are carriers of the 
mutation, indicating that V837fsX930 has arisen de novo in this family. The fact 
however that his father shows minor abnormalities, which are consistent with a mild 
form of ARVC, while his son shows a severe form of the disease should raise 
suspicions that the proband is a carrier of a second mutation. He was screened for
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mutations in plakoglobin, desmocollin2, desmoglein2 and desmoplakin and found 
negative, but that does not exclude the possibility of him being a carrier of a mutation in
198a yet non-identified ARVC-related gene.
II: 1
Figure 27: The constructed pedigree of family GR3 shows that V837fsX930 has arisen 
de novo in this case. The proband is indicated by the arrow.
Further plakophilin2 mutations:
Four further mutations were identified in 6 patients with a confirmed diagnosis of ARVC 
based on the Task Force criteria. A C->T transition was detected in exon 3 of 
plakophilin2, in the proband of family A191 (C419T). The mutation, which has 
previously been reported,77 alters a highly conserved serine for a phenylalanine residue 
within the N-terminal domain of the protein (S140F, Figure:28). A C->T transition was 
detected in exon 11 of plakophilin2, in the proband of family A207 (C2203T). The 
mutation, which has also been reported previously,77 alters an arginine residue 
introducing a premature termination codon within the armadillo repeat domain of the 
protein (R735X, Figure:29). The same splice site mutation was identified in the 
probands of three ARVC families; A203, A184 and A188 (2146-1 G-»C, Figure:30). The 
mutation, also reported by Gerull et al,77 is predicted to cause skipping of exon 11 
during the translation of the plakophilin2 mRNA molecule. Finally, a splice site mutation 
was identified in the proband of family A193 (2489+1 G->A, Figure:31). The mutation, 
previously seen in a cohort of German ARVC patients,77 is predicted to allow 
continuation of translation after the splice site of plakophilin2 exon12, possibly 
introducing a number of new amino acid residues.
Figure 28: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. C419T is indicated by the arrow.
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Figure 29: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. C2203T is indicated by the arrow.
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Figure 30: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. 2146-1 G-^C is indicated by the arrow.
Figure 31: Electropherograms showing the wildtype (A) and the mutant (B) PKP2 
sequences. 2489+1 G->A is indicated by the arrow.
Unfortunately, no further clinical or genotyping data on the probands’ families is 
available yet.
Discussion:
In agreement with the belief that ARVC is a disease of the desmosome, a large number 
of PKP2 mutations were found in a cohort of 120 affected individuals of German 
origin,77 suggesting that mutated forms of PKP2 are a major cause of the condition. 
However, that study lacked a detailed clinical evaluation of probands, and data on 
family members were limited. A large number of white patients with ARVC (in whom 
mutations in plakoglobin and desmoplakin had been excluded) were screened for 
mutations in PKP2. Fourteen disease-causing changes in 26 familial and sporadic
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ARVC cases were found.197,198 Furthermore, wherever possible, the families of those 
patients with PKP2 mutations were investigated both clinically and genetically to 
provide a detailed analysis of the genotype-phenotype relation in individuals carrying a 
mutation. PKP2 is known to bind desmoplakin and recruit it to the membrane, thus 
strengthening and stabilizing desmosomal interactions. 199 It can therefore be 
speculated that lack of or incorporation of mutated PKP2 into cardiac desmosomes 
impairs cell-cell contacts and as a consequence causes disruption of adjacent cardiac 
myocytes, particularly in response to mechanical stress.
The data presented herein show that clinical expression of PKP2 mutations is 
heterogeneous even among first-degree relatives ranging from a complete lack of 
symptoms and/or clinical manifestations to a severe disease phenotype. Retrospective 
evaluation of genotyped family members exposes the limitations of the currently 
available diagnostic criteria. Strict adherence to the Task Force criteria could have led 
to omitting many gene-positive relatives with incomplete disease expression, leading 
potentially to a less vigilant follow-up than may be desirable. Interestingly, in the 
families examined herein penetrance was higher in men than in women. This might be 
caused by factors such as exposure to vigorous athletic activity or biological factors 
such as the inhibitory effects of estrogens on myocardial cell apoptosis.183 Also, a 
review of the affected families with PKP2 mutations shows that the majority have 
evidence of right-sided involvement only. It can be therefore suggested that PKP2 
mutations are likely to result in predominantly RV disease but that exceptions do occur. 
None of the patients investigated in our study had cutaneous involvement. This is 
consistent with the findings by Gerull et al in which probands carrying PKP2 mutations 
were apparently free of skin abnormalities.77 In myocardial cells PKP2 is the only PKP 
isoform found in desmosomes, whereas PKP1a seems to be confined exclusively to the
1 T7nucleus. In contrast, in suprabasal cell layers of epidermis, PKP1a is detected in 
desmosomal plaques and PKP2 is located in the nucleus.153 Therefore it seems 
possible that a compensatory mechanism involving PKP1a may explain the absence of 
a skin phenotype in individuals carrying a PKP2 mutation. Conversely, mutations in 
PKP1 result in ectodermal dysplasia/skin fragility syndrome characterized by skin, hair 
and nail abnormalities but no cardiac phenotype.156 The identification of the same 
mutation in apparently unrelated probands may be due to an ancient founder effect or 
to mutational “ hot spots” along the plakophilin2 gene. Nevertheless, the fact that some 
of the mutations identified by our group were also identified by Gerull et al in a cohort of 
different ethnical origin77 may implicate the presence of recurrent mutations. However; 
unless haplotype analysis is performed this conclusion remains purely speculative.
Since the identification of the mutations herein presented, further ARVC-associated 
plakophilin2 mutations have been reported in the literature. Dalai et al reported 13
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different PKP2 mutations in 43% of the ARVC probands investigated.200 Genotype- 
phenotype correlations suggested that the presence of a PKP2 mutation correlates with 
earlier onset of symptoms and arrhythmia and that patients with a PKP2 mutation 
experience ICD interventions irrespective of the classic risk factors determining ICD 
intervention in ARVC.200 Kannankeril et al reported a novel 28 base pair insertion in 
exon 11 of the PKP2 gene in a family showing incomplete penetrance and variable 
expression of ARVC.201 Nagaoka et al reported a novel insertion in exon 8 of the PKP2 
gene in an ARVC patient of Japanese origin.202 Finally, Van Tintelen et al reported that 
the vast majority of Dutch patients fulfilling the ARVC criteria are carriers of PKP2 
mutations.203
4) Desmoalein2:
Family A:
The proband (lll:4), a 40-year old female aerobics teacher upon examination, had 
experienced episodes of sustained palpitation and recurrent pre-syncope. Her 12-lead 
ECG demonstrated sinus rhythm with poor R-wave progression, and inverted T-waves 
in V1-6 and the inferior leads (Figure 32). 2D contrast-enhanced echocardiography 
identified regional wall motion abnormalities in both ventricles and an LV apical 
aneurysm. A CMR study revealed biventricular dilatation, structural abnormalities, and 
multiple RV aneurysms in addition to the LV apical aneurysm (Figure 33). Ambulatory 
ECG (Holter) monitoring demonstrated 1400 ventricular extra-systoles in a 24 h period, 
including a triplet of non-sustained VT. An ICD was implanted. Histology of 
endomyocardial biopsy from the proband was characteristic of ARVC showing loss of 
myocardium and replacement by fibro-adipose tissue. The proband's mother (ll:2, 79 
years) was asymptomatic with a normal ECG and conventional 2D echo to the age of 
75. However, she did not undergo specific ARVC evaluation due to other medical 
problems. The proband's daughter (IV:2, aged 11) was asymptomatic. Twelve-lead 
ECG showed sinus rhythm with T-wave inversion in V1, V2, and a biphasic T-wave in 
V3. In view of her age, this finding could be considered compatible with a juvenile 
repolarization pattern and is not valid for inclusion using the current diagnostic criteria. 
Transthoracic echocardiography, however, was abnormal with an area of hypokinesia in 
the RV lateral wall (indicated with a grey symbol on the family pedigree). Individuals 
111:1 and IV: 1 were examined and found to be normal.
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Figure 32: Electrocardiogram from individual III: 4 showing characteristic T-wave 
inversion, poor R-wave progression and diminutive voltages in V5-V6 consistent with 
LV involvement.
Figure 33: CMR images from individual III: 4, four chamber view in diastole and 
systole. The black arrows indicate regions of diastolic bulging and hypokinesia in the 
RV and LV apex.
A deletion of two bases in exon 12 of desmoglein2 (1773_1774delTG) was detected in 
the proband. This mutation results in a premature termination codon in the extracellular 
domain of the DSG2 protein (C591X, Figure 34). Both the proband’s mother (ll:2) and 
daughter (IV:2) were heterozygous for the mutation, while individuals 111:1 and IV:1 
were gene-negative (Figure 35).204
Figure 34: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmoglein2 sequences. 1773_1774delTG is indicated by the arrow.
IV: 1 IV: 2
Figure 35: Pedigree of family A indicating an autosomal dominant pattern of 
inheritance for C591X with reduced penetrance. The proband is indicated by the arrow.
Family B:
The proband (111:1) died suddenly, aged 15, with ARVC identified as cause of death on 
post-mortem. Her brother (lll:3) showed widespread T-wave inversion on ECG, LV and 
RV enlargement and impaired systolic function (LV ejection fraction 25%), a positive 
SA-ECG and an excess of 3000 ventricular ectopics on 24-hour Holter monitoring, with 
salvos of non-sustained VT of predominantly RV origin. He has an ICD which has 
delivered several appropriate therapies for VT. Two more siblings (lll:2 and lll:4) were 
found to be normal upon cardiac evaluation. The proband's mother (ll:6) showed 
features of ARVC both on ECG and contrast-enhanced echocardiography. Il:6’s brother 
(11:7) was reported to have died as an infant but no post-mortem data is available. A 
deletion of 12 nucleotides (829_840delCTTGAAGGGATG) was detected in exon 8 of 
desmoglein2 gene in ll:6 (Figure 36). The mutation is predicted to result in abnormal
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splicing within the EC3 extracellular domain of the protein. Ill: 3 was also a carrier of 
the mutation, while both III: 2 and III: 4 were gene-negative (Figure 37).204
Figure 36: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmoglein2 sequences. 820_840delCTTGAAGGGATG is indicated by the 
arrow.
Figure 37: The pedigree of family B shows an autosomal dominant manner of 
inheritance for 820_840delCTTGAAGGGATG with high penetrance. All gene positive 
individuals are affected with ARVC. The proband is indicated by the arrow.
Family C:
The proband (IV:4), a young boy, was first presented with exertional syncope at age 14. 
He had diagnostic features of ARVC on ECG and imaging with gross biventricular 
enlargement and severe impairment of systolic function (LV ejection fraction 15-20%). 
An ICD was implanted following recurrent VT and there has been one appropriate 
discharge 2 years later for VF. Systolic function did not change during 10 years of
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follow-up, and he remained clinically stable. His father (111:5) also had clinical features 
suggestive of disease expression. Echo showed predominantly LV dilatation with mildly 
impaired systolic function, but also RV wall motion abnormalities. The proband’s sister 
(IV:5) and a paternal brother (111:7) were clinically normal. One paternal second cousin 
(111:1) though, fulfills the Task Force criteria for ARVC and two of his three children (IV: 1 
and IV:2) showed minor ECG and echo abnormalities, which given their young age, 
could represent an early form of the disease. His third child (IV:3) was examined and 
found to be normal.
A G-» C transversion was found in the start codon of the desmoglein2 gene in the 
proband (3G>C, Figure 38). This change alters the translation initiation codon ATG to 
ATC and leads to a substitution of a methionine by an isoleucine residue, predicted to 
abolish initiation of translation. 111:1, lll:5, IV: 1, IV:2 and IV:3 were carriers of the 
mutation, while lll:6, lll:7 and IV:5 were gene-negative. IV:3 did not show any 
phenotypic abnormalities but given the high penetrance of the mutation, based on the 
constructed pedigree (Figure 39), he is at risk of developing the condition later on in 
life. Obligatory mutation carriers are indicated with diagonal lines on the pedigree. 
Individuals showing minor abnormalities, not fulfilling the Task Force criteria are 
indicated with grey symbols on the pedigree.204
Figure 38: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmoglein2 sequences. 3G>C is indicated by the arrow.
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Figure 39: The constructed pedigree of family C shows an autosomal pattern of 
inheritance for 3G>C with high penetrance. The proband is indicated by the arrow.
Family D:
The proband (111:4), a young man, died suddenly, aged 26 and post-mortem findings 
were diagnostic of ARVC. His brother (111:3) had low voltage complexes and 
widespread T-wave inversion on ECG, RV wall motion abnormalities and fatty 
infiltration of both ventricles on CMR and non-sustained VT on exercise testing. Two 
sisters (111:2 and 111:5) are clinically normal. The proband’s mother (11:2) showed LBBB 
on ECG, but further specific clinical evaluation was not possible. A maternal sister (11:3) 
is clinically normal.
A C-> T transversion was found in exon 5 of the desmoglein2 gene in the family 
(462C>A). The mutation results in the substitution of an aspartic acid by a glutamic acid 
(D154E, Figure 40) within the EC1 extracellular domain of the protein. Both affected 
family members (lll:3 and ll:2) were carriers of the mutation, while both lll:2 and lll:6 
were gene-negative. No genetic data on the maternal sister (ll:3) is available (Figure 
41 ).204
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Figure 40: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmoglein2 sequences. 462C>A is indicated by the arrow.
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Figure 41: The constructed pedigree of family D shows an autosomal pattern of 
inheritance for D154E with a high penetrance. The proband is indicated by the arrow.
Family E:
The proband (ll:3), a man of English origin, died suddenly at 48 years of age, and his 
post-mortem was consistent with a diagnosis of ARVC. In his family, two individuals 
fulfil the Task Force diagnostic criteria for typical ARVC. The proband’s sister (ll:8) 
showed positive findings on ECG, contrast-enhanced echo and CMR, while the 
proband’s nephew (111:10) had positive findings on SA-ECG and imaging. The 
proband’s daughter (lll:4) fulfilled only the proposed modified diagnostic criteria, but 
given her young age, these minor abnormalities can be considered diagnostic (lll:4 is 
indicated by a grey symbol on the family pedigree). The proband’s father (1:1) showed 
changes confined to the LV. In particular, his cardiac imaging demonstrated an 
apparently normal RV but a dilated LV with regional wall motion abnormalities (akinesia
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of the anterior septum and apex with hypokinesia of the mid-apical inferior and anterior 
walls) and globally mild-to-moderate reduction of systolic function (EF: 40-45%). A H  
G change in exon 5 of the desmoglein2 gene was identified in the family (473T>G). The 
mutation results in the substitution of a valine by a glycine residue within the EC1 
extracellular domain of the protein (V158G, Figure 42). All affected individuals (1:1, 11:8, 
IV:4 and IV: 10) were heterozygous carriers of the mutation, while all clinically normal 
individuals were gene-negative (Figure 43).204
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Figure 42: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmoglein2 sequences. 473T>G is indicated by the arrow.
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Figure 43:The constructed pedigree for family E shows an autosomal dominant pattern 
of inheritance for V158G with high penetrance. The proband is indicated by the arrow.
Family F:
The proband (ll:3), a man of English origin, presented with recurrent syncope aged 45. 
His ECG demonstrated partial RBBB, T-wave inversion in V1-V3 and prominent epsilon 
waves. Cardiac imaging showed global enlargement of the RV with impaired systolic 
function. Recurrent VT of LBBB morphology was documented and an ICD was
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implanted. The proband’s sister (11:2) showed repolarization and depolarization 
abnormalities on ECG. Il:2’s daughters (111:1 and lll:2) showed minor ECG 
abnormalities, which however do not fulfil the Task Force criteria. They are indicated by 
grey symbols on the family pedigree. The same mutation identified in family E (V158G, 
Figure 42) was also found in family F. All affected individuals (ll:2, ll:3, 111:1 and lll:2) 
were heterozygous carriers of the mutation. Clinical and genetic screening of the 
proband’s children (111:3,111:4 and 111:5) has been deferred for the present in view of their 
young age (Figure 44).204
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Figure 44: The constructed pedigree of family F shows an autosomal dominant pattern 
of inheritance for V158G, just like in family E. The proband is indicated by the arrow.
Further desmoglein2 mutations:
In family A198, a T ->G change was identified in the desmoglein2 gene. The mutation 
(2759T>G) results in a substitution of a valine by a glycine residue within the repeat unit 
domain of the protein (V920G). Further clinical and genetic data on this family are 
presented in a later section (Chapter 1 ;7).
In family H, the proband, a woman of English origin, presented with recurrent syncope 
aged 45. Diagnostic findings included localized prolongation of QRS duration in V1-V3, 
T-wave inversion and a mildly dilated RV with regional wall motion abnormalities, in 
particular hypokinesia of the anterior RV outflow tract and of the apical lateral wall. The 
proband has had a prophylactic ICD implanted. She is a carrier of a G ->A change in 
the desmoglein2 gene (165G>A). The mutation results in the substitution of a valine by 
a methionine residue within the EC1 extracellular domain of the protein (V56M).
In family I, the proband, a man of English origin, died suddenly aged 59 years. His 
post-mortem was consistent with a diagnosis of ARVC. The proband’s asymptomatic
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son, showed positive findings on ECG, SA-ECG and echo and he was found to be a 
carrier of a G->A change in the desmoglein2 gene (1174G>A). The mutation results in 
a substitution of a valine by an isoleucine residue within the EC4 extracellular domain 
of the protein (V392I). Other family members in families G, H and I were either 
unavailable for or declined clinical and genetic screening.204
Discussion:
The identification of ARVC-causing mutations in 3 desmosomal genes (PG, DP and 
PKP2), the implication of desmoglein isoforms in disease characterized by loss of 
epidermal adhesion, and the phenotype exhibited by animals expressing defective 
desmoglein molecules, led to the idea to screen ARVC probands for mutations in 
DSG2, the only DSG isoform expressed in the heart.
Eight novel mutations in the desmoglein2 gene are described herein. All gene-positive 
individuals were screened for mutations in other candidate ARVC-causing genes and 
found negative. Also, none of the mutations were found in 400 ethnically-matched 
control chromosomes examined, which eliminates the possibility of non-pathogenic 
polymorphisms. All mutations are predicted to disrupt functionally important parts of the 
DSG2 molecule. The C591X mutation in family A is predicted to cause truncation of the 
DSG2 protein with subsequent loss of the transmembrane and cytoplasmic 
components, where the binding sites for plakoglobin and plakophilin2 are found.93,120 A 
question is whether this mutation activates nonsense-mediated mRNA decay, resulting 
in the disease phenotype due to haploinsufficiency. The small size of the cardiac biopsy 
sample obtained, which was used for immunofluorescence studies (results presented in 
chapter 2) precluded supportive immunoblotting evidence.
The 829_840delCTTGAAGGGATG mutation in family B may cause skipping of exon 8 
or alternatively activate a cryptic splice site in exon 8 or intron 8. Indeed, use of splice 
prediction computer programmes showed that the splice acceptor site for the mutant 
allele would be GTTII  GCAG//GTTG resulting in deletion of 5 amino acid residues. 
However, since heart or skin biopsies from an affected individual were not available for 
further analysis, these predictions remain purely speculative. The 3G>C mutation seen 
in family C is predicted to affect the initiation of translation of the DSG2 protein. 
Beginning of mRNA translation in eukaryotes takes place via a scanning mechanism, 
based on the first AUG codon and its flanking sequences. Studies of diseases caused 
by mutations that destroy the normal start codon have shown that translation may in 
fact start from alternative AUG codons, or be entirely abolished.205 In the case of the 
3G>C mutation it is unclear what the precise effect on the DSG2 protein would be. 
Unfortunately, cardiac tissue, which could have provided an answer, was not available 
from affected individuals in family C.
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The five missense mutations found in families D, E, F, H, I and A198 affect amino acid 
sequences highly conserved among DSG2 homologues (mouse, dog, chimpanzee and 
human). Mutations V56M and V392I disrupt conserved regions in EC1 and EC4 
extracellular domains, respectively. The extracellular domains of DSG2 and in 
particular EC1 and EC2 are involved in the formation of heterodimers between 
desmogleins and desmocollins in a Ca+2 dependent manner.123 Such interactions are 
thought vital in achieving desmosomal adhesion.93 Desmogleins contain conserved 
sequence motifs in the extracellular domains which represent putative calcium binding 
sites (DXNDN and A/VXDXD).119 The fact that all gene-negative individuals were 
clinically normal provides further evidence to support disease causation.
Although DSG2 is expressed in the epidermis, none of the individuals carrying a DSG2 
mutation had clinical evidence of hair or skin abnormalities. It is likely that other 
desmoglein isoforms expressed in the skin, specifically DSG1 and DSG3 functionally 
substitute DSG2 providing a potential explanation for the lack of cutaneous phenotype 
in DSG2 mutation carriers.
The penetrance of DSG2 mutations in the families described in this study is relatively 
high. Using the Task Force criteria as the definition of complete penetrance, DSG2 
mutations are 58% penetrant. Using the proposed modified diagnostic criteria, 
penetrance rises to 75%. ARVC is a progressive cardiac disorder and younger 
individuals with few or no clinical features may develop disease later in life. If we 
separate the gene positive individuals into age groups (20-40 and >40years of age), the 
older group shows significantly higher penetrance. It can be argued that strict 
adherence to Task Force criteria, which by definition excludes LV disease, is no longer 
defensible. In family C, individual lll:5 had almost exclusively left-sided disease, both on 
imaging and in T-wave inversion on ECG. Similarly, in family E, individual 1:1 had 
disease which clinically was restricted to the LV. If we included those with isolated LV 
involvement, the penetrance would increase to 83%. The only gene positive patient 
with no evidence of ARVC on clinical investigation was the 79-year old mother of the 
proband in family A (ll:2).Our clinical information on her is limited to a previous ECG, 
which did not show features of ARVC. However, further clinical investigation in her now 
would not be informative, as she has undergone intervention for complex coronary 
disease. This was complicated by RV perforation by a temporary pacing lead, which 
could have resulted from pre-existing structural abnormalities. Therefore, we can 
neither prove nor disprove gene penetrance in her case. Differential clinical findings 
even among members of the same family reflect once again the heterogeneity of 
disease expression in ARVC, even within individuals carrying the same mutation. The 
probands described herein, were part of a study population comprised of 86 unrelated 
patients with ARVC. The identification of DSG2 mutations in 8 families, suggests that
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DSG2 mutations contribute genetically to ARVC pathogenesis in 9.3% of the cases, 
although further studies in larger cohorts are required to confirm these numbers.
Since the identification of the mutations presented herein, further ARVC-associated 
desmoglein2 mutations have been reported in the literature. Pilichou et al reported nine 
heterozygous DSG2 mutations in 8 probands from a series of 80 unrelated ARVC 
patients.206 Of these mutations, 5 were missense, 2 were insertions-deletions, 1 was 
nonsense and 1 was a splice site mutation. Their identification of DSG2 mutations in 
10% of ARVC individuals examined is in agreement with the number presented in our 
study.206 Shortly after, Awad et al reported DSG2 mutations in 4 unrelated ARVC 
individuals, three of which are heterozygous carriers for missense mutations and one is 
a compound heterozygous for a missense and a nonsense DSG2 mutation.207
5) Desmocollin2a:
Family i:
The proband (111:1), a 44-year-old woman upon examination, was referred to the clinic 
for cardiac evaluation following episodes of syncope. She showed prolongation of QRS 
duration in both the right and left precordial leads, but no depolarization abnormalities 
on ECG. 24-hour Holter monitoring recorded frequent extra-systoles and on echo she 
showed global biventricular dilatation. She fulfilled one major and two minor Task Force 
Criteria and was thus given the diagnosis of ARVC. Following the proband’s diagnosis; 
her mother was referred for cardiac evaluation. She had long experienced palpitations 
but had never been examined. Her ECG was normal but on echo she showed mild 
segmental RV and LV hypokinesia. She thus fulfilled two minor criteria, which were not 
diagnostic, but in the context of familial ARVC may represent a mild form of the 
disease. She is indicated by a grey symbol on the family pedigree. The proband’s uncle 
(ll:3) had died of non-cardiac reasons. Il:3’s daughters though (lll:3 and lll:4) were 
examined and found normal. Also, the probands’ sister (lll:2) was clinically normal.
A deletion of a single nucleotide was detected in exon 10 of the desmocollin2 gene 
(1430delC) in the family. The mutation leads to a frameshift and is predicted to insert a 
premature termination codon at position 480 of the protein (M477fsX480, Figure:45). 
Both the proband and her mother were carriers of the mutation while all clinically 
normal family members were gene negative (Figure 46).208
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Figure 45: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmocollin2 sequences. 1430delC is indicated by the arrow.
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Figure 46: The constructed pedigree of family i shows an autosomal dominant manner 
of inheritance of M477fsX480 with incomplete penetrance. The proband is indicated by 
the arrow.
Family ii:
The proband in family ii (lll:2) died suddenly at age 15 years. Shortly prior to her death 
she had experienced a syncope episode. Her ECG at the time showed T-wave 
inversions and 24-hour ambulatory ECG showed runs of non-sustained VT. Her post­
mortem examination showed extensive fibrofatty replacement of the RV and LV 
myocardium, consistent with a diagnosis of ARVC. The proband’s father (11:1), aged 59, 
was also affected by the disease. In particular he had experienced episodes of syncope 
and palpitations; he showed prolongation of QRS duration in V1-V3 on ECG and 
segmental RV hypokinesia on echo. No arrhythmic episodes have been recorded. The 
proband’s sister (111:1), currently 19 years old, also showed mild RV hypokinesia and
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frequent extra-systoles on ambulatory ECG. Given the family history of SCD, she 
fulfilled 1 major and 2 minor Task Force criteria and was thus considered affected. 
Individual lll:3, 13 years of age upon examination, was found to be clinically normal. An 
insertion of two bases was detected in exon 17 of the desmocollin2 gene 
(2687_2688insGA) in the family. The mutation is predicted to generate a premature 
termination codon 4 amino acid residues downstream (E896fsX900, Figure:47). Both 
affected individuals (11:1 and 111:1) were heterozygous carriers of the mutation. DNA was 
extracted from cardiac tissue preserved at autopsy of lll:2, and the presence of 
E896fsX900 was also confirmed in the proband. Individual lll:3 declined genetic testing
Figure 47: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmocollin2 sequences. 2687_2688insGA is indicated by the arrow.
Figure 48: The constructed pedigree of family ii shows an autosomal dominant manner 
of inheritance for E896fsX900 with high penetrance. The proband is indicated by the 
arrow.
Two further carriers of E896fsX900:
The proband (11:1) in family iii, aged 42 upon examination, showed major structural 
abnormalities of the RV, consistent with ARVC, as well as multiple episodes of non-
(Figure:48).208
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sustained VT on ambulatory ECG. Her 12-lead resting ECG though was normal. 11:1 ’s 
brother (ll:2), had died suddenly, at age 40, and his post-mortem examination was 
consistent with biventricular ARVC. Therefore 11:1 fulfilled 2 major and 1 minor criteria 
and was thus considered affected by the disease. II: 1 ’s sister, 43 years of age upon 
examination was found to be clinically normal. The proband was a carrier of the same 
mutation also detected in family ii (E896fsX900, Figure:47). Unfortunately no tissue
was preserved from the autopsy of individual ll:2 and thus genotyping could not be
208performed. Individual ll:3 was gene negative (Figure:49).
Figure 49: The constructed pedigree of family iii. Since the proband is only an 
heterozygous carrier of the mutation, E896fsX900 is dominantly inherited, however the 
small size of the pedigree does not allow us to draw conclusions as to the degree of 
penetrance of the mutation in this family. The proband is indicated by the arrow.
E896fsX900 was also detected in a third ARVC proband who presented with a 
biventricular form of the disease. However lack of clinical and genotyping information 
on her family members prevented us from constructing a pedigree (Family iv).
Discussion:
Following the association of plakoglobin, desmoplakin, plakophilin2 and desmoglein2 
mutations with ARVC, desmocollin2 remained the only major desmosomal protein 
expressed in cardiac tissue that had not been implicated in the pathogenesis of the 
disease. Consequently, 77 ARVC patients who were screened for mutations in all other 
candidate genes and found negative, were screened for mutations in the desmocollin2 
gene. Two heterozygous DSC2 mutations, a deletion and an insertion, were detected in 
4 unrelated probands and 3 family members. Neither mutation was found in 400 
ethnically-matched control chromosomes examined. This is the first time that mutations 
in the DSC2 gene have been described in families with ARVC. Interestingly, to date, no 
mutations in other human desmocollin isoforms have been reported. Of the three 
isoforms, only DSC1 has been implicated in human disease, since it was identified as 
an auto-antigen for sub-corneal pustular dermatosis-type IgA pemphigus.209 This is in 
marked contrast to the involvement of desmoglein isoforms in several diseases,
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including ARVC, striate PPK, and autoimmune disorders. However, animal studies 
have shown that Dsc1-null mice exhibit severe skin abnormalities due to loss of cell-cell 
adhesion.210
The two DSC2 mutations presented herein are considered to be pathogenic since they 
result in frameshift and premature termination codons. In particular, mutation 
M477fsX480 is in the fourth extra-cellular cadherin repeat and is predicted to truncate 
approximately one half of the desmocollin2 protein, with loss of the transmembrane and 
cytoplasmic components. It can be speculated that this leads to a completely non­
functional mutant protein; however it is more likely that the deletion causes DSC2 
haploinsufficiency by nonsense-mediated mRNA decay.
It is believed that the binding site for plakoglobin is located within the ICS domain of the 
DSC2a isoform.211 In particular, the last 37 amino acids in the carboxy-terminal domain 
of DSC2 are essential for binding plakoglobin. Experiments in epithelial cells have 
shown that desmocollin mutants lacking this short segment in their C-terminus could 
not bind plakoglobin or effect the formation of the desmosomal plaque and the IF 
anchorage.211
Mutation E896fsX900 is located in exon 17 and would affect the C-terminus of DSC2 by 
altering 4 amino acid residues before a termination codon introduced prematurely. In 
the absence of functional studies, it is difficult to predict exactly how these two 
mutations would affect desmosomal formation. However, since desmocollins are crucial 
in cell-cell adhesion and tissue morphogenesis, it can be speculated that the absence 
of DSC2 or the incorporation of mutant DSC2 in desmosomes would result in 
structurally and functionally impaired desmosomes.
The presence of the E896fsX900 mutation in three families indicated either that this 
insertion is recurrent in patients with ARVC who harbour DSC2 mutations or that 
families ii, iii and iv have a common founder. However, haplotype analysis with use of 
microsatellite DNA markers in close proximity to the DSC2 locus in individuals carrying 
E896fsX900 identified no allele sharing, suggesting that E896fsX900 is a recurrent 
mutation. Although DSC2 expression in tissues is widespread, individuals carrying a 
DSC2 mutation did not show clinical evidence of hair or skin abnormalities. This is 
consistent with previous studies in which only a cardiac phenotype was present in 
patients with PKP2 and DSG2 mutations. Therefore, it seems likely that DSC1 and 
DSC3 compensate for a dysfunctional DSC2 isoform in epithelial cells, but not in 
cardiac myocytes where only DSC2 is expressed.
It is striking that five of seven individuals in this group had evidence of significant LV 
involvement which was more obvious than the RV disease in two individuals. The 
current Task Force criteria do not account for LV disease but the results presented 
herein would suggest that DSC2 mutations may be more frequently associated with a
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predominantly LV phenotype of ARVC. However, since this study was limited by the 
small number of mutation carriers, this observation needs to be confirmed in larger 
kindreds in future studies. In conclusion, this part of the study identified DSC2 as the 
fifth desmosomal gene causing ARVC providing further evidence that ARVC is a 
disease of cell adhesion.
6) Desmin, an ARVC-causing or simply a modifier gene?
A213V:
The proband (lll:3) in family A174 has had documented episodes of sustained VT, also 
induced on an electrophysiological study. She underwent an ablation procedure in 
1997, following which VT recurred, necessitating cardioversion. Her most recent ECG 
showed inverted T-waves in both right and left precordial leads while a previous MRI 
investigation showed a grossly dilated RV with wall motion abnormalities and prominent 
fibrosis in the LV infero-lateral wall. Given the severity of the disease expression, she is 
now being considered for an ICD implantation. The proband’s father (ll:4) also had a 
history of palpitation. His ECG and SA-ECG were normal; however he showed isolated 
premature ventricular contractions of predominantly LV origin during exercise. On 
contrast echo, he presented with a mildly dilated RV. He is currently being treated with 
flecainide. The proband’s brother (111:1) presented with late potentials on SA-ECG and 
an MRI investigation showed a mildly dilated RV with regional wall motion 
abnormalities. Exercise testing and 24-hour Holter monitoring showed only rare PVCs. 
The proband’s mother (ll:5) and sister (lll:2) showed only minor abnormalities of 
uncertain significance and were not considered to be affected by ARVC. Individual lll:4 
presented with late potentials on SA-ECG, multi-focal PVCs on exercise testing and 
256 PVCs on Holter monitoring. An MRI scan showed mild RV and LV dilatation. 
Individual lll:5 was suspicious but not diagnostic of ARVC. She had a history of 
palpitations and syncope, although the latter was usually triggered by pain or fever. Her 
ECG showed inverted T-waves in V1-V2, an MRI showed mild wall motion 
abnormalities while her Holter and exercise testing were unremarkable.
A transition was detected in the proband in the gene coding for desmin. The mutation 
substitutes an arginine for a valine residue within the highly conserved 1B helix of the 
rod domain (A213V, Figure:50). Seven family members were genotyped, and other 
than the proband, none was a carrier of the mutation. It seemed therefore, that A213V 
had arisen de novo (Figure:51). Of note is that A213V was also identified in 1 of 200 
ethnically-matched control individuals examined, raising doubts concerning the 
pathogenecity of the mutation.
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Figure 50: The electropherograms show the wildtype (A) and mutant (B) sequences of 
the desmin gene. A213V is indicated by the arrow.
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Figure 51: The constructed pedigree of the family A174 shows that A213V has arisen 
de novo and does not co-segregate with the disease phenotype in the family. The 
proband is indicated by the arrow.
A213V was also detected in two more probands with early disease onset and 
biventricular involvement since a young age. Like in the case of family A174, A213V 
seemed to have arisen de novo, and did not co-segregate with disease expression in 
the families (data not shown).
A285V:
The proband (III: 1) in family A19, was first referred for cardiac evaluation following a 
syncope episode at age 15. His ECG was consistent with an ARVC diagnosis, showing 
T-wave inversions in V1-V4, prolongation of QRS duration and epsilon waves. On 
echo, he showed global dilatation and hypokinesia of both ventricles, also confirmed by 
MRI. An SA-ECG performed recently, showed late potentials and he also had previous
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documented episodes of non-sustained VT. His mother (11:2) died suddenly at age 40. 
Her medical history had been unremarkable. Her post-mortem examination was 
consistent with ARVC. The proband’s sister (111:2) was asymptomatic and showed 
borderline LV enlargement upon examination. She also had positive late potentials on 
SA-ECG on one occasion. She does not fulfil the Task Force criteria, but in the context 
of a familial disease, and given her young age, these findings could represent an early 
form of ARVC. She is indicated by a grey symbol on the family pedigree. The proband’s 
grandmother (1:2) was also affected by the disease based on both ECG and echo 
abnormalities. Individuals 11:2, 11:5 and 11:7 were clinically normal. A transition was 
detected in the gene coding for desmin in 111:1. The mutation substitutes an arginine for 
a valine residue within the 2A helix of the rod domain (A285V, Figure:52). Six family 
members were genotyped, and other than the proband, none was a carrier of the 
mutation. It seemed therefore, that A285V had arisen de novo (Figure:53).
Figure 52: The electropherograms show the wildtype (A) and mutant (B) sequences of 
the desmin gene. A285V is indicated by the arrow.
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Figure 53: The constructed pedigree of the family A19 shows that A285V has arisen de 
novo and does not co-segregate with the disease phenotype in the family. The proband 
is indicated by the arrow.
116
A285V was also detected in one more proband with early disease onset and 
biventricular involvement since a young age. Like in the case of family A19, A285V 
seemed to have arisen de novo, and did not co-segregate with disease expression in 
the family (data not shown).
Discussion:
Pathogenic mutations in the type I and II epidermal keratins occur within regions 
thought to be involved in keratin intermediate filament assembly, namely the H1
1 78domain, the helix initiation motif, the L12 linker region and the helix termination motif. 
Mutations in these regions of the supra-basally expressed keratins K1 and K10 underlie 
bullous congenital ichthyosiform erythroderma/epidermolytic hyperkeratosis. However, 
two missense mutations outside the “ hot spots” have been identified in exon 9 of the 
gene coding for keratin 1 (Kl) in individuals presented with striated PPK. Both mutations 
seem to affect intermolecular connections rather than filament assembly.178, 212 
Mutations in the gene coding for the IF protein desmin have been implicated in an 
heterogeneous group of diseases collectively known as desmin myopathies. More 
specifically, two splice site mutations (IVS3+3A->G and IVS-1G->A) were found to 
underlie two unrelated cases of sporadic skeletal and cardiac myopathy.213 Also, two in­
frame deletions (E359_S361del and N366del) were associated with three cases of 
skeletal or cardio-skeletal myopathy.214 A337P was identified in a family with adult- 
onset skeletal myopathy and mild cardiac involvement, while compound heterozygosity 
for A360P and N393I was detected in another family characterized by childhood onset 
aggressive course of cardiac and skeletal myopathy.215 Mutations N342D and 1451M 
were identified in two families with features of adult-onset slowly progressive skeletal 
myopathy without cardiomyopathy.216 1451M has previously been associated with a 
case of idiopathic DCM, raising the point that the tail of desmin may play an important 
functional role exclusively in cardiac tissue.217 Finally, the R406W mutation was 
identified in a sporadic patient presented with symmetrical muscle weakness and 
atrophy combined with atrio-ventricular conduction block.218 The pathological hallmark 
of all these cases was the accumulation of mis-folded mutant desmin forming toxic, 
insoluble cytoplasmic aggregates. 180
Although the anchorage of the IF network to the membrane may be disrupted in the 
context of ARVC, cytoplasmic aggregation of mis-folded filaments has not been 
reported. However, given the high similarity of desmin and keratin I and the implication 
of desmin C-terminal mutations in cases of cardiomyopathy without skeletal muscle 
involvement 217, it has been suggested that mutations in exon 9 of desmin may be 
affecting the intermolecular connections, rather than the assembly of the IF network, 
thus causing ARVC instead of a more generalized cardio-skeletal myopathy.217 ARVC
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probands that were previously screened for mutations in desmoplakin, plakoglobin, 
desmoglein2, desmocollin2 and plakophilin2 and found negative were screened for 
mutations in exon 9 of the desmin gene. After no sequence changes were identified, 
the same cohort of patients, was screened for mutations along the entire length of the 
desmin gene.
Two mutations were identified, A213V and A285V, in a total of 5 ARVC probands. Both 
mutations had arisen do novo, as is the case with many previously reported desmin 
mutations, and did not co-segregate with the disease phenotype in the families. A213V 
has previously been implicated in a case of restrictive cardiomyopathy,219 and in a case 
of progressive skeletal myopathy without cardiac involvement (M.de Visser, 
unpublished datam ). In particular, Bowles et al. have performed in vitro experiments to
71Qestablish the pathogenetic mechanism of A213V. Cells expressing the mutant protein 
are able to assemble IFs under resting conditions. However the IF network breaks 
down when the cells are exposed to mechanical stress.219 This observation is in 
agreement with the hypothesis that desmosomal ARVC-causing mutations affect 
primarily the cardiac myocytes since they are constantly subjected to mechanical 
stress. Interestingly, a recent study comparing the phenotypic, molecular and functional 
characteristics of seven desmin mutations including A213V, suggested that A213V 
exhibits a pathogenic potential only if combined with other mutations in desmin or other 
genes and should therefore be considered conditionally pathogenic.220 Based on this 
suggestion, and on the observation that the probands carrying either mutation show a 
much more severe phenotype than their ARVC-affected relatives, it can be speculated 
that A213V and A285V are not pathogenic. Instead, they act synergistically with other 
yet un-identified mutations to worsen the expression of the disease.
Of note is a publication by Melberg et al in 1999 concerning a family with both 
myofibrillar myopathy and ARVC.221 Although limited by the small number of mutation 
carriers, these results indicate that desmin mutations, though not disease-causing per 
se, may still play a role in ARVC pathogenesis.
7) Mutations in two desmosomal genes:
Family A198:
The proband (111:1) presented with SCD at age 15 years. Initial post-mortem 
examination did not identify a cause of death. However, subsequent expert review of 
histology identified fibro-fatty replacement predominantly of LV myocardium. The 
proband’s mother (ll:4) had experienced an isolated unexplained syncope episode at 
age of 42. Her ECG showed T-wave inversion in precordial leads V1-V3 and
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flat/inverted T-waves in precordial leads V4 and V5. There was localized prolongation 
of QRS duration in V1 to V4 and poor R-wave progression. SA-ECG was positive for 
late potentials. Cardiac imaging identified RV dilatation with aneurysms of the RV free 
wall, and the LV was mildly dilated with mild systolic impairment. She had frequent 
ventricular ectopics and couplets at low workloads on exercise testing (LBBB 
morphology). 24-hour ECG showed less than 50 ventricular ectopics during 24 hours of 
recording. The mother’s siblings have declined screening investigations or genetic 
testing. One nephew (lll:3) has been evaluated and shows no evidence of disease 
expression. The proband’s father (ll:3) has never experienced cardiac symptoms. His 
ECG was unremarkable but SA-ECG was reproducibly positive for late potentials. 
Cardiac imaging showed regional wall motion abnormalities of the RV. Specifically he 
showed segmental hypokinesia of the anterior RV outflow tract and apical free wall. He 
also showed global mildly reduced systolic function. The proband’s brother (lll:2), his 
father’s siblings (11:1 and ll:2) and extended family have refused clinical or genetic 
testing.
Mutation analysis in the mother revealed a nonsense mutation (1237C>T) in exon 5 of 
the plakophilin2 gene. The mutation is predicted to signal premature termination of 
translation within the armadillo repeat domain of the protein (R413X, Figure:54). 
Mutation analysis in the father revealed a missense mutation (2759T>G) in 
desmoglein2. The mutation alters a highly conserved valine for a glycine residue within 
the repeat unit domain of the protein (V920G, Figure:55). A small amount of tissue from 
the proband was made available for DNA extraction. Unfortunately, DNA of adequate 
quantity was not obtained so we suspect but cannot confirm whether the proband had 
inherited both mutations (Figure:56). The clinical characteristics and genotype of this 
family are included in: Ward et al. “ Multiple desmosomal gene mutations in familial 
ARVC result in a more severe phenotype” ; manuscript submitted to Circulation.
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Figure 54: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) plakophilin2 sequences. 1237C>T is indicated by the arrow.
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Figure 55: Electropherograms of the sense strands showing the wildtype (A) and 
mutant (B) desmoglein2 sequences. 2759T>G is indicated by the arrow.
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Figure 56: The constructed pedigree of family A198. “ + ” indicates a carrier of the 
V920G mutation in the desmoglein2 gene. “ * ” indicates a carrier of the R413X 
mutation in the plakophilin2 gene. Unfortunately, lack of genetic data did not allow us to 
establish the mode of inheritance or the penetrance of the two mutations. The proband 
is indicated by the arrow.
Discussion:
The presence of 2 mutations in A198.1 could only be assumed because of his SD at a 
very young age, evidence of biventricular involvement based on histological 
examination of an autopsy sample and both his parents being carriers of different 
disease-causing mutations. A case of confirmed compound heterozygosity for two 
novel nonsense desmoplakin mutations was presented in detail above (Chapter 1:1). 
From the ARVC cohort examined, compound heterozygosity for two desmosomal 
mutations was confirmed in 6 probands and assumed in 1 (not all cases presented 
herein). The clinical presentation in these 7 probands was significantly more severe
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than in those family members evaluated clinically and genetically. The presence of a 
severe phenotype with compound mutations at a relatively young age is to some 
degree analogous to the findings in Naxos disease. In Naxos families, homozygous 
individuals for plakoglobin mutations have 100% penetrance by adolescence, while 
20% of heterozygous adults have some evidence of disease expression without 
fulfilling the Task Force criteria.60 This suggests that at least in young patients 
presenting with significant arrhythmia and marked morphological changes, the 
possibility of 2 mutations should be considered.
Although only a small percentage of the cohort examined had two documented 
mutations, this represents 13% of all families in whom any desmosomal mutation was 
found. This is similar to the reported occurrence in HCM, where between 3 and 5% of 
cohorts have been found to carry two sarcomeric gene mutations. Such patients were 
shown to present earlier, display a greater degree of hypertrophy, a more frequent 
need for surgical septal reduction and have a higher familial incidence of SD.222,223 
The finding of double mutations in 13% of the probands with confirmed desmosomal 
ARVC was not anticipated. Understanding of the mechanism and predisposing factors 
for 2 mutations is limited. There is however nothing to suggest that having a mutation in 
one gene should predispose to having another mutation in another gene. These are 
then assumed to be independent events and suggest that mutations in desmosomal 
genes are more common than previously estimated. In HCM, the prevalence of clinical 
disease in young adults is estimated to be approximately 1 in 500. Though mutation 
analysis has only been performed in small numbers, studies revealed that between 5- 
17% of patients with confirmed sarcomeric HCM have more than one mutation.222 The 
fact that at least as many ARVC patients appear to have 2 mutations, in a clinical 
condition with an estimated prevalence that is only one tenth of that of HCM, may relate 
to the clinical difficulties of making an accurate diagnosis and reliance on diagnostic 
criteria which are recognized to be very specific but insensitive. Patients with ARVC 
may suffer disease-related complications including SCD during what is considered to 
be the concealed phase of the disease. Clinical diagnosis based on existing criteria is 
problematic for recognition of early disease. This highlights the importance of 
developing more sensitive clinical diagnostic criteria and the potential importance of 
mutation analysis of all the recognized genes in the assessment of families.
Finding a mutation may help the diagnostic clarification of "borderline” cases. Also, 
although the clinical course of the disease cannot be predicted from DNA analysis, it 
can help identify individuals at risk, thus facilitating timely diagnosis, with the 
subsequent possibility of preventing complications and reducing morbidity and 
mortality. Genetic predisposition may lead to alteration in lifestyle such as avoiding 
strenuous exercise. Given the low penetrance, however, a mutation carrier is not
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automatically assumed to be destined for the severe phenotype that once was 
encountered in a family member. However, advances in molecular biology will enable 
cascade screening in family members with a high negative-predictive value. It is 
common practice to cardiologically screen close relatives of an index case at regular 
intervals. Identifying a pathogenic mutation in a family, would allow family members 
who have not demonstrated abnormalities and do not carry the respective mutation to 
be dismissed from regular cardiological follow-up.183
Finally, it is important to mention that of the 47 cases in which a single mutation was 
identified, 4 probands who presented with a more severe phenotype than other 
mutation carriers in their families, had additional desmosomal mutations, now 
recognized as polymorphisms. The possibility exists that these supposed 
polymorphisms are frequently occurring mutations which in isolation are not 
significantly pathogenic, but in the presence of other mutations may have a synergistic 
effect on disease expression.
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Moving to the next step:
Early daguerreotype photographs required long exposure times, so long that the only 
visible features were permanent and stationary, such as roads, bridges and buildings. 
The lack of dynamic features, such as crowded streets, rendered the scenes empty and 
lifeless. The rest had to be imagined. So it is sometimes with genetics. The 
identification of mutations gives invaluable information when it comes to genetic 
disorders. However, we still have a daguerreotype in which we have to imagine the 
dynamic processes leading from the mutation to the actual disease phenotype.224 
Discovering gene mutations provides a strong foundation. However, considerable in 
vitro and animal work is needed before we can transfer this translational research from 
the laboratory bench to the bedside.225
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CHAPTER 2:
“Histopathology and immunohistochemistry 
studies of heart and skin samples from 
ARVC patients”
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FOUNDATIONS AND OVERVIEW:
In 2004, the heart of an 11-year-old girl diagnosed with Carvajal syndrome was 
macroscopically and microscopically examined.64 Histological investigation disclosed 
diffuse scarring of the free walls of both ventricles with areas of extensive myocardial 
loss and replacement fibrosis in the outer third of the LV. There was no evidence of 
fatty infiltration in either ventricle. Myocyte hypertrophy and attenuation with bizarre 
nuclei and non-specific myocytolytic changes were prominent. Scant, patchy foci of 
inflammatory cells were visible adjacent to degenerative myocytes and TUNEL staining 
revealed an increased apoptotic index in both ventricles. The distribution of intercalated 
disc proteins was characterized by immunohistochemistry and confocal microscopy. 
Immunoreactive signal for desmoplakin, the mutant protein in Carvajal syndrome, was 
virtually undetectable at intercellular junctions where abundant signal was seen in 
controls that had undergone similar fixation and processing. Immunoreactive signal for 
plakoglobin was also markedly diminished as was signal for Cx43, the major cardiac 
gap junction protein. The amount and distribution of selected transmembrane adhesion 
proteins including N-cadherin and desmocollin2 appeared to be normal. Finally, desmin 
failed to localize at intercalated discs, suggesting that interactions between desmin and 
desmoplakin are disrupted in Carvajal syndrome.64
Similarly, the amount of Cx43 immunoreactive signal localized to intercalated discs was 
markedly reduced in both right and left ventricular samples from 4 patients with Naxos 
disease compared to controls.226 Quantitative analysis showed that Cx43 signal at 
junctional sites was diminished to a greater extent in pathologic areas of the RV than in 
the LVs of patients with Naxos disease, and that it was significantly reduced even in a 
young patient who did not exhibit clinical or pathologic features of structural heart 
disease. The amount of immunofluorescence signal for plakoglobin, the mutant protein 
in Naxos disease, was also dramatically reduced at cell-cell junctions, while N- 
cadherin, desmoplakin, desmocollin2 and a-catenin, all exhibited normal localization.226 
Pathologically, ARVC is characterized by the presence of fat and fibrous tissue 
embedded within degenerative, apoptotic cardiac myocytes with the occasional 
presence of inflammatory infiltrates. Following the publications described above, it 
appears that mutations in one desmosomal gene have cascade effects on the amount 
and localization of further mechanical and electrical proteins at cell-cell junctions. A 
number of heart and skin samples from ARVC patients with known or yet un-identified 
mutations have been analysed by histological examination, immunostaining and 
confocal microscopy. Herein we shall present the results obtained and discuss their 
implications in understanding and managing the disease.
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METHODS:
1) Tissue acquisition and processing for microscopy and immunohistochemistry:
The tissue samples were excised, rinsed in phosphate buffered saline (PBS) and fixed 
in 10% neutral-buffered formalin. Each formalin-fixed sample was subsequently cut into 
transverse slices ~1mm thick, dehydrated in a series of alcohols, embedded in paraffin, 
sectioned at a thickness of ~6pm, and mounted on gelatin-coated slides (VWR 
International). The slides were deparaffinised and re-hydrated by serial immersion in 
xylene, 100% ethanol, 70% ethanol, 50% ethanol and distilled water (dH20).
2) Hematoxylin and eosin staining (H&E):
Sections were over-stained with hematoxylin for 3-5min. Sections were then 
differentiated and de-stained through serial immersions in acidic alcohol (usually 4-5
immersions) until they looked red. The sections were immersed in blueing agent for
2min until the nuclei were stained sharp blue, following which they were rinsed with 
dH20  and immersed in 70% ethanol for 3min. Slides were then immersed in eosin for 
2min and cleared through a series of 95% ethanol solutions. The hematoxylin stain is 
made from hematoxylin powder (6.4g), ammonium alum (60g), ethanol (200ml), 
glycerol (160ml) and dH20  (640ml). Acidic alcohol is made by mixing 4 ml of
hydrochloric acid with 396ml of 95% ethanol. Eosin stain is made by mixing 1 g of
Eosin Y, with 5 ml of glacial acetic acid and 1 It of dH20  and subsequently diluting the 
solution 1:1 with 70% ethanol. Finally, blueing agent is made by diluting 1 g of 
bicarbonate blue in 1 It of dH20. This technique stains fat white, nuclei dark blue/purple 
and residual tissue (cardiac myocytes or epithelial cells) light red.
3) Masson’s trichrome staining:
Deparaffinised and re-hydrated sections were stained first in Weiger’s iron hematoxylin 
working solution and then in Biebrich scarlet-acid fuchsin solution. The sections were 
then differentiated in phosphomolybdic-phosphotungstic acid solution and transferred to 
aniline-blue solution. The slides were then further differentiated in 1% acetic acid 
solution, dehydrated through 95% ethyl alcohol, absolute ethyl alcohol and xylene 
before being mounted with resinous mounting medium. Weiger’s iron hematoxylin 
solution is prepared by mixing equal parts of stock solutions A (1 g hematoxylin, 100ml 
95% ethanol) and B (4ml 29% ferric chloride in dH20, 95 ml dH20, 1 ml 1M HCI). 
Biebrich scarlet-acid solution is prepared by mixing 90ml 1% aqueous Biebrich scarlet, 
10ml 1% aqueous acid fuchsin and 1ml glacial acetic acid. Phosphomolybdic- 
phosphotungstic acid solution is prepared by mixing 25 ml 5% phosphomolybdic acid 
solution with 25ml 5% phosphotungsitc acid solution. Aniline blue solution is made by
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dissolving 2.5g of aniline blue and 2ml of glacial acetic acid in 100 ml dH20. Finally, 1% 
acetic acid solution is prepared by diluting 1ml of glacial acetic acid in 99ml of dH20. 
This technique stains collagen fibers blue, fat white, nuclei black and residual myocytes 
red.
4) Immunohistochemistry
In preparation for immunohistochemistry, deparaffinised, re-hydrated slide-mounted 
sections were placed in citrate buffer (10mmol/l, pH 6.0) and heated in a microwave 
oven until boiling for 10min to enhance specific immunostaining. After being cooled to 
room temperature, the tissue sections were rinsed in PBS (5min) and simultaneously 
permealised and blocked by incubating them in PBS containing 1% Triton X-100, 3% 
normal goat serum (Jackson Immunoresearch) and 1% bovine serum albumin (BSA, 
SIGMA). The sections were then incubated with the primary antibody (diluted 1:10- 
1:2000 in blocking buffer depending on preliminary data for condition optimization) 
overnight at 4°C, brought to room temperature, washed three times in PBS and 
incubated with indocarbocyanine-conjugated goat anti-rabbit or anti-mouse IgG (diluted 
1:400 in PBS) for 2 hours at room temperature. Following incubation with the 
secondary antibody, the sections were washed three times in PBS and mounted with 
mounting medium made by mixing equal volumes of PBS and glycerol.
Primary antibodies included: mouse monoclonal anti-connexin43 (Chemicon), mouse 
polyclonal anti-desmoplakin I & II (Fitzgerald), mouse monoclonal anti-plakoglobin 
(SIGMA), mouse monoclonal anti-pan cadherin (SIGMA), mouse monoclonal anti- 
desmoglein2 (AbCam), mouse monoclonal anti-desmocollin2/3 (ZYMED), rabbit 
monoclonal anti-connexin43 (SIGMA), rabbit polyclonal anti-connexin43 (ZYMED), 
rabbit polyclonal anti-beta catenin (AbCam) and mouse monoclonal anti-pan 
desmoglein (AbCam). Secondary antibodies included cyanine 3 (Cy3) conjugate affini- 
pure goat anti-mouse IgG (H+L, Jackson Immunoresearch) and Cy3 conjugate affini- 
pure goat anti-rabbit IgG (H+L, Jackson Immunoresearch). Immunostained 
preparations were analysed by laser scanning confocal microscopy (Sarastro model 
2000, Molecular Dynamics, Figure: 1) as described below.227
5) Analysis of immunoreactive signal by confocal microscopy:
Stained sections from each tissue sample were examined by fluorescence microscopy 
at a magnification of x400 using a x40 oil immersion lens with numerical aperture of 
1.0, lateral resolution of 0.23 pm, and depth resolution of 1.06pm. Use of this lens in 
combination with a 50-pm pin hole resulted in a full-width, half-maximal focal plane with 
a thickness of ~1.0 pm. Each individual test area encompassed ~26.400 pm2 and 
included profiles of 30-50 cells. Five test areas were analysed for each antibody in each
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tissue sample. Each test area was scanned by the laser at the approximate mid-depth 
of the section and digitized into a 1024 x 1024 matrix. In general, the level of 
background fluorescence was low and the immunoreactive material recognized by all 
antibodies was concentrated in discrete spots at points of intercellular apposition. The 
low background and highly localized intense signal facilitated the identification of a 
signal intensity threshold exceeded only by the specific discrete spots of signal at 
appositional membranes. Accordingly, an arbitrary threshold was identified for each set 
of sections stained with a given primary antibody that clearly distinguished the high- 
intensity signal concentrated in discrete spots from all other areas in the test field. Any 
structures with a signal intensity that exceeded this threshold were assumed to 
represent electrical or mechanical adhesion components of the intercalated discs. A 
much lower threshold value was also identified below by which only areas of the slide 
not covered by cells were defined. Thus, the proportion of total tissue area occupied by 
gap junctions or anchoring junctions was defined as the number of pixels with signal 
intensity exceeding the high threshold divided by the total number of pixels exceeding 
the lower threshold. The percentage of total test area occupied by tissue was defined 
as the total number of pixels exceeding the low threshold divided by the total number of
227pixels in the image space.
6) Tissue processing for electron microscopy:
The tissue samples were excised, rinsed in PBS and fixed for 24 hours in 2% 
glutaraldehyde in 0.1mmol/l cacodylate buffer (pH 7.4). The fixed tissue was then post­
fixed in 1% 0 s0 4, dehydrated in ethanol and embedded in Spurr’s low-viscosity epoxy 
resin. After the resin had been polymerized, ultra-thin (50-100 nm) sections were 
prepared and examined by electron microscopy.227
Figure 1: Confocal microscope, Sarastro model 2000, Molecular Dynamic
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RESULTS AND DISCUSSION
1) H isto logical exam ination o f heart sam ples:
Heart biopsy samples from individuals diagnosed with ARVC according to the Task 
Force criteria and heart autopsy samples from individuals with confirmed ARVC 
postmortem were stained with hematoxylin& eosin and Masson’s trichrome for 
microscopic examination. Heart autopsy samples from individuals with no history of 
heart disease were stained using the same conditions for control purposes. 
Representative images and observations are presented below.
Control A. B. C and D:
Figure 2. Heart autopsy samples from individuals with no history of heart disease, who 
died of non heart-related etiology were stained with H&E (A and B) and Masson’s 
trichrome (C and D). Magnification 10x (A and C) and 20x (B and D). Samples A, B and 
C were obtained from the LV, while sample D was obtained from the RV.
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A1.1: case presented in Chapter 1 (pg. 67-68)
Figure 3: Heart autopsy samples from a female who was diagnosed with ARVC 
postmortem were stained with H&E (A and B) and Masson’s trichrome (C and D). 
Magnification x4 (A) and x20 (B, C and D). All samples were obtained from the RV.
A208.1: case presented in Chapter 1 (pg. 73-74)
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Figure 4: Heart autopsy samples from a female who was diagnosed with ARVC 
postmortem were stained with H&E (A and B) and Masson’s trichrome (C and D). 
Magnification x4 (C), X10 (D) and x20 (A and B). Sample A was obtained from the LV, 
while samples B, C and D were obtained from the RV.
D0074: case presented in Chapter 1 (pg. 84-85)
Figure 5: Heart biopsy samples from a male diagnosed with ARVC in his early-40s 
were stained with H&E (A) and Masson’s trichrome (B). Magnification is x20 in both 
images. Both A and B were obtained from the affected RV.
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GR3. case presented in Chapter 1 (pg. 94-95)
Figure 6: Heart biopsy samples from a male diagnosed with biventricular ARVC in his 
teens were stained with Masson’s trichrome. Magnification x20 (A) and x40 (B). Both A 
and B were obtained from the RV.
A188.1: case presented in Chapter 1 (pg. 95-96)
Figure 7: Heart autopsy samples from a young male who was diagnosed with ARVC 
postmortem were stained with H&E (A and B) and Masson’s trichrome (C and D). 
Magnification x20 in all images. Samples A and C were obtained from the LV, while 
samples B and D were obtained from the RV.
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Family A, Individual III: 4 case presented in Chapter 1 (pg. 98-100)
Figure 8: Heart biopsy samples from a female diagnosed with biventricular ARVC in 
her early-30s were stained with H&E. Magnification is x20 in both images. Both A and B 
were obtained from the affected LV.
A176.1:
Figure 9: Heart autopsy samples from a male who was diagnosed with ARVC 
postmortem were stained with H&E (A and B) and Masson’s trichrome (C and D). 
Magnification x20 (A, B and D) and x10 (C). Samples A and C were obtained from the 
LV, while samples B and D were obtained from the RV.
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A223.1:
Figure 10: Heart autopsy samples from a male in his early teens whc was diagnosed 
with ARVC postmortem were stained with H&E (A and B) and Masson’s trichrome (C 
and D). Magnification x20 in all images. Samples A and C were obtained from the LV, 
while samples B and D were obtained from the RV.
A220.1:
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Figure 11: Heart autopsy samples from a male in his mid-40s who was diagnosed with 
ARVC postmortem were stained with H&E (A and B) and Masson’s trichrome (C and 
D). Magnification x4 (C), x10 (A and B) and x20 (D). Sample D was obtained from the 
LV, while samples A, B and C were obtained from the RV.
Among the 9 individuals examined, 2 were carriers of desmoplakin mutations, 1 was a 
carrier of a plakoglobin mutation, 2 were carriers of plakophilin2 mutations, 1 was a 
carrier of a desmoglein2 mutation and 3 individuals, diagnosed with ARVC postmortem, 
were at the time screened for mutations in plakoglobin and desmoplakin and found 
negative (Table 3).
ARVC case Figure Mutation Outcome
A1.1 3 DP: R1113X Nonsense, premature truncation
A208.1 4 DP: 1218+1G^A Splice site, premature truncation
D0074 5 PG: S39 K40insS Insertion, additional serine residue
GR3 6 PKP2: V837fsX930 Deletion, premature truncation
A188.1 7 PKP2:2146-1G^C Splice site, exon skipping
Family A, III: 4 8 DSG2: C591X Nonsense, premature truncation
A176.1 9 Unknown .
A223.1 10 Unknown .
A220.1 11 Unknown _
Table 3: ARVC-causing mutations of patients examined histologically.
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In A208.1 (Figure 4), A1.1 (Figure 3) and A176.1 (Figure 9) there is massive fibrofatty 
infiltration in the RV while in the LV, cardiac myocytes are primarily replaced by fibrotic 
tissue. In A188.1 (Figure 7), A III: 4 (Figure 8) and A2201. (Figure 11) there is extensive 
fibrofatty replacement in both ventricles. In particular, in A188.1 there is also evidence 
of disarray amongst the residual myocytes of the RV, but not of the LV, which is 
typically a characteristic of HCM instead of ARVC. This case provides another piece of 
evidence for the great phenotypic variation characterizing the disease. In D0074 
(Figure 5), there is fibrofatty replacement in the RV. A biopsy from the LV was not 
obtained. Clinically, the proband does not show evidence of left ventricular disease 
however this does not preclude the possibility of minor histological abnormalities being 
present in the LV muscle. Finally, in GR3 (Figure 6) and A223.1 (Figure 10) there is 
only fibrous tissue embedding residual myocytes in the RV and in both ventricles 
respectively. Collectively in all cases, a marked decrease in myocardial fibers with 
myocardium usually replaced with an inconstant amount of fat and/or fibrous tissue was 
evidenced. Noteworthy, at higher magnification, degeneration of the remaining 
myocytes with dystrophic and pyknotic nuclei was detected; a typical characteristic of 
cell death.
Discussion:
Embryologically the heart, like the rest of the cardiovascular system, develops from a 
tubular channel. Its basic organization of tissues is divided into three layers: the 
endocardium, the myocardium and the epicardium. The myocardium is the thickest 
layer and consists primarily of cardiac myocytes with intervening connective tissue, 
blood vessels and nerves. In the normal heart, a certain amount of fatty tissue is always 
present within the myocardium of the RV free wall particularly at the level of the antero­
lateral and apical regions. However, this fatty infiltration is not associated with fibrosis, 
is confined to specific areas, occupies less than 3% of the myocardium and the cardiac 
muscle fibers seem to be pushed apart by the fat rather than degenerating.228 
Histologically, cardiac muscle consists of myocytes (fibers) of about 15-20 pm diameter 
and 120 pm length. Cells are branched and are joined to each other at their ends by 
intercalated discs. Linder a light microscope, cardiac muscle shows a number of cross- 
striations which represent the Z-discs. Each myocyte has one or two nuclei, sited 
centrally. The region around each nucleus is filled with mitochondria, Golgi apparatus 
and glycogen (Figure 2).229
The analysis of a large series of SCDs from the Veneto region of Italy prompted the 
subdivision of the ARVC pathology into 2 distinct patterns based on the nature of 
myocardial replacement: if myocytes are replaced by fat it is recognized as the fatty or
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lipomatous pattern, while if myocytes are replaced by fat as well as by fibrous tissue, it 
is recognized as the fibrofatty or the fibrolipomatous pattern.230 In the fatty variant, the 
adipose tissue reaches the endocardium (transmural infiltration) and the wall thickness 
may even increase (pseudo-hypertrophy). The antero-lateral and infundibular regions 
are usually affected, whereas the postero-inferior wall appears normal. Small areas of 
fibrous tissue, usually focal and only detectable at higher magnification power may exist 
but could be overlooked with limited histological sampling. This fatty pattern is usually 
confined to the RV, sparing both the septum and the LV, with only occasional cases of 
aneurysms.231232 Burke et al. reviewed 25 hearts from SCD with either pattern.233 Most 
of the patients with the lipomatous pattern were female, they were significantly older, 
none had a history of arrhythmia or family history of arrhythmia and SCD and in almost 
every case, there were one or more factors present that could possibly have 
contributed to the SCD of the patient.233 In the fibrofatty variant, the wall is thinner and 
translucent, and in nearly 50% of the cases, saccular aneurysms are visible at the 
apex, the infundibulum or at the postero-inferior wall. Involvement of the ventricular 
septum occurs in 20% and of the LV in 47% of the cases. At histology, myocardial 
substitution by extensive replacement-type fibrosis and fatty tissue is evident, with 
aspects of myocyte degeneration, features indicating an injury and repair process. The 
fibrofatty variant also exhibits in two thirds of the cases inflammatory cell infiltrates 
associated with focal myocyte necrosis. This pattern seems more prone to electrical 
instability and SD and may progress with time to heart failure.232 Following this 
distinction though, the controversy arose as to whether pure fatty replacement of the 
RV actually represented a true pathologic entity.234
The current belief is that pure fatty infiltration is an entity that should not be considered 
as ARVC and that is not necessarily a cause of death when identified at autopsy. A 
diagnosis of ‘‘sudden cardiac death in a heart with extensive RV fatty infiltration” would 
be better, because it does not imply a cause-effect relationship and leaves the door 
open for other hypotheses on the final cause of death. 235 Fat is possibly the least 
reliable criterion for the diagnosis of ARVC and should be viewed in conjunction with 
other histopathological features that refer to both myocytes and fibrous tissue 
deposition. In keeping with the current belief, all cases presented herein are of the 
fibrolipomatous pattern and involve a wide spectrum of histological abnormalities in 
association with the evident fatty infiltration. When a pathologist is dealing with a case 
of SCD in which the only morphologic finding consists of an increased amount of fat, a 
more convincing arrhythmogenic substrate, such as myocardial inflammatory infiltrates, 
fibrosis, anomalous pathways and ion channel disease should always be searched for 
to avoid over-diagnosis of ARVC. The expectation is that molecular biology will make a 
difference in cases where the differential diagnosis is difficult to consent to a
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postmortem genetic diagnosis. Meanwhile, the need to adopt strict diagnostic criteria is 
warranted not only in the clinical setting, but also in the pathology arena. These criteria 
are mandatory both for epidemiological purposes and for clinical implication, since the 
identification of a genetic disease as the cause of an individual’s death is the starting 
point for familial screening and consequently timely disease management and 
prevention of SCD.228
Of note is that the individuals where only fibrotic replacement was observed (GR3 and 
A223.1) were significantly younger than the rest of the group. Also, in A208.1, A1.1 
and A176.1 there was fibrofatty replacement in the RV, while there was primarily 
fibrous tissue embedding the residual myocytes in the LV. These observations help 
enlighten our knowledge when it comes to the evolution of ARVC. The disease 
advances with age, and the LV involvement becomes increasingly severe. Fletcher et 
al. suggested that in the context of ARVC, muscle is gradually replaced by fibrosis first 
in the RV and then in the LV, which changes to fat as the disease advances. The 
presence of fat may explain why older people present with heart failure, while the 
predominance of fibrosis in the younger age may explain sudden death.236 This 
hypothesis, currently widely accepted, is in contrast with the evolutionary pathway 
suggested by Fontaine et al, according to whom myocarditis is superimposed on the 
background of myocardium interspersed by fat, eventually transforming the fatty to the 
fibrofatty form.237
The question therefore arises whether there is a role for myocarditis in the frame of 
ARVC. The inflammatory/infective theory supports that the disease is expressed in the 
presence of a viral trigger. This theory does not exclude a familial occurrence, since 
genetic alteration regarding host immunological status or myocyte receptor may 
predispose the patient to viral infection. However, this theory can not explain the large 
number of ARVC cases where no evidence of inflammation and/or infection is present. 
It is therefore more likely that a genetic alteration, instead of predisposing the patient to 
viral infection, may bring about by itself changes of structural and functional proteins. In 
this case, the possible viral genome or inflammatory infiltrate detection in ARVC should 
be interpreted differently. The viral agent might either be an innocent bystander or play 
a secondary but still important role, such as promoting ventricular arrhythmias by 
itself.238 Hoffman et al. studied reperfusion arrhythmia and demonstrated for the first 
time the role played by the activation of neutrophils in producing early after­
depolarizations.239 These results demonstrate a direct link between inflammation and 
an electrophysiological phenomenon that is a possible trigger of arrhythmias.240 
In 2000, a 40-year old woman with a clinical diagnosis of DCM underwent cardiac 
transplantation. 241 Upon gross examination of the heart, the clinical diagnosis was 
challenged and the pathologic diagnosis of ARVC was given instead. Histologically,
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myocytes adjacent to the adipose tissue showed multiple sarcoplasmic vacuoles, 
ultrastructurally confirmed as lipid droplets. This case posed a dilemma when it comes 
to the foundations of ARVC: do cardiac muscle cells transform into adipocytes, or do 
they undergo apoptosis and subsequently get replaced by fat and fibrous tissue?
In 1996 the case of an infant, who died aged 7 weeks from heart failure was 
presented.242 Microscopic examination of the heart showed massive apoptotic 
destruction of the RV, sparing the LV and both atria. James et al. argued that postnatal, 
the RV wall is excessively but disadvantageously thick and that programmed cell death 
is responsible for reducing the thickness of the wall to achieve optimal conduction and 
function.242 James et al. suggested that in the case of this infant, apoptosis started but 
was not “ turned o ff ’.242 ARVC is rarely manifested in infancy and becomes fully 
penetrant in adolescence. It would therefore seem impossible that non-switching off of 
the postnatal apoptotic process is responsible for this entity. There is however a role for 
apoptosis
Apoptosis in all metazoan cells is mediated by caspases, a multi-gene family of 
cysteine proteases that hydrolyze peptide bonds. Synthesized as zymogens, pro- 
caspase activation involves cleavage and re-association of two fragments into a 
functional holo-enzyme. Caspases can be activated by at least two mechanisms: either 
already activated upstream caspases cleave pro-caspases or certain pro-caspases can 
be auto-activated when forced in close proximity through interactions with other 
proteins.243 Nishikawa et al. examined the apoptotic index in a number of pediatric 
ARVC cases, where no profound structural abnormalities were present versus a 
number of adult cases, where significant fibrofatty replacement was evident.244 There 
was no statistically significant difference in the numbers obtained suggesting that 
apoptosis was a primary phenomenon that preceded fibrofatty degeneration.244 The 
precise triggering factors for apoptotic myocardial death though, remain to be 
elucidated.55 If we accept that mutations in the RyR2 gene may underlie certain cases 
of ARVC, we could claim that altered levels of Ca+2 could be triggering apoptosis. 
Moreover, plakoglobin, the gene found to underlie Naxos disease, is an apoptotic 
inhibitor,245 thus a mutation that impairs the function of this protein, could be affecting 
the balance of programmed cell death. As mentioned at the beginning of the chapter, 
mutations in one junctional component may alter the expression levels and distribution 
patterns of other adhesion molecules. It can therefore be hypothesized that alterations 
in the localization of plakoglobin due to primary defects in other desmosomal proteins, 
could promote myocyte cell death. Furthermore in certain cases the super-imposed 
presence of inflammatory infiltrates could be involved in the propagation of 
programmed cell death. Finally, mutations in genes involved in programmed cell death, 
such as CPP-32 cannot be ruled out and have to be examined in the future.
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2) Histological and microscopic examination of ARVC skin samples:
Skin biopsy samples were obtained from an ARVC patient bearing a nonsense 
mutation in DSG2 (A, III: 4, pg. 98-100) and an ARVC patient, found to be a compound 
heterozygous for two novel nonsense desmoplakin mutations (A131.1, pg. 74-79). The 
skin samples were stained with H&E and examined under a light microscope. An 
additional skin sample was obtained from A III: 4 and processed accordingly for 
electron microscopy examination. Characteristic images and observations are 
presented below.
Figure 12: H&E staining of a skin biopsy sample obtained from A, III: 4 (magnification 
x20).
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Figure 13: Electron microscopy of a skin section from A III: 4. Individual desmosomes 
are indicated by the arrows.
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Figure 14: Microscopic appearance of a plantar skin biopsy sample obtained from 
A131.1 (magnification x40).
Discussion:
The human skin is composed of three primary layers: the epidermis, the dermis and the 
hypodermis. The epidermis, the outermost layer of the skin, forms the waterproof 
protective wrap over the body’s surface and is made up of stratified squamous 
epithelium and an underlying basal lamina. The main type of cells that make up the 
epidermis are keratinocytes while melanocytes and Langerhans cells are also present. 
It can be further sub-divided into the stratum corneum, the stratum lucidum, the stratum 
granulosum, the stratum spinosum and the stratum germinativum, also known as the 
stratum basale. Cells are formed through mitosis at the basale layer. The daughter cells 
move up the strata changing shape and composition as they die due to isolation from 
their blood source. The cytoplasm is released, keratin is inserted while the cells finally 
reach the stratum corneum and slough off, a process known as desquamation.246 
A skin sample was obtained from a female individual diagnosed with ARVC and 
processed for histological and electron microscopy examination. A III: 4 (pg. 98-100) is 
a carrier of a nonsense mutation in DSG2, which causes premature termination of 
translation within the extracellular portion of the protein. No microscopic abnormalities
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were evident under the light microscope (Figure 12), and similarly, both the number and 
structure of desmosomes appeared normal under the electron microscope (Figure 13). 
The observations indicate that possibly other desmoglein isoforms (primarily DSG1 and 
DSG3) can compensate for the defect in DSG2 in the patient’s skin, therefore 
preventing the development of cutaneous abnormalities.
On the other hand, the plantar skin biopsy sample obtained from A131.1 (pg. 74-79) 
showed marked hyperplasia of the corneal layer (hyperkeratosis) and suprabasal 
clefting between the granular and keratin layers, mimicking acantholysis. The stratum 
spinosum demonstrated widening of the intercellular spaces, a feature known as 
spongiosis, supporting the finding of a cell adhesion defect underlying the disease. 
The basal cells however appeared normal (Figure 14). The proband was a compound 
heterozygote for two desmoplakin mutations (Q673X and Q1446X), which both lead to 
premature termination of translation within the N-terminal and the central domain of the 
protein respectively. Lack of desmoplakin tails can be compatible with life as cells 
bearing the truncated protein can still assemble unless they are subjected to stress. 
This can explain why the proband’s basal epidermal layer appeared normal in the 
histological examination, as it is subjected to less stress compared to the suprabasal 
layers. Another plausible explanation could be that the lack of an intact desmoplakin 
peptide can be compensated by another member of the plakin family or that IF 
assembly is differentially controlled at the basal layers. No other desmoplakin mutation 
carrier of those presented in Chapter 1 showed any gross cutaneous abnormalities. 
This can be explained by the fact that apart from A131.1, all other patients examined 
had one complete functional desmoplakin allele which might have been enough to 
maintain epidermal integrity. However, skin samples from individuals bearing the 
desmoplakin mutations presented in Chapter 1 were not obtained; therefore the 
presence of minor histological or ultrastructural abnormalities cannot be excluded.
3) Immunohistochemistry: mechanical adhesion molecules:
A number of tissue samples from individuals diagnosed with ARVC, were stained for 
selected mechanical adhesion proteins and examined by confocal microscopy. 
Samples were obtained both from patients with an identified ARVC-causing mutation 
and from patients with an un-identified pathogenic mechanism. A total of 13 heart and 4 
skin samples were examined. Three heart and three skin samples from individuals with 
no history of heart disease were subjected to the same immunostaining protocol and 
used for control purposes. Since only once specimen per case was available, statistical 
analysis could not be performed.
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Figure 15: Immunostaining against plakoglobin in control heart tissue (A, B) and in 
tissue from a patient with Naxos disease (C, D). Confocal quantitative analysis (E). The 
error bars represent standard deviations.
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Figure 16: Immunostaining against desmoplakin in control heart tissue (A, B) and in 
tissue from a patient with Carvajal syndrome (C, D). Confocal quantitative analysis (E). 
The error bars represent standard deviations.
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Figure 17: Immunostaining against N-cadherin, plakophilin2, plakoglobin and 
desmoplakin in control heart tissue (A) and in two ARVC patients with identified 
desmoplakin mutations (B and C). The graph shows quantitatively the mean signal per 
protein, per sample as measured by confocal microscopy.
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Figure 18: Immunostaining against N-cadherin, plakophilin2, plakoglobin and 
desmoplakin in control heart tissue (A) and in two ARVC patients with identified 
plakophilin2 mutations (B and C). The graph shows quantitatively the mean signal per 
protein, per sample as measured by confocal microscopy.
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Figure 19: Immunostaining against N-cadherin, plakophilin2, plakoglobin and 
desmoplakin in control heart tissue (A) and in an ARVC patient with an identified 
plakoglobin mutation (B). The graph shows quantitatively the mean signal per protein, 
per sample as measured by confocal microscopy.
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Figure 20: Immunostaining against N-cadherin, plakophilin2, plakoglobin and 
desmoplakin in control heart tissue (A) and in two ARVC patients with identified 
desmoglein2 mutations (B and C). The graph shows quantitatively the mean signal per 
protein, per sample as measured by confocal microscopy.
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Figure 21: Immunostaining against N-cadherin, plakophilin2, plakoglobin and 
desmoplakin in control heart tissue (A) and in an ARVC patient bearing a desmoplakin 
and a plakophilin2 mutation (B). The graph shows quantitatively the mean signal per 
protein, per sample as measured by confocal microscopy.
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Figure 22: Immunostaining against N-cadherin, plakophilin2, plakoglobin and 
desmoplakin in control heart tissue (A) and in 3 ARVC patients with non-yet identified 
pathogenic mutations (B, C and D). The graph shows quantitatively the mean signal per 
protein, per sample as measured by confocal microscopy.
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In both specimens obtained from individuals with an identified ARVC-causing 
desmoplakin mutation (1218+1 G->A, R1113X), the immunoreactive signal for 
desmoplakin and plakoglobin was significantly reduced at cell junctions compared to 
controls, while there was no obvious difference in the expression levels of N-cadherin 
and plakophilin2 (Figure 17). The same was true for the sample obtained from the 
individual with a plakoglobin ARVC-causing mutation (S39_K40insS, Figure 19). In both 
specimens obtained from individuals with an identified ARVC-causing plakophilin2 
mutation (2146 -1G->C, V837fsX930), the immunoreactive signal for all plakophilin2, 
desmoplakin and plakoglobin was significantly reduced at cell junctions compared to 
controls, while there was no obvious difference in the expression levels of N-cadherin 
(Figure 18). The same was true for the samples obtained from the two individuals with 
a desmoglein2 ARVC-causing mutation (C591X, T335A, Figure 20) and from the 
compound heterozygous for a desmoplakin and a plakophilin2 mutation (DP R270X, 
PKP2 R735Q, Figure 21). Finally, in all three specimens with unidentified molecular 
changes, plakophilin2, desmoplakin and plakoglobin were all down-regulated at the cell 
junctions compared to controls, while the levels of N-cadherin were undistinguishable 
(Figure 22). All 8 positively genotyped individuals were heterozygous carriers of the 
respective mutations. Though reduced, there was still immunoreactive signal at cell 
junctions corresponding to the “pathogenic” protein (i.e. the protein encoded by the 
mutant gene). Conversely, immunostaining for plakoglobin in a Naxos disease 
specimen (Figure 15) and desmoplakin in a Carvajal syndrome specimen (Figure 16) 
rendered no signal, highlighting the difference between homozygous and heterozygous 
carriers of ARVC-causing mutations. The results obtained are summarized in Table 4.
Specimen N-cadherin PKP2 DP PG
Carvajal syn. Not examined Not examined Immeasurable Not examined
Naxos disease Not examined Not examined Not examined Immeasurable
A208.1 (DP) Unaltered Unaltered Reduced Reduced
A1.1 (DP) Unaltered Unaltered Reduced Reduced
D0074 (PG) Unaltered Unaltered Reduced Reduced
A188.1 (PKP2) Unaltered Reduced Reduced Reduced
GR3 (PKP2) Unaltered Reduced Reduced Reduced
A,iii:4 (DSG2) Unaltered Reduced Reduced Reduced
DanA (DSG2) Unaltered Reduced Reduced Reduced
A176.1 (u/a) Unaltered Reduced Reduced Reduced
A220.1 (u/a) Unaltered Reduced Reduced Reduced
A223.1 (u/a) Unaltered Reduced Reduced Reduced
151
Table 4: Immunoreactive signal of ARVC specimens compared
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Figure 23: Immunostaining against plakoglobin and desmoplakin in control plantar skin 
tissue and in a plantar skin sample from an ARVC patient identified as a compound 
heterozygote for two nonsense desmoplakin mutations. The graph shows quantitatively 
the mean signal per protein, per sample as measured by confocal microscopy.
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Figure 24: Immunostaining against plakoglobin and desmoplakin in control skin tissue 
and in a skin sample obtained during an ICD implantation procedure from an ARVC 
patient heterozygous for a desmoglein2 mutation. The graph shows quantitatively the 
mean signal per protein, per sample as measured by confocal microscopy.
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Figure 25: Immunostaining against E-cadherin, plakoglobin, desmoplakin, pan- 
desmoglein and desmoglein2 in control skin tissue (A), in a skin sample obtained from 
an ARVC patient heterozygous for a desmoglein2 mutation (B) and an ARVC patient 
homozygote for the same desmoglein2 mutation (C).The graph shows quantitatively the 
mean signal per protein, per sample as measured by confocal microscopy.
Discussion:
Immunohistochemistry of heart specimens with antibodies against adhesion molecules 
gives characteristic images where intercalated discs stand out decorating and adjoining 
myofibrils. Immunostaining of heart samples from patients with Carvajal syndrome64 
and Naxos disease226 showed a significant decrease in the immunoreactive signal for 
desmoplakin and plakoglobin, and for plakoglobin, respectively, leading to the 
hypothesis that a molecular defect in one structural adhesion molecule may have 
effects on the localization pattern and expression levels of other desmosomal proteins. 
A total of 11 heart autopsy/biopsy samples from individuals diagnosed with ARVC were 
stained for N-cadherin, plakophilin2, desmoplakin and plakoglobin to add further 
evidence to this hypothesis and draw conclusions that could in the future facilitate 
timely disease diagnosis and guide genetic screening. Five sections of each specimen 
were examined quantitatively by confocal microscopy. For each section, the number of 
pixels with signal intensity exceeding the high threshold was divided by the total 
number of pixels exceeding the lower threshold. Mean values were then calculated and 
used to compare protein expression levels between ARVC and control heart samples. 
All specimens were stained for N-cadherin. Being a major component of adherens,
A B C A B C A B C A B C A C
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rather than desmosomal junctions, N-cadherin was not anticipated to be affected by 
defects in desmosomal proteins. It was therefore used for control purposes. 
Postmortem autolysis may alter the structure of the tissue, giving misleading 
information during immunohistochemical studies. The fact that N-cadherin levels at 
intercalated discs in all ARVC specimens were not significantly different from control 
specimens precluded non-specific postmortem and/or post-fixation effects.
A question arises whether the proteins whose localization is reduced at the cell 
junctions are actually expressed at normal levels but fail to traffic to the intercalated 
discs or are expressed at lower levels altogether due to decreased transcription or 
increased destruction. Unfortunately, the small amount and the type of fixation of the 
tissue samples available precluded Western immunoblotting analysis, which could have 
provided an accurate answer. However, Western immunoblotting performed on a 
sample from a patient with Naxos disease, showed that the mutant plakoglobin is in fact 
expressed at control levels in the patients’ hearts but fails to make it to the cell 
membrane.226 We could therefore hypothesize that the same is true for the cases 
presented herein, however considering the lack of supporting immunoblotting evidence, 
at this point, this hypothesis is purely speculative. A possible explanation for the 
abnormal distribution of desmosomal proteins is outlined below.
It is believed that desmosome assembly depends on the formation of cadherin/catenin 
complexes as cells which lack E-cadherin/plakoglobin complexes cannot form 
desmosomes.247 The head domain of PKP2 is known to bind the N-terminal part of 
desmoplakin and target it to the membrane.248 Both individuals A188.1 (Figure 18B) 
and GR3 (Figure 18C) bear PKP2 mutations that do not affect the head of the protein. 
Nevertheless since, as shown by the images presented, mutant PKP2 fails to localize 
at the cell borders in these cases, localization of desmoplakin is expected to be altered 
as well. The same stands for individual D0074 (Figure 19B), who bears a mutation in 
plakoglobin. In plakoglobin-deficient keratinocytes, both localization of DP at the cell 
membrane as shown by immunohistochemistry and expression levels of DP as shown 
by Western immunoblotting are significantly reduced.249 Plakoglobin is known to bind 
desmoplakin and recruit it to the desmosomes. It is therefore understandable how a 
defect in the gene coding for plakoglobin could lead to altered distribution of 
desmoplakin in this patient’s heart. In another study though, desmoplakin was shown to 
be able to bind desmosomal cadherins even in the absence of plakoglobin,250 which 
could explain the presence of immunoreactive signal, though reduced, at the cell 
junctions of D0074’s heart sample. Furthermore, the head domain of plakophilin2 is 
able to bind the tails of desmosomal cadherins including DSG1, DSG2, DSC1 and 
DSC2, and this interaction seems sufficient to drive PKP2 to the cell borders.154 These
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data may explain why PKP2 levels at the cell membrane are not altered in the presence 
of the S39_K40insS plakoglobin mutation.
Binding of desmogleins to plakoglobin is facilitated by a small region in the cytoplasmic 
domain of the cadherin molecules and particularly in the intracellular cadherin segment 
domain.251 This part of DSG2 would be absent in the specimen obtained from individual 
A iii: 4 (C591X, Figure 20B), thus impairing interactions between DSG2 and 
plakoglobin. The cytoplasmic part of DSG2 is also responsible for its interaction with 
PKP2,154 which could explain why PKP2 is down-regulated in this specimen. 
Desmoplakin binds desmosomal cadherins either directly, or through plakophilin2 and 
plakoglobin. In any case, since DSG2, PKP2 and PG are all mis-localized in the 
patient’s sample, distribution of desmoplakin would also be expected to be affected. 
Desmosomal adhesiveness is a multi-step process mediated by heterophilic 
interactions between desmocollins and desmogleins. In particular, the N-terminal 
domains of the two desmosomal cadherin types bind in a Ca+2-dependent manner.252 
C591X does not affect the N-terminal part of the protein. It could therefore be 
speculated that the interaction of DSC2 with DSG2 would not be affected. Still, the 
mere binding of a desmocollin to a desmoglein isoform is not adequate to provide 
adhesion.253 Expression of DSG and DSC in the absence of plakoglobin in mouse L 
cells resulted in no adhesion.254 Individual Dan1 (Figure 20C) bears a missense 
mutation which affects a crucial, highly conserved amino-acid within the extracellular 
domain of the cadherin (T335A). In the presence of this mutation, binding of DSG2 to 
DSC2 would be disrupted consequently leading to mis-localization of all 3 plaque 
proteins.
It is known that the plakin repeat domains of desmoplakin are responsible for binding 
intermediate filaments and anchoring them to the membrane.255 Since desmoplakin 
localization is altered in all specimens examined, irrespective of the pathogenic 
mutation underlying the disease, it would be logical to hypothesize that the IF network 
in all these samples would be affected and that the desmin protein would be re­
distributed. Immunostaining with a desmin antibody could help prove this hypothesis. It 
is of note that desmin failed to localize at intercalated disks in Carvajal syndrome 
myocytes suggesting that interactions between desmin and desmoplakin are disrupted 
in the presence of this desmoplakin mutation.64
Although the number of the specimens examined was small, certain preliminary 
conclusions could be drawn. It seems that when an ARVC patient is harboring a 
desmoplakin or a plakoglobin mutation, only the distribution of desmoplakin and 
plakoglobin is altered. On the other hand, when an ARVC patient is harboring a 
mutation in plakophilin2 or in a desmosomal cadherin, plakophilin2, desmoplakin and 
plakoglobin are all down-regulated at intercalated discs. In all three specimens obtained
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from individuals with non-yet identified mutations (A176.1, A220.1 and A223.1, Figure 
22B, C, D) all 3 plaque proteins were mal-distributed. Could we therefore hypothesize 
that these three patients are harboring mutations either in PKP2 or in a desmosomal 
cadherin? A much higher number of specimens would have to be examined before 
these preliminary conclusions can be confirmed. Screening a patient for mutations in all 
ARVC-candidate genes is a time-consuming and uneconomical procedure, while 
immunostaining of a tissue sample is relatively quick and inexpensive. If in the future, 
immunostaining could guide genetic screening, so that time and expenses could be 
reduced, it would be a highly significant step forwards towards an accurate and timely 
disease diagnosis and possibly genotype-related prognosis. Still, obtaining a heart 
biopsy is an invasive procedure to be performed merely for the purpose of research 
immunostaining. However, all desmosomal proteins are also present in the skin and 
even if an ARVC patient does not show any gross cutaneous abnormalities, similar re­
distribution of selected adhesion molecules would be expected to be also found in 
keratinocytes.
Immunohistochemistry of a sample obtained from the affected plantar skin of an ARVC 
patient bearing two nonsense desmoplakin mutations (Q673X, Q1446X) showed 
diminished expression levels of desmoplakin and plakoglobin (Figure 23). Since both 
mutations lead to premature termination of translation and truncation of the C-terminal 
domain of desmoplakin, an antibody directed against the head domain of the protein 
was used. The presence of signal corresponding to desmoplakin at the cell membrane, 
albeit reduced, suggests that Q1446X and/or Q673X do not lead to nonsense-mediated 
mRNA degradation. Immunoblotting studies to measure the presence of either or both 
truncated peptides in the proband’s epidermis were not possible due to the limited 
amount of tissue obtained. However, because the first 584 amino acids of the 
desmoplakin N-terminal domain are known to bind plakoglobin and cluster the 
desmosomal cadherin-plakoglobin complexes256 it can be speculated that even the 
peptide bearing the Q673X mutation could, if present, localize at the cell membrane. 
Immunohistochemistry of a skin sample obtained from the chest of an ARVC patient 
bearing a DSG2 nonsense mutation (C591X) did not show altered expression levels or 
distribution for both plakoglobin and desmoplakin (Figure 24). As mentioned earlier in 
the chapter, DSG2 though the only desmoglein isoform expressed in the heart, is not 
the major isoform expressed in keratinocytes. A defect in DSG2 could be compensated 
by other isoforms, particularly DSG1 and DSG3 at the epidermis, which could explain 
the unaltered expression of both plaque proteins compared to control tissue. Similarly, 
immunohistochemistry of a skin sample from an ARVC patient heterozygous for a 
missense DSG2 mutation and a patient homozygous for the same missense mutation 
(T335A) using antibodies that recognize E-cadherin, desmoplakin, plakoglobin and an
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epitope present in all desmoglein isoforms did not show any significant differences in 
protein expression compared to control samples (Figure 25). It was only when an 
antibody specifically directed against DSG2 was used, that the signal was virtually 
absent in the homozygous mutation carrier (Figure 25). The lack of profound 
differences in the localization of mechanical adhesion molecules in the 3 latter 
specimens may explain the lack of cutaneous manifestations in these patients.
Of note is that in all specimens examined, plakoglobin expression was depressed at the 
cell junctions whether the sample was obtained from the heart or from the epidermis, 
possibly suggesting a final common molecular pathogenetic pathway underlying ARVC. 
Indeed, plakoglobin is shown to increase stability and recruitment of all desmosomal 
components and is also known to act as a rheostat that tunes the strength of 
connections in response to environmental cues.249 Whether down-regulation of 
plakoglobin is merely due to its adhesive properties or could also be related to its 
signaling role remains to be elucidated. Also, prior to concluding that mis-localization of 
plakoglobin is specifically related to ARVC, samples from individuals diagnosed with 
other heart conditions, such as DCM, HCM or even ischemic heart disease must be 
subjected to the same staining protocol and examined quantitatively by confocal 
microscopy. If however this finding is indeed confined to ARVC cases, it would provide 
a very useful tool in assigning a definite diagnosis. Given the vast phenotypic variation 
of ARVC, and its overlapping clinical features with other conditions, such a molecular 
tool could greatly help resolve the existing problems in differential disease diagnosis.
4) Immunohistochemistry: electrical coupling molecules:
As mentioned in the introduction a number of experiments have shown that the 
assembly of mechanical adhering junctions is a pre-requisite for the assembly of 
electrical coupling junctions.113,114 A question therefore arises whether in the frame of 
ARVC a defect in desmosomes would also disrupt the formation and maintenance of 
gap junctions. Indeed, the amount of Cx43 immunoreactive signal localized at cell 
junction sites was markedly reduced in heart samples obtained both from patients with 
Naxos disease226 and Carvajal syndrome.64 To investigate whether reduction of Cx43 
at intercalated discs is a consistent feature in diverse genetic forms of ARVC, 10 heart 
and 1 skin samples were immunostained for Cx43, the major ventricular gap junction 
protein, and examined quantitatively by confocal microscopy. Since only once 
specimen per case was available, statistical analysis could not be performed. 
Representative images are presented below.
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Figure 26: Immunostaining against Cx43 in control heart tissue samples (A-E) and in 
heart specimens obtained from ARVC patients with known or yet-non identified 
mutations. The graph shows quantitatively the mean Cx43 immunoreactive signal per 
sample as measured by confocal microscopy.
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Figure 27: Immunostaining against Cx43 in control plantar skin tissue (A) and in a 
plantar skin sample from an ARVC patient identified as a compound heterozygote for 
two nonsense desmoplakin mutations (B).The graph shows quantitatively the mean 
Cx43 immunoreactive signal per sample as measured by confocal microscopy.
Discussion:
Mammalian ventricular myocytes are connected by numerous gap junctions. More than 
enough current flows across the borders, so that conduction in the normal ventricular 
muscle occurs in a highly continuous fashion as if current is flowing through a uniform 
conductive medium rather than across a network of discrete, individual conducting 
units. However, because the membrane containing the gap junctions is potentially 
susceptible to disruption due to shear stress, there is a risk that the gap junctions may 
encounter deleterious effects, caused by contractile activity. This may explain why gap 
junctions are always surrounded by cell-cell adhesion junctions, which presumably 
stabilize the sarcolemmas of the inter-connected cells and create membrane regions 
conducive to the formation and maintenance of large arrays of gap junctions.257 The 
degree to which neighboring cells are coupled by gap junctions depends on the 
structure and function of adhesion junctions. Cells with limited mechanical connections 
are unable to maintain normal gap junction communication. For instance, highly 
malignant tumors, typically composed of dys-cohesive cells, are also communication- 
deficient.258,259 A similar situation occurs in cardiomyocytes. When freshly 
disaggregated rat ventricular cardiomyocytes are placed in culture and allowed to re­
form cell junctions, the initial event in the re-formation of the intercalated disc is the 
development of adherens junctions and it is not until adherens junctions are well 
formed that gap junctions develop.260,113 In Naxos disease226 and Carvajal syndrome,64 
there is a marked decrease of immunoreactive signal for Cx43 at the cardiac
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intercalated discs. Collectively, these observations led to the hypothesis that defects in 
cell-cell adhesion or discontinuity in the linkage between mechanical junctions and the 
cytoskeleton, may lead to remodeling of gap junctions, which in turn may cause 
conduction disturbances and increase the risk for life-threatening arrhythmias. To 
investigate if gap junction remodeling occurs generally in the set of ARVC, irrespective 
of the specific genetic background underlying the disease, 10 heart samples were 
immunostained for Cx43 and examined quantitatively by confocal microscopy.
In all specimens analyzed, there was a significant decrease in the amount of Cx43 
localized at cell junctions. Careful observation of the samples under the confocal 
microscope indicated that normal-sized gap junctions are still formed, though 
significantly fewer in number. This is in agreement with immunofluorescence studies 
performed on ventricular myocytes isolated from heterozygous Cx43 knockout mice. In 
this animal model, ventricular myocytes become interconnected by a reduced number 
of normally sized gap junctions, rather than a normal number of smaller junctions. 
Maintenance of normally sized electrical junctions may be an adaptive response 
supporting safe ventricular conduction.261 In Naxos disease, although Cx43 signal at 
the cell borders is reduced, the protein is still abundantly expressed in the myocardium, 
but just fails to localize at the intercellular junctions. These results suggest that in 
Naxos disease, remodeling of gap junctions is not due to reduced expression of Cx43, 
but due to defects in gap junction assembly and/or trafficking.257 Immunoblotting studies 
that would have supported this hypothesis in the cases presented herein were not 
possible due to the limited amount of tissue available. Nevertheless, though the 
numbers examined were small, a new horizon is emerging, where gap junction 
remodeling seems to be characterizing ARVC regardless of the causative mutation. 
Remodeling is a change in the structure of an organ in response to injury or disease. In 
the heart, remodeling starts with alteration in gene expression, which in turn leads to 
alterations in the types and amounts of proteins expressed. Alterations in structure are 
accompanied by alterations in function, although the structure-function relationships 
have only recently started to be unraveled. Remodeling happens to aid adaptation of an 
organ to change.262 For instance, formation of scar tissue following a myocardial infarct 
is a beneficial response, as it helps avoid ventricular rupture. Similarly hypertrophy, as 
a response to increased mechanical load, may also be beneficial as it aids the heart 
deal with the increased pressure it is subjected to. However, though beneficial, these 
changes have maladaptive consequences. In the frame of ARVC, remodeling of gap 
junctions, which may diminish communication between healthy tissue and apoptotic, 
dys-cohesive cells, may change the electrical activation of the heart and offer the 
substrate for lethal ventricular arrhythmias.263,264
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Still, are gap junction alterations by themselves enough to promote arrhythmogenesis? 
An approximately 50% reduction causes significant conduction velocity slowing in the 
Cx43 +/- mouse heart but no spontaneous arrhythmias.265 However, reduced 
expression of Cx43 accelerates the onset and increases the incidence, frequency and 
duration of ventricular tachyarrhythmias after coronary artery occlusion.266 In the 
absence of secondary stimuli, in the absence of an appropriate trigger, just the 
presence of the substrate, such as decreased Cx43 localization at intercalated discs is 
not enough to bring about arrhythmias.267 Analysis by positron emission tomography 
and l-meta-iodobenzylguanidine (l-MIBG) scintigraphy have shown significantly 
increased amounts of nor-epinephrine at the synaptic clefts and markedly reduced 
density of postsynaptic beta-adrenergic receptors underlying myocardial sympathetic 
dys-innervation and arrhythmogenesis in ARVC patients.268,269 Dying cells in the ARVC 
heart may themselves exhibit transiently increased automaticity, while the mere 
presence of fat and fibrous tissue within the myocardium would alter the normal route of 
RV activation, thus providing an anatomic substrate for micro-reentrant or macro­
reentrant circuits.242 What if these defects are coupled with alterations in electrical 
communication? Gap junction remodeling may by itself not be arrhythmogenic. 
However, super-imposed on the structural and functional abnormalities characterizing 
ARVC, it may act synergistically to cause ventricular tachycardias, late potentials and 
epsilon waves that may lead to SCD.226
Eight different connexins, including Cx43 are expressed in the epidermis with 
overlapping expression patterns in different epidermal layers.270 A plantar skin sample 
obtained from an ARVC patient bearing two nonsense desmoplakin mutations was 
immunostained for Cx43 and examined by quantitative confocal microscopy. Not only 
was the signal for Cx43 markedly reduced in the affected skin sample, but the protein 
was also mis-localized, being restricted mainly to the spinal layer, instead of across all 
epidermal layers as demonstrated by controls (Figure 27). Abnormal distribution of 
Cx43 in keratinocytes has also been observed in mouse skin carcinogenesis,271 while 
transgenic mice lacking the C-terminal region of Cx43 demonstrate a defective 
epidermal barrier.272 Though not the mere causative agent, the altered Cx43 expression 
observed in the sample examined may in fact contribute to the profound cutaneous 
abnormalities demonstrated by the patient (case discussed in Chapter 1).
Altered patterns of cardiac electrical junction distribution have also been observed in 
HCM,273 DCM274 and ischemic cardiomyopathy.275 In fact, gap junction remodeling 
seems to be a common finding in the failing heart. Though not exclusive to ARVC, the 
results presented herein may contribute to the understanding of the mechanisms of 
arrhythmogenesis underlying the disease and open new horizons for future 
investigations.
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5) Beta catenin: another player in ARVC?
Beta-catenin null mice die during gastrulation due to abnormalities in the development 
of all embryonic structures276 while plakoglobin null mice on a C57BL/6 genetic 
background, develop further and die around birth due to severe heart defects.74 The 
two armadillo proteins are structurally very similar with occasionally overlapping 
adhesive and signaling properties. As discussed above, down-regulation of plakoglobin 
at intercalated discs seems to be a constant feature in ARVC. The redundancy 
between the two catenins suggests that beta-catenin may be up-regulated in ARVC 
cell-cell junctions thus compensating for the reduced amounts of plakoglobin. To 
investigate this hypothesis, 4 ARVC heart samples with known mutations were 
immunostained for beta-catenin and examined by confocal microscopy. The samples 
were also stained for N-cadherin to preclude non-specific postmortem effects.
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Figure 28: Immunostaining against N-cadherin and beta-catenin in control heart tissue 
samples (A-D) and in heart specimens obtained from ARVC patients with known 
mutations. The graphs show quantitatively the mean immunoreactive signal per protein, 
per sample as measured by confocal microscopy.
Discussion:
A major lesson learned from gene knockout studies in mice is that functions of many 
proteins overlap significantly, which enables the organism to carry out many 
physiological processes when a key component in a biological pathway is genetically 
eliminated. Another lesson has to do with the “other side of the coin” , namely the multi­
functionality characteristic of certain proteins which enables cells to coordinate the
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regulation of what sometimes appear to be unrelated biochemical processes. In these 
cases, the same protein participates in several different processes, which are often 
carried out at different locations in the cell and form an independent network of cellular 
events. Beta-catenin provides an intriguing example of both these lessons. It combines 
the features of a major structural protein at cell-cell junctions with those of a 
transcription factor in the nucleus. Its close homolog, plakoglobin, shares with beta- 
catenin common protein partners and can fulfill some of the same functions.277 There is 
a fine balance between the two armadillo proteins where they compete with each other 
both at the nucleus and at the membrane while one may at least partially compensate 
for the other when either is eliminated.
Although under physiological conditions beta-catenin’s junctional role is confined to the 
adherens junctions, in plakoglobin-null keratinocytes, beta-catenin has been shown to 
localize at the desmosomes, associate with desmoglein 1 and promote the assembly of 
further desmosomal proteins.278 In agreement with this observation, a different study 
showed that over-expression of beta-catenin in plakoglobin-null skin increased the 
Triton-insoluble pool of desmoplakin.249 Furthermore the contractile parameters of heart 
fibers obtained from plakoglobin-deficient embryonic mice are indistinguishable from 
those of control mice, suggesting that beta-catenin may be taking over this role in the 
absence of plakoglobin.140 Similar seems to be the case in the opposite situation. When 
the beta-catenin gene is specifically ablated from adult mice cardiac myocytes, the 
expression levels of plakoglobin are significantly elevated as shown both by 
immunohistochemistry and Western immunoblotting suggesting that plakoglobin may in 
fact compensate for the loss of beta-catenin to maintain cardiac structure and 
function.279
Beta-catenin was significantly elevated in all ARVC samples examined herein 
compared to controls (Figure 28). It is not known however, whether this increased 
localization of beta-catenin at intercalated discs is due to increased gene expression, 
decreased degradation or increased sequestering of the catenin at the cell borders. To 
our knowledge, this is the first immunohistochemical study for beta-catenin on ARVC 
heart samples. However, a larger number of samples have to be examined before we 
can conclude that this compensation between the two armadillo proteins is in fact a 
consistent finding in all ARVC cases. More importantly, the significance of this finding 
still remains unclear. Whether this increased localization of beta-catenin at the cell 
membrane is merely rescuing the depressed adhesive function of plakoglobin or it also 
has effects on downstream signaling pathways is a big challenge that still has to be 
faced.
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CHAPTER 3:
“Unraveling the effects of the ARVC-causing 
S39_K40insS plakoglobin mutation”
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Whv S39 K40insS?
As presented in Chapter 1, a novel mutation in plakoglobin was identified in a German 
family affected by ARVC. The 3-base insertion does not alter the frame of translation 
but is predicted to result in the insertion of an additional serine residue within the N- 
terminal domain of the protein. S39_K40insS co-segregated with the disease 
phenotype in the family and was absent in 400 ethnically-matched control 
chromosomes. It is likely therefore that it is in fact pathogenic. The proband was part of 
a large cohort of ARVC patients who were screened for mutations in known disease- 
causing and other candidate genes. A high number of ARVC-causing mutations in 
desmoplakin, plakophilin2, desmoglein2 and desmocollin2 were identified amongst 
patients of this cohort. S39_K40insS was the only mutation in plakoglobin identified in 
the cohort and the only other mutation in plakoglobin ever to be reported, after the 
identification of 2057del2 as the underlying cause of Naxos disease. In contrast to 
2057del2, S39_K40insS is inherited in an autosomal dominant manner and is not 
associated with any gross cutaneous abnormalities. It therefore presented a good 
opportunity to investigate how two mutations in the same gene can have different, yet 
similar effects at the clinical phenotype level. Moreover, many of the mutations 
presented both in this project, and generally in the literature, cause premature 
termination of translation. Very little work has been done to date to functionally 
characterize these sequence changes. It would be logical to assume that their 
mechanism of action stems at least in part from the inability of the truncated proteins to 
interact with their protein binding partners. This could compromise the formation and 
maintenance of desmosomes and consequently the strength and stability that allow 
adjacent cardiomyocytes to deal with increased levels of mechanical stress. 
S39_K40insS is a unique mutation, whose mechanism of action would be more 
challenging to unravel since its only obvious effect seems to be the insertion of an 
additional amino acid. Furthermore, plakoglobin is a unique protein amongst all 
desmosomal molecules, because it has a well recognized role in all desmosomes, 
adherens junctions and nucleus thus encompassing both structural and signaling 
properties.
People with Marfan syndrome live with a ticking bomb. Unless surgically corrected, 
their aortas gradually enlarge and weaken until they fatally rupture. In 1991, mutations 
in the gene coding for fibrillin-1 were reported as responsible for this syndrome.280 Such 
mutations could explain the aortic aneurysms, lung problems and many other features 
of Marfan syndrome. Interestingly though, there was still a number of features that 
could not be explained by a mere structural defect. Ten years later, a signaling 
molecule, TGF-p was implicated in the disease.280 Fibrillin-1 binds TGF-(3 keeping it
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inactive. In the presence of a fibrillin-1 mutation though, the growth factor is unleashed, 
exerting effects that could in fact justify the "unexplainable” features.280 
Similar could be the case for plakoglobin. Given its dual role both at the membrane and 
nuclear sites and its seemingly ubiquitous involvement in ARVC, functionally 
characterizing S39_K40insS would allow us to understand whether the features of 
disease are merely due to structural defects at the cell-cell junctions or also due to 
disruption of signaling pathways.
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METHODS AND MATERIALS:
1) Polymerase chain reaction (PCR)
Platinum PfX DNA polymerase or EXL DNA polymerase was used for the amplification
of large DNA fragments (>400kb). For each PCR reaction with PfX DNA polymerase,
the following were added:
5 pi of 10x PfX Amplification Buffer (Invitrogen)
10 pmoles of forward primer (Invitrogen)
10 pmoles of reverse primer (Invitrogen)
1.5 pi of dNTP mix, 2.5mM each of dATP, dGTP, dCTP and dTTP (Invitrogen)
1 pi of MgS04, final concentration: 50mM (Invitrogen)
1 pi of Platinum PfX DNA polymerase enzyme, 2.5 units/pl (Invitrogen)
150-500 ng of DNA template. dH20  was added up to a total volume of 50 pi 
PCR reactions were performed under the following program:
95°C for 10min
95°C for 1min
50-55°C for 1min 
72°C for x min
25-30 cycles
72°C for 10min
4°C oo
For each PCR reaction with EXL DNA polymerase, the following were added: 
5 pi of EXL Reaction Buffer (Stratagene)
200 ng of forward primer (Invitrogen)
200 ng of reverse primer (Invitrogen)
2.5 pi of dNTP mix, 2.5mM each of dATP, dGTP, dCTP and dTTP (Invitrogen) 
1 pi of stabilizing solution (Stratagene)
0.5 pi of DMSO (Stratagene)
1 pi of EXL DNA polymerase enzyme, 5 units/pl (Stratagene)
150-500 ng of DNA template. dH20  was added up to a total volume of 50 pi 
PCR reactions were performed under the following program:
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92°C for 2min
92°C for 20 sec
50-55°C for 45 sec
68°C for x min
25-30 cycles
68°C for 20min
4°C oo
The annealing temperature, extension time and number of cycles varied according to 
the fragment amplified. All PCR reactions were performed on a TE-412 PCR block 
(TECHNE) using 0.5 ml Thermo-Tubes (ABgene).
2) DNA gel extraction:
DNA gel extraction was performed using a QIAquick gel extraction Kit (QIAGEN) 
according to the protocol. Briefly:
The DNA fragment was excised from the agarose gel with a sterile scalpel and placed 
in a micro-centrifuge tube. The tube was filled with QG solubilization buffer and 
incubated on a heated block at 50°C until the gel was dissolved. The contents of the 
tube were mixed by pulse vortexing, loaded on a spin column assembled on a 
collection tube, centrifuged and the flow-through discarded. PE wash buffer was added 
to the column, centrifuged and the flow-through discarded. An additional centrifugation 
step was performed to remove residual ethanol following which, the column was 
assembled on a micro-centrifuge tube and EB elution buffer was added. The mixture 
was allowed to equilibrate to room temperature, was centrifuged and kept at -20°C.
3) Site-directed mutagenesis:
For each sample the following was added:
5 pi of PFU buffer (Invitrogen)
125 ng of forward mutagenic primer (Invitrogen)
125 ng of reverse mutagenic primer (Invitrogen)
1 pi of dNTP mix, 2.5mM each of dATP, dGTP, dCTP and dTTP (Invitrogen) 
3 pi of Quick solution (Invitrogen)
50 ng of DNA template
172
1 pi of Pfu DNA polymerase enzyme (2.5 units/pl). dH20  was added up to a total 
volume of 50 pi
PCR reactions were performed on a TE-412 PCR block (TECHNE) using 0.5 ml 
Thermo-Tubes (ABgene) under the following program:
95°C for 1min
95°C for 50 sec
50-55°C for 50 sec
68°C for x min
18 cycles
1min per Kb of template DNA.
68°C for 
4°C
10min
The number of amplification cycles used was kept to no higher than 18, so as to 
eliminate the possibility of introduction of unwanted sequence changes.
4) Cloning
a) Gateway-compatible cloning:
Primers flanking the DNA fragment of interest were designed so that they contained the 
Gateway-compatible attB sites. This allows the BP clonase enzyme to perform a site- 
specific recombination reaction and insert the DNA fragment of interest into the 
linearized vector carrying the complementary attR sites. The following were added in a 
micro-centrifuge tube:
150 ng of pDONR vector (Invitrogen)
150-450 ng of DNA template 
2 pi of BP clonase enzyme mix (Invitrogen)
TE buffer, up to a final volume of 8 pi
The recombination reaction was performed either over 1 hr at room temperature or for 
12-16 hrs on a thermal cycler at 16°C. Following the recombination reaction, 1 pi of 
proteinase K (Invitrogen) was added to the mixture and the tube was incubated at 37°C 
for 10min to denature the enzyme.
To convert a final destination vector into a Gateway-compatible form, a Gateway vector 
conversion reagent system Kit (Invitrogen) was used. Briefly:
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A restriction enzyme was selected to linearize the vector creating blunt ends. The 
following were added in a micro-centrifuge tube:
1-5 fig of final destination vector 
2 (j.l of digestion enzyme buffer
5 pi of digestive enzyme. dH20  was added to a total volume of 20 pi.
The reaction mix was incubated and subsequently the digestive enzyme was
inactivated according to the instructions of the enzyme used. The correct Gateway
reading frame cassette was selected (A, B or C.1). The three reading frame cassettes 
provided with the Kit differ by one nucleotide to allow generation of attR sites in all three 
reading frames. The following were added in a micro-centrifuge tube:
20-50 ng of linearized destination vector 
2 pi of the selected Gateway reading frame cassette 
2 pi of T4 ligase buffer (Invitrogen)
1 pi of T4 ligase enzyme (Invitrogen). dH20  was added to a total volume of 10 pi 
The ligation reaction was performed either over 1 hr at room temperature or for 12-16 
hrs on a thermal cycler at 4°C.
To perform a recombination reaction between pDONR and a Gateway-compatible final 
destination vector, the following were added in a micro-centrifuge tube:
300 ng of the DNA fragment of interest in pDONR vector 
300 ng of the Gateway-compatible final destination vector 
4 pi of LR clonase enzyme mix (Invitrogen)
TE buffer was added up to a final volume of 16 pi
The recombination reaction was performed either over 1 hr at room temperature or for 
12-16hrs on a thermal cycler at 16°C. Following the recombination reaction, 2pl of
proteinase K (Invitrogen) was added to the mixture and the tube was incubated at 37°C
for 10min for the enzyme to be denatured.
This system was used in order to clone plakoglobin cDNA (purchased from OriGene) 
first into pDONR and subsequently into the pcDNA4/His-Max and the pDEST™32 
vectors (Invitrogen).
b) Zero blunt TOPO PCR cloning:
The DNA fragment of interest was first amplified using Taq, PfX or EXL polymerase. 
For the ligation reaction, the following were added in a micro-centrifuge tube:
0.5 - 4 pi of purified PCR product 
1 pi of TOPO vector (Invitrogen)
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2 pi of T4 ligase enzyme (Invitrogen) and 
TE buffer to a final volume of 8 pi
The reaction was performed either over 5min at room temperature or at 16°C overnight.
This system was used in order to clone TGF-beta induced apoptosis protein-2 cDNA 
(purchased from Biosearch Technologies, USA) into the PCR blunt TOPO vector.
c) Restriction enzyme-based cloning:
Wherever possible, 2 restriction enzymes were used to avoid self-ligation of the vector. 
For linearization of the vector DNA, the following were added in a micro-centrifuge tube: 
5 pi of 10X restriction enzyme buffer
0.5 pi of 100X BSA (optional, depending on the enzymes selected)
7.5 pg of vector DNA
2.5 pi of restriction enzyme A (10-20 units/ pi)
2.5 pi of restriction enzyme B (10-20 units/ pi) 
dH20  to a final volume of 50 pi
The reaction mixture was incubated at 37°C for 1-4 hrs according to the enzyme 
manufacturer’s instructions. Following digestion, the mixture was loaded on a 1% 
agarose gel, and the DNA fragment of interest excised as described above.
Primers bearing recognition sites for the selected enzymes were designed and used for 
amplification. The PCR product was digested in the same way as the vector, and 
purified by agarose gel electrophoresis and subsequent excision.
For the ligation reaction the following were added in a micro-centrifuge tube:
100 ng of the digested DNA fragment of interest 
100 -  300 ng of the linearized digested vector 
2 pi of T4 ligase (Invitrogen)
TE buffer to a final volume of 20 pi
The reaction was performed either over 2hrs at room temperature or at 16°C overnight.
Following these instructions, plakoglobin was sub-cloned into the pcDNA5/FRT/TO 
vector (Invitrogen, UK) using the BamHI and EcoRV restriction sites and in the pGFP- 
C3 vector (Clontech, USA) using the BamHI and EcoRI restriction sites. Similarly, TGF- 
beta induced apoptosis protein-2 was sub-cloned into the pcDNA V5 His 3.1 vector 
(Invitrogen, UK) using the EcoRI restriction sites.
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d) Transformation of chemically competent E.coli cells:
Chemically competent E.coli cells (100 pi) were mixed with the recombination/ligation 
reaction (7.5 pi) in a micro-centrifuge tube, left on ice for 45min and then heat-shocked 
in a water bath according to the bacterial cell type used. For instance, DH5a cells get 
heat shocked at 42°C for 30 sec while DB3.1™ cells get heat shocked at 42°C for 45 
sec. Following the heat-shock, SOC medium (Invitrogen) was added to the cells and 
the micro-centrifuge tube was shaken in an incubator at 275rpm. The duration of the 
shaking varied according to the antibiotic resistance gene the vector was expressing. 
For instance, kanamycin and ampicillin resistance genes get expressed within 1 hr of 
shaking, while a gemtamycin resistance gene requires 3 hrs to be efficiently expressed. 
Following shaking, three dilutions of the transformation reaction were plated on 
appropriate plates (antibiotic concentration: 50-100pg/pl), which were then incubated 
for 12-16 hrs at 37°C.
Each colony selected was placed in falcon tubes along with LB broth and the 
appropriate antibiotic (concentration: 50-100pg/pl). The tubes were shaken (12-16 hrs, 
275rpm, 37°C), centrifuged and the plasmid extracted from the cell pellets using a 
QIAprep Spin mini Prep Kit (QIAGEN) according to the protocol. Briefly:
P1 re-suspension buffer was added to each pellet and mixed by pulse vortexing. The 
mix was transferred to 1.5 ml micro-centrifuge tubes, P2 lysis buffer was added and the 
tubes inverted vigorously. N3 neutralization buffer was added, the tubes were inverted 
vigorously, centrifuged and the supernatant was placed in a spin column assembled to 
a 2 ml collection tube. The spin columns were centrifuged and the flow-through 
discarded. PE wash buffer was added; the spin columns were centrifuged twice and 
transferred on 1.5 ml micro-centrifuge tubes. 55 pi of EB elution buffer was added. The 
columns were allowed to equilibrate to room temperature, centrifuged and kept at - 
20°C. The A260 of each sample was measured using a spectrophotometer in order to 
estimate the DNA concentration. The technique is predicted to yield 5-15 pg of DNA. 
Two pi of each sample was digested with an appropriate enzyme under the conditions 
suggested by the manufacturer to ensure the correct recombination or ligation reaction 
had taken place. Following incubation with a digestive enzyme, the entire reaction 
mixture (total volume: 10pl) was loaded on a 1% agarose gel for electrophoresis. 
Specific samples were selected according to the band pattern obtained from digestion 
and 500-600ng of DNA was used to set up a sequencing reaction. Samples were 
sequenced on an ABI3100 sequencer as described above.
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e) Midi/Maxi plasmid purification:
Plasmid (100-250 |ig) was added to 50 pi of DH5a chemically competent E.coli cells in 
a micro-centrifuge tube and incubated on ice for 45min. The mixture was heat-shocked 
in a water bath (42°C for 30 sec), SOC medium (Invitrogen) was added and the tube 
shaken at 37°C at 275rpm. The duration of the shaking varied according to the 
antibiotic resistance gene the plasmid was expressing. The contents of the micro­
centrifuge tube were mixed with LB broth and the appropriate selective antibiotic 
(concentration: 50-100pg/fxl) and shaken at 275rpm at 37°C for 24-36 hrs. Following 
shaking, the culture was poured in falcon tubes and centrifuged. Plasmid purification 
from cell pellets was performed with a QIAGEN Midi Plasmid Purification Kit according 
to the protocol. Briefly:
The bacterial pellets were first re-suspended in P1 re-suspension buffer, then in P2 
lysis buffer and incubated at room temperature for 5min. P3 neutralization buffer was 
added to the lysate which was then poured in a QIAfilter cartridge (QIAGEN) and 
incubated at room temperature for 10min. QBT equilibration buffer was added to a 
QIAGEN-tip, pre-assembled to a 50-ml falcon tube, and the column was allowed to 
empty by gravity flow. The lysate was then allowed to enter the resin of the previously 
equilibrated QIAGEN-tip by gravity flow and the flow-through was discarded. The 
QIAGEN-tip was washed twice with QC wash buffer, the column was allowed to empty 
by gravity flow and the flow-through was discarded. Following the washes, the 
QIAGEN-tip was assembled to a new 50ml falcon tube, QF elution buffer was added 
and the column was allowed to empty by gravity flow. Isopropanol was added to the 
flow-through, the mixture was centrifuged, the pellet re-suspended in 70% ethanol and 
transferred to a micro-centrifuge tube. The tube was then centrifuged and the pellet 
allowed to air-dry in a 37°C incubator before being eluted in 55 fil of TE elution buffer. 
The A260 of the sample was measured using a spectrophotometer. The technique is 
predicted to yield 20-100 pg of DNA. The samples were kept at -20°C.
5) Cell culture:
a) Maintenance of Flp-ln 293 cells:
The cell line is supplied from Invitrogen in vials containing 3 x 106 cells in 1 ml of 
freezing medium (90% complete medium and 10% DMSO). The cells were thawed in a 
37°C water bath and transferred to a T-75 flask containing 10 ml complete medium. 
Complete medium consisted of Dulbeccois Modified Eagle Medium (DMEM, GIBCO) 
supplemented with 10% Foetal Bovine Serum (FBS, GIBCO), 2mM L-glutamine 
(GIBCO) and 1% penicillin-streptomycin (GIBCO). The cells were incubated at 37°C, 
5% C 02 in order for them to attach to the flask. Twelve to sixteen hours later, the
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medium was replaced with new growth complete medium supplemented with 15^g/ml 
blasticidin and 100pg/ml zeocin. The growth medium was then replaced after every 48- 
72 hours. When 80-90% confluent, the cells were washed with PBS and trypsinized 
with 50% versene (GIBCO)-50% trypsin-EDTA 1x (GIBCO). Following incubation 
(37°C, 5-7min), 10 ml of complete medium lacking antibiotics was added to stop 
trypsinization and the entire mixture was aspirated from the flask and transferred to a 
falcon tube. The tube was centrifuged, the pellet re-suspended in complete medium 
and part of the mixture transferred to a new T-75 flask containing complete medium 
supplemented with blasticidin and zeocin at the recommended concentrations. The 
flasks were incubated in a humidified, 37°C, 5% C 02 incubator.
b) Transfection and selection of Flp-ln 293 cells:
Flp-ln-293 cells were transfected using the Flp-ln system (Invitrogen). Briefly:
The cells were harvested as described above and 1/20 of the cell suspension was 
transferred in a P90 plate, containing complete medium supplemented with blasticidin 
and zeocin. The plate was incubated in a humidified, 37°C, 5% C 02 incubator until the 
cells became 30-40% confluent. Four \ig of the pcDNA5/FRT/TO vector containing the 
gene of interest along with 4 p.g of pOG44 (Invitrogen), which expresses the Flp 
recombinase gene were added to a micro-centrifuge tube. DMEM and polyfect 
transfection reagent (QIAGEN) were also added to the tube and the mixture was 
incubated at room temperature for 20min, during which it was occasionally mixed by 
pulse-vortexing. Following incubation, the contents of the tube were poured in a falcon 
tube containing complete medium supplemented with blasticidin only (15[xg/ml). The old 
growth medium was aspirated from the P90 plate, replaced with the new medium and 
the plate was incubated in a humidified, 37°C, 5% C 0 2 incubator. Twenty-four to 48 
hours after transfection, the growth medium in the P90 plate was replaced with fresh 
complete medium supplemented with blasticidin (15jj.g/ml) and hygromycin (1 OOpig/ml). 
The medium was aspirated and replaced with fresh medium every 48-72 hrs for 10-14 
days until distinct surviving cell colonies could be detected.
In order to further grow and characterize the individual colonies that had survived 
selection with hygromycin, the colonies were transferred to a 24-well plate. Briefly, the 
old growth medium was aspirated from the P90 plate and the cells were washed with 5 
ml of DMEM. Following the wash, a cloning disc immersed in 50% versene-50% 
trypsin-EDTA 1x was placed above each colony and the plate was incubated for 5-7min 
at room temperature. Once the cells had detached from the surface of the plate, the 
cloning disc was transferred to a well of the 24-well plate containing complete medium 
supplemented with blasticidin and hygromycin. The growth medium was replaced every
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48-72 hours until the cells became confluent, after which they were trypsinized and 
transferred first to a T-25 flask and subsequently to a T-75 flask.
When the cells in the T-75 flask reached 80% confluence, stocks were made and 
maintained in liquid nitrogen. Briefly: the cells were harvested as described above, 
however after centrifugation the pellet was re-suspended in freezing medium (95% FBS 
and 5% DMSO). The suspension was then transferred in cryo-vials, which were kept at 
-80°C for 12-16 hours before immersion in liquid nitrogen. The cell line was maintained 
in 2 T-75 flasks, one containing 10 ml of complete medium supplemented with 
blasticidin, hygromycin and tetracycline (100ng/ml medium) and the other containing 10 
ml of complete medium supplemented with blasticidin, hygromycin and 70% ethanol 
(10|il/ ml medium). Tetracycline was added to the first flask to induce expression of 
pcDNA5/FRT/TO, while the second flask was used for control purposes.
6) Immunostaining of stably transfected Flp-ln 293 cells:
Flp-ln 293 cells, transfected to stably express the gene of interest were seeded on 
plastic coverslips. Forty-eight hours following seeding, the cells were washed with PBS 
and incubated with 4% paraformaldehyde in PBS at room temperature for 10min. 
Following fixation, the cells were washed first with PBS, then with 0.5% Triton-X/PBS 
and again with PBS. To block non-specific signal, the cells were incubated with 10% 
fetal calf serum/PBS for 30min. The primary antibodies were added diluted in the same 
blocking buffer and the cells incubated at 4°C overnight. The following day, the cells 
were equilibrated at room temperature for 30min, washed first with PBS, then with 0.1% 
Tween/PBS and again with PBS. The secondary antibodies were added diluted in 
blocking buffer and the cells were incubated at 4°C overnight. On the third day of the 
procedure, the cells were equilibrated at room temperature for 30min, washed first with 
PBS, then with 0.1% Tween in PBS and again with PBS. The coverslips were then 
placed on slides and mounted with 50% glycerol-50% PBS.
7) Western immunoblotting:
In preparation for Western immunoblotting, the cells were harvested as described 
above and the cell pellets re-suspended in RIPA buffer. RIPA buffer was prepared with 
50mM Tris-HCI pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150mM NaCI, 1 mM 
EDTA, 1mM Na3V 0 4, 1mM NaF and protease inhibitor cocktail (Roche: 1 tablet per 7 
ml of buffer). The mixture was transferred in a micro-centrifuge tube, incubated on ice 
for 45min, mixed by pulse vortexing and centrifuged. Following centrifugation, a 
spectrophotometer was used to measure the A540 of the supernatant and the value 
was compared to a standard curve in order to estimate total protein concentration. The
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standard curve was generated by measuring the absorbance values of solutions with 
known protein concentrations (Protein standard set, SIGMA).
The following were then added to a micro-centrifuge tube:
50 mg of protein lysate
6 pi of Laemmle dye, previously denatured at 96°C for 10min 
dH20  was added up to a total volume of 22pil.
The samples were incubated at 96°C for 5min and were then loaded on a 1.5mm 10% 
Tris-Glycine gel (Invitrogen) along with 8 pi of Precision Plus Protein Dual Color 
Standards (BIO-RAD). Tris-glycine buffer 1x (Fisher Scientific) was used for 
electrophoresis, while the current and duration varied according to the size of the 
protein of interest. Eight 6x8 cm pieces of absorbent paper (Whatman paper) and one 
similar size piece of nitrocellulose membrane (Amersham Biosciences) were cut and 
wetted with transfer buffer. For proteins larger than 100KDa, 1x Tris-glycine buffer was 
used while for proteins smaller than 100KDa, 1x CAPS buffer was used (SIGMA). The 
semi-dry Western blot method was used to transfer the protein bands from the gel to 
the membrane. The gel was removed from the container and the modules were 
assembled starting from the bottom electrode plate in the following order: four layers of 
absorbent paper, followed by the membrane, the polyacrylamide gel and another four 
layers of absorbent paper. The current and the duration of the transfer depended on the 
size of the protein of interest. The blot was then blocked with PBS-5% skimmed dried 
milk on a rotating shaker for 30min and then incubated at 4°C overnight. Following 
incubation, the blot was washed twice with PBS and incubated with the primary 
antibody in a plastic bag for 1 hr at room temperature or overnight at 4°C on a rotating 
shaker. The blot was then washed three times in PBS and incubated with the 
secondary antibody in a plastic bag for 1 hr on a rotating shaker. The antibodies were 
diluted in PBS-5% milk according to the instructions of the manufacturer. Following 
incubation with the secondary antibody, the blot was washed three times with PBS and 
blocked with 500 pi of each of the two Western blotting detection reagents (Amersham 
Biosciences) in a plastic bag. The blot was then exposed to X-ray film. The duration of 
exposure before the development of the film was optimized for each protein 
individually.
8) Cell-proliferation assay:
Proliferation rates in Flp-ln 293 cells transfected to stably express the gene of interest 
were measured using the CellTiter96 Cell proliferation assay (Promega, UK) according 
to the manufacturer’s instructions. Briefly:
Cells (150,000, as measured with the aid of a haemocytometer) of each cell line were 
seeded in each of 20 wells (13mm diameter) supplemented with complete selective
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medium and incubated overnight. Selective medium was added in 5 cell-free wells for 
control purposes. The following day the growth medium was aspirated from 4 cell- 
containing wells and 1 cell-free well, and replaced by 250 pi non-selective medium and 
50 pi of CellTiter 96 Aqueous One Solution Reagent. The plate was incubated for a 
further 1 hour, following which the contents of the 5 pre-treated wells were aspirated 
and their absorption at 490nm measured by spectrophotometry. On the 3d, 4th, 5th, and 
6th day of the experiment, the same procedure was repeated for a further 4 cell- 
containing wells and 1 cell-free well at a time. For each day, the absorbance value 
obtained from the control cell-free well was subtracted from the absorbance values 
obtained from each of the 4 cell-containing wells. The mean values per day were 
calculated and plotted on a graph.
9) Caspase-3 assay:
Cells were grown in 10-cm dishes, harvested and re-suspended in cell lysis buffer (10 
mM HEPES pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 1 mM PMSF, 10 pg/ml 
pepstatin A, 10 pg/ml aprotinin, and 20 pg/ml leupeptin). After repeated freeze-thaw 
cycles, lysates were centrifuged and aliquots of the supernatant fraction equivalent to 
40 pg of protein were obtained. Caspase-3 activity was measured using the CaspACE 
assay system (Promega, UK) according to the manufacturer’s instructions. Briefly, for 
each sample the following were added in a micro-centrifuge tube:
32 pi of assay buffer
2 pi DMSO
10 pi DTT (100mM)
40 pg sample
2 pi DEVD-pNA (10mM). dH20  was added to a final volume of 10Opl.
A mixture containing the same amounts of assay buffer, DMSO, DTT and DEVD-pNA 
but no sample was prepared and used for control purposes. The tubes were incubated 
at 37°C for 4 hours, following which the absorbance of their contents at 405nm was 
measured by spectrophotometry. A standard curve for pNA amounts was constructed 
using serial dilutions of the 10mM pNA stock provided. The following mixtures were 
prepared:
1)20 pi DMSO and 80 pi dH20
2) 10 pi pNA (10pM), 10 pi DMSO and 80 pi dH20  (final concentration 1 pM)
3) 20 pi pNA (10pM) and 80 pi dH20  (final concentration 2 pM)
4) 5 pi pNA (100pM), 15 pi DMSO and 80 pi dH20  (final concentration 5 pM)
5) 10 pi pNA (100pM), 10 pi DMSO and 80 pi dH20  (final concentration 10 pM)
6) 5 pi pNA (1 mM), 15 pi DMSO and 80 pi dH20  (final concentration 50 pM)
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7) 10 p.1 pNA (1 mM), 10 pi DMSO and 80 pi dH20  (final concentration 100 pM)
The absorbance of all 7 mixtures at 405nm was measured by spectrophotometry and 
the values plotted on a graph against the solutions’ final concentrations. The slope of 
the best-fit line and the Y-axis interception were estimated from the graph.
The caspace-3 activity for each sample was calculated using the following formula:
X = [(AA -  Y)/ time] x volume/slope
Where, AA = (the absorbance value of each sample) -  (the value of the control)
Y = the intercept of the pNA curve constructed 
Time = the incubation time of the tubes (4 hours)
Volume = the volume of each sample (100 pi)
And slope = the slope estimated from the pNA curve constructed.
Finally, the specific caspase-3 activity for each sample was calculated using the 
following formula:
Specific activity = XI amount
Where X= the caspase activity calculated as described above and 
Amount= the pg of protein contained in 100 pi of each sample (40 pg).
10) Transient transfection of human embryonic kidney (HEK) 293 cells:
The cells were seeded in 10cm P90 dishes and grown in complete medium until 40- 
60% confluent. On the day of the transfection the following were added in a micro­
centrifuge tube:
300 pi of DMEM
80 pi of polyfect transfection reagent (QIAGEN)
8 pg of total DNA
The reaction was mixed by pulse vortexing and equilibrated at room temperature for 
10min. The reaction solution was then diluted with 1 ml DMEM, mixed gently and 
added to the cells along with fresh complete medium.
11) Electron microscopy of cultured cells:
Cells were grown to confluence on glass coverslips and then fixed for 24 hr in 2% 
glutaraldehyde in 0.1 mM cacodylate buffer (pH 7.4). Fixed cells were post-fixed in 1% 
Os04, dehydrated in ethanol and embedded in Spurr’s low-viscosity epoxy resin. Ultra- 
thin sections were cut in a plane parallel to the plane of the culture dish and examined 
with a JEOL 100SX transmission electron microscope. The number and size of 
individual desmosomes was measured in 10 randomly selected electron micrographs 
(final magnification x9000) of each cell line examined.
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12) Yeast-two hybrid (Y2H):
a) Preparing dsDNA from a plasmid cDNA library:
Terrific Broth (500 ml) containing 100mg/pl ampicillin was inoculated with 2.5 x 109 cells 
from the library (16 hours, 30°C, 275rpm). The cells were supplied in 80% SOB 
medium-20% glycerol from Invitrogen, while Terrific Broth was prepared in the following 
way: Tryptone (6g, Fisher Scientific), yeast extract (12g, Fisher Scientific) and glycerol 
(2 ml, AnalaR) were dissolved in dH20  and adjusted to a final volume of 450 ml. 
KH2P04 (1.15g, SIGMA) and K2HP04 (6.25g, SIGMA) were dissolved in dH20  and 
adjusted to a final volume of 50 ml. Both solutions were autoclaved on liquid cycle for 
20min, allowed to cool to 55°C and mixed. The chosen antibiotic was added at the 
desired concentration and Terrific Broth was stored at 4°C. Following the incubation 
period, a sample from the culture was taken and its A590 was measured using a 
spectrophotometer. The predicted value is within 0.2 and 0.8. The culture was then 
centrifuged, the supernatant discarded and the pellets stored at -20°C. Plasmids were 
extracted from the pellets using a MEGA QIAGEN plasmid purification kit according to 
the Instructions given. Briefly:
The yeast pellets were re-suspended first in P1 re-suspension buffer, then in P2 lysis 
buffer and allowed to equilibrate to room temperature for 5min. A QIAfilter Mega-Giga 
cartridge (QIAGEN) was assembled onto a 45mm-neck glass bottle and connected to a 
vacuum source. P3 neutralization buffer was added to the lysate which was poured into 
the cartridge. The lysate was incubated at room temperature for 10min and then the 
vacuum source was switched on. FWB2 wash buffer was added to the cartridge and 
the vacuum source was switched on again until the liquid had passed through 
completely. QBT equilibration buffer was added to a QIAGEN-tip, pre-assembled onto a 
beaker, and the column was allowed to empty by gravity flow. The lysate was then 
applied onto the equilibrated QIAGEN-tip, allowed to enter the resin by gravity flow and 
the flow-through was discarded. The QIAGEN-tip was washed with a total of 200ml of 
QC wash buffer, the column was allowed to empty by gravity flow and the flow-through 
discarded. Following the washes, the QIAGEN-tip was assembled to a falcon tube, QF 
elution buffer was added and the column was allowed to empty by gravity flow. 
Isopropanol was added to the eluted DNA and the mixture was centrifuged. Following 
centrifugation, the supernatant was discarded, the pellet was re-suspended in 70% 
ethanol and centrifuged again. The pellet was allowed to air-dry in an incubator at 37°C 
and then eluted in TE elution buffer. The A260 of the sample was measured. The 
predicted value was 0.5-2.5mg of DNA. The samples were kept at -20°C.
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b) Preparation and transformation of competent S.cerevisae:
The desired S.cerevisae strain was plated on Yeast Extract Peptone Dextrose (YPD, 
Fisher Scientific) plates at 30°C for 48 hours until isolated, single colonies had grown. 
In order for competent S.cerevisae cells to be generated, the S.c. EasyComp 
Transformation Kit (Invitrogen) was used according to the instructions provided. Briefly: 
A single yeast colony was inoculated in YPD (30°C, 275rpm, 16-18 hrs). Following the 
inoculation period, a sample was taken from the culture and its O D 6oo was measured 
using a spectrophotometer. The predicted value is between 3 and 5. The cells from the 
overnight culture were then diluted to an O D 6oo value of 0.2-0.4 in a total volume of 10 
ml of YPD. The cells were grown at 30°C in a shaking incubator for 3-6 hours until the 
O D 6oo reached a value of 0.6-1.0. The cells were pelleted by centrifugation and the 
pellet re-suspended in Solution I. The mixture was again centrifuged, the supernatant 
discarded and the cell pellet re-suspended in Solution II.
Competent S.cerevisae cells were transformed with the plasmid of interest using the 
S.c. EasyComp Transformation Kit (Invitrogen) according to the instructions provided. 
Briefly: Vector DNA (1 -5p.g) was added to 50 fil of competent yeast cells. Solution III 
was added to the mixture and mixed by vortexing. The transformation reaction was 
then incubated for one hour (30°C) during which it was occasionally mixed by vortexing. 
Following the incubation period, the tube was centrifuged, the supernatant discarded, 
the pellet re-suspended in YPD medium and plated on YPD plates.
c) Co-transformation of Library-Scale MaV203 Yeast cells:
Library-Scale Frozen Competent MaV203 Yeast cells (Invitrogen) were co-transformed 
with the:
1) pDEST™32 plasmid (expresses the DNA-binding domain and the gene of interest)
2) pEXP-AD502 plasmid (expresses the activation domain and the cDNA library)
Both the competent MaV203 yeast cells and the PEG/LiAc solution (Invitrogen) were 
thawed. A 250|al cell aliquot was transferred to a Falcon tube. pDEST™32 (1 Ojag) and 
pEXP-AD502 (10pg) were added to the cells and mixed gently. PEG/LiAc solution (1.5 
ml) was added and mixed well by swirling. The solution was incubated in a 30°C water 
bath for 30min, during which the tube was occasionally swirled. Following incubation, 
88|il of DMSO (Fisher Scientific) was added and mixed by swirling. The cells were then 
heat-shocked (42°C, 20min) with occasional swirling. The solution was centrifuged, the 
supernatant discarded, the pellet re-suspended in sterile saline (0.9% NaCI) and two 
dilutions (1:800 and 1:8000) of the transformation reaction were plated on two 10-cm 
SC-Leu-Trp-plates to estimate the total number of transformants. Aliquots (400^1) of the 
transformation were then plated on twenty 15-cm SC-Leu-Trp-Ura-His+3-Amino-1,2,4-
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Triazole (3AT, SIGMA) plates and incubated for 60-72hrs at 30°C. The optimum 
concentration of 3AT for the DNA binding domain vector was previously determined by 
titrating HIS3 activity on plates lacking histidine containing 3AT at concentrations: 
10mM, 25mM, 75mM and 100mM to a point at which growth in the absence of histidine 
was inhibited. The number of transformants was estimated by multiplying the number of 
colonies on the 10-cm plates by the dilution factor. The colonies that grew on the 
twenty 15-cm SC-Leu-Trp-Ura-His+3AT plates were picked individually and plated on 
two replica YPD plates under the same selective conditions.
d) Beta-galactosidase filter assay:
Beta-mercaptoethanol (150pil, SIGMA) was added to 50ml of Z-buffer. (Z buffer was 
made by adding 4.26g of Na2HP04l 2.76g of NaH2P04H20 , 0.4g KCI and 0.1 g of 
MgS047H20  in dH20  at pH7, final volume: 500ml). 5-bromo-4-chloro-3-indolyl-beta-D- 
galactopyranoside (X-gal, 100mg, Fermentas) was dissolved in 2ml of formamide 
(Applied Biosystems). 200pl of the X-gal solution was added to 10ml of the beta- 
mercaptoethanol-Z-buffer solution and mixed gently. A circular piece of nitrocellulose 
filter cut to fit a 15-cm plate was placed across the master plate of yeast colonies and 
allowed to equilibrate to room temperature for 2min. The filter was removed from the 
yeast plate and placed in an aluminium foil "boat” , colonies facing up. The foil was 
slowly lowered into liquid nitrogen and raised again after 10 sec. Immersion of the filter 
in liquid nitrogen was repeated three times. A circular piece of absorbent paper was 
placed in an empty clean 15-cm plate and soaked with Z-buffer-X gal solution. The 
nitrocellulose filter was allowed to warm in room temperature for 2min and transferred 
colony side up, on top of the absorbent paper. The dish was covered and incubated 
(30°C, 3-4 hrs) during which it was regularly checked. The colonies that turned blue 
after the beta-galactosidase filter assay were marked, picked from the master yeast 
plate, plated on non-selective yeast medium and incubated at 30°C for 72hrs (Figure 
1).
e) Characterization of yeast two hybrid protein interactions:
Yeast cells were mixed with TE buffer (QIAGEN). Lyticase (SIGMA) was added and the 
lysate was incubated at 37°C for 1 % hr during which it was occasionally mixed by 
vortexing. Following incubation, the plasmids were extracted using a QIAprep 
SpinminiPrep Kit (QIAGEN) as described above. The eluted product (5pl) was then 
used to transform 10Opil of competent E.coli cells as described above and the cells 
were plated using the appropriate antibiotic for selection of the pEXP-AD502 plasmid. 
The plates were incubated at 37°C for 16-18hrs, colonies were picked and grown 
individually in LB broth containing the appropriate antibiotic and the plasmid was
185
isolated using a QIAprep Spin mini Prep Kit (QIAGEN) as described above. DNA (500- 
600ng) was used to set up a sequencing reaction and samples were sequenced on an 
ABI3100 sequencer. In order to identify putative interacting partners of the protein of 
interest isolated by the yeast-two-hybrid library screening, the data obtained were 
compared against the Human Reference DNA Sequences by a sequence similarity 
searching computer program (BLAST)
Heart cDNA library
Gene of interest
Transcription
Reporter gene
Selection on deficient media
Figure 1: The basic concept of the Y2H technique: The gene of interest, which acts as 
a bait, is fused to a vector also expressing a DNA binding domain, while a heart cDNA 
library is fused to a vector that also expresses the activation domain. When the protein 
of interest interacts with any protein encoded by the heart cDNA library, the DNA 
binding domain and the activation domain are brought together and the complete 
transcription factor can drive the expression of a reporter gene.
13) Co-immunoprecipitation:
HEK293 cells were transiently transfected with epitope-tagged plasmids (A and B) 
expressing the proteins of interest as described above. The cultures were grown to 
confluence, harvested and the pellets washed in PBS. Cells were lysed by re­
suspension of the pellets in IP buffer (25 mM Hepes-KOH pH 7.5, 150 mM KCI, 1 mM 
EDTA, 12.5 mM MgCI2, 0.1% NP-40), sonicated and centrifuged. Aliquots of the 
supernatant fraction (equivalent to 2mg of protein) were mixed with an antibody raised 
against the epitope expressed by plasmid A and protein G-Sepharose beads slurry 
(Santa Cruz Biotechnology) in IP buffer and rotated overnight at 4°C. Following 
centrifugation, the supernatant was discarded; the pellet was washed three times and 
re-suspended in IP buffer. Western immunoblotting was performed using an antibody
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raised to recognize the epitope expressed by plasmid B. Similarly, the procedure was 
repeated using the two antibodies in the reverse order.
14) In vitro protein binding assay:
BL21 star cells (Invitrogen, UK) were transfected with recombinant plasmids 
constructed for the expression of GST as well as the GST-fused N-terminal, central and 
C-terminal domains of the histidine-rich calcium binding protein (HRC-BP, kindly 
donated by Dr. Ho). The transformation reactions were plated on agar plates 
supplemented with ampicillin and incubated at 37°C overnight. A scrape of transformed 
bacterial cells was obtained from each plate and grown in 20ml LB supplemented with 
ampicillin (37°C, overnight). The 20ml cultures were diluted in a bigger volume of LB 
supplemented with ampicillin (500ml) and grown until an O D 6oo value of 2.0 was 
reached as measured by spectrophotometry. An O D 6oo value of 2.0 is preferable, since 
the cells need to still be in the growing phase prior to the induction of protein 
expression (Figure 2). A 1ml sample was taken, kept at -20°C, and isopropyl-beta-D- 
thiogalactopyranoside (IPTG) was added to the remaining cultures (final concentration 
1mM). The cells were inoculated for a further 3 hours at 30°C, and another 1ml sample 
was taken. The gene fragments in the plasmids are under the control of the lac 
promoter. Following the transfection of the bacterial cells with the plasmids though, the 
gene fragments are not expressed as the lac promoter is inhibited by the presence of a 
repressor molecule. IPTG acts by binding the repressor and allowing transcription and 
therefore expression of the proteins of interest (Figure 3). IPTG is used instead of 
lactose (the natural activator of the lac promoter) since it is an artificial substance and 
cannot be metabolized by the cells. After induction of expression by IPTG, the cultures 
are incubated at 30°C, so as to avoid over-expression of the exogenous proteins, which 
may have deleterious effects to the cells.
Stationary phase
Growing phase Death phase
Log phase
Figure 2: Bacterial growth curve showing the four typical phases of growth.
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Lac promoter Gene fragment
Repressor
Lac promoter Gene fragment
Gene transcription
Lac promoter Gene fragment
Figure 3: Mechanism of action of isopropyl-beta-D-thiogalactopyranoside (IPTG).
The two 1ml samples taken from the culture, one prior and one after induction by IPTG, 
were centrifuged, the pellets re-suspended in Laemmle buffer, heated, loaded on an 
acrylamide gel and subjected to electrophoresis. The gel was subsequently stained 
with Coomassie blue dye and de-stained with 20% acetic acid- 80% ethanol. The 
remaining cultures were centrifuged and the pellets re-suspended in a solution made of 
50mM Tris-HCI, 1% Triton-X 100, 100mM NaCI and protease inhibitors (pH=8.0). The 
re-suspended samples were sonicated, centrifuged and the protein concentration of the 
supernatant fraction measured by spectrophotometry. For each 2mg of protein, 50pl of 
glutathione-agarose beads were added and the mixture rocked at room temperature for 
30min. The mixtures were then centrifuged, the supernatant removed, and the beads 
washed with PBS four times. Each time the supernatant fraction was being removed 
and kept aside. Following the washes, the beads were re-suspended in a solution 
made of 0.1%Tween/PBS and protease inhibitors, and a small sample was kept aside 
for control purposes. This control bead sample along with the supernatant samples kept 
aside were subjected to acrylamide gel electrophoresis. The gel was stained with 
Coomassie blue dye and de-stained as described above. At this stage, the beads 
should be bound only to the purified protein expressed by the plasmid, while the 
supernatant fractions should contain the remaining proteins expressed by the bacterial 
cells.
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Cells transfected to stably express the protein of interest (in this case, plakoglobin) 
were grown in T75 flasks until confluency was reached. The cells were then harvested 
and the pellets re-suspended in a detergent/PBS solution. The exact composition of the 
re-suspension buffer was optimized. The detergent selected should not be too mild, so 
that the protein of interest can be separated from its partners and not too harsh either 
so that the protein of interest will not be denatured. The samples were sonicated twice 
and centrifuged. The protein concentration of the supernatant fraction was measured 
by spectrophotometry and an amount corresponding to 0.5mg of protein was mixed 
with 25 pi of the re-suspended glutathione-agarose beads bound to the protein 
fragments. The mixture was rocked at room temperature for 30min, centrifuged, 
washed in 0.2%Tween/PBS 4 times, re-suspended in Laemmle buffer and loaded on 
an acrylamide gel. Western immunoblotting using an antibody directed against 
plakoglobin was performed as described above.
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METHODS VALIDATION. RESULTS AND DISCUSSION
1) S39_K40insS; effects on the binding properties of plakoglobin:
Plakoglobin cDNA was amplified by PfX and EXL polymerase and inserted into the 
pDONR™221 vector. (Figure 4).
A B
1 kb ---------►
500 bp ---------►
250 bp ---------►
Figure 4: The bands indicated by the red arrow, correspond to plakoglobin cDNA 
amplified by PfX (A) and EXL (B) polymerase. The higher bands correspond to super­
coiled DNA, which tends to migrate at a lower speed during electrophoresis. The lower, 
fainter bands may represent amplification products stemming from non-specific primer 
binding.
Following the generation of the pDONR™221-plakoglobin entry clone, site-directed 
mutagenesis was performed in order to create an entry clone expressing the mutant 
plakoglobin protein. Both wildtype and mutant genes were then transferred to the 
pDEST™32-DNA binding domain containing-vector (Figures 5 & 6).
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Figure 5: Electropherogram showing the incorporation of the wildtype plakoglobin 
sequence in the pDEST™32 vector.
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Figure 6: Electropherogram showing the incorporation of the mutant plakoglobin 
sequence in the pDEST™32 vector.
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Competent S.cerevisae cells were transformed with pDEST™32-wtPG, pDEST™32- 
mutPG and pEXP-AD502-library cDNA separately to test for self-activation and to 
determine the concentration of 3-Amino-1,2,4-Triazole (3AT) required to titrate basal 
HIS3 expression levels. Even 10mM 3-AT prevents the wild-type protein from activating 
HIS3. At this 3AT concentration the mutant protein shows a level of self-activation 
which is however inhibited when 3AT concentration is increased to 25mM. (Figure 7).
Figure 7: Different concentrations of 3-AT were titrated in plates lacking histidine in 
order to determine the concentration that inhibits self-activation of HIS3. (I) 10mM, (II) 
25mM, (III) 75mM and (IV) 100mM. [A], [B], [C], [D] and [E] are control strains which 
express proteins of known interaction strength. [A] contains only empty vectors, which 
do not interact. [B], [C] ,[D] and [E] contain vectors fused with proteins that are known 
to interact weakly, moderately, strongly and very strongly respectively.
Following the control transformations, pDEST™32-wtPG and pEXP-AD502 plasmids 
were introduced into yeast cells and plated on SC-Leu-Trp-His+ 10mM 3AT plates. 
Similarly, pDEST™32-mutPG and pEXP-AD502 were introduced into yeast cells and 
plated on SC-Leu-Trp-His+ 25mM 3AT plates. The total number of transformants was
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estimated to be 3.6 x 104 and 1.2 x 104 colonies per 250- pi transformation in the WT 
and the MUT reactions respectively (Figure:8).
Figure 8: Estimation of transformation efficiency for pDEST™32-wtPG (A) and 
pDEST™32-mutPG (B).
pEXP-AD502 plasmids, which through interaction with pDEST™32-wtPG or 
pDEST™32-mutPG could induce the transcription of lacZ were isolated and identified 
by direct sequencing. The yeast-two-hybrid library screening showed that mutant 
plakoglobin interacts with all the proteins wildtype plakoglobin does. However, it also 
interacts with two clones which have not previously been associated with the 
desmosomal protein: TGF-beta induced apoptosis protein 2 (TAIP-2, Figure 9) and 
histidine-rich calcium binding protein (HRC-BP, Figure 10).
Features: TGF-beta induced apoptosis protein 2
Score = 3690 bits (1998),Identities = 2002/2004 (99%), Gaps = 0/2004 (0%) 
Strand=Plus/Plus
Query 1576 AGGTGGATCGTATGTCTTTCCCATGCGGCTGCACTAAAGAAGGATGTAGTAACACAGCAG
I I I I I I I I I I I I I I I I  I I I I I I I  I I I I I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I  I I I 
Sbj ct 16744 627 AGGTGGATCGTATGTCTTTCCCATGCGGCTGCACTAAAGAAGGATGTAGTAACACAGCAG
Query 1636 GTAGAATTGAATTTAATCCTATCCGTGTTCGGACTCACTTTTTGCACACAATAATGAAAC
I I I I I I I I I I  I I I I  I I I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I I  I I I I I I I  I I I I I 
Sb j ct 16744687 GTAGAATTGAATTTAATCCTATCCGTGTTCGGACTCACTTTTTGCACACAATAATGAAAC
Query 1696 TTGAACTGGAGAAAAACCGAGAGCAGCAAATCCCCACGCTGAATGGCTGCCACAGTGAGA
I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I II I I I I I I I I I I I I I I I I I I I I I II II I 
Sbj ct 16744747 TTGAACTGGAGAAAAACCGAGAGCAGCAAATCCCCACGCTGAATGGCTGCCACAGTGAGA
Figure 9: Alignment of a mutPG-binding plasmid sequence with human TGF-beta 
induced apoptosis protein-2 as shown by BLAST.
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Features: histidine-rich calcium-binding protein precursor
Score = 3552 bits (1923),Identities = 1944/1953 (99%), Gaps = 6/1953 (0%) 
Strand=Plus/Minus
AAAGGACAAAGGAGAGACACAGAGaaa a iaGAGACCAACCCCAAAGGGACAAAGACCCC 
I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
AAAGGACAAAGGAGAGACACAGAGAAAAAAAGAGACCAACCCCAAAGGGACAAAGACCCC
AACGTTTGTCCACATTGCCGCAGAGGCAGCTGGAGCCAGTGCTGCCTGTCCGTCCCCATG 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
GGCCACCATAGGCCATGGCTGCACGCTTCTGTCCTCTGGGCTGGGGTGGCCAGCCTGCTC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I
CTCCCCCCGGCCATGACCCAGCAGCTCAGAGGGGATGGGCTAGGCTTCAGAAACCGGAAC
I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Figure 10: Alignment of a mutPG-binding plasmid sequence with human histidine-rich 
calcium-binding protein as shown BLAST.
Query 537
Sbjct 1199197
Query 597
Sbj ct 1199137
Query 657
Sbjct 1199077
Query 717
Sbjct 1199017
Although the beta-galactosidase assay typically offers a high degree of confidence as 
to the true existence of the interactions revealed by Y2H screening, all interactions 
identified should be confirmed by further in vitro methods prior to drawing conclusions 
as to their implications in human physiology and pathology.
The plakoglobin-TAIP2 interaction was tested by co-immunoprecipitation. In contrast to 
the results obtained from the Y2H screening, both wildtype and mutant plakoglobin 
were shown to bind the TAIP2 protein (Figures 11, 12).
A B
~ 2kb
Figure 11: The bands indicated by the red arrow correspond to TAIP2 cDNA as 
amplified by PfX (A) and EXL (B) polymerase.
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Figure 12: Lysates of cell lines induced to express wildtype (lane 1) and mutant 
plakoglobin (lane 2) were loaded for control purposes. Co-immunoprecipitation of 
wildtype PG and TAIP-2 (lane 3), mutant PG and TAIP-2 (lane 4), wildtype PG and V5 
vector (lane 5), mutant PG and V5 vector (lane 6) His Max vector and TAIP-2 construct 
(lane 7) and His Max vector and V5 vector only (lane 8).
The plakoglobin-HRC BP interaction was tested by an in vitro protein binding assay. 
Four recombinant plasmids, encompassing glutathione-s-transferase (GST) as well as 
the GST-fused N-terminal, central and C-terminal domains of HRC-BP were used to 
transfect competent bacterial cells and their expression was induced by IPTG (Figure 
13). Subsequently the lysates were incubated with glutathione agarose beads, which 
couple GST (Figure 14).
Figure 13: The bands on the Coomassie blue-stained acrylamide gel represent the 
proteins expressed by the cells prior (A) and after (B) induction by IPTG. [N] stands for 
the N-terminal HRC BP domain, [M] stands for the central (middle) protein part, while 
[C] stands for the C-terminal protein domain.
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Figure 14: Purified glutathione agarose beads bound to the protein constructs of 
interest (A), and non-bound proteins present in the 5 supernatant fractions isolated 
during the bead purification (B).
A number of detergent solutions were used to optimise solubilization of mutant 
plakoglobin from a stably-transfected cell line. The largest amount of plakoglobin, as 
shown by Western immunoblotting, was isolated when 1% Tween/PBS or 1% NP- 
40/PBS were used (Figure 15). 1% NP-40 was selected for optimal solubilization. The 
cell lysate was subsequently incubated with the glutathione beads bound to the HRC 
BP fragments, to test whether mutant plakoglobin interacts with any domain of the HRC 
binding protein. Mutant plakoglobin not only interacted with all 3 fragments, but also 
with GST only, indicating that the detergent solution selected was not stringent enough 
(Figure 16). Addition of 250mM NaCI to the solubilization 1% NP-40 buffer prevented 
the non-specific interaction between mutant plakoglobin and GST (Figure 17).
1 2 3 4 5 6
Figure 15: The bands represent plakoglobin solubilised from a stably transfected cell 
line using a number of different detergent solutions: [1] 0.5% Tween/PBS, [2] 1% 
Tween/PBS, [3] 0.5% Triton-X/PBS, [4] 1% Triton-X/PBS, [5] 0.5% NP-40/PBS and [6] 
1% NP-40/PBS.
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Figure 16: Western immunoblotting against plakoglobin. Cell lysate only was loaded on 
lane [1] for control purposes. Cell lysate along with beads bound to the N-HRC BP 
fragment was loaded on lane [2]. Cell lysate along with beads bound to the middle-HRC 
BP fragment was loaded on lane [3]. Cell lysate along with beads bound to the C-HRC 
BP fragment was loaded on lane [4] and cell lysate along with beads bound to GST 
was loaded on lane [5].
1 2 3 4
Figure 17: Western immunoblotting against plakoglobin. Cell lysate along with beads 
bound to GST was loaded on lane [1]. Cell lysate along with beads bound to the N- 
HRC BP fragment was loaded on lane [2], Cell lysate along with beads bound to the 
middle-HRC BP fragment was loaded on lane [3], Cell lysate along with beads bound to 
the C-HRC BP fragment was loaded on lane [4].
The pGFP-C3-wtPG plasmid, which expresses GFP-tagged wildtype plakoglobin was 
used to transiently transfect HEK293 cells. Plakoglobin was solubilised by the same 
detergent solution used for isolation of the S39_K40insS bearing protein (1% NP- 
40/PBS-250mM NaCI) and incubated with the glutathione beads bound to the HRC BP 
fragments.
Wildtype plakoglobin does not bind any of the three HRC BP fragments. Western 
immunoblotting of the control cell lysate gave two bands, a higher one corresponding to 
the GFP-bound recombinant plakoglobin construct, and a lower one, corresponding to 
the endogenous plakoglobin naturally expressed the HEK293 cells. The size of GFP 
(27 kDa) may explain the difference between the two bands observed (Figure 18).
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Figure 18: Western immunoblotting against plakoglobin. Cell lysate only was loaded on 
lane [1] for control purposes. Cell lysate along with beads bound to the N-HRC BP 
fragment was loaded on lane [2]. Cell lysate along with beads bound to the middle-HRC 
BP fragment was loaded on lane [3], Cell lysate along with beads bound to the C-HRC 
BP fragment was loaded on lane [4] and cell lysate along with beads bound to GST 
was loaded on lane [5]. Protein standards are not shown.
Discussion:
Plakoglobin consists of three structurally distinct regions: the unique amino- and 
carboxy-terminal segments and a 560- amino acid long central region comprising 13 
arm repeats. Specific regions along the plakoglobin protein are involved in a complex 
pattern of interactions with other proteins.281 In transfected human A-431 carcinoma 
cells, a chimeric protein combining the cytosolic vesicle-forming glycoprotein 
synaptophysin with the complete human plakoglobin sequence localized at the cell 
borders and was incorporated into desmosomal structures. This strong topogenic effect 
was driven by associations of plakoglobin with desmosomal cadherins.282 To determine 
the sites of plakoglobin responsible for this topogenic effect, a synaptophysin insertion 
mutagenesis approach was undertaken. Synaptophysin was inserted at various parts of 
the plakoglobin protein resulting in the formation of plakoglobin-coated vesicles, where 
one domain was functionally affected while the remaining domains maintained their 
ability to engage in protein-protein interactions. Chimeras containing a synaptophysin 
insertion in any of the three first arm repeats of plakoglobin were unable to interact with 
either desmocollins or desmogleins. On the contrary, chimeras containing a 
synaptophysin insertion in either the forth or the fifth arm repeat could interact with 
desmocollins and desmogleins, however their association with E-cadherin was 
abolished. These data clearly indicate that the first three armadillo repeats of 
plakoglobin are responsible for interaction with desmosomal cadherins, while it is the
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281forth and fifth arm repeats that mediate interaction with E-cadherin. In fact, yeast-two 
hybrid experiments showed that only the third arm repeat is essential for the 
association of plakoglobin with desmogleins, while the first two arm repeats merely 
enhance and stabilize the interaction.283
Further experiments, where segments of beta-catenin were substituted by homologous 
segments of plakoglobin indicated that the plakoglobin sequence Arg142-Arg233 is 
essential for binding to desmoglein molecules. Similar studies showed that a 
plakoglobin molecule lacking the Leu304-Arg320 segment is unable to bind E-cadherin.281 
Plakoglobin constructs lacking the last three armadillo repeats do bind desmosomal
cadherins though weakly, indicating that the C-terminal part of the arm region has a
282role in stabilizing and strengthening these interactions. Moreover, these last arm 
repeats were shown to have a role in targeting the protein to the cell borders.282 
Transfections of carboxy-terminal plakoglobin deletion constructs into the human 
fibrosarcoma HT-1080 cells suggested a gradual decrease in the ability of plakoglobin 
and N-cadherin to associate as plakoglobin was shortened from the end of repeat 8 to 
the end of repeat 6 (amino acids: 375-458).284
It has been reported that a plakoglobin construct encompassing only the first 114 amino 
acids does not immunoprecipitate a-catenin. However, when plakoglobin was truncated 
at 161 amino acids it could readily associate with a-catenin, suggesting that the 47 
residues from 115 to 161 play a major role in the interaction of the two catenins. 
Plakoglobin’s binding site for a-catenin partially overlaps with the site required for 
association with desmosomal cadherins. This may be a way to ensure that only the 
right components are incorporated into each junction type. If plakoglobin binds a- 
catenin, it is unable to bind desmosomal cadherins and will therefore be incorporated 
into adherens junctions. Conversely, if plakoglobin binds desmosomal cadherins, it is 
unable to bind a-catenin and will therefore anchor intermediate filaments instead of 
actin microfilaments.285 Plakoglobin constructs lacking the C-terminal domain do 
incorporate into desmosomes. However, extremely long junctions are formed, 
indicating a role of the C-terminus in limiting the size of desmosomes.286 S39_K40insS 
is predicted to lead to the insertion of a serine residue at position 39 of plakoglobin. 
Despite the numerous bonds that plakoglobin establishes with many adhesion proteins, 
this part of the protein does not seem to be involved in any of the above-mentioned 
protein-protein interactions (Figure 19). In fact, Palka et al. have shown that an N- 
terminal truncation of plakoglobin does not affect the protein’s incorporation into 
junctional complexes and does not have a dramatic effect on the structure of 
desmosomes.286 A question therefore arises: since S39_K40insS does not seem to 
affect the interaction of plakoglobin with its known adhesion partners, how does it 
cause ARVC?
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Figure 19: Schematic representation of plakoglobin domains involved in adhesive 
interactions in comparison to mutation localization.
The S39_K40insS-bearing protein was shown to interact with two additional proteins 
that have not previously been associated with plakoglobin: histidine-rich calcium 
binding protein (HRC-BP) and TGF-(3 induced apoptosis protein 2 (TAIP-2). HRC-BP 
localizes at the sarcoplasmic reticulum of cardiac and skeletal muscle cells, where it 
controls Ca+2 release during excitation-contraction coupling.287 The first phase of the 
cardiac action potential is the depolarization of the cell membrane initiated by the influx 
of sodium. Membrane depolarization activates the L-type voltage-activated Ca+2 
channels resulting in the influx of Ca+2 inside the cell. The Ca+2 entry activates the 
ryanodine receptors at the SR membrane, leading to further Ca+2 release from the SR 
stores to the cytoplasm. The influx of Ca+2 together with the Ca+2 release from the 
intracellular stores, contribute to the increase of Ca+2 concentration in the cell. As a 
result, Ca+2 binds troponin C switching on the contractile machinery. In order for the cell 
to relax, Ca+2 must dissociate from troponin C. The ryanodine receptor channels close, 
the release of Ca+2 from the stores stops, the Na/Ca+2 pumps pump Ca+2 outside the 
cell and the Ca+2 ATPase pumps force calcium back to the SR stores.88 Recently, it 
was shown that HRC-BP binds to triadin and is able to control Ca+2 release through the 
ryanodine receptor.288
This is not the only time that ARVC has been associated with the excitation-contraction 
coupling mechanism. As mentioned in the introduction, one of the first genes 
associated with ARVC2 was RyR2, the gene coding for the cardiac ryanodine 
receptor.85 Mutations in RyR2 were thought to permit leakage of Ca+2 into the 
cytoplasm, thereby causing electrical instability that could trigger arrhythmias.89 RyR2 
mutations are currently believed to be underlying catecholaminergic VT rather than 
ARVC. However, recent studies suggest that certain polymorphisms in the RyR2 gene 
can contribute to arrhythmogenesis and HF in a subset of ARVC patients bearing 
specific genotypes.289 The fact that mutant plakoglobin binds a sarcoplasmic reticulum 
protein in vitro might reflect a change in the protein’s structure, which would allow it to
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engage in non-physiological interactions. This association may therefore be not 
pathogenic per se, but constitute a secondary effect of the protein’s altered properties. 
On the other hand, this potential association may affect the normal Ca+2 release, 
therefore contributing to the arrhythmogenesis characterizing the disease. It is crucial 
however to highlight that both yeast-two-hybrid screening and protein binding assays 
are in vitro models, which do not necessarily reflect the situation that exists in vivo. A 
heart tissue sample from an S39_K40insS carrier could be immunostained for both 
mutant plakoglobin and HRC-BP. Co-localization of the two proteins in this case would 
provide solid evidence in support of the finding presented herein. Nevertheless, though 
not “waterproof’ as yet, this result constitutes a provocative observation in 
understanding the mechanism of ARVC pathogenesis that is certainly worth further 
investigation.
Although TGFp-induced apoptosis protein 2 (TAIP-2) has not previously been 
associated with ARVC, there is evidence that links plakoglobin to the mechanism of 
apoptosis. Plakoglobin regulates the expression of BCL-2, a prototypic member of 
apoptosis-regulating proteins, which prevent the proteolytic activation of caspases, the 
major executors of programmed cell death. 290,291 Desmin-null mice develop a type of 
cardiomyopathy characterized by extensive cardiomyocyte death, fibrosis, calcification 
and eventual heart failure. Over-expression of Bcl-2 in these hearts inhibits apoptosis 
thus decreasing the occurrence of fibrotic lesions, restoring cardiomyocyte 
ultrastructure and significantly improving the overall cardiac function.292 The anti- 
apoptotic function of plakoglobin is independent of its role in mediating cell-cell 
adhesion.293 Still, the fact that both wildtype and mutant plakoglobin co- 
immunoprecipitate with TAIP-2 suggests that this interaction may in fact not play a vital 
role in the development of ARVC. The significance of this novel finding may therefore 
lie in exploring the complex functions of plakoglobin rather than unraveling the 
mechanisms of disease pathogenesis. Nevertheless, the question still remains of how 
S39 K40insS causes ARVC.
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2) S39_K40insS; effects on the subcellular localization of plakoglobin and 
desmosomal structure.
To investigate the functional consequences of a plakoglobin molecule bearing an 
additional serine residue, mammalian cell lines stably expressing the wildtype or the 
S39_K40insS-bearing protein were generated (Figure 20).
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Figure 20: Electropherogram showing the incorporation of the mutant plakoglobin 
sequence in the pcDNA5/FRT/TO vector.
Western blotting revealed differences in the electrophoretic mobility of plakoglobin 
expressed by the transfected cells. In non-induced control cell lines, one band was 
observed which matched the predicted size of plakoglobin (82kDa) and corresponded 
to the endogenous protein naturally expressed by HEK293 cells. In contrast, two 
bands were observed in cells induced to express the S39_K40insS mutation; a lower
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band (82kDa) corresponding to native plakoglobin and a higher band (~90kDa) which 
was the mutant protein (Figure 21A). Because cytoplasmic plakoglobin is degraded by 
the ubiquitin-proteasomal system,294 we investigated the possibility that the mutant 
protein migrated with an apparent molecular weight of ~90kDa because it was bound to 
ubiquitin. Western blotting with an anti-ubiquitin antibody typically reveals a smearing 
band pattern reflecting the abundance of ubiquitin and its numerous interactions. 
However, brief film exposure revealed two major bands, a lower one which matched 
the size of free ubiquitin (~8kDa), and a higher one (~90kDa) at the same position seen 
in the plakoglobin blot prepared from cells induced to express the mutant protein 
(Figure 21B).
90  k D a  
82  kD a
8 kD a
Figure 21: (A) Four non-induced cell lines (lanes 2, 4, 6, 8) express the endogenous 
plakoglobin only (82kDa), whereas 4 induced cell lines (lanes 1, 3, 5, 7) express both 
endogenous plakoglobin (82kDa) and the mutant form of plakoglobin which migrates at 
~90kDa. (B) Ubiquitin is present in the cell line expressing the highest levels of the 
exogenous construct (indicated by the red arrow) both in its free form (8kDa) and at a 
form (~90kDa) consistent with it being covalently bound to mutant plakoglobin.
If S39_K40insS does indeed enhance the interaction of plakoglobin with ubiquitin, then 
the mutant protein might be expected to show increased cytoplasmic localization. To 
investigate the cellular distribution of S39_K40insS plakoglobin as distinguished from 
endogenous plakoglobin, HEK293 cells were transiently transfected to express wildtype
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or mutant plakoglobin tagged with GFP. Transfected cells were counter-stained with 
DAPI to mark nuclei before being examined by confocal microscopy to visualize the 
GFP-tagged plakoglobin. In cells expressing wildtype plakoglobin, GFP signal was 
localized mainly at cell junctions. In contrast, signal in cells expressing mutant 
plakoglobin was markedly shifted to the cytoplasm (Figure 22)
DAPI Plakoglobin-GFP Merge
\
y Wildtype
\
y Mutant
Figure 22: Confocal microscopy showing the distribution of wildtype and mutant 
plakoglobin in transiently transfected HEK293 cells.
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Reduced amounts of S39_K40insS plakoglobin at junctional sites, as suggested by 
fluorescent microscopy, might affect desmosomal formation. To investigate this 
hypothesis, HEK293 cells stably expressing wildtype or mutant plakoglobin were 
examined by electron microscopy. The mutant cells form fewer and smaller 
desmosomes that wildtype cells (Figure 23). Representative micrographs are shown in 
Figure 24.
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Figure 23: The number and size of individual desmosomes was measured in 10 
randomly selected electron micrographs (final magnification 9000) of each cell line. 
Mutant cells formed fewer (3.2 ±1.2 vs. 6.4 ±1.9  desmosomes per micrograph, p< 
0.001, graph A) and smaller (0.87 ± 0.42 vs. 2.68 ± 0.83 pm per desmosome profile, p< 
0.001, graph B) desmosomes than wildtype cells. The bar lines represent standard 
deviations.
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Figure 24: Electron micrographs of HEK293 cells stably expressing wildtype (A & B) or 
mutant (C & D) plakoglobin. The arrows indicate adhesive junctions between adjacent 
cells.
Discussion:
The N-terminus is known to play an important role in determining the stability of 
armadillo proteins. This region appears to be a target for O-glycosylation by N- 
acetylglucosaminyltransferase (O-GlcNAc). O-GlcNAc modification has been proposed 
to counteract phosphorylation, provide protection from proteasomal degradation, 
mediate signal transduction, silence transcription and regulate multi-molecular protein 
assembly.295,296 Investigations using a number of plakoglobin deletion constructs 
indicated that the site for O-GlcNAc modification lies within the first 32 amino acids of 
the protein. A total of six threonine and serine residues are found within this stretch of
the molecule, however it appears that only when Thr14 gets mutated, O-glycosylation is 
totally abolished.297 Since S39_K40insS does not affect this site, it is unlikely that the 
ARVC-causing mutation identified disrupts the O-GlcNAc modification of the 
plakoglobin protein.
Apart from regulating stability though, the N-terminus is also known to control the 
turnover kinetics of armadillo proteins. The ubiquitin-proteasomal system is the major 
non-lysosomal pathway for intracellular protein degradation, generally requiring a 
covalent linkage of one or more chains of polyubiquitins to the protein intended for 
degradation.298 Ubiquitin is a highly conserved globular protein consisting of 76 amino 
acids that is expressed in all eukaryotes but very few prokaryotes. Proteasomes on the 
other hand, have a highly conserved architecture and are found in one form or another 
in all forms of life. The complete eukaryote proteasome is composed of two complexes 
of proteins: the proteolytic core, or 20S proteasome (on the basis of its sedimentation 
value), containing 28 subunits and having a molecular mass in excess of 700kDa, and 
one or two regulatory complexes, also known as the 19S complexes, consisting of at 
least 17 additional proteins and having a molecular mass of almost 900kDa. 
Association of the proteolytic core with the regulatory complex results in the formation 
of a macro-molecular structure that has become known as the 26S proteasome (Figure 
25).298 Experiments utilizing inhibitors of different degradation pathways have proven 
that the ubiquitin-proteasomal system is the major regulator of both plakoglobin and 
beta-catenin turnover.299 Ubiquitination proceeds along a three-step cascade. In the 
first step, the ubiquitin-activating enzyme, E1, uses ATP to activate ubiquitin to a higher 
energy state. The activated ubiquitin is then transferred onto one of several ubiquitin- 
conjugated proteins, E2, by the formation of an additional high-energy bond and then 
covalently linked, generally at a lysine residue, to a protein substrate, which in turn is 
bound to a specific ubiquitin protein ligase, E3. In general, if the substrate is to be 
degraded by the 26S proteasome, it must be poly-ubiquitinated, which occurs via the 
successive addition of activated ubiquitins to internal lysine residues of the previously 
conjugated ubiquitin. In some instances, poly-ubiquitin chain formation is facilitated by a 
multi-ubiquitin elongation factor, E4. Once a substrate is poly-ubiquitinated, it is either 
recognized directly by the proteasome or bound to some shuttling protein, which will 
transport it to the proteasome (Figure 26).300
207
298Figure 25: Structure of the mammalian 26S proteasome.
298Figure 26: The ubiquitin-proteasome pathway.
When not engaged in cell-cell adhesion or nuclear signaling pathways, plakoglobin is 
recognized by glycogen synthase kinase 3b (GSK-3(3). GSK-3P forms a complex with 
two further scaffolding proteins: axin and adenomatous polyposis coli (APC) and 
together they phosphorylate the target armadillo protein at a series of serine residues 
within its N-terminus.294 Five residues (S28, T32, S36, S38 and S39) at the amino 
terminal part of plakoglobin form the consensus site for phosphorylation by GSK-3(3,
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come to be known as the “destruction box” .301 The phosphorylated plakoglobin may 
then interact with the ubiquitin ligase E3 complex, consisting of Skp1, Cullin and b- 
TRCP 302 b-TRCP, whose homologue in Drosophila is Slimb, is an F-box protein, which 
can bind both Skp1 through its F-box domain and the phosphorylated target protein 
through a series of C-terminal WD repeats (Figure 27).303
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Figure 27: Proteolysis of plakoglobin by the ubiquitin-proteasomal system.
In response to Wnt signaling though, GSK-3p is prevented from phosphorylating 
plakoglobin, which therefore becomes stabilized, enters the nucleus and participates in 
regulating gene expression.304 There is a fine balance between the amount of 
plakoglobin engaged in cell junctions, the fraction of plakoglobin involved in signaling 
and the quantity of plakoglobin that is degraded. A plausible hypothesis is that 
S39_K40insS disrupts this balance, perhaps because the presence of an extra N- 
terminal serine increases the protein’s turnover rate. The resultant decrease in the total 
amount of plakoglobin may limit its accumulation at cell junctions leading to impaired 
intercellular adhesion and development of ARVC. This hypothesis could also explain 
the increased levels of (3-catenin observed at the intercalated discs of the proband’s 
cardiac tissue (Chapter 2). Plakoglobin and (3-catenin compete at all junctional, nuclear 
and proteasomal sites maintaining a constantly dynamic balance. When plakoglobin is 
over-expressed, (3-catenin gets released from the junctions and displaced to the 
cytoplasm, where it becomes available for degradation. Similarly, mutations that perturb 
the function of the (3-catenin degradation complex, lead to increased accumulation of (3- 
catenin in the nucleus, and subsequent displacement of plakoglobin.305 If S39_K40insS 
plakoglobin is indeed driven away from the cell borders by its increased association 
with the degradation machinery, [3-catenin could conversely be driven away from the 
saturated proteasomes and recruited at the cell junctions.
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To test this hypothesis, HEK293 cell lines were transfected to stably express the 
mutant protein. Cells containing the S39_K40insS mutation expressed plakoglobin with 
a greater molecular weight than the wildtype protein. This could be explained by a 
number of post-translational modifications However, confocal microscopy showed that 
more of the S39_K40insS protein was localized in the cytoplasm and less at the cell 
junctions, which could be related to enhanced ubiquitylation of the mutant plakoglobin. 
The increased cytoplasmic plakoglobin localization observed at HEK293 cells does not 
however necessarily represent the situation in vivo. The distribution of the mutant 
protein in the heart or skin of affected patients should be analysed in future studies. 
Furthermore, although consistent with enhanced ubiquitylation, the higher molecular 
weight of S39_K40insS plakoglobin does not prove that the mutant molecule is 
covalently bound to ubiquitin.
A co-immunoprecipitation approach would have provided stronger evidence in favor of 
the proposed hypothesis. Moreover, since a protein targeted for degradation by the 26S 
proteasomes typically has to be poly-ubiquitinated, one may wonder why only a 
~90kDa form (consistent with mono-ubiquitination) is observed at the Western 
immunoblot prepared from the mutant cell line. It could be speculated that poly- 
ubiquitinated forms of the mutant protein get degraded and therefore cannot be traced 
in the cell lysates. Also, even if the mutant protein is indeed covalently bound to 
ubiquitin, this does not necessarily mean that its turnover rate is increased. A way to 
approach this question would be to generate a recombinant construct of wildtype or 
mutant plakoglobin fused to the HaloTag protein (Promega) and use it to transiently 
transfect cells. A synthetic ligand, tagged with a fluorescent molecule can then be 
added to trace HaloTag and consequently the protein under investigation. Serial 
microscopy could be used to investigate the turnover rates of the target mutant 
molecule and compare them with those of its wildtype counterpart. Finally, even if 
S39_K40insS does not seem likely to affect the action of O-GlcNAc, the question still 
remains of whether the mutation can disrupt other types of post-translational 
modification. The consensus sequence for phosphorylation by GSK-3(3 overlaps with a 
potential N-glycosylation site, although modification at this site has not been proved
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experimentally. To examine the possibility that S39_K40insS disturbs the potential N- 
glycosylation, the cell line stably expressing mutant plakoglobin should be treated with 
tunicamycin prior to Western immunoblotting. Tunicamycin is an antibiotic that blocks 
the reaction of UDP-GlcNAc and Dol-P in the first step of glycoprotein synthesis, thus 
inhibiting the synthesis of all N-linked glycoproteins. If following tunicamycin incubation, 
S39_K40insS plakoglobin still migrates at a higher molecular weight than the wildtype 
protein then this possibility could be ruled out. Also, the hypothesis that the additional
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serine does get phosphorylated and disrupts the degradation pathway has to be 
investigated further.
Another approach would be to develop an antibody specifically recognizing a 
plakoglobin molecule phosphorylated at this additional residue and apply it to heart 
tissue from affected individuals. Still, even if the additional residue does get 
phosphorylated, it does not necessarily mean that it alters the turnover kinetics of 
plakoglobin. For instance, phosphorylation of specific plakoglobin C-terminal tyrosine 
residues following epidermal growth factor receptor activation leads to dissociation of 
desmoplakin from the desmosomal plaques without affecting the degradation 
pathway.306 Though fascinating and plausible, the “altered turnover kinetics’’ hypothesis 
still contains gaps and unless they get filled it remains purely speculative. On the other 
hand, immunohistochemistry of cardiac tissue obtained from the actual proband 
showed altered localization of both structural and electrical coupling molecules 
(Chapter 2). In support of this observation, electron microscopy showed that mutant 
HEK293 cells form significantly fewer, smaller and less distinct desmosomes than 
wildtype cells. Whether through altered turnover kinetics or not, S39_K40insS does 
compromise cell-cell adhesion, and does lead to the development of ARVC.
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3) S39_K40insS; effects on cell proliferation and cell death:
Apart from its role in cell junctions, plakoglobin is also known to participate in Wnt 
signaling pathways where it associates with Tcf/Lef transcription factors and regulates 
functions such as cell proliferation and apoptosis. To investigate the effects of 
S39_K40insS on cell proliferation, a CellTiter 96 Cell Proliferation Assay was 
performed. HEK293 cells stably expressing the mutant plakoglobin showed higher 
proliferation rates than cells expressing the wildtype protein, the difference being 
statistically significant in the fourth and fifth day of the assay (Figure 28). The effect of 
S39_K40insS on programmed cell death was examined using the CaspACE™ Assay 
method. HEK293 cells stably expressing S39_K40insS plakoglobin showed 
significantly less caspase activity than cells expressing the wildtype protein (Figure 29), 
suggesting lower rates of apoptosis in cells expressing the mutant protein.
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Figure 28: CellTiter 96 Cell Proliferation Assay over the course of five consecutive 
days; * p=0.014, ** p= 0.006.
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Figure 29: CaspACE™ assay. Specific caspase activity was measured in 10 individual 
wildtype and mutant cultures; * p=0.038.
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Discussion:
Plakoglobin, (3-catenin and Drosophila armadillo are closely related multi-functional 
proteins that regulate cell adhesion and participate in signal transduction cascades. All 
three proteins are found in cytoplasmic and nuclear complexes where they direct cell 
fate and govern aspects of cell proliferation.307 Up-regulation of (3-catenin, either by 
mutations in regulatory genes involved in degradation and signaling pathways or by 
direct mutations in the p-catenin gene, has been implicated in hyper-proliferation and 
tumor formation.308,309 To investigate the role of plakoglobin in these functions, a full- 
length and an N-terminally truncated form of plakoglobin have been expressed in 
mouse epidermis and hair follicles, tissues which undergo continuous and easily
192observed postnatal renewal and remodeling. Expression of these constructs resulted 
in stunted hair growth, and reduced proliferation of epidermal cells, indicating that 
plakoglobin suppresses epithelial proliferation and hair growth in vivo.192 It is possible 
therefore that if S39_K40insS disrupts the normal signaling mediated by plakoglobin, 
cell proliferation may be expected to increase. Indeed, HEK293 cells induced to stably 
express the mutant protein showed significantly greater proliferation rates than wildtype 
cells (Figure 28).
Consistent with our results, in a recent experiment, desmoplakin down-regulation in 
HaCaT keratinocytes by siRNA interference led to increased cell proliferation.310 
Increased proliferation stemming from plakoglobin disruption may also explain the 
development of palmoplantar keratoderma in patients with Naxos disease. Such a 
mechanism would also be consistent with the reduced plakoglobin expression levels 
observed in a number of cancers. 146,148 In 2002, Polychronopoulou et al. suggested a 
possible pathogenetic association between myelodysplasia and Naxos disease. The 
myelodysplastic syndromes (MDS) are an heterogeneous group of blood disorders 
characterized by ineffective hemopoiesis and an increased tendency for evolution into 
acute leukemia. The link between the two pathogenetic entities was based on the case 
of two siblings diagnosed with both conditions. It was therefore suggested that 
plakoglobin dysfunction may predispose to the development of MDS since a decreased 
tumor suppressing activity may facilitate the acquisition of genetic lesions, while 
disrupted intercellular adhesion in the marrow may by itself contribute to the 
establishment of dysplastic alterations once the neoplastic clone has emerged.311 
Dusek et al. investigated the effects of plakoglobin on the survival of mouse 
keratinocytes by challenging both plakoglobin-null cells and their heterozygous 
counterparts with apoptotic stimuli.312 The results obtained suggested that plakoglobin 
deletion protects keratinocytes from apoptosis, with null cells exhibiting delayed 
mitochondrial cytochrome release and activation of caspase-3, and increased levels of 
the anti-apoptotic molecule Bcl-XL compared to heterozygous controls. Collectively
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these observations indicated that plakoglobin may function to potentiate death in cells 
damaged by apoptotic stimuli, perhaps limiting the potential for the propagation of 
mutations and cellular transformations.312 To investigate the effect of S39_K40insS on 
plakoglobin-mediated apoptosis, a caspace-3 assay was used.
Consistent with the results of Dusek et al., HEK293 cells expressing the mutation 
exhibited lower caspace-3 activity than wildtype cells, consistent with decreased rates 
of programmed cell death (Figure 29). In contrast to our results though, suppression of 
desmoplakin expression using siRNA in atrial myocyte cell lines or heterozygous 
desmoplakin-deficient mice led to increased rates of apoptosis, related to increased 
nuclear plakoglobin translocation and inhibition of the canonical Wnt signaling 
pathway.313 This controversy may be explained by the fact that S39_K40insS seems to 
increase the cytoplasmic, rather than the nuclear accumulation of the mutant 
plakoglobin molecule (based on results presented earlier in this chapter). Translocation 
of S39_K40insS to the cytoplasm but not the nucleus, may lead to activation of the 
canonical Wnt signaling pathway and therefore decreased rates of apoptosis. Still, our 
results do not agree with the increased cardiomyocyte apoptotic rates reported in 
patients with ARVC.55 The discrepancy therefore may well be cell type-specific instead 
of mutation-specific.
Although HEK293 cells have certain advantages, such as their rapid division rate and 
their ability to form desmosomes and therefore incorporate an exogenous desmosomal 
protein into cell junctions, we hasten to point out that the effects of S39_K40insS on 
signaling pathways in HEK293 cells cannot necessarily be translated to cardiac 
myocytes. Further studies will be needed to determine whether this ARVC-related 
mutation disrupts the signaling properties of ventricular myocytes. Furthermore, Garcia- 
Gras et al. also reported that suppression of desmoplakin expression using siRNA in 
atrial myocyte cell lines or heterozygous desmoplakin-deficient mice led to increased 
expression of genes involved in adipogenesis and collagen generation therefore 
shifting cells from a myocyte to an adipocyte fate.313,314 If expression of S39_K40insS in 
ventricular myocytes is shown to have similar effects on cell fate, it would add further 
evidence to the hypothesis that a final common pathway involving plakoglobin is 
underlying ARVC pathogenesis.
Since the discovery of Wnt1 as an oncogene, the Wnt gene family, which includes 19 
members in the human genome, has been found in all animal species examined.315 As 
mentioned above, in the absence of a Wnt ligand, the level of cytosolic p-catenin is kept 
low by its amino terminal phosphorylation-dependent ubiquitination/proteasomal 
degradation. However, in the presence of a Wnt ligand, transmembrane lipoprotein 
receptors such as LRP5, LRP6 and their Drosophila homolog Arrow, activate the 
frizzled receptor. This receptor binds a molecule known as disheveled, which in turn
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anchors axin, thus preventing the phosphorylation and subsequent degradation of p- 
catenin.316,317 In response to activation of the Wnt signaling pathway, p-catenin 
accumulates in the nucleus, where it cooperates with lymphoid enhancer factor and T- 
cell factor (LEF/TCF) transcription factors to activate gene expression.318 LEF/TCF 
factors are sequence-specific DNA-binding proteins which lack classical trans­
activation domains.319 Hecht et al. showed that p-catenin serves as a transcriptional co­
activator of the DNA-binding proteins, thus driving expression of genes such as c-Myc 
and cyclinDI (Figure 29).320
Although the signaling role of p-catenin is well established, a major controversy 
remains as to the involvement of plakoglobin in the Wnt pathway. Simcha et al. report 
that plakoglobin is unable to bind the Tcf/Lef transcription factors and therefore its role 
in the Wnt signaling pathway is confined to antagonizing p-catenin at the junctional and 
proteasomal sites, therefore allowing it to enter the nucleus.321 Miravet et al. though 
report that while plakoglobin does bind Tcfs it does not compete with p-catenin for the 
same binding sites on the transcription factors.322 Its inhibitory action is brought about 
because the Tcf/plakoglobin complex is unable to bind DNA sequences and thus 
activate transcription.323 In this way, by antagonizing p-catenin, plakoglobin can inhibit 
proliferation and prevent cancer and metastasis.324 Augmenting the existing 
controversy, Rubenstein et al. report that plakoglobin has its own transcriptional 
activity, independently of p-catenin.325 Members of the Tcf/Lef family are characterized 
as architectural transcription factors, since they bind DNA bending it in such a way so 
that transcription is inhibited. Rubenstein et al. showed that plakoglobin can alleviate 
this inhibition driving the expression of genes.325 Actually, Maeda et al. suggested that 
the downstream genes of plakoglobin may be different than those of p-catenin,326 while 
Kolligs et al. presented evidence that plakoglobin can in fact drive the expression of 
oncogenes, possessing a tumorigenic activity itself equivalent to, but distinct from that 
of p-catenin.327
Figure 30: A simplified prevailing view of Wnt/p-catenin signaling.315
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Even if all the genes recognized to date as disease-causing encode desmosomal 
proteins and even if a lot of the disease characteristics are indeed stemming from 
defects in cell-cell coupling, ARVC is more than a disease of the desmosome. 
Compromised cell-cell adhesion is only the beginning if not merely a part of the whole 
story. The results reported in this chapter are included in: Asimaki et al. "A novel 
dominant mutation in plakoglobin causes arrhythmogenic right ventricular 
cardiomyopathy” ; manuscript in press, The American Journal o f Human Genetics.
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CHAPTER 4:
“S39_K40insS versus 2057del2; differential 
effects on cellular responses to mechanical 
load and cellular biomechanics”
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ARROWS POINTING THE WAY:
In 2005, Wlodarska et al. described the case of a patient diagnosed with ARVC after 
episodes of non-sustained polymorphic VT and multiple premature ventricular beats of 
LBBB morphology.328 Clinical investigation showed RV enlargement, focal apex 
hypokinesia and evidence of adipose tissue in the RV free wall. Identical RV 
morphology was seen in the proband’s asymptomatic monozygotic twin brother. The 
symptomatic proband had been training in rowing for years, while his asymptomatic 
brother had never practiced any sport.328 Kirchhof et al studied the cardiac effects of
2^9heterozygous plakoglobin deficiency (+/-) in mice. Ten-month old +/- mice had 
increased RV volume, reduced RV function and spontaneous ventricular ectopy. 
Isolated perfused +/- hearts had spontaneous VT of RV origin and prolonged RV 
conduction times compared to wildtype hearts. Interestingly, endurance training (8 
weeks of daily swimming) caused premature RV dilatation and dysfunction in the +/- 
mice at 5 to 6 months of age while training intensity correlated with training-induced RV 
enlargement in the plakoglobin deficient animals.329 The precise incidence of sudden 
cardiac death in young athletes is unknown. Estimates from the United States suggest 
1 in 200.000 although the true incidence is likely to be much higher.330 It seems though 
that the vast majority of SCD in young athletes occur either during or immediately after 
strenuous physical activity.331 In the first chapter, the case of an aerobics teacher 
bearing a mutation in the desmoglein2 gene (C591X) was presented. The 40-year old 
woman had evidence of severe biventricular ARVC, while her mother, a carrier of the 
same mutation, was asymptomatic and had a normal ECG and conventional 2D echo 
at the age of 75. Collectively, these observations suggest that sports per se are not a 
cause of enhanced mortality; they may however promote fatal arrhythmias or speed-up 
disease progression in individuals affected by certain cardiac disorders. In other words, 
physical activity may act as a trigger in the presence of an underlying cardiovascular 
disorder.332 Despite the broad expression pattern of desmosomal proteins, all mutations 
identified to date affect only the heart and in specific cases the epidermis, presumably 
because these organs are subjected to increased mechanical stress. An increase in 
wall stress is known to be inversely proportional to wall thickness. This may explain 
why disruption of cell-cell adhesion may predominantly affect the thin-walled but highly- 
pressurized RV.333
Exercise, physical activity, training, stress, pressure; they all seem to have a role in 
ARVC, although the molecular path through which they bring about their effects is yet 
poorly defined. To investigate the relationship between stress and disease expression, 
HEK293 cells transfected to stably express plakoglobin bearing either the novel 
dominant S39_K40insS mutation or the 2057del2 mutation (previously identified to
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underlie Naxos disease) were subjected to increased mechanical stress. In this 
chapter, we shall describe the effects of defined mechanical load on the expression and 
distribution of intercalated disc proteins as well as the signaling pathways through 
which stretch brings about its effects in the cellular model developed. S39_K40insS and 
2057del2 are two mutations in the same gene that have different yet similar effects at 
the clinical phenotype level. We compared the effects the two mutations have at the 
cellular level, in an attempt to unravel the path that leads from the cell to the overall 
disease phenotype and ultimately from the laboratory bench to the bedside.
Despite the high number of mutations currently recognized to be underlying clinical 
ARVC, most previous studies have not rigorously characterized the effects of 
desmosomal protein mutations on cell biomechanics. As part of this project, the 
biomechanical properties of HEK293 cells expressing the two mutant variants of 
plakoglobin were characterized. Wound-healing, individual cell migration, cell stiffness 
and cell-cell adhesion were examined to assess the similarities and differences in cell 
mechanical behavior. However, as mentioned at the end of the previous chapter, 
although HEK293 cells constitute an advantageous model for studying desmosomal 
gene mutations, it should be emphasized that the results obtained cannot necessarily 
be applied to cardiac myocytes. To overcome this limitation, a recombinant adenovirus 
expressing the S39_K40insS plakoglobin has been generated and used to transfect 
neonatal rat ventricular cardiomyocytes. In this chapter, we shall present the effects of 
this novel mutation on cardiac myocytes, thus getting a step closer to accurately 
modeling this highly complex cardiac disorder.
219
METHODS AND MATERIALS:
1) Stretch and immunofluorescence protocol for HEK293 cells:
HEK293 cells were plated on collagen IV-pre-coated silicone membranes and grown to 
confluency before experimentation. The cultures were then subjected to linear pulsatile 
stretch using a custom-designed apparatus, illustrated in Figures 1 and 2. The lateral 
borders of a rectangular sheet of silicone membrane (C, thickness 0.01 inch) were fixed 
to bars (A) that could move freely in the x direction along two stainless steel axes (B). 
The two bars were in contact with an elliptical Teflon wheel (E) mounted in the centre of 
the device. The silicone membrane was cut to a length that produced tension slightly 
above the slack length when the short diameter of the wheel was in contact with the 
Teflon bars. The 1.1/1 ratio of the long to the short diameter of the elliptical wheel 
produced stretch of 10% during a 90° rotation of the wheel. The frequency of the stretch 
pulsations (half a wheel cycle) was monitored by a photodiode mounted on the stretch 
apparatus and controlled from outside the tissue culture incubator. A stretch frequency 
of 3 Hz was used in the present experiments. Transverse compression (shrinkage) in 
the y direction during linear stretch in the x direction was prevented by attaching 2 
clamps (F) that stretched the membranes slightly along the transverse central axis. 
Cells were cultured in a chamber created by fixing a ring of silicone tubing (D, thickness 
2 mm, diameter 24 mm) at the centre of the membrane with silicone sealant. 
Transverse deformation of the membrane at maximal longitudinal stretch was <1%, 
hence stretch was uniaxial.334
Figure 1: Schematic representation of the custom-fabricated stretch apparatus.334
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Figure 2: Image of the custom-fabricated stretch apparatus.
Following stretch, the medium was aspirated and the cells washed with PBS and 
incubated with 4% paraformaldehyde in PBS at room temperature for 10min. Following 
fixation, the cell-covered silicone membranes were cut in quadrants and placed in 24- 
well plates along with PBS. The cells were washed first with 0.5% Triton-X/PBS and 
then with PBS. To block non-specific signal, the cells were incubated with 10% fetal calf 
serum/PBS for 30min. The primary antibodies were added, diluted in the same blocking 
buffer, and the cells incubated at 4°C overnight. The following day, the cells were 
equilibrated at room temperature for 30min, washed first with PBS, then with 0.1% 
Tween/PBS and again with PBS. The secondary antibodies were added diluted in 
blocking buffer and the cells incubated at 4°C overnight. On the third day of the 
procedure, the cells were equilibrated at room temperature for 30min, washed first with 
PBS, then with 0.1% Tween/PBS and again with PBS. The membrane quadrants were 
then placed on slides, mounted with 50% glycerol-50% PBS and examined by 
quantitative confocal microscopy as described above.
In selected experiments, stretch-conditioned medium obtained from cultures previously 
stretched for 1-4 hours was collected and applied to other cultures that had not been 
stretched. In another set of experiments, cultures were incubated with a mouse 
monoclonal anti-VEGF antibody (directed against recombinant human VEGFies, R&G 
systems).335 In all experiments, control cultures that were neither stretched nor exposed 
to any exogenous reagent were grown on silicone membranes under the same 
conditions and incubated in serum-free medium for 1-4 hours (depending on the length 
of the experimental procedure).
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2) Primary cultures of neonatal rat ventricular myocytes:
Primary cardiac myocyte cultures (NRVM) were prepared from ventricles of 1-day old 
Wistar rat pups (Charles River, Indianapolis) as previously described.336 Briefly, hearts 
from 8-10 neonatal rats were removed and finely minced. The pieces were immersed in 
a dissociation solution (Ca+2 and Mg+2-free Hanks’ balanced salt solution, GIBCO) 
containing 0.1% trypsin, 60pg/ml pancreatin (SIGMA), 20 units/ml penicillin and 20 
pg/ml streptomycin and repeatedly stirred for 15min at 37°C. Four to five incubation 
periods were required to dissociate the mixture completely. The solutions obtained after 
all incubation periods, except for the first one, were decanted into tubes and 
sedimented by centrifugation. The resulting cell pellets were re-suspended in M199 
medium (GIBCO) containing 20 units/ml penicillin, 20 pg/ml streptomycin and 10% 
neonatal calf serum (Boehringer). This medium will be referred to as high serum 
medium (HMS), while the same medium containing 5% neonatal calf serum only will be 
denoted as normal serum medium (NMS). The fibroblast content of the cell suspension 
was reduced by a differential attachment method. Briefly, the cell suspension was 
transferred to a T-75 culture flask and incubated in a 37 °C, 0.1% C 02 incubator for 2 
hours. During this incubation period the fibroblasts preferentially attach to the flask. The 
remaining myocytes were counted with a haemocytometer and diluted in HMS to 
achieve a concentration of 3 x 105 cells/ml. Simultaneously with the differential 
attachment procedure, silicone membranes pre-coated with collagen I, were washed in 
PBS and incubated with HMS for 2 hours under UV-light. This procedure increases the 
number of adhering cells. After the pre-incubation medium was withdrawn from the 
silicone membranes, 2 ml of the enriched myocyte solution was plated onside each 
ring, and the cultures transferred to a 37 °C, 0.1% C 02 incubator for 24 hours. After this 
incubation period, the silicone membranes were shaken gently to suspend un-attached 
cells and the HMS medium was removed and replaced with NMS. Thereafter, medium 
exchanges with NMS were performed every other day.336
3) Stretch and immunofluorescence protocol for NRVMs:
Neonatal rat ventricular myocytes isolated as described above, were plated on
collagen-coated silicone membranes and grown for 4 days prior to experimentation. 
Monolayers of ventricular myocytes were subjected to linear pulsatile stretch for 1 hour 
in serum-free medium (M199) using the custom-designed apparatus presented above. 
Non-stretched myocytes were also incubated in M199 medium for 1 hour and used for 
control purposes. Following stretch, the cultures were immunostained and examined by 
quantitative confocal microscopy. Primary antibodies included polyclonal rabbit anti- 
connexin43 (Cx43) (SIGMA, UK), monoclonal mouse anti-plakoglobin (Sigma, UK) and 
monoclonal mouse anti-N-Cadherin (Sigma, UK) antibodies. In preparation for
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immunostaining, cultures were rinsed in serum-free medium (M199) and fixed in 4% 
paraformaldehyde/PBS for 5min at room temperature. Following fixation, the cell- 
covered membranes were cut, placed in 24-well plates and washed in PBS three times. 
To block non-specific signal, the cultures were incubated in PBS containing 0.1% Triton 
X-100, 1% bovine serum albumin (BSA) and 3% normal goat serum at room 
temperature for ~40min. The cultures were then incubated with the primary antibody 
overnight at 4°C, brought to room temperature, washed 3 times with PBS, and 
incubated with indocarbocyanine (Cy3)-conjugated goat anti-mouse or anti-rabbit IgG 
(diluted 1:400 in PBS) for 2 h at 25 °C. Following incubation with the secondary 
antibodies, the membrane quadrants were washed 3 times in PBS, transferred onto 
glass slides and mounted with 50% glycerol- 50% PBS.
4) Generation and amplification of recombinant adenoviral constructs:
Recombinant adenoviral constructs were created using the ViraPower Adenoviral 
Expression system (Invitrogen). This system allows creation of a replication- 
incompetent adenovirus that can be used to deliver and transiently express a gene of 
interest in either dividing or non-dividing mammalian cells, such as ventricular 
myocytes. An overview of the system is presented below:
The gene of interest is first transferred from pDONR221 to the Gateway-compatible 
pAd/CMVA/5-DEST vector through LR clonase-mediated recombination. The 
recombinant plasmid is then introduced in 293A cells. These cells contain a stably 
integrated copy of E1 that supplies the E1 proteins (E1a and E1b) in trans required for 
the production of an adenovirus. The viral particles enter the target cells by binding to 
the Coxsackie/Adenovirus receptors (CAR). After the initial binding, the particles are 
internalized through integrin-mediated endocytosis, followed by active transport to the 
nucleus. Once in the nucleus, the early events are initiated, such as the transcription 
and translation of the E1 genes, followed by expression of the adenoviral late genes 
and viral replication. The crude adenoviral stock produced is then used to transfect 
293A cells in order to create an amplified adenoviral stock which is then titred, and 
used to promote expression of the recombinant protein of interest in the mammalian 
cell line of choice (Figure 3).
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Figure 3: Schematic representation of the ViraPower Adenoviral expression system.
224
To perform a recombination reaction between pDONR221 and pAd/CMVA/5-DEST, the 
following were added in a micro-centrifuge tube:
300 ng of the DNA fragment of interest in pDONR vector 
300 ng pAd/CMVA/5-DEST vector 
4 pi of LR clonase enzyme mix (Invitrogen)
TE buffer was added up to a final volume of 16 pi
The recombination reaction occurred for either 1 hr at room temperature or for 12-16hrs 
on a thermal cycler at 16°C. Following the recombination reaction, 2pl of proteinase K 
(Invitrogen) was added to the mixture and the tube was incubated at 37°C for 10min for 
the enzyme to be denatured.
Prior to using the recombinant pAd/CMVA/5-DEST plasmid to transfect 293A cells, the 
left and right viral ITRs must be exposed to allow for proper viral replication and 
packaging. The pAd/CMVA/5-DEST vector contains Pac I restriction sites. Digestion of 
the plasmid with Pac I allows exposure of the left and right ITRs and removal of the 
bacterial sequences, such as the pUC origin and ampicillin resistance genes (Figure 4). 
At least 5pg of the recombinant plasmid was digested with Pac I according to the 
enzyme manufacturer’s instructions and the digested DNA was then purified using 
phenol/chloroform extraction followed by ethanol precipitation. The purified plasmid was 
then eluted in TE buffer, pH = 8.0, to a final concentration of 0.1 -  3 pg/ pi.
attR2 V5 epitopeartR1
pAd/CM V/V5
DEST™
36686 bp
Pac I
Figure 4: Schematic representation of the pAd/CMVA/5-DEST vector.
The day before transfection, the 293A cells were trypsinized and plated at 5 x 105 cells 
per well in a 6-well plate in complete medium. On the day of the transfection the culture 
medium was withdrawn from the 293A cells are replaced with 1.5 ml of normal growth 
medium containing serum but lacking antibiotics. For each transfection sample, 1 pg of
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Pac I digested pAd/CMVA/5-DEST plasmid was diluted in 250 pi DMEM. Lipofectamine 
2000 (3pl, Invitrogen) was diluted in 250 pi DMEM in a separate tube and incubated at 
room temperature for 5min. The two solutions were then mixed and incubated at room 
temperature for 20min, in order for lipofectamine complexes to be formed. Following 
the incubation period, the lipofectamine complexes were added drop-wise to each well, 
and the cells incubated in a 37°C incubator overnight. Twenty-four hours post­
transfection the lipofectamine-containing medium was removed and replaced by 
complete medium. Forty-eight hours post-transfection the cells were trypsinized and 
transferred to 10cm culture plates containing complete medium. The culture medium 
was replaced every 2-3 days thereafter, until clear regions of cytopathic effects were 
observed (usually 7-10 days post-transfection). The infections were allowed to proceed 
until approximately 80% of the culture showed regions of cytopathic effects (usually IQ- 
13 days post-transfection). The adenovirus-containing cells were then harvested and 
transferred to 15 ml tubes.
The tubes were placed at -80°C for 30min, followed by a 15-minute incubation in a 
37°C water bath. The freeze-thaw cycle was repeated twice. The cell lysate was 
centrifuged to pellet the cell debris, and the adenoviral stock supernatant was 
transferred to cryo-vials and stored at -80°C. In order for the adenoviral stock to be 
amplified, 293A cells were once again used. The day before the infection, 293A cells 
were trypsinized and plated at 3 x 106 cells per 10cm plate. On the day of the infection 
the desired amount of crude adenoviral stock was added to each plate. The plates were 
then incubated in a 37°C incubator until 80-90% of the cells were rounded up and 
floating or just lightly attached to the tissue plate, implying that they were loaded with 
adenoviral particles (usually 2-3 days post-infection). The adenovirus-containing cells 
were then harvested and transferred to 15 ml tubes. The tubes were placed at -80°C for 
30min, followed by a 15-minute incubation in a 37°C water bath. The freeze-thaw cycle 
was repeated twice. The cell lysate was centrifuged to pellet the cell debris, and the 
adenoviral stock supernatant was transferred to cryo-vials and stored at -80°C. Before 
expressing the recombinant protein of interest in the mammalian cell line of choice, the 
titer of the adenoviral stock had to be determined. The day before the infection, 293A 
cells were plated on 6-well plates and incubated in a 37°C incubator until 80-90% 
confluent. On the day of the infection, ten-fold dilutions of the adenoviral stock in 
complete medium were prepared to a final volume of 1 ml. The culture medium was 
withdrawn from the 293A cells, replaced with the adenoviral dilution and the plate 
incubated at 37°C overnight. Twenty four hours post-infection the medium containing 
the virus was removed and the cells were over-layed with 2ml of agarose solution (4% 
agarose solution was prepared in dH20, autoclaved at 121°C for 20min, equilibrated to 
65°C in a water bath and used immediately). Forty eight hours following the initial over­
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lay, the cells were over-layed with an additional 1 ml of agarose solution and returned 
to a humidified 37°C incubator. The plates were monitored thereafter until plaques were 
visible (usually 8-12 days post-infection). Then 5 pg/ml 3-[4,5 Dimethylthiazol-2-yl]- 2,5 
-diphenyltetrazolium bromide; Thiazolyl blue (MTT) solution was evenly distributed on 
top of the solidified agar to stain the plaques and the plates were incubated for 3 hours 
at 37°C. The stained plaques were then counted and the titer of the adenoviral stock 
was thus determined. MTT (Sigma), 5ml/ml solution was prepared in PBS, filter- 
sterilized and kept at 4 °C in 5ml aliquots.
5) Adenoviral transfection and immunostaining of NRVMs:
MOI (multiplicity of infection) is defined as the number of virus particles per cell and 
generally correlates with expression. Typically expression levels increase linearly as 
the MOI increases. A number of factors can influence determination of MOI including 
the nature of the mammalian cell line, its transduction efficiency and the nature of the 
gene of interest. A range of MOIs (1, 5, 10, 20 and 50) were used on NRVMs to 
determine the MOI required to obtain optimal expression of the recombinant protein. 
pAd/CMVA/5-DEST expresses the V5 epitope as a C-terminal fusion to the protein of 
interest, therefore allowing detection of the recombinant protein by Western 
immunoblotting or immunostaining. NRVMs were plated on silicone membranes as 
described above and incubated in a humidified 37°C incubator overnight. The cultures 
were transfected with the pAd/CMVA/5-DEST plasmid 18 hours after initially being 
plated. Cells were rinsed twice in NMS and infected with the replication-defective 
adenovirus diluted in M199 for 1 hour at room temperature. Thereafter, the cells were 
rinsed and cultured for an additional 72 hours before being subjected to experimental 
protocols. In preparation for immunostaining, cultures were rinsed in PBS and fixed with 
ice-cold methanol for 10min at -20 °C. Following fixation, the cell-covered membranes 
were allowed to dry, cut, placed in 24-well plates and washed in PBS three times. To 
block non-specific binding, the cultures were incubated in PBS containing 1% bovine 
serum albumin at room temperature for ~30min. The cultures were then incubated with 
the primary antibody (diluted in PBS/albumin) overnight at 4°C, brought to room 
temperature, washed 3 times with PBS, and incubated with indocarbocyanine (Cy3)- 
conjugated goat anti-mouse or anti-rabbit IgG (diluted 1:400 in PBS/albumin) for 2 h at 
25 °C. Following incubation with the secondary antibodies, the membrane quadrants 
were washed 3 times in PBS, transferred to glass slides and mounted with 50% 
glycerol- 50% PBS. In all experimental procedures, non-transfected cultures were used 
for control purposes.
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The following methods were developed/ applied to study the effects of known 
plakoglobin mutations on cellular biomechanics. These experiments were performed by 
Dr. Hayden Huang, PhD, at the Cardiovascular Division, Brigham and Women’s 
Hospital, Harvard Medical School, Boston in close collaboration with us.
6) Magnetic micromanipulation:
Receptor-dependent cell adhesiveness and cell stiffness were measured using a 
previously described magnetic micromanipulator.337,338,339 Briefly, this apparatus 
consists of a core of CMI-C rod (CMI-C metals) which was machined to a sharp chisel 
tip, annealed and coated with a thin gold film to minimize corrosion, and wrapped with 
300 turns of 18 gauge copper wire. Magnetic beads, 4.5 pm in diameter (M-450, Dynal, 
Invitrogen) were coated with antibodies against beta-1 integrins (HACD29, Fitzgerald) 
according to the manufacturer’s protocol. A limiting number of beads were added to 
dishes of confluent HEK293 cells such that a cell had no more than one bead on its 
surface. After being incubated for 30min at 37°C, the cells were rinsed to remove 
unattached beads and placed on a temperature controlled stage (Warner Instruments, 
Hamden, CT) maintained at 37°C on an inverted microscope (Olympus IX-71, Center 
Valley, PA). The tip of the magnetic micromanipulator was brought into close proximity 
of a bead identified on the surface of a cell. Magnetic force was applied in five 
increasing steps to a maximum of 5 nN. Bead detachment rates were recorded, along 
with the maximum displacement of the beads during the step-wise application of 
magnetic force using custom Matlab tracking algorithms.338,340 To measure the amount 
of beta-1 integrins expressed on the surface of HEK293 cell lines expressing wildtype 
or mutant forms of plakoglobin, flow cytometry was used as previously reported.341 
Cells were re-suspended in 1 ml Hanks balanced salt solution and split into 2 aliquots. 
One was incubated with an FITC-conjugated anti-rat CD29 (beta-1 integrin) antibody 
and the other was incubated with an Alexa488-conjugated anti-rat IgG antibody to 
control for non-specific binding. Cells were incubated on ice for 1 hr, centrifuged, re­
suspended in 1 ml Hanks solution, and analyzed using a Becton-Dickinson flow 
cytometer.
7) Wound-healing experiment protocol:
HEK293 cells were plated on 35mm fibronectin-coated plastic dishes and grown to 
confluence. A linear wound approximately 1 mm in width was created by scraping the 
tip of a P-1000 pipette across each dish. The extent to which cells had filled in the 
wound was determined at 2 and 24 hr post-wounding by imaging at the same location 
at 4x magnification. To determine whether cells expressing mutant forms of plakoglobin
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exhibited different rates of cell division in response to wounding, cells were plated on 
fibronectin-coated glass coverslips (to permit use of a high-NA water immersion 
objective for fluorescence microscopy), grown to confluence and wounded as before. At 
24 hr post-wounding, cells were loaded with BrdU (Sigma) for 30min, and then fixed in 
4% paraformaldehyde (Sigma) for 15min at room temperature. Cells were made 
permeable in 0.1% triton-X100 for 5min at room temperature, and then incubated with 
G3G4, an antibody against BrdU (Developmental Studies Hybridoma Bank342) in PBS 
containing 1% BSA for 1 hr at 37°C. The cells were then incubated with a fluorescent 
secondary antibody, washed several times and loaded with propridium iodide for 5min 
at room temperature to label nuclei. The cells were examined by fluorescence 
microscopy under the green channel to identify dividing cells (BrdU-positive)) and red 
channel to identify all nuclei (propridium iodide staining). The percentage of BrdU- 
positive nuclei in cells near the wound was then calculated. Four representative images 
were taken in each of three separate dishes.
8) Cell migration assay protocol:
To assess the speed of migration of isolated cells, HEK293 cells were plated at low 
density (20,000 cells/cm2) on fibronectin-coated plastic dishes and allowed to attach 
overnight. The dishes were placed on the temperature-controlled microscope stage and 
images of individual cells were acquired every 10min at 10x for 2.5 hr. Displacements 
between successive cell centroids were measured using a custom Matlab program and 
averaged to yield a measure of cell migration speed.
9) Cell-cell adhesion assay using a deform-drag method:
HEK293 cells were plated on fibronectin-coated glass coverslips and grown to 
confluence. Cell nuclei were labelled by incubating them in a 1:10,000 dilution of 
Hoechst. The dishes were placed on a temperature-controlled microscope stage and 
imaged at 10x magnification. A 1 mm diameter glass rod in a motorized 
micromanipulator (Eppendorf) was positioned so that the tip was just touching the cell 
surface. The rod was moved by the manipulator at a constant rate of 100 pm/sec 
across the field of view. Images were acquired using the CoolsnapHQ at 1 frame/sec 
throughout the entire interval of rod motion and for several sec thereafter. The 
detachment and dragging of cells in the rod’s path resulted in deformation of the cell 
monolayer adjacent to the cells being dragged. The extent of this deformation is an 
indicator of the relative strength of cell-cell adhesion and cell-matrix adhesion. To 
quantify this parameter, the frames acquired during each second were merged into a 
single image and the vertical extent of nuclear smearing was used as a quantitative 
measure of cell-cell adhesion.
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10) Immunohistochemical analysis of cytoskeletal proteins:
HEK293 cells on fibronectin-coated glass coverslips were grown to confluence, fixed in 
4% paraformaldehyde and permealised with 0.1% Triton x100 at room temperature. For 
actin staining, cells were incubated with Alexa488-conjugated phalloidin according to 
manufacturer’s instructions. For identification of intermediate filaments and 
microtubules, cells were incubated for 1 hr in PBS containing 1% BSA and either anti- 
vimentin (Sigma) or anti-alpha tubulin (University of Iowa NIH repository) antibodies 
followed by incubation with Alexa488-conjugated anti-mouse secondary antibody. After 
being rinsed in PBS, cells were imaged using a confocal microscope.
230
RESULTS AND DISCUSSION
1) HEK293 cells subjected to stretch:
To determine the effect of S39_K40insS on the way HEK293 cells respond to defined 
mechanical load, cells induced to stably express the mutant plakoglobin variant were 
subjected to pulsatile stretch (110% of resting length, frequency 3Hz) for 1 or 4 hours. 
HEK293 cells stably expressing the wildtype protein, and non-stretched cultures of both 
cell lines were used for control purposes. The amount of signal at intercalated discs 
corresponding to the mechanical junction proteins N-cadherin and plakoglobin as well 
as the electrical junction protein Cx43 was analysed by immunostaining and 
quantitative confocal microscopy (Figures 5-7).
Non-stretched stretch 1 hr stretch 4 hrs
W ildtype
S39_K40insS J
\
In all figures presented in this sub-chapter, the error bars represent standard 
deviations.
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Figure 5: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch on expression of N-cadherin in 
HEK293 cells expressing wildtype and S39_K40insS plakoglobin. n=5 for each line, 
*p<0.05 compared with wildtype cells subjected to 4 hours of stretch.
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Figure 6: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch on expression of JUP in 
HEK293 cells expressing wildtype and S39_K40insS plakoglobin. n=5 for each cell line,
* p<0.05 compared with wildtype cells subjected to 4 hours of stretch.
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Figure 7: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch on expression of Cx43 in 
HEK293 cells expressing wildtype and S39_K40insS plakoglobin. n=5 for each cell line, 
* p<0.05 compared with wildtype baseline levels. **p<0.05 compared with wildtype cells 
subjected to 4 hrs of stretch.
The amount of signal at intercalated discs corresponding to N-cadherin, plakoglobin 
and Cx43 was highly increased in response to stretch (~3-fold in cells expressing the 
wildtype protein). However, stretch-induced signal up-regulation corresponding to both 
mechanical and electrical junction proteins was significantly blunted in cells bearing the 
S39_K40insS mutation. Interestingly, even the baseline expression levels of Cx43 at 
intercalated discs were significantly down-regulated in mutant cells compared to 
wildtype controls. To investigate whether the blunted response observed in the 
S39_K40insS-bearing cells was due to reduced protein content, Western 
immunoblotting was used. Expression of N-cadherin, plakoglobin and Cx43 seemed to 
be higher in wildtype than in mutant cells following exposure to 4 hours of pulsatile 
stretch (Figure 8). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a catalytic 
enzyme involved in glycolysis. Since its levels of expression are not anticipated to be 
affected by mechanical stress, it may be used as a loading control in these 
experiments. Indeed, all stretched and non-stretched, wildtype and mutant cells 
expressed similar levels of GAPDH (Figure 8).
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Connexin 43 
GAPDH (ctr)
Figure 8: Expression levels of N-cadherin, plakoglobin, connexin43 and GAPDH in 
HEK293 cells bearing wildtype or S39_K40insS plakoglobin in response to 4 hours of 
pulsatile stretch. Non-stretched cells were subjected to Western immunoblotting for 
control purposes.
To investigate the mechanism of junctional protein stretch-induced up-regulation, 
conditioned medium was removed from cultures stretched for 4 hours, and added to 
non-stretched cells. The distribution of all 3 proteins was subsequently examined by 
immunostaining and quantitative confocal microscopy (Figures 9-11).
W ildtype
S39 K40insS
Non-stretched stretch 4 hrs conditioned medium
W ild ty p e  S 3 9 _ K 4 0 in s S  W ild ty p e  S 3 9 _ K 4 0 in s S
Protein standards
are not shown
Non-stretch 4hrs stretch Non-stretch 4hrs stretch
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Figure 9: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch (4hrs) and conditioned medium 
(con/med) application on the expression of N-cadherin in HEK293 cells expressing 
wildtype and S39_K40insS plakoglobin. n=5 per experiment, per cell line. For each cell 
line: * p<0.05 compared with protein expression following 4 hours of stretch.
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Figure 10: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch (4hrs) and conditioned medium 
(con/med) application on the expression of plakoglobin in HEK293 cells expressing 
wildtype and S39_K40insS plakoglobin. n=5 per experiment, per cell line. For each cell 
line: * p<0.05 compared with protein expression following 4 hours of stretch.
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Figure 11: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch (4hrs) and conditioned medium 
(con/med) application on the expression of Cx43 in HEK293 cells expressing wildtype 
and S39_K40insS plakoglobin.
Localization of Cx43 at intercalated discs was significantly elevated in both wildtype 
and mutant HEK293 cells when stretch-conditioned medium was applied to the 
cultures. Conversely, the levels of expression of both mechanical junction proteins at 
the membrane sites remained unchanged. These observations indicate that stretch- 
induced up-regulation of Cx43 is mediated by a secreted chemical signal, while in the 
case of N-cadherin and plakoglobin, intracellular mechanotransduction pathways are 
involved.
It was previously shown that in neonatal rat ventricular myocytes, stretch-induced up- 
regulation of Cx43 is mediated by secretion of vascular endothelial growth factor 
(VEGF).335 To investigate whether in HEK293 cells Cx43 expression in response to 
stretch is mediated through the same signalling pathway, cells stably expressing 
wildtype or mutant plakoglobin were incubated with an anti-VEGF antibody prior to 
being subjected to pulsatile stretch. Cx43 up-regulation was completely blunted in both 
cell lines, indicating that in HEK293 as well, expression of the gap junction protein in 
response to mechanical stimuli is mediated by VEGF secretion (Figure 12).
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Figure 12: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch (4hrs) and incubation with an 
anti-VEGF antibody on the expression of Cx43 in HEK293 cells expressing wildtype 
and S39_K40insS plakoglobin. Non-stretched cells and cells not incubated with the 
antibody were used as controls. n=5 per experiment, per cell line. For each cell line: * 
p<0.05 compared with cells subjected to 4 hrs of stretch in the absence of an anti- 
VEGF antibody.
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To compare the effects of S39_K40insS on cellular responses to mechanical load with 
those of 2057del2, the plakoglobin mutation previously identified to underlie Naxos 
disease, HEK293 cells induced to stably express 2057del2 plakoglobin (kindly donated 
by Denise Lo) were subjected to pulsatile stretch (110% of resting length, frequency 
3Hz) for 1 hour. Cells expressing the wildtype protein, and non-stretched cultures of 
both cell lines were used for control purposes (Figures 13-15).
Non-stretch wildtype Stretch 1 hr wildtype Stretch 1 hr wildtype
Non-stretch 2057del2 Stretch 1 hr 2057del2 Stretch 1 hr 2057del2
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Figure 13: Representative confocal 
immunofluorescence images and 
quantitative confocal microscopy 
data showing the effects of stretch 
on expression of N-cadherin in 
HEK293 cells expressing wildtype 
and 2057del2 plakoglobin. n=5 for 
each cell line.
240
Non-stretch wildtype Stretch 1 hr wildtype Stretch 1 hr wildtype
Non-stretch 2057del2 Stretch 1 hr 2057del2 Stretch 1 hr 2057del2
Figure 14: Representative confocal immunofluorescence images showing the effects of 
stretch on expression of plakoglobin in HEK293 cells expressing wildtype and 2057del2 
plakoglobin.
Non-stretch wildtype Stretch 1 hr wildtype Stretch 1 hr wildtype
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Non-stretch 2057del2 Stretch 1hr 2057del2 Stretch 1hr 2057del2
W ild ty p e  2 0 5 7 d e l2
N o n  1 h r  N o n  1 h r
Figure 15: Representative confocal 
immunofluorescence images and 
quantitative confocal microscopy data 
showing the effects of stretch on 
expression of Cx43 in HEK293 cells 
expressing wildtype and 2057del2 
plakoglobin. n=5 for each cell line. 
*p<0.05 compared with wildtype 
cells subjected to 1 hr of stretch.
Stretch-induced up-regulation of signal corresponding to N-cadherin is slightly reduced 
in cells bearing the 2057del2 mutation compared to wildtype controls, though the 
difference is not statistically significant (Figure 13). On the contrary, 1 hour of pulsatile 
stretch does not up-regulate the signal corresponding to Cx43 at intercalated discs 
(Figure 15). Interestingly, 2057del2 plakoglobin forms cytoplasmic aggregates, thus 
prohibiting quantitative confocal microscopy analysis (Figure 14).
Subsequently, HEK293 cells induced to stably express 2057del2 plakoglobin were 
subjected to pulsatile stretch (110% of resting length, frequency 3Hz) for 4 hours. Cells 
expressing the wildtype protein, and non-stretched cultures of both cell lines were used 
for control purposes. Analogously, the amount of signal corresponding to N-cadherin, 
plakoglobin and Cx43 at junctional sites was investigated by immunostaining and 
confocal microscopy (Figures 16-18), while protein content in response to defined 
mechanical load was assayed by Western immunoblotting (Figure 19).
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Figure 16: Representative confocal
immunofluorescence images and
quantitative confocal microscopy data 
showing the effects of stretch on
expression of N-cadherin in HEK293 cells
expressing wildtype and 2057del2
plakoglobin. n=5 for each cell line, * p<0.05 
compared with wildtype cells subjected to 
4 hrs of stretch.
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Figure 17: Representative confocal immunofluorescence images showing the effects of 
stretch on expression of plakoglobin in HEK293 cells expressing wildtype and 2057del2 
plakoglobin.
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Figure 18: Representative confocal 
immunofluorescence images and 
quantitative confocal microscopy data 
showing the effects of stretch on 
expression of Cx43 in HEK293 cells 
expressing wildtype and 2057del2 
plakoglobin. n=5 for each cell line, 
*p<0.05 compared with wildtype 
baseline levels. **p<0.05 compared 
with wildtype cells subjected to 4 hrs
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Figure 19: Expression levels of N-cadherin, plakoglobin, connexin43 and GAPDH in 
HEK293 cells bearing wildtype or 2057del2 plakoglobin in response to 4 hours of 
pulsatile stretch. Protein standards are not shown.
Similarly to S39_K40insS, 2057del2 inhibits the stretch-induced up-regulation of N- 
cadherin and Cx43, as shown both by confocal microscopy (Figures 16 & 18) and 
Western immunoblotting (Figure 19). As mentioned above, 2057del2 plakoglobin forms 
cytoplasmic aggregates. Therefore the effects of this mutation on cellular responses to 
mechanical load could not be evaluated by quantitative confocal microscopy (Figure 
17). Western immunoblotting though, showed that even 4 hours of pulsatile stretch, 
does not up-regulate expression of the plakoglobin gene bearing the Naxos deletion. 
There were differences in the electrophoretic mobility of wildtype and 2057del2 
plakoglobin. As mentioned in the introduction, the mutation underlying Naxos disease
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introduces a premature stop codon, leading to the production of a C-terminally 
truncated protein which migrates with a molecular weight of 75 instead of 82kDa 
(Figure 19).
Discussion:
It is now well established that both gene expression and protein synthesis are subject 
to regulation by mechanical forces, resulting in alterations of growth and differentiation 
in a number of tissues and cells.343,344 The responses of neonatal rat ventricular 
cardiomyocytes (NRVMs) to uniform pulsatile and static stress were previously 
investigated using an innovative approach developed in the laboratory of Dr. Andre 
Kleber. These experiments demonstrated a dramatic up-regulation of intercellular 
junction proteins after only 1 hour of pulsatile stretch, with a further increase after 6 
hours accompanied by a concomitant increase in propagation velocity.334 Following the 
generation of the cell line models described in the previous chapter, it was natural to 
wonder how HEK293 cells respond to mechanical load and whether these responses 
are altered in the presence of an ARVC-causing mutation. To our knowledge, there are 
only two ARVC-causing plakoglobin mutations identified to date: 2057del2, a deletion 
previously identified to cause Naxos disease, and S39_K40insS, a recently-described 
insertion shown to cause a dominant form of the cardiomyopathy without associated 
cutaneous abnormalities (Chapter 1). HEK293 cells induced to stably express wildtype 
plakoglobin or either mutant protein variant were grown on a flexible foundation 
constructed of thin silicone rubber. Typically, human embryonic kidney-derived cells are 
capable of producing extracellular matrix proteins and can therefore adhere to surfaces 
when cultured. Previous experiments though have shown that these cells tend to 
detach from silicone substrates when stretched, and that they have difficulties surviving 
and growing thereafter.345 Therefore in all experimental procedures performed, the 
flexible foundations were pre-coated with collagen IV prior to cell seeding. Once the 
cells were firmly attached to this surface, the edges of the silicone membrane were 
connected to a mechanical device that would deform the silicone base in a controlled 
fashion. Experiments on NRVMs have shown that stretching cells at 110% of their 
resting length at a frequency of 3Hz is enough to bring about changes in the distribution 
of intercalated disc proteins.334 The same protocol was therefore maintained when 
HEK293 cells were subjected to linear pulsatile stretch.
There was a marked up-regulation of the mechanical junction proteins N-cadherin and 
plakoglobin and of the major ventricular gap junction protein Cx43 in wildtype HEK293 
cells in response to 1 hour of pulsatile stretch, which became significantly more 
profound following 4 hours of stretch as shown by confocal microscopy. However, is the 
increase in signal intensity observed a result of increased gene expression, decreased
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degradation or increased trafficking of already present protein molecules to the 
membrane sites?334 To clarify this issue, protein expression in response to 4 hours of 
linear pulsatile stretch was assayed by Western immunoblotting. Indeed, it appears that 
expression of all three genes examined is up-regulated as a consequence of 
mechanical forces. Still, is the increase in the immunoreactive signal observed due to 
increase in junction number or individual junction size? When interpreting 
immunoreactive signals, it is important to remember that there is a complex non-linear 
relation between the amount of antibody bound to an epitope and the intensity of the 
secondary detection signals. Therefore, the number and size of those signals do not 
necessarily represent the number and dimension of the immunoreactive target. It is 
possible that the immunofluorescent signal that is emitted from several closely spaced 
junction plaques would appear as a single spot. This would artificially lower the number 
of target structures while raising their apparent size. In addition, it is also possible that 
small junctions, especially gap junctions, below the resolution of the detection system 
could be missed. On the other hand, an over-estimation of the number of junctions 
could occur as a result of non-uniform staining of individual junction plaques. Despite 
these limitations, it is likely that changes in the total immunoreactive signal parallel the 
changes in the total content of each preparation.334,346 Electron microscopy studies 
would be required though to determine whether it is the number of junctions, their size, 
or both that increase in response to stretch.
In the present experiments, cells were stretched at 110% of their resting length for 1 or 
4 hours. Since changes in the distribution of intercalated disc proteins were significantly 
greater in the 4-hour stretch protocol, compared to the 1-hour stretch protocol, it is 
logical to assume that the duration of stretch is correlated with the magnitude of the 
adaptive response. However, is this relationship linear? We could speculate that the 
response observed after 1 hour of stretch, is primarily due to increased trafficking of 
already synthesized protein molecules and their increased incorporation to the 
junctional sites. Lengthier stretch regimes could promote transcription further, 
increasing the synthesis rate of novel protein particles. Further stretch regimes should 
be applied to identify the point where observable responses plateau.
Stretch-induced up-regulation of all intercalated disc proteins examined was 
significantly blunted in cells expressing the S39_K40insS mutation. Western 
immunoblotting showed that apart from trafficking, gene expression in response to 
stretch is also disrupted in the presence of S39_K40insS. Furthermore, even the 
baseline expression levels of Cx43 are reduced in the mutant cells compared to the 
wildtype controls as shown by both confocal microscopy and protein assays. Reduced 
accumulation of Cx43 at membrane sites, was also observed in the cardiac biopsy of 
the proband expressing this mutant plakoglobin variant (Chapter 2). Additionally,
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decreased baseline localization of Cx43 at gap junctions was observed in HEK293 cells 
expressing the 2057del2 plakoglobin variant. Similarly to S39_K40insS, 2057del2 
inhibits up-regulation of Cx43 in response to 4 hours of pulsatile stretch. In contrast to 
S39_K40insS though, 2057del2 totally abolishes Cx43 up-regulation in response to 1 
hour of pulsatile stretch. On the other hand, expression levels of N-cadherin seem to be 
altered similarly in response to mechanical load in the presence of both mutant 
plakoglobin variants. Alterations of the localization patterns of 2057del2 plakoglobin at 
intercalated discs could not be examined by confocal microscopy, as the mutant protein 
tended to form cytoplasmic aggregates of very high signal intensity. Western 
immunoblotting though showed that in contrast to S39_K40insS, 2057del2 totally 
abolishes up-regulation of the plakoglobin gene expression in response to stretch. 
S39_K40insS and 2057del2 are two mutations in the same gene underlying different 
manifestations of apparently the same disease. Could the differences observed in the 
experiments presented herein, account at least in part for the differences in the clinical 
phenotype manifested by individuals with Naxos disease and ARVC patients bearing 
the S39_K40insS mutation?
In cultured human endothelial cells, there is a rapid up-regulation of c-Fos and Egr-1 
mRNA following a mere 10min of stretch.347 In cultured rat cardiac myocytes, pulsatile 
stretch rapidly phosphorylated p44/p42 mitogen-activated protein kinases (MAPKs), 
stress-activated protein kinase (SAPK), p38MAPK and p125FAK.348 Similar studies have 
shown that stretch enhances production of brain natriuretic peptide through calcineurin 
and calmodulin-dependant kinase II activation in cultured myocytes,349 and increases 
adrenomedullin production through activation of the rennin-angiotensin system.350 It is 
therefore already well-established that numerous complex signaling pathways respond 
to mechanical forces, and from the results presented herein, that both ARVC-causing 
plakoglobin mutations disrupt communication through these pathways. Whether and to 
what extent however, this disruption is related to the development of the actual 
phenotype characterizing the disease is yet to be determined. In 2004, Liao et al 
described the responses of both neonatal rat ventricular myocytes and cardiac 
fibroblasts to 24 hours of stretch (20% of resting length).351 Cardiac myocytes 
underwent mitochondria-dependent apoptosis as evidenced by cytochrome c release, 
and showed increased expression of the pro-apoptotic Bcl-2 family proteins. 
Furthermore, p21 was up-regulated and cyclin B1 was down-regulated in cardiac 
fibroblasts, which seemed to be associated with G2/M accumulation.351 It appears 
therefore, that mechanical stress can be associated with physiologically increased 
apoptosis and fibrosis in in vitro models. What if the presence of a desmosomal 
mutation alters these responses causing them to become pathological? Could that 
partially explain the increased levels of apoptosis and the accumulation of fibrotic tissue
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characterizing ARVC? Experiments on cardiac myocytes would be needed to address 
these questions.
When conditioned medium is removed from stretched cultures and added to non- 
stretched cultures, the localization of Cx43 at intercalated discs is increased, while the 
levels of expression of N-cadherin and plakoglobin remain unchanged. This 
observation implies that distinct pathways regulate expression of electrical and 
mechanical junction proteins in response to stretch, and in particular that stretch- 
induced up-regulation of Cx43 is mediated by secreted chemical signals, while in the 
case of mechanical junction proteins, intracellular mechanotransduction pathways are 
involved. It has been shown that in response to stretch, transforming growth factor-(3 
(TGF-P) levels increase promoting increased secretion of vascular endothelial growth 
factor (VEGF).352 It has also been shown that stretch-induced up-regulation of Cx43 in 
cultured myocytes is blocked by either anti-VEGF or anti-TGF-p antibodies, indicating 
that VEGF is in fact the secreted chemical molecule mediating this stretch-induced 
response in cardiac myocytes.335 To investigate whether the same is true for HEK293 
cells, cultures were incubated with an anti-VEGF antibody prior to being subjected to 
pulsatile stretch. Stretch-induced up-regulation of Cx43 was totally abolished in the 
presence of the antibody, indicating that the same signaling pathway is operating in 
both cardiac myocytes and human embryonic kidney-derived cells. Stretch induces 
remodeling of the heart, thus helping it cooperate with increased functional demands. 
One adaptation is gap junction remodeling, which was shown to be inhibited in HEK293 
cells in the presence of either S39_K40insS or 2057del2. Could this inhibition be 
contributing to disruption of electrical signal transmission and thus the increased risk of 
arrhythmogenesis characterizing ARVC? Experiments on cultured rat myocytes have 
shown that a major mechanism underlying stretch-induced up-regulation of structural 
junction protein expression involves mechanotransduction by integrin activation via 
FAK and src kinase pathways.353 To examine if the same signalling pathways are 
operating across different cell types, HEK293 cells should be incubated with inhibitors 
of FAK- and src kinase-dependent signalling prior to being subjected to mechanical 
stretch. Distribution of junctional proteins could then be examined by immunostaining 
and quantitative confocal microscopy.
As mentioned in the previous chapter, plakoglobin and p-catenin are both found at the 
membrane mediating adhesion and at the nucleus regulating the Wnt signalling 
pathway. It is natural therefore to wonder whether the effects exerted by S39_K40insS 
and 2057del2 on cellular responses to stretch are in part mediated by alterations in 
Tcf/Lef activity. Future experiments will be needed to address this question.
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2) S39 K40insS versus 2057del2: effects on cellular biomechanics:
The experim ents described in this sub-chapter were performed by Dr. Hayden Huang, 
PhD, at the Cardiovascular Division, Brigham and W om en’s Hospital, Harvard Medical 
School, Boston in close collaboration with us and are included in: Huang H, Asimaki A 
et al. “ D isparate effects of different mutations in plakoglobin on cell mechanical 
behavior” , m anuscript submitted to the American Journal of Physiology; Cell 
Physiology.
No obvious difference in cell size or morphology was observed when HEK293 cells 
expressing w ildtype, S39_K40insS, or 2057del2 plakoglobin were grown and 
passaged. However under sub-confluent conditions, it was readily apparent that cells 
expressing the 2057del2 plakoglobin showed a lower degree of clustering than cells 
expressing e ither the wildtype or the S39_K40insS-bearing protein (Figure 20). This 
observation provided the first hint that cells expressing the 2057del2 mutation exhibited 
abnorm al cell-cell adhesion.
Figure 20: Differences in the degree of cell 
aggregation seen in sub-confluent cultures of 
cells expressing 2057del2 plakoglobin (C) 
compared to cells expressing wildtype (A) or 
S39_K40insS plakoglobin (B). Magnification 
4x, scale bars: 200pm.
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To determine whether the presence of either mutant plakoglobin variant affects the cell- 
extracellular matrix adhesiveness or the cell stiffness, magnetic micro-manipulation was 
used. Measurements were made on confluent cells incubated with magnetic beads 
coated with anti-beta-1 integrin antibodies. Such beads would bind to cell surface 
receptors that link common matrix components to the actin cytoskeleton. The strength 
of cell-matrix adhesion was first assessed by measuring the rate of bead detachment. 
The tendency for beads to detach from the cell surface is a reasonable surrogate for 
the strength of adhesion of the cell to the surface of the culture dish. Bead detachment 
rates were similar for all three cell lines (28 of 90 beads detached from S39_K40insS 
cells versus 25 of 88 for wildtype controls and 24 of 90 beads detached from 2057del2 
cells versus 29 of 90 for wildtype controls, p>0.05 for both experiments). To determine 
whether there is any difference in the amount of beta-1 integrins expressed by the three 
cell lines, flow cytometry of cells labeled with fluorescently-conjugated antibodies 
against beta-1 integrins was employed. No differences were seen (data not shown). 
Taken together, the bead detachment and flow cytometry data indicate that the strength 
of cell-matrix adhesion was roughly similar in cells expressing the wildtype or either of 
the two mutant plakoglobin variants.
To assess cell stiffness the extent of bead displacement from the cell surface with step­
wise increases in magnetic force was measured. Only firmly attached beads were 
included in the analysis. Beads that detached or moved more than one bead diameter 
(indicating loose attachment) were excluded from the analysis. Greater bead 
displacement indicated lower cell stiffness. Cells expressing S39_K40insS plakoglobin 
were significantly less stiff than wildtype controls, while there was no significant 
difference in stiffness between cells expressing wildtype and 2057del2 plakoglobin 
(Figure 21).
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Figure 21: Magnetic micromanipulation experiments revealed differences in cell 
stiffness as measured by bead displacement. Cells expressing the S39_K40insS 
plakoglobin are significantly less stiff than cells expressing the wildtype protein 
(*p<0.05), while cell stiffness is not significantly different between cells expressing the 
2057del2 and the wildtype molecule (p>0.05).
To determ ine whether ARVC-causing plakoglobin mutations alter cell mobility, two 
assays were used: a wound-healing and a single-cell migration assay. Cells grown to 
confluence were wounded with a pipette tip and allowed to heal. The wound-healing 
rate was measured by determining the distance of closure between the two leading 
edges o f the wound. As shown in Figure 22, would healing occurred more rapidly 
during the first 24 hours in cell expressing either mutant form of plakoglobin compared 
with cells expressing wildtype plakoglobin (p<0.01 for both).
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Figure 22: W ound healing is significantly accelerated in cells expressing either mutant 
p lakog lob in  va rian t com pared to w ild type contro ls (magnification 4x).
To de te rm ine  if increased rates o f wound-healing are related to increased rates of cell 
d iv is ion in the two m utant cell lines, cultured cells were labeled with BrdU during active 
w ound-hea ling  and the num ber o f labeled nuclei was counted. Cell division rates were 
s im ila r in all cell lines over the first 24 hours (Figure 23). Therefore, increased wound- 
healing is not related to increased rates o f proliferation.
Naxos
Figure 23: The graph shows the proportion of BrdU-positive nuclei in the vicinity of the 
w ound, n=12 fo r each group, p>0.05.
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To determine whether changes in the speed of cell migration contributed to the 
increased wound-healing, the movements of cells grown in low density were tracked 
over 2 hours. Cell expressing either mutant plakoglobin variant exhibited greater rates 
of migration compared to wildtype cells (p<0.05, Figure 24). These results indicate that 
increased wound-healing rates are related, at least in part, to enhanced cell mobility 
caused by expression of either ARVC-causing mutation.
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Figure 24: The speed of migration of individual cells in low density cultures is 
significantly increased in cells expressing either mutant form of plakoglobin compared 
with cells expressing the wildtype protein, n>11 for each group,*p<0.05.
Since magnetic micro-manipulation experiments did not show any differences in the 
strength of cell-matrix adhesion, we turned our attention to the effects of the 
plakoglobin mutations on cell-cell adhesion. Such analysis is of obvious relevance, 
given the role of abnormal inter-cellular adhesion in ARVC pathogenesis. However, we 
were unaware of any specific assays designed to directly measure pure cell-cell 
adhesion forces. Accordingly, Dr. Hayden Huang designed a new method was and 
named it: deform-drag method. A glass rod is dragged across a cell monolayer and the 
extend of deformation of the adjacent monolayer is assessed (Figure 25). By taking 
images in sequence as the glass rod is dragged across the field of view, and then 
merging the images together, neighboring cells that moved significantly could be 
detected by the smearing of a nuclear label across the field of view. The distance of the 
deformation, as assessed by this nuclear label smearing, was used as a quantitative 
measure of the strength of cell-cell adhesion across the monolayer. As shown in 
Figures 26 and 27, the deformation was equivalent between cells expressing wildtype 
and S39_K40insS plakoglobin. However in marked contrast, cells expressing the 
2057del2 plakoglobin variant exhibited virtually no smearing at all, indicating that 
compared to the other two cell lines, these cells had dramatically reduced inter-cellular 
adhesion.
254
Figure 25: Representative images
illustrating the principle of the deform-drag 
method in a culture of cells expressing 
wildtype plakoglobin (magnification 10x).
VVMdtype S39_K 40insS
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Figure 26: By merging the frames acquired 
during dragging, the motion of nuclei in 
adjacent cells from cultures expressing 
wildtype or either mutant form of plakoglobin 
can be visualized and quantified.
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Figure 27: The extent of motion in the vertical direction (perpendicular to the direction 
of the wound) can be used as a measure of the strength of cell-cell adhesiveness. The 
graph shows that cells expressing the 2057del2 mutation, but not the S39_K40insS 
mutation, exhibit markedly diminished cell-cell adhesiveness compared to wildtype 
cells, n=6 for each group, *p<0.05.
To determine if mutations in plakoglobin cause apparent changes in the structure or 
distribution of the cytoskeleton, cells were grown to confluency and stained with 
antibodies against actin, alpha-tubulin and vimentin. Examination by confocal 
microscopy showed no obvious differences in cytoskeletal density, distribution or 
structure (Figure 28).
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actin microtubule vimentin
Figure 28: Representative confocal microscopy images of cells expressing all three 
forms of plakoglobin stained with antibodies against actin, alpha-tubulin and vimentin to 
visualize actin, microtubule and intermediate filament components of the cytoskeleton 
respectively. Scale bars= 10pm.
Discussion:
While significant progress has been made in identifying ARVC-causing mutations, 
much less is known about the mechanisms by which these mutations lead to the 
disease. One leading hypothesis involves loss of mechanical integrity within the heart; 
defects in linkage lead to injury and ultimately degeneration of cardiac myocytes and 
their replacement by fibrofatty tissue. Although the importance of cell-cell coupling in 
the setting of ARVC has been well-established, to our knowledge there has not been a 
study describing the effects of pathogenic mutations on cellular biomechanics. In this 
part of the project, the effects of two ARVC-causing mutations on cellular 
biomechanical properties have been characterized; the first is a C-terminal mutation in
257
the gene coding for plakoglobin (2057del2), previously identified to underlie Naxos 
disease, a syndrome characterized by ARVC, palmoplantar keratoderma and wooly 
hair and the second is an N-terminal mutation in the same gene (S39_K40insS), 
recently shown to underlie a form of late-onset typical ARVC without associated 
cutaneous abnormalities (Chapter 1).
Both standard and novel techniques were used to study mechanical behavior of 
HEK293 cells expressing different plakoglobin mutations. For instance, in order to 
assess the relative strengths of cell-cell and cell-matrix interactions, a novel technique 
was developed by Dr. Hayden Huang and named “ deform-drag method” . It was 
assumed that the interaction between cells and a fibronectin-coated culture dish 
surface is mediated by beta-1 integrins. Since magnetic micromanipulation experiments 
did not manifest any significant differences in such cell-matrix interactions, the dramatic 
differences obtained from the deform-drag experiments was interpreted as being 
primarily due to changes in cell-cell adhesion. This conclusion is significantly 
strengthened by the markedly decreased degree of cell clustering seen in sub-confluent 
cultures of cells expressing the 2057del2 mutation. It is possible though that slight 
differences in adhesion via beta-1 integrins or differences mediated by other cell- 
surface receptors could contribute to overall changes in cell-matrix adhesion. Further 
work to isolate these effects and to elucidate the mechanism of action in regulating cell 
mechanics is currently underway.
The experiments performed demonstrated that cells expressing either plakoglobin 
mutant exhibited increased wound-healing rates and higher cell migration speed 
compared to cells expressing the wildtype protein and that these changes are not due 
to differences in cell proliferation rates, at least not over the first 24 hours examined. 
While these results are generally consistent with results previously reported by Yin et 
al,249 who observed both cell-cell adhesion-dependent and -independent changes in 
keratinocyte mobility mediated by plakoglobin, this is the first time that clinically- 
relevant mutations have been assessed. Additionally, Yin et al found that expression of 
an N-terminal variant of plakoglobin, but not a C-terminal truncation, suppressed cell 
mobility in keratinocytes lacking wildtype plakoglobin.249 The results concerning cells 
expressing the 2057del2 mutation are consistent with those of Yin et al. On the contrary 
though, we showed that an S39_K40insS-bearing plakoglobin, which contains an 
additional N-terminal serine residue but has otherwise intact N- and C-termini, does not 
suppress cell mobility in a manner similar to wildtype plakoglobin. These data suggest 
that the presence of an excess serine affects cell mobility in an active manner. Simply 
removing the entire N-terminus does not apparently have the same effect as a single 
amino-acid residue insertion.
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Interestingly, the observations presented above indicate that the S39_K40insS insertion 
in plakoglobin significantly diminishes cell stiffness without affecting cell-cell adhesion, 
while the 2057del2 deletion in the same gene has the opposite effect; it significantly 
reduces cell-cell adhesion strength without affecting cell stiffness. The disparate effects 
on cell biomechanical behavior are significant because they underlie potential 
differences in the pathogenesis of ARVC. They suggest for example that myocardial 
injury may arise from loss of cell-cell adhesion in Naxos disease, whereas similar 
problems could, amongst others, arise from diminished cell stiffness in the 
S39_K40insS form of ARVC. Diminished cell stiffness could for instance indicate 
persistently increased mechano-sensitive responses. However, although analysis of 
HEK293 cells has several advantages, we once again hasten to point out that the 
effects of different plakoglobin mutations on the biomechanical behavior of HEK293 
cells cannot necessarily be translated to cardiac myocytes. Future studies will be 
needed to determine whether these known ARVC-related mutations alter the 
biomechanical properties of ventricular myocytes. Additional insights though may be 
gained by studying keratinocytes. These cells contain abundant desmosomes and are 
subjected to significant mechanical stress. As mentioned in the introduction, apart from 
2057del2, further recessive mutations in desmosomal genes have been associated with 
syndromes that affect both the heart and the skin.63,66 Similarly, a case of compound 
heterozygosity for two novel nonsense desmoplakin mutations underlying a unique 
cardiocutaneous syndrome was presented in Chapter 1. Future work involving 
keratinocytes may provide new insights into the biomechanical mechanisms by which 
mutations in desmosomal genes promote cell injury and cause human disease. 
Obtaining human cardiac myocytes from patients bearing ARVC-causing mutations 
would require an invasive heart biopsy procedure and such cells would not even be 
able to be maintained and propagated in culture. On the contrary, obtaining human 
keratinocytes from affected individuals would require a simple skin punch-biopsy 
procedure and they could potentially be immortalized and utilized in in vitro 
experiments. For instance, in 2003, Chamulitrat et al described a detailed method 
through which human epidermal cells can be isolated, immortalized and maintained in 
culture.354 Although desmosomal junctions are formed throughout the entire epidermis, 
in such syndromic forms of ARVC it is mainly the palms and soles that are affected, 
presumably because these parts of the skin are subjected to increased mechanical 
stress. It would be fascinating to be able to recapitulate this “ keratoderma” phenotype 
by subjecting cultured immortalized keratinocytes to stress in vitro. In this way we may 
be able to understand the pathways and mechanisms through which abnormalities 
emerge in response to increased mechanical load.
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This part of the project showed that different mutations in the same gene, both of which 
known to cause the same disease, lead to different biomechanical responses at the 
cellular level. It therefore seems that there may not be a single common pathway by 
which ARVC develops. There are still many unanswered questions in this disease. It is 
becoming increasingly clear though, that ARVC cannot be fully characterized without 
considerations of cell mechanics and mechanotransduction.
3) Expressing S39 K40insS in ventricular mvocvtes:
Cardiomyocytes are terminally differentiated cells that to date have been characterized 
as poor targets for non-viral gene transfer. Therefore, to achieve high transfection 
efficiency, a recombinant adenoviral construct was generated. S39_K40insS 
plakoglobin was cloned into the pAd/CMVA/5-DEST vector via an LR clonase-mediated 
recombination reaction. A virus expressing the mutant gene was subsequently 
generated, amplified and titred. Similarly, a virus expressing the wildtype gene was 
generated and used for control purposes. Neonatal rat ventricular myocytes (NRVMs) 
were isolated and seeded on collagen I pre-coated culture chambers. A series of viral 
transfections were set up to determine the optimal MOI (multiplicity of infection). Cells 
were transfected 18 hours post-seeding and incubated for 72 hours prior to 
experimental procedures. Optimization studies showed that this time period was 
sufficient for expression of the exogenous gene and its targeting to the appropriate 
cellular compartment, in this case, the membranous cell-cell junctions. The 
pAd/CMVA/5-DEST vector expresses the V5 epitope as an C-terminal fusion to the 
inserted gene, therefore allowing immuno-localization of the exogenous protein 
separately from the endogenous protein, naturally expressed by the cells. Transfection 
efficiency was first tested with immunostaining and fluorescent or confocal microscopy. 
Using an MOI=10, >90% of the myocytes expressed the recombinant plakoglobin 
(Figure 29). Lower MOIs decreased transfection efficiency, while higher MOIs 
increased cell death rates in the transfected cultures. Therefore an MOI of 10 was 
interpreted as optimal for all experimental procedures. Though non-transfected control 
myocytes did not express V5, there was abundant signal corresponding to the epitope 
in cells transfected with both the wildtype and the S39_K40insS plakoglobin viruses 
(Figure 29).
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Transfection efficiency was also tested by Western immunoblotting. NRVMs transfected 
with either viral construct express significantly higher amounts of total plakoglobin 
protein compared to non-transfected controls (Figure 30). Subsequently, the effects of 
the adenoviruses on the distribution of N-cadherin were examined by immunostaining. 
Transfected myocytes show comparable levels of expression of the major adherens 
junctions’ protein with non-transfected controls, indicating that the plasmids do not have 
non-specific deleterious effects (Figure 31).
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Figure 30: Western immunoblotting against plakoglobin in NRVMs transfected with a 
wildtype plakoglobin-pAd/CMV plasmid and an S39_K40insS plakoglobin-pAd/CMV 
plasmid. The middle lanes were loaded with lysate from non-transfected myocytes and 
used for control purposes. Protein standards are not shown.
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Figure 31: Non-transfected NRVMs and NRVMs transfected with pAd/CMV WT-PG 
plasmid or the pAd/CMV S39_K40insS-PG plasmid stained against N-cadherin.
To examine the effects of S39_K40insS on the responses of cardiac myocytes to 
increased mechanical load, NRVMs were seeded on silicone membranes, incubated for 
18 hours, transfected with the mutant plakoglobin-expressing adenovirus, incubated for 
a further 72 hours and subsequently subjected to 1 hour of pulsatile stretch in serum- 
free medium (frequency 3Hz). Non-transfected myocytes, myocytes transfected with 
the wildtype plakoglobin-expressing adenovirus and non-stretched cultures were used 
for control purposes. Following exposure to mechanical stress, the cultures were fixed 
with ice-cold methanol, immunostained and examined by quantitative confocal 
microscopy (Figures 32-35).
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Figure 32: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch on expression of N-cadherin in 
NRVMs cells. The error bars represent standard deviations. n=5 for each group, * 
p<0.05 compared with WT virus-transfected NRVMs subjected to stretch.
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Figure 33: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch on expression of Cx43 in 
NRVMs cells. The error bars represent standard deviations. n=5 for each group, * 
p<0.05 compared with non-transfected control baseline levels. ** p<0.05 compared with 
WT virus-transfected NRVMs subjected to stretch.
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Figure 34: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch on expression of the V5 
epitope in virally transfected NRVMs cells. The error bars represent standard 
deviations. n=5 for each group, * p<0.05 compared with wildtype transfectants.
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Figure 35: Representative confocal immunofluorescence images and quantitative 
confocal microscopy data showing the effects of stretch on expression of total 
plakoglobin in NRVMs cells. The error bars represent standard deviations. n=5 for each 
group, * p<0.05 compared with non-transfected control baseline levels. ** p<0.05 
compared with WT virus-transfected NRVMs subjected to stretch.
The resting levels of N-cadherin are not affected by the presence of either viral 
construct. However, in marked contrast to the wildtype exogenous plakoglobin, the 
S39_K40insS-bearing exogenous plakoglobin significantly inhibits the stretch-induced 
up-regulation of the adherens junctions’ protein (Figure 32). Furthermore, the resting 
levels of Cx43 and its stretch-induced up-regulation are not affected by the wildtype 
exogenous protein. However, both the resting levels of the gap junction protein and its 
up-regulation in response to 1 hr of pulsatile stretch are significantly reduced in the 
presence of S39_K40insS (Figure 33). As expected, the distribution of the V5 epitope 
at the cell membrane, corresponding to the exogenous protein expressed, is not 
affected by stretch. However, a higher amount of the exogenous protein seems to be 
incorporated at the cell junctions in myocytes transfected with the mutant virus
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compared to those transfected with the wildtype virus (Figure 34). The amount of total 
plakoglobin protein localizing at intercalated discs is comparable between non- 
transfected controls and myocytes transfected with the wildtype virus. On the contrary, 
total plakoglobin at intercalated discs is significantly reduced in myocytes transfected 
with the S39_K40insS virus. Finally, stretch-induced up-regulation of total plakoglobin 
seems to be reduced in myocytes transfected with the wildtype viral construct 
compared to non-transfected controls but the difference is not statistically significant. 
On the other hand, plakoglobin up-regulation in response to stretch is markedly 
inhibited in the presence of the ARVC-causing mutation (Figure 35).
4) Generating a “Naxos” virus:
To compare the effects of S39_K40insS on cardiac myocytes with those of 2057del2, a 
recombinant adenoviral construct bearing the Naxos disease-causing mutation was 
generated. The pDONR221-plakoglobin plasmid was first subjected to site-directed 
mutagenesis and the mutant plakoglobin sequence was subsequently cloned into the 
pAd/CMVA/5-pDEST vector via an LR clonase-dependent recombination reaction 
(Figures 36 & 37).
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Figure 36: Electropherograms showing the wildtype (A) and 2057del2-plakoglobin (B) 
sequences cloned into the pDONR221 vector. When the sequences are aligned the 2- 
nucleotide deletion is clearly evident (C).
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Figure 37: Electropherogram showing the incorporation of 2057del2 plakoglobin in the 
pAd/CMVA/5-pDEST vector.
Discussion:
To characterize the effects of the ARVC-causing S39_K40insS mutation in cardiac 
myocytes, a recombinant adenoviral construct expressing the mutant plakoglobin 
sequence was generated. Cardiomyocytes exit the cell cycle and terminally differentiate 
in vivo in the peri-natal period. Unlike skeletal muscle, the myocardium does not have 
satellite cells capable of proliferating. Studies of skeletal myoblast cultures derived from 
muscle satellite cells have contributed significantly to our understanding of the 
mechanisms underlying genetic myopathies.355 By contrast, no analogous human 
ventricular cardiomyocyte cell line is available for similar studies, since cultures of 
cardiac tissue have a finite lifespan in vitro.356 Attempts to establish immortalized 
cardiomyocyte cell lines that can proliferate in culture include AT-1 cells, established 
from a mouse atrial tumor,357 MC29, a quail cell line from a rhabdomyosarcoma 
tumor,358 cell lines established from transgenic mice that express the SV40 T-ag359 and 
by transformation of fetal cardiomyocytes with the SV40 oncogene.360 These
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transformed cells though suffer from numerous deficits including limited capacity to be 
passaged and tendency to undergo morphological and functional changes thereby 
creating an heterogeneous cell population.356 As no permanent cardiac myocyte cell 
line exists, the majority of cardiac myocyte gene expression studies have used 
transient gene transfer into primary cultures of fetal and neonatal cardiomyocytes. 
Although useful, this methodology has several limitations, including low efficiency and 
restriction to fetal and neonatal stages of development. As an alternative, in vivo 
studies of cardiac myocyte gene regulation and gene transfer have been successfully 
carried out in transgenic mice. However, the generation of transgenic mouse lines is 
costly and time-consuming. Another approach to cardiac gene transfer in vivo has 
relied on injecting plasmid DNA into the myocardium and measuring reporter gene 
expression in the cells which have successfully taken up sufficient quantities of DNA. 
The major drawback of direct DNA injection is its relative insufficiency, since only 
0.02% of the myocytes in the adult rat heart take up and express injected DNA.361 Many 
of the above-mentioned disadvantages though can be solved through adenoviral gene 
delivery. Adenoviral expression vectors have been in use for over two decades and 
more recently, thoroughly exploited for the purpose of gene therapy. Features which 
make these vectors attractive include very efficient uptake into cells, and their ability to 
carry up to 7.5kb of foreign DNA.361
S39_K40insS plakoglobin was cloned into the pAd/CMVA/5-pDEST vector. Benefits of 
the chosen vector include the presence of the CMV promoter, which ensures high-level 
constitutive expression of the gene of interest and the presence of the V5 epitope 
sequence, which allows detection of the recombinant protein using anti-V5 antibodies. 
Transfection efficiency was determined both by immunostaining and Western 
immunoblotting. When neonatal rat ventricular cardiomyocytes were transfected with a 
concentration of 10 viral particles per cell, >90% of the cultured cells took up and 
expressed the recombinant protein. Transfected NRVMs were subsequently subjected 
to linear pulsatile stretch. Myocytes transfected with an adenoviral recombinant 
wildtype plakoglobin construct, non-transfected and non-stretched myocytes were used 
for control purposes. It is well-established that under conditions of stretch, cells seem to 
be maturing and developing faster. Furthermore, when cells are subjected to chronic 
stretch they even tend to orient in the direction of the applied vector.362 Consequently, 
efforts to re-constitute conditions of heart failure through application of increased, 
continuous mechanical load with the custom-designed system described in the 
methodology section of this chapter, have been unsuccessful. Still, though mechanical 
load does seem to “ improve” myocytes in vitro, it also tends to induce morphological 
and functional changes, one of which is hypertrophy.363 Indeed, early studies with 
animal models using the technique of aortic banding have shown that mechanical
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stress and neurohumoral activation are the two major stimuli for cardiac hypetrophy.364 
Such alterations in cell physiology would render our system disadvantageous for 
studying the effects of desmosomal gene mutations. However, previous studies have 
shown that 1 hour of pulsatile stretch does not alter the morphology and physiology of 
cultured myocytes, while it does induce dramatic responses at the desmosomal sites.334 
In non-transfected control myocytes, N-cadherin, plakoglobin and Cx43 were all 
significantly up-regulated in response to 1 hour of pulsatile stretch as quantified by 
confocal microscopy. These observations are in agreement with those described by 
Yamada et al. in 2000.353 Moreover, transfection of myocytes with the wildtype 
recombinant plakoglobin does not affect the stretch-induced cellular responses. In 
marked contrast though, stretch-induced up-regulation of all three proteins is 
significantly inhibited in the presence of the S39_K40insS mutation. Furthermore, in 
cells bearing the ARVC-causing mutation, even the baseline levels of expression of 
Cx43 and plakoglobin at junctional sites is significantly reduced. Down-regulation of 
plakoglobin and Cx43 expression at intercalated discs was also observed in myocardial 
tissue obtained from the patient carrying S39_K40insS (Chapter 2), and in HEK293 
cells induced to stably express the mutant protein (Chapter 4.1). Interestingly, although 
myocytes were transfected with the same concentration of the wildtype and mutant 
adenoviral constructs, the S39__K40insS recombinant protein was expressed at higher 
levels at cell-cell junctions than the wildtype construct, as shown by immunostaining 
using an anti-V5 antibody. This observation may indicate that S39_K40insS plakoglobin 
acts in a dominant negative manner displacing and replacing the endogenous wildtype 
protein that is naturally expressed by the cardiac myocytes. Collectively, the results 
obtained from NRVMs are consistent with those obtained from HEK293 cells rendering 
the human embryonic kidney-derived cell model advantageous for similar studies. 
Finally, in order to compare S39_K40insS with 2057del2, a recombinant adenoviral 
construct bearing the Naxos disease-causing plakoglobin molecule was generated. 
Experiments to determine the transfection efficiency of the “ Naxos” virus and to 
investigate the effects of 2057del2 on cardiomyocyte responses to mechanical load are 
currently underway. Future plans also include the generation of recombinant adenoviral 
constructs expressing the firefly luciferase and Renilla reporter proteins. Transfection of 
NRVMs with these reporter genes would allow us to study the effects of ARVC-causing 
mutations on signaling pathways under conditions closely mimicking their “naturally- 
acting environment” , the heart.
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CONCLUSIONS:
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle 
disease that may result in arrhythmia, heart failure and sudden cardiac death. The main 
pathological feature is the progressive loss of myocardial cells, which become replaced 
by adipose and fibrous tissue. Characteristic clinical abnormalities include delayed 
depolarization, epsilon waves and inverted T-waves in the right precordial leads on a 
baseline ECG, late potentials on a SA-ECG and ventricular dilatation, systolic 
impairment and wall motion abnormalities on imaging. Arrhythmia is predominantly of 
right ventricular origin and ranges from frequent premature ventricular contractions to 
ventricular tachycardia and fibrillation. The natural history of the disease is sub-divided 
into four phases based on clinical and pathological correlations. Early ARVC is often 
described as “ concealed” owing to the frequent absence of clinical findings, although 
minor arrhythmia and subtle structural changes may still be present. Patients are 
mostly asymptomatic but may nonetheless be at risk of sudden cardiac death 
particularly during or immediately after intense physical activity. The “overt electrical 
disorder” that subsequently develops is characterized by symptomatic arrhythmia, 
while morphological changes are usually detectable by imaging. In the third stage, 
extension of the disease through the right ventricle causes impaired contractility and 
isolated right ventricular failure. Left ventricular involvement with consequent 
biventricular heart failure occurs in the end-stage, which may be difficult to distinguish 
from DCM. It must be emphasized though that this clinical picture is representative of 
severe forms of typical ARVC only. Recent studies suggest a far broader spectrum of 
disease expression.
The prevalence of familial ARVC is usually cited as 30-50% although this is likely to be 
a conservative estimate for a number of reasons. Since the disease may be clinically 
silent, elucidation of family history alone, without clinical assessment of relatives may 
be insufficient. Another major factor is the reduced penetrance that often accompanies 
autosomal mode of inheritance. In some kindreds, penetrance may be as low as 20%. 
Therefore, evaluation of small families at clinical practice may create the false 
impression of sporadic disease. In the past, the predilection for the right ventricle had 
been considered the principal distinguishing factor of ARVC from overlapping clinical 
syndromes such as DCM. Recent years however have seen pathological descriptions 
of fibrofatty replacement exclusive to the left ventricle of sudden cardiac death victims. 
The existence of this entity, best described as arrhythmogenic left ventricular 
cardiomyopathy (ALVC), was subsequently confirmed in the clinical setting. Family 
members of patients with ALVC may have the classic right ventricular variant, 
highlighting the genetic affiliation of the two entities. Predominant right ventricular 
involvement is therefore not a necessary attribute; nor is the presence of myocardial fat 
pathognomonic of ARVC. Significant fatty infiltration has been documented in >50% of
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hearts in normal elderly subjects. The most important finding in the diagnostic 
management of the disease to date is that there is no single diagnostic test. Diagnosis 
remains a puzzle including data from different imaging techniques, electrocardiographic 
examination tests and family history. The conflicts that still remain in the diagnostic 
arena constitute the predominant reason for the underestimation of the disease 
prevalence. Originally, the prevalence was estimated to be 1 in 5000 inhabitants. 
Meanwhile, data showed that the disease affected in fact 1 in 1000 inhabitants. After 
the original publication of diagnostic criteria in 1994, there was an agreement among 
international experts in the field of ARVC that a re-evaluation of diagnostic methods 
and a correction/modification of criteria were necessary. The introduction of these 
revised criteria represented a major step towards better characterization of individuals 
at risk. A tremendous step however was also made by molecular genetics.
Although ARVC is most commonly inherited in an autosomal dominant fashion, the 
molecular studies that led to the identification of the first disease-causing gene were 
preformed on a recessive variant known as Naxos disease. One of the major syndromic 
forms of ARVC, Naxos disease is characterized by non-epidermolytic palmoplantar 
keratoderma and wooly hair. The cutaneous manifestations, coupled with nearly 100% 
penetrance in cardiac disease, facilitated the recognition of affected individuals in this 
population. In 2000, a 2-base pair deletion in the plakoglobin gene (2057del2) was 
identified as the cause of Naxos disease. Plakoglobin, a major constituent of cell 
adhesion junctions, and its isolation in Naxos disease paved the way for the search of 
related genes. Within months of the identification of 2057del2, a deletion in the 
desmoplakin gene was identified as the causative mutation in another syndromic form 
of ARVC, known as Carvajal syndrome. Since then, a variety of mutations in 
desmoplakin and in a further cell adhesion molecule; plakophilin2 have been identified 
in a number of ARVC probands. It therefore became obvious that unraveling the 
pathogenesis of ARVC was dependent on understanding the function and interplay of 
cell adhesion junctions. ARVC was emerging as a disease of the desmosome.
Skeletal muscle consists of long multi-nucleated myofibrils that originate from fusion of 
mono-nucleated myoblasts. Cardiac myocytes in contrast do not form a syncytium. 
Instead they rely on specialized structures known as intercalated discs for both 
mechanical and electrical coupling. Intercalated discs contain three distinct types of 
connections: gap junctions, adherens junctions and desmosomes. Gap junctions 
mediate ion transfer between cells. Each channel is composite of two hemi-channels 
known as connexons, while each connexon is in turn formed by 6 connexin sub-units. 
Connexin43 is the major gap junction protein expressed in the heart, while connexin40 
and connexin45 are also expressed but in lower levels. The transmembrane 
component of an adherens junction, which provides inter-cellular connection in the
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heart, is N-cadherin. Attached to the cytoplasmic tail of N-cadherin are plakoglobin and 
beta-catenin, both of which bind a-catenin, which in turn interacts with actin 
microfilaments. Desmosomes share with adherens junctions the responsibility for 
providing mechanical attachment between cells. In contrast to adherens junctions 
though, desmosomes are associated with the intermediate filament network. In a 
desmosome, the intracellular portions of desmosomal cadherins, namely desmogleins 
and desmocollins, interact with members of the armadillo family, namely plakoglobin 
and plakophilins. These in turn bind desmoplakin, whose C-terminus anchors the 
intermediate filaments to the cell surface. It should be noted that both plakoglobin and 
beta-catenin have additional non-adhesive functions as regulators of transcription. A 
new model for the pathogenesis of ARVC was arising; impaired desmosome 
functioning under conditions of mechanical stress is thought to cause myocyte 
detachment and death. Since regeneration of cardiac myocytes is limited, repair by 
fibrofatty replacement occurs. However, is loss of mechanical integrity, injury and 
repair, the whole story? The initial purpose of this project was to identify novel 
mutations in known disease-causing genes as well as further candidate genes. More 
importantly though, a journey subsequently began to understand the complex 
mechanisms of ARVC pathogenesis, moved a step ahead of the “ loss of mechanical 
integrity” hypothesis in an attempt to unravel the "rest of the story” ...
Mutation analysis was performed on a large cohort of patients of English, German, 
Greek and Cypriot origin. A large number of novel mutations were identified in 
desmoplakin and plakophilin2, rendering these molecules as the two major players in 
the ARVC arena known to date. A single plakoglobin mutation was identified in an 
ARVC family of German origin (S39_K40insS). Both desmoglein2 and desmocollin2 
were shown to have a causative role in the disease accounting for - 20% of positively 
genotyped cases. Though not disease-causing per se, sequence changes in the gene 
coding for desmin were shown to have a role in ARVC pathogenesis, possibly acting 
synergistically with pathogenetic mutations to modify phenotypic expression. Wherever 
possible, relatives were examined, pedigrees were constructed and the pattern of 
inheritance was established. Consistent with previous reports, the vast majority of the 
novel mutations identified were inherited in an autosomal dominant manner. The 
degree of penetrance though was highly variable and in certain cases very low, 
particularly in kindreds bearing plakophilin2 mutations. Collectively, ~40% of all 
probands screened were positively genotyped. Logically though, one may wonder: what 
of the rest?
Subsequently, a number of heart autopsy/biopsy samples from individuals diagnosed 
with ARVC were subjected to histological examination. The results obtained added 
further evidence to the existing argument that ARVC is not merely a matter of fat. In the
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majority of the cases examined, myocardial cells were gradually being replaced by 
fibrous tissue first in the right and then in the left ventricle, which turned into fat as the 
disease progressed. A small number of skin samples were also subjected to 
histological and ultrastructural examination. Interestingly, only one individual, identified 
as a compound heterozygous for two nonsense desmoplakin mutations, showed 
profound cutaneous abnormalities, consistent with loss of epidermal integrity, while all 
heterozygous mutation carriers examined showed no evidence of ultrastructural skin 
defects. A number of heart and skin samples from ARVC patients were subsequently 
stained for selected mechanical and electrical coupling proteins and examined by 
quantitative confocal microscopy. The results obtained indicated that disruption of one 
desmosomal protein leads to down-regulation of expression of its interacting protein 
partners at intercalated discs. The spectrum of proteins affected depended on the 
mutated gene in each case. However, irrespective of the mutated gene, plakoglobin 
distribution at junctional sites was universally disrupted, suggesting a final common 
pathogenetic pathway. Furthermore, in all samples examined, Cx43 at intercalated 
discs was significantly re-distributed, consistent with gap junction remodeling. These 
observations suggest another pathway that could be acting synergistically with the 
anatomic defects characterizing ARVC to promote arrhythmogenesis. Interestingly, 
junctional protein re-distribution was also evident in the skin samples examined, 
irrespective of whether or not the affected individual manifested any cutaneous 
abnormalities. Finally, expression of p-catenin at the cell surface was significantly 
increased, possibly compensating for the reduced levels of plakoglobin. One may 
wonder again: what are the implications of these findings in diagnosing and managing 
ARVC?
The functional effects of a single ARVC-causing mutation were subsequently 
examined. To our knowledge, S39_K40insS is the only autosomal dominant ARVC- 
causing mutation in plakoglobin to be reported to date. Yeast-two-hybrid analysis was 
used to investigate the effects of the novel mutation on the protein interactions 
established by plakoglobin. Two novel interacting partners for the mutant armadillo 
protein were hence recognized: histidine-rich calcium binding protein and TGFp 
induced apoptosis protein2, raising questions about the role of S39_K40insS and of 
plakoglobin itself in calcium release and programmed cell death regulation. A human 
embryonic kidney 293 cell line induced to stably express S39_K40insS plakoglobin was 
generated and used to study the effects of the mutation on desmosomal structure, cell 
proliferation, cell death and subcellular localization. Cells expressing the mutant 
plakoglobin variant showed higher proliferation and lower caspase activity than wildtype 
cells highlighting the effects that ARVC-causing mutations may have on signaling 
pathways. Moreover, differences in the electrophoretic mobility of the mutant protein as
276
well as in its sub-cellular localization introduced the hypothesis that S39_K40insS may 
be acting through altering the turnover kinetics of plakoglobin, increasing its 
degradation by the ubiquitin-proteasomal system. Increased degradation could result in 
reduced amounts of the armadillo protein being available for incorporation into inter­
cellular junctions. This hypothesis was also supported by the observation that cells 
bearing S39_K40insS formed fewer and smaller desmosomes than wildtype cells. The 
same in vitro model was used to study the effects of S39_K40insS on cellular 
responses to defined mechanical load and cellular biomechanics and compare them to 
those of 2057del2. The two ARVC-causing plakoglobin mutations have dramatic but 
similar effects on wound-healing and cell migration rates compared to wildtype cells. In 
contrast, S39_K40insS and 2057del2 have disparate effects on intercalated disc 
protein expression in response to stretch, cell-cell adhesion and cell stiffness. Finally, a 
recombinant adenoviral construct bearing S39_K40insS plakoglobin was generated 
and used to study the effects of the mutation on neonatal rat ventricular myocytes. 
Consistent with the results obtained from HEK293 cells, both mobilization/targeting of 
existing molecules to the membrane and gene expression in response to stretch were 
significantly disrupted in the presence of S39_K40insS. Collectively, the third part of 
this project presented the vast spectrum of effects that a mutation may have, rendering 
ARVC as “ much more than a disease of compromised cell-cell adhesion” . The mere 
involvement of plakoglobin in ARVC, a molecule holding both structural and signaling 
positions, suggests that we are in fact battling in more than one fields. Still, one may 
wonder; where do we go from here?
Approximately 40% of the ARVC probands subjected to mutation screening were 
positively genotyped. So, what of the rest? Plectin, like desmoplakin, is a member of 
the plakin family of proteins also present in desmosomes. While its absence does not 
alter the structure of desmosomes, plectin appears to contribute significantly to the 
mechanical stengthening of cells.365 Mutations in the plectin gene result in skin fragility, 
demonstrating blister formation at the level of hemidesmosomes. These blistering 
disorders belong to the spectrum of epidermolysis bullosa (EB) phenotypes. Three 
distinct variants of this condition have been identified. EB with muscular dystophy is an 
autosomal recessive condition frequently caused by premature termination codon- 
causing mutations leading to the absence of plectin both in skin and muscle. Secondly, 
heterozygous missense mutations in the plectin gene have been documented in 
patients with EB simplex of the Ogna type, a rare autosomal dominant disorder. Finally, 
recent studies have disclosed plectin mutations in patients with EB with pyloric atresia, 
an autosomal recessive condition frequently with lethal consequences.366 Though not 
associated with ARVC yet, plectin’s role in maintaining mechanical integrity renders it a 
plausible candidate gene. Recent mutation analysis performed by our group has
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identified plectin missense mutations in a small number of ARVC probands. Though not 
present in a large number of ethnically-matched control individuals also tested, in vitro 
studies are required prior to drawing conclusions as to their potential role in ARVC 
pathogenesis (unpublished data).
And what if we looked beyond the desmosomal model? An obvious extra-desmosomal 
candidate gene is GJA1, the gene coding for connexin43. Mutations in Cx43 have not 
been identified in conjuction with cardiac disease, but have the obvious potential to be 
arrhytmogenetic. The capacity of Cx43 defects to produce structural abnormalities is 
evidenced by its association with oculo-dento-digital dysplasia; an autosomal dominant 
syndrome presented with craniofacial and limb dysmorphisms, spastic paraplegia and 
neurodegeneration. Ventricular tachyarrythmia and sudden deaths have been recorded 
in some families affected by the disorder.367
Sarcoendoplasmic reticulum Ca+2-ATPase (SERCA) is expressed at its highest levels 
in the cardiac muscle, where it controls calcium levels in the sarcoplasmic reticulum 
and therefore regulates the excitation-contraction coupling. SERCA2 knockout mice do 
not survive birth. On the contrary, heterozygous knockout animals are viable, fertile and 
do not show any sign of disease. When subjected to increased mechanical load 
though, these animals show largely impaired cardiac function, heart dilatation, evidence 
of hypertrophy and fibrosis and high incidence of sudden cardiac death.368,369 Could 
SERCA2 therefore constitute another candidate ARVC-causing gene?
Infants with Neterton syndrome typically present with a generalized exfoliative
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erythroderma. Histologically, they show acantholysis with super-imposed 
parakeratosis. Their stratum corneum is usually thin, often detached from the 
underlying epidermis and sometimes even absent. Mutations in SPINK5 have 
previously been associated with the syndrome. SPINK5 codes for a serine protease 
inhibitor (LEKT1) localized in the most differentiated layers of stratified epithelial 
tissues. Defects in LEKT1 allow for hyper-activity of the stratum corneum tryptic 
enzyme SCTE, which leads to increased desmosomal cleavage. Immunohistochemical 
analysis on skin from SPINK5 -/- mice showed significant reduction in expression levels 
of desmogleinl and desmoplakin stemming from abnormal protein degradation.370 
Could mutations in the cardiac isoform of SPINK5 account for the desmosomal defects 
observed in the setting of ARVC? Finally, a large set of proteins are currently 
recognized that link the intermediate filaments to other cytoskeletal components in 
many tissue types.371 Given their key position and their well-recognized role in 
maintaining tissue integrity, this class of proteins could also be underlying “ loss of 
integrity” conditions, such as ARVC.
Phenocopies of ARVC may provide additional insight into its genetic heterogeneity. 
Surprisingly, very convincing phenocopies of ARVC may reside amongst the muscular
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dystrophies. Skeletal muscle degeneration with fibrous and adipose replacement is 
characteristic of this group of disorders. Similar histological changes may be observed 
in the heart, while myocardial disease may even occur in the absence of significant 
skeletal myopathy. Melacini et at. found evidence of cardiomyopathy in 68% of patients 
with sub-clinical Becker’s muscular dystrophy, undergoing routine cardiac evaluation.372 
ECG features included T-wave inversion in the right precordial leads, while right 
ventricular dilatation was a common finding on echocardiography. Serial evaluation of a 
single patient suggested preferential involvement of the right ventricle in early disease, 
followed by progression to a DCM-like phenotype.372 The dystrophin-glycoprotein 
complex provides a mechanical connection between the cytoskeleton and the extra­
cellular matrix.373 Mutations in dystrophin may initially compromise cellular adherence 
to the matrix and thereby predispose to sarcolemmal damage by shear stress. As with 
desmosomal abnormalities, this process is more likely to primarily affect the thin-walled 
right ventricle. Subsequent involvement of the cytoskeleton could lead to left ventricular 
impairment. Defects of the dystrophin-glycoprotein complex should therefore be 
considered in families with right ventricular cardiomyopathy progressing to a DCM-like 
phenotype.
The histopathological appearances of the heart in X-linked Emery-Dreifuss muscular 
dystrophy (EDMD) mirror those of ARVC.374 There is myocardial atrophy with fibrofatty 
replacement, with preponderance for the right heart.375 The disease-causing gene 
codes for emerin,376 a protein that localizes to the inner nuclear membrane, 
desmosomes and adherens juctions.377 Novel mutations in emerin and related proteins 
could conceivably result in an ARVC phenotype. Perhaps the closest phenocopy of 
ARVC is the cardiac disease of myotonic dystrophy, which shares the propensity 
toward tachyarrhythmia in the absence of overt ventricular dysfunction. The disease is 
caused by expansion of an unstable CTG trinucleotide repeat in the 3’ untranslated 
region of the DMPK gene. The affected protein, myotonic dystrophy protein kinase, 
localizes to the intercalated discs of cardiac muscle. Immunohistochemical analysis has 
demonstrated close proximity to gap junctions and co-sedimentation with Cx43.378 
Significant clinical overalp, suggests that novel mutations in the DMPK gene may 
produce an ARVC phenotype.378 The presence of disease phenocopies though, may 
make one wonder: is what we are dealing with really ARVC?
In clinical practice, the disease that most frequently mimics ARVC is idiopathic right 
ventricular outflow tract tachycardia (RVOTT). A benign arrhythmic disorder, with no 
familial basis, RVOTT may nonetheless be extremely diffucult to distinguish from the 
concealed phase of ARVC, in which typical ECG and imaging abnormalities are 
absent.379 Furthermore, although most patients with Brugada syndrome have 
structurally normal hearts, it appears that some individuals with the clinical features of
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Brugada syndrome may in fact have structural heart disease broadening the area of 
overlap between "conduction diseases” and ARVC and making their differentation even 
harder.380 Clinical diagnosis of ARVC is impeded by the non-specific nature of disease 
features and marked phenotypic diversity. Molecular genetics analysis will eventually 
assume a pivotal role in the clinical area by facilitating timely diagnosis, guiding 
interpretation of borderline investigations and enabling cascade screening of relatives. 
However, early identification of genetically affected individuals raises complex 
management issues in its own right while risk stratification remains elusive. A small 
number of patients may suffer arrhythmic events without warning symptoms or clinical 
evidence of overt disease. Conversely, a sizable proportion of gene carriers will not 
develop clinically significant disease owing to reduced penetrance. Furthermore, 
among relatives with disease expression, the majority are likely to follow a benign 
course. The ICD confers optimal protection against sudden cardiac death, but the 
notable complication rate and psychological impact especially in the younger age group 
argue stongly against indiscriminate device placement in all gene-positive patients. 
Similarly, the adverse prognostic impact of harboring an ARVC-causing mutation is too 
small to justify the use of mutation analysis in prenatal diagnosis. At present, there is 
little evidence to support the notion that certain mutations may portend a less favorable 
outcome than others.186 Until definitive genotype-phenotype correlations are developed, 
the role of genetic analysis in ARVC diagnosis and management is limited and should 
be used with caution.
And what of sporadic gene-negative ARVC cases? Are all of these familial cases 
masquerading as sporadic owing to reduced penetrance? Are all of these stemming 
from de novo non-yet-identified mutations? Antibodies to the p1-adrenergic receptor 
are detected in a substantial number of patients with idiopathic dilated cardiomyopathy. 
Jane-wit et al. recently showed that these specific auto-antibodies elicit DCM by 
agonistically inducing cardiomyocyte apoptosis.381 Equivalently, could a subset of 
ARVC cases be autoimmune? Loss of epidermal cell-cell adhesion, also known as 
acantholysis, in pemphigus may be caused by binding of auto-antibodies to the extra­
cellular domains of desmogleinl or desmoglein3 at the keratinocyte membrane.382 
Although widely expressed in the skin, these two desmosomal cadherin isoforms are 
not found in the myocardium. In the heart, the major isoform expressed is desmoglein2. 
In a similar fashion, could autoantibodies directed against the extracellular portion of 
desmoglein2 or desmocollin2 account for ARVC? To investigate this possibility, an 
immunostaining approach is currently being undertaken. Serum is being collected from 
patients with severe forms of what appears to be non-familial ARVC. All these patients 
have been screened previously for mutations in all known disease-causing genes and 
found negative. The serum will subsequently be applied to heart muscle specimens
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obtained from control individuals with no history of heart disease. In essense, the 
serum will act as a “ primary antibody” . The specimens will then be incubated with 
appropriate secondary antibodies and examined by fluorescent microscopy. To 
eliminate the possibility of auto-antibodies developing as a secondary degenerative 
phenomenon in the setting of ARVC, serum from gene-positive ARVC patients is also 
being collected and will be used for control purposes.
When myocardial tissue is examined under an electron microscope, only very few 
desmosome-like structures appear interspersed at the adjoining membranes. 
Conversely, when tissue is immunostained for so-called “desmosomal molecules” , 
such as desmoplakin or plakophilin2, numerous areas of high signal intensity are 
observed at the cell membranes under a fluorescent microscope. Under a high 
resolution scanning electron microscope, the intra-cellular surface of an intercalated 
disc appears like an extremely erose structure with peaks and valleys. The fact that 
particles of different sizes are distributed at random at the intercalated disc surface 
makes their separation into desmosomes and adherens junctions impossible.383 The 
term “ area composita” was hence given to ID regions occupied by cadherin-based cell 
adhesion structures.384 Immunoelectron microscopy studies have shown that molecules 
known to be components of epithelial desmosomes such as desmoglein2, 
desmocollin2, desmoplakin, plakoglobin and plakophilin2 are not only confined to 
junctions with a typical desmosome morphology but are also found in junctions with a 
more fascia adhaerens-like appearance. It was also shown that typical molecular 
components of fascia adhaerens can have the same localization as desmosomal 
molecules regardless of whether the junction has a more desmosome-like or a more 
fascia adhaerens-like appearance. The question arises then whether the area 
composita represents the major part of the cardiomyocyte intercalated discs and 
whether there is only a low proportion in which true desmosomes or true fascia 
adhaerens exist separately. This seems to be the case at least in some amphibian and
T 0 4
fish species. The idea of “ mixed” junction types is further supported by recent 
studies showing a-catenin to have a pivotal regulatory role in desmosomal formation385 
and studies showing N-cadherin interacting to a certain degree with plakophilin2.154 If in 
fact there are no “ true” desmosomes, or at least not according to the model currently 
accepted, could the genes coding for classical adherens junction proteins also be 
underlying ARVC pathogenesis?
Based on both previous reports and the results presented herein, it appears that 
plakoglobin expression at intercalated discs is universally down-regulated in all cases 
of ARVC examined. Myocardial samples from patients with hypertrophic, dilated or 
ischemic cardiomyopathy are currently being immunostained for desmosomal proteins. 
This approach has showed that plakoglobin re-distribution is in fact specific to ARVC.
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Though preliminary, these observations are highly promising potentially rendering 
immunostaining as a powerful tool in diagnosis of borderline ARVC cases.
When it comes to ARVC, a lot of questions still remain unanswered and a lot of issues 
need to be re-visited. One such question concerns the observed right ventricular 
predilection, and one such issue concerns the very name of the disease. During 
embryonic development, the heart is initially formed as a simple linear tube located at 
the ventral midline of the organism. During subsequent development, the tube 
undergoes a complex series of movements and tissue remodeling events that lead to 
the formation of the mature, four-chambered, septated organ. The morphologic events 
are accompanied by an equally complex series of cellular and molecular processes that 
lead different regions of the heart to express different genes and to adopt different 
physiological properties. The atrial and ventricular chambers, for instance, contain 
distinct isoforms of the myosin light chain genes, MLC2a and MLC2v respectively, 
which contribute to distinct contractile properties of the chambers. 386,387 Were the two 
ventricles to be expressing different isoforms of desmosomal genes, the “ preference” 
that ARVC is showing to the right ventricle, would have been easier to explain. Yet, 
both the left and the right ventricle express the same set of “ adhesive” genes, and as 
shown by immunohistochemical approaches, they also appear to have equivalent 
protein expression and distribution patterns. On the other hand, if we accept that the 
predilection is driven merely by the right ventricle having a thinner wall than the left 
ventricle, we would not be able to explain the increasing number of arrhythmogenic left 
ventricular cardiomyopathy cases that are being recognized. What is the factor that 
decides which ventricle is to be primarily affected in each case? Could differential 
expression of non-desmosomal cardiac genes across the ventricles determine which 
chamber is more susceptible to the disease in each case? Or similarly, could genetic 
polymorphisms in desmosomal or even non-desmosomal genes have a role in 
“directing” the "primary site of action” of the disease? It is now well-established that 
cases of ALVC do exist both in the pathology arena and in the clinical setting. Also, 
since ARVC and ALVC may exist in the same kindred, it is recognized that they are in 
fact different "expressions” of the same entity. Does that mean that the ground under 
the mere name "ARVC” is shaking? Leading experts in the field met in Colorado, USA 
in May 2007 to discuss among others, the possibility of changing the name originally 
given to the disorder over a decade ago. “ Desmosomal cardiomyopathy” could very 
efficiently describe the -40% of ARVC cases that are positively genotyped but would at 
least at the moment be largely inaccurate for the remaining cases.
Collectively this project described the effects that ARVC-causing mutations may have 
far beyond disrupting mechanical integrity, hence highlighting the deeply complex 
nature of this disease. The novel disease-causing pathways presented herein do not
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preclude the mechanisms previously suggested. On the contrary, they underscore how 
multiple routes can combine and intersect to bring about a disease. What would the 
next step be though? Although investigating the effects of pathogenic mutations in 
cardiac myocytes provides highly physiologically significant results, transfecting 
NRVMs with recombinant adenoviral constructs still comprises an in vitro model. The 
next step would be to study animal models expressing S39_K40insS or 2057del2 
plakoglobin. Though a time-consuming, expensive and laborious procedure, the 
generation of such transgenic animals would give us a different and even superior 
perspective in understanding and subsequently managing ARVC. Steps towards the 
development of these in vivo models are currently being undertaken. With an efficient 
collaboration between the clinical arena, improving diagnosis and applying more 
effective therapies, the genetic arena, identifying the root of ARVC, and molecular 
biology explaining how we can get from the “ root to the branches” , from the mutation to 
the disease, understanding and fighting ARVC is finally becoming a reality.
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APPENDIX I I  List o f primers used for mutation analysis
Desmoplakin I
Exon Primer sequence Length GC% Size exon/PCR 
(base pairs)
Annealing T 
°C
DPexIR AGT CGT CCAGAGGAGGACGGT 21 62
DPex2F G C AAGTTT G AAATT ATTT CAG 21 28 103/245 48
DPex2R AGAAGCTAACCAGAGGACAGT 21 48
DPex3F CTTGCTTCCATTAATGCCCATGAA 24 41 149/291 60
DPex3R AGTGTAACTGGTTATGAGGAGTTC 24 41
DPex4F CCAGAACGGGTTTTCATAGGC 21 52 175/314 55
DPex4R CACACAAACACAT GGGCT GAC 21 52
DPex5F GGTGTGCGT AAGT G AAACAGGT 22 50 129/260 55
DPex5R GTAATTACACGATCCTTCGGTAG 23 43
DPex6F AGGAGGCTTAGAAGGGCCACTC 22 59 51/218 55
DPex6R TCCCCGCCAGGATGTGCTTGAT 22 59
DPex7F CAGAGAACACCAGTCACTGCA 21 52 162/282 60
DPex7R CCAGCT CTT CAAGGCAACAGG 21 57
DPex8F AACAGCGT GATT CTTT GGCA 21 38 105/237 50
DPex8R CCAACCCCTGGTGTAGGGTA 21 33
DPex9F TGGTGTTCATGCATCTGTACAA 22 41 96/214 50
DPex9R CAAAAGATTAG GTATTAAG ACC 22 53
DPexlOF CTACT AG AT G AAATT GCT CAT 21 33 126/254 55
DPexlOR TCCAAGGCATGTGTTTTATCT 21 38
DPex11F T GCAGGTT GAAAAT CTCCT CT 21 43 153/302 55
DPex11R AAT GTTGCTTT CTT GAT GGAC 21 38
DPex12F CATCTCTGTTTCCATCATTGAG 22 41 155/313 55
DPex12R TATAAACACCTGCCCTCTTCCT 22 45
DPex13F T CCCATTTGGGAT GAAGT GTG 22 45 127/263 60
DPex13R AACT GTT GGACACAGGCACT G 22 52
DPex14F CTCTTCTT GATT GCATT GTG G 21 43 202/340 55
DPex14R AGTTTTATGCAAACTCCCTTC 21 38
DPex15F TAGCACCTTGATACCTAGGTAT 22 41 227/377 60
DPex15R GCCTACAAACATTTAAACCAGG 22 41
DPex16F CAG CAT ATT GT ACACCTT AAAT 22 32 167/340 55
DPex16R AGAAACT GTAAGGCAAGCAT CT 22 41
DPex17F GT GAGAGGC AAAT CTT CACAGA 22 45 139/270 55
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DPex17R TGGGAGCTCAGATCTGAATTAG 22 45
DPex18F AGTGTAGCATACAATGGGAGAA 22 41 194/319 55
DPex18R G ACATT AT CTT GT G AAC AACC A 22 36
DPex19F T CAAGT G AATTT CTGGGT GA 22 36 163/298 55
DPex19R AAGCCTTCACAAAATGGGTT 22 36
DPex20F AAGGGTACAAATAACAGTGGTA 22 36 84/246 52
Dpex20R AT CAG CAAGT CAT G C AGTT AAT 22 36
DPex21 F GTGGAACTGTAGCTGTTAGTGA 22 45 108/265 55
DPex21R GAAAAGGGAAGAGGCAGGAGAC 22 54
DPex22F ATCGGTCAAATTACATAGGACT 22 36 99/257 48
DPex22R CCAAATCCATGTTATAATGTGG 22 36
DPex23.1F CTTCTTTCTTGGAATGTGAGGT 22 41 2295/420 55
DPex23.1R ACATTGCCTTGCTTTCTGCAGT 22 45
DPex23.2F GACCAACAGAAGAAT GACTAT G 22 41 2295/381 60
DPex23.2R CT GCT CAGT GGCCT GCAAGAT 21 57
DPex23.3F GGAT GAAATT GT CAGGCT CAA 21 43 2295/415 58
DPex23.3R TATCCTCTTCCTTCTGCATGG 21 47
DPex23.4F ACCAAGACCACCAT CCACCAG 21 54 2295/416 55
DPex23.4R TGGACCCTTTGTAATCTCGCG 21 52
DPex23.5F ACCGGAAATGCCTGGAAGATG 21 52 2295/397 55
DPex23.5R CTCTTCTTAACAATGGATGCC 21 43
DPex23.6F AT CACCAACCT GACCCAGCAG 21 54 2295/351 55
DPex23.6R CCTCAGGTTCCGCAGTTCTTC 21 54
DPex23.7F CT CACAGAGAACCTGACCAAG 21 52 2295/333 58
DPex23.7R GAGCACAGTTCAGATGAGATA 21 56
DPex24.1F GTTAAGTCGTGATAGTAATATG 22 32 3931/420 55
DPex24.1R CTTGATCTCTGCTTGGAGTCTT 22 45
DPex24.2F GAAGAACAGTCTTAGGAGTGA 21 43 3931/409 55
DPex24.2R T CCTT AGGAGAAG CAGATGCT 21 47
DPex24.3F CCTTCTGGGTGCAGGATCTAT 21 57 3931/466 60
DPex24.3R TCGGGGATCATTCAGGGATCG 21 52
DPex24.4F GTAGACCCT GT GAACAGT GT C 21 52 3931/417 65
DPex24.4R CGGAAGCTT CT GTTTT GT GGT 21 48
DPex24.5F CAAGCT GCATAGCAGGCATAT 21 48 3931/410 55
DPex24.5R CTTATATGCTATGTCAACTGG 21 38
DPex24.6F ATT GACCCAAAGGAGAGCCAT 21 48 3931/406 55
DPex24.6R CATCTGATCCCGTGATGGTTA 21 48
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DPex24.7F T GT G AGCAGGAAT GT GAATGG 21 48 3931/413 55
DPex24.7R GTAATGGAGATTTTCTCCAGG 21 43
DPex24.8F TTGCAGCCAT CTTT GACACAG 21 48 3931/416 60
DPex24.8R ATCTATGAACCCCTTCCGGAT 21 48
DPex24.9F AGGATAAGCACCGAAGAAGC 21 48 3931/480 60
DPex24.9R CTGCAAGCACCGGGATTTTCT 21 53
Plakoglobin
Exon Primer Sequence Length GC% SizeExon/PCR 
(base pairs)
Annealing T 
°C
JUPex2F CTGGGCCAGGTGACTTCCTGCT 22 63 216/323 65
JUPex2R T CT CT CCAGGACCCAGGCAGGT 22 63
JUPex3F AGTGTCTGCCCAGCCCACTGC 21 66 260/372 67
JUPex3R ACAAT GTCCCT CCCCT G AGGACAT CT 21 66
JUPex4F GCCTCTCCTTAGTGCTCACGTC 22 59 239/344 58
JUPex4R AGGGGAGAGGCCCAAGTGAGAG 22 63
JUPex5F GCTCACATGTATGCCAGGCCTC 22 59 202/323 60
JUPex5R GCAGGATAGAAGATGGCGCAAG 22 54
JUPex6F CCCGCGCTTCCTTGTTCCTGTCA 22 66 145/293 62
JUPex6R CATCAGCCACGGGGAGCATGGCT 21 62
JUPex7F CCATT GT GGAGGCT GGT GAGT AT G 21 52 104/295 65
JUPex7R AGATGCCCAGACAGGAGGCTGGAT 21 52
JUPex8F TGGAGTTGGCTGCTCCCTGAC 21 62 339/434 62
JUPex8R ACCTAAGCCTGCTGCAGGGTG 21 62
JUPex9F AAGCTGGGATCCTTCAGATGTC 21 50 156/289 55
JUPex9R ATTCACACACACACCCACAGAG 22 50
JUPexlOF CATT CGGCTGT CAT GGGGAGGA 22 59 120/266 55
JUPexlOR CTGGGACTCCTAACCTTGCCCT 22 59
JUPex11F TGTCCGGCCTGCCTCACCCCTT 22 68 151/276 65
JUPex11R ACGTCGGCCAGCCTCCATCGTG 22 68
JUPex12F CACGATGGAGGCTGGCCGACGT 22 68 122/234 65
JUPex12R CCATGGGCAGTGCCCAACTTGC 22 63
JUPex13F AGAAGCATCTCTCCCTGCCCAC 22 59 40/223 55
JUPex13R CCTCTGGCCCCGGAGACATAAT 22 59
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JUPex14F GACTGCTCCCTGCAGGGTAGCT 22 63 166/288 58
JUPex14R GAGGGCCTCCAACAGAAGGAGG 22 63
Plakophilin II a
Exon Primer Sequence Length GC% Size Exon/PCR 
(base pairs)
Annealing T 
°C
PKP2ex1R ACTCCCAGCACGCGGGGTGAG 21 71
PKP2ex2F CTGTAAATATTAATTAGCCTAC 22 27 113/219 55
PKP2ex2R CAT G GTAGT AAT CT GAT CACTA 22 36
PKP2ex3AF AGTCCT CAGC AAAGTT G AAATTT G 24 38 698/423 53
PKP2ex3AR GT CAAAAACGGT GT CGCTAACAGA 24 46
PKP2ex3BF CACATACCACAGACAGTACCAG 22 50 698/443 58
PKP2ex3BR TGTGCTGGCAATGACTGAACTG 22 50
PKP2ex4F AGTATTCGCTGAGTCGTCTCT 21 48 136/291 55
PKP2ex4R GC AAAGT CACCATAATAGAAG 21 38
PKP2ex5F T GAAT GCCTT GAT GCCACAT C 21 48 208/333 60
PKP2ex5R GATGATGTAAGGCATCTGGCT 21 48
PKP2ex6F TTGCTGTGTTCATAAAGGAGCC 22 45 132/258 55
PKP2ex6R ATTACAGGCGCAGACCACGACA 22 54
PKP2ex7F TTCAGCGGTCATTTTGGTCCCA 22 50 178/305 55
PKP2ex7R TGACTTCCTTGGGGCTACCTAA 22 50
PKP2ex8F CAAAGACCT GTTGGATACACA 21 43 118/250 55
PKP2ex9R GCCGATATATACCAAGTACTT 21 38
PKP2ex10F GT G AAATTATAG C CAT C ACCTG 22 41 174/303 55
PKP2ex10R CT GAATT GAAT GT AGGT AAGT C 22 36
PKP2ex11F CAT CTT CAT CAACCT CTGGTA 21 43 154/322 58
PKP2ex11R GGTGATACAGACAACATTTCA 21 38
PKP2ex12F TGGGATCTTGGGATTAAGAAAC 22 41 190/321 62
PKP2ex12R GATTATTTACACACAGGCTGGT 22 41
sequencing was performed with 
nested primers
12F nested AAGAAACTCTCCCT GATTTGGT
12R nested TTACGCATCGCCTGCACTAATG
PKP2ex13F AGGCCGCATCCAGAAGCCTCA 21 62 88/224 55
PKP2ex13R TT CCCAGGGT CAAGT CAAGT GG 22 54
PKP2ex14F CCACTTGACTTGACCCTGGGAA 22 54 1639/246 58
PKP2ex14R GGTTTCTTGGGCTGGGTAGTAG 22 54
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Desmoglein 2
Exon Primer Sequence Length GC% SizeExon/PCR 
(base pairs)
Annealing T 
°C
DSG2ex1F CCAGGGAGGAGCCGAGTGCGCGCT 24 75 55/226 60, GC rich
DSG2ex1R AACGCGCACAAGGGCGGCGGGCAA 24 70
DSG2ex2F CAATGCAGTAGGTTATTCATGA 22 36 36/220 55
DSG2ex2R C AAC AT GTGTCTT CAAT CTAGT 22 36
DSG2ex3F TAGGACAGCATACTAATGTTC 21 38 135/266 55
DSG2ex3R AAAGTCCTCTCACACCACATT 21 42
DSG2ex4F TGGCTAAGATCAAATCTAGTAA 22 31 162/292 52
DSG2ex4R CAAAT G AC ACTTATT AT GACAG 22 31
DSG2ex5F GTT ACCAGCATT CTT GAT CGAG 22 45 145/436 52
DSG2ex5R TGTTCTGTAGGTAATACTCAAC 22 36
DSG2ex6F AGGTAAATATGCTTAAAGTTGA 22 27 167/323 55
DSG2ex6R AGGAATACAGAACAAAATAAGA 22 27
DSG2ex7F GAAAGCCAGAT GTAAGAGT GA 22 40 138/315 53
DSG2ex7R CT GCAAAACAT GAACACAT GA 22 36
DSG2ex8AF G GAT GT CAAT G ACAATATACCTGT 24 37 186/315 58
DSG2ex8AR GTTT GAGCAT CT GTTT CTAT GTGG 24 41
DSG2ex8BF AATAGGTTCTGATAATTGGCTGGC 24 41 186/295 52
DSG2ex8BR TAGTGTGACCACTTCCTAACCACA 24 46
DSG2ex9F GTAT CT AACATT AAAACCACAC 22 32 266/455 55
DSG2ex9R TT G AAG GAAT G AAGT GTT CAG 22 36
DSG2ex10F T GTTAGAGGTTTCCAATT CAT G 22 36 143/285 58
DSG2ex10R CAAT CAAAT CAAT G GTTT CT GA 22 32
DSG2ex11F GTCCTAAGTGGTTAGTACCTTC 22 45 228/485 60
DSG2ex11R T GT CAGT AGGTT CAGGACCT CA 22 50
DSG2ex12F ATGTTGCCTCATCCTTGGTAAT 22 41 228/357 55
DSG2ex12R AT AGT AACACAT CT CCAGGAGT 22 41
DSG2ex13F AAGT C C AGG AAG G G ACAT G C AA 22 50 122/321 55
DSG2ex13R GATCACTTTACTCACTCAACCA 22 41
DSG2ex14F AAGG AT GAAGGATT CCCTCCAT 22 45 333/484 58
DSG2ex14R GATCCAAGGCAAT GATTACCCT 22 45
DSG2ex15.1F ACATT ACT GCATTTT GAACAGG 22 36 1023/412 52
DSG2ex15.1R T CT CT GCATT GGCTT CTTGCA 21 47
DSG2ex15.2F GAGAATACCTACTCCTCTGGCA 22 50 1023/420 55
DSG2ex15.2R TT CCCT CACCAT GACGT AAGGT 22 50
DSG2ex15.3F AAGGCACT CAGCAT CTT CAAG A 22 45 1023/395 50
DSG2ex15.3R GTCACTGCTAATTAAACTCTGG 22 41
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Desmocollin II a
Exon Primer sequence Length GC% Size Exon/PCR 
(base pairs)
Annealing T
°C
DSC2ex1 R GTTTTCCTCTGCACCCTAGGCG 22 59
DSC2ex2F GCCTTTTTATGTGTATATCAT 21 28 85/245 58
DSC2ex2R TTCCTTTTTATGGCTGTGTAG 21 33
DSC2ex3F CACGT GCAT ACATT ACT GTT AA 22 36 200/335 55
DSC2ex3R GT AAT GTT GATT ACGTCT GAAG 22 36
DSC2ex4F GT C ATT GTTT AAT GTTT GAG AA 22 27 120/246 50
DSC2ex4R ATAATGGTAAGAGATGGAAACT 22 31
DSC2ex5F ATAGATGAAAGCTCTGCTGAA 21 38 156/268 50
DSC2ex5R AAATGGCCAAGCATCATCATT 21 38
DSC2ex6F TGAATTTGAAGCATACCTCAT 21 33 145/267 50
DSC2ex6R T GT AT GAATT GAAACACAGTT 21 28
DSC2ex7F AT AAAGGGAACATAG AACAT GT 22 32 167/286 50
DSC2ex7R GAGTTATACAGGTACTATTGAA 22 32
DSC2ex8F GG AGT GT AAAGTAAG ATTT CAA 22 32 135/278 50
DSC2ex8R C AGAG AT GTG CAT ATT AAACAA 22 32
DSC2ex9F GATTT ACTT CACAT CGT GTT CA 22 36 186/319 50
DSC2ex9R ATTCTAGCATGCTATTCTATGA 22 32
DSC2ex10F GCATTGCCAAATATTAAATGA 21 28 257/378 48
DSC2ex10R G CTAAATTATAATAACGTAAC 21 23
DSC2ex11F GGTACTTACCATTCTATTTTAG 22 32 143/299 50
DSC2ex11R ATGTATGTAGCCAAGGAAGTAT 22 36
DSC2ex12F T CAGT GCAT ACTTTT GTGGTGA 22 41 225/347 50
DSC2ex12R AGTAT CGCAGACAT CCT GAT GT 22 45
DSC2ex13F AGAAGAAATCAGTGACATT GTA 22 32 237/347 48
DSC2ex13R CTTGAAAGTTACTTTAAAGGGT 22 32
DSC2ex14F TGTGTGTATTAACCATTGTACA 22 32 125/259 60
DSC2ex14R TACGCATTATAAGCGAATTCAT 22 32
DSC2ex15F TTGTGTTCCTCTCTGTATTATC 22 36 258/384 60
DSC2ex15R ATAGTCAGAATCCAGTTAGTTA 22 32
DSC2ex16F G CTATACT G AATTTAT AGT GT GAT 24 29 198+36/438 55
DSC2ex16R TAAAAGTCATAAAGCCACTGGCTT 24 37
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Desmin
Exon Primer sequence Length GC% Size Exon/PCR 
(base pairs)
Annealing T
°C
DESexlaR CG GT GAACCAGGAGTTT CT G AC 22 55
DESexIbF CTACGGCGCAGGCGAGCTGCTG 22 72 578/339 68
DESexIbR CAGGAGGCTAGGCCTGGGGTCT 22 68
DESex2F GGCCAGTCGTTTCCACTGCCAG 22 63 61+96/384 65
DESex3R AGCAGCCGGAAAGTGGGGTTGG 22 63
DESex4F TGAGGCTCTGGCTGGGAATAGG 22 59 162/310 65
DESex4R CAGCTT GGAT GTGCT GCCT GT G 22 59
DESex5F CCAGAGGCTTCATGCTCCCTTG 22 59 126/285 65
DESex5R CTCACTTTGTGACCTTGGGCCC 22 59
DESex6F GTTGCCTGCCAGCCCCAAAGC 21 66 221/296 65
DESex6R TGCGGGGTGCTGGGTGGTCCAT 22 68
DESex7F ATGGTCTCGATCTCCTGACCT 21 52 44/226 68
DESex7R AGGAGTCCAGCATGGGCACT 20 60
DESex8F CCTGGTATAGCCCAGCCTGGA 21 62 83+784/455 68
DESex9R TGCTCCCTGAAGCCAGCCTTC 21 62
“ F” stands for forward and “ R” stands for reverse. All primers are in the 5’ -  3’ direction.
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